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4In the past decade, drug control has matured. Policy has 
become more responsive to the needs of those most seri-
ously affected, along the whole chain of the drug indus-
try – from poor farmers who cultivate it, to desperate 
addicts who consume it, as well as those caught in the 
cross-fire of the traffickers. Countries are learning from 
each others’ experiences, and drawing on expertise from 
the international community. 
Drug control is also increasingly taking a more balanced 
approach, focussed on development, security, justice and 
health to reduce supply and demand, and disrupting 
illicit flows. There is an understanding that in regions 
where illicit crops are grown, it is vital to eradicate pov-
erty, not just drugs. There is a realization that under-
development makes countries vulnerable to drug 
trafficking, and other forms of organized crime: therefore 
development is part of drug control, and vice versa. 
Most importantly, we have returned to the roots of drug 
control, placing health at the core of drug policy. By 
recognizing that drug addiction is a treatable health 
condition, we have developed scientific, yet compassion-
ate, new ways to help those affected. Slowly, people are 
starting to realize that drug addicts should be sent to 
treatment, not to jail. And drug treatment is becoming 
part of mainstream healthcare. 
Beware the side effects of complacency 
This approach is paying off. The world’s supply of the 
two main problem drugs – opiates and cocaine – has 
been declining over the last two years. The global area 
under opium cultivation has dropped by almost a quar-
ter (23%) in the past two years, and opium production 
looks set to fall steeply this year due to a blight that could 
wipe out a quarter of Afghanistan’s production. Coca 
cultivation is down by 28% in the past decade. Heroin 
and cocaine markets are stable in the developed world. 
Indeed, cocaine consumption has fallen significantly in 
the United States in the past few years. The retail value 
of the US cocaine market has declined by about two 
thirds in the 1990s, and by about one quarter in the past 
decade. One reason behind the violence in Mexico is that 
drug traffickers are fighting over a shrinking market. 
Shifting the problem to the developing world 
Most worrisome are recent developments in the third 
world. Market forces have already shaped the asymmet-
ric dimensions of the drug economy; the world’s biggest 
consumers of the poison (the rich countries) have 
imposed upon the poor (the main locations of supply 
and trafficking) the greatest damage. 
But poor countries have other priorities and fewer 
resources. They are not in a position to absorb the con-
sequences of increased drug use. As a result, there is now 
the risk of a public health disaster in developing coun-
tries that would enslave masses of humanity to the 
misery of drug dependence – another drama in lands 
already ravaged by so many tragedies. The warning 
lights are already flashing. Look at the boom in heroin 
consumption in Eastern Africa, or the explosion of 
cocaine use in West Africa or South America, or the 
surge in the production and abuse of synthetic drugs in 
the Middle East and South East Asia. We will not solve 
the world drugs problem by shifting consumption from 
the developed to the developing world. 
Changing to other drugs 
Furthermore, stabilization of the cocaine and heroin 
markets masks a growing problem of the misuse of pre-
scription drugs in many parts of the world. And the 
global number of people using amphetamine-type stim-
ulants (ATS) is likely to exceed the number of opiate and 
cocaine users combined. The ATS market is harder to 
track because of short trafficking routes (manufacturing 
usually takes place close to main consumer markets), 
and the fact that many of the raw materials are both 
legal and readily available. Furthermore, manufacturers 
are quick to market new products (like ketamine, 
Mephedrone and Spice) and exploit new markets. We 
will not solve the world drugs problem if addiction 
simply shifts from cocaine and heroin to other addictive 
substances. 
What do we propose, at UNODC? We champion plac-
ing drug policy at the intersection of health, security, 
development and justice. Let me explain.
The right to health 
a.) Universal access to drug therapy. At the United 
Nations, we are working with the World Health Organ-
ization, and advocate universal access to drug treatment. 
We work with UNAIDS to prevent an HIV epidemic 
among injecting addicts. I appreciate the support that is 
coming from the community level for these initiatives. 
FOrEWOrD
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should not only stop the harm caused by drugs: we 
should unleash the capacity of drugs to do good. What 
do I mean? Recall that the Preamble of the Single Con-
vention (from 1961) recognizes that “… the medical use 
of narcotic drugs is indispensible for the relief of pain, ….
and adequate provision must be made to ensure their avail-
ability …” Although there is an over-supply of opium in 
the world, many people who suffer major illnesses have 
no access to palliative care. Why should a Nigerian con-
sumed by AIDS or a Mexican cancer patient, be denied 
medication offered to their Swedish or American coun-
terparts? Help us overcome cultural, professional, 
administrative and socio-economic factors that conspire 
to deny people the opium-based relief (morphine) they 
need. 
The right to development
While the pendulum of drug control is swinging back 
towards the right to health and human rights, we must 
not neglect development. 
As illustrated in various recent UNODC reports, includ-
ing this one, drug production and trafficking are both 
causes and consequences of poverty. Indeed, 22 of the 
34 countries least likely to achieve the Millennium 
Development Goals are in the midst – or emerging from 
– conflicts, located in regions that are magnets for drug 
cultivation and trafficking. More development means 
less crime and less conflict. That is why UNODC is 
working with governments, regional organizations and 
development banks to promote drug control policy as 
ways to foster development, and vice-versa – for example 
in the Balkans, Central and West Asia, Mesoamerica, 
West and East Africa. 
The right to security
Yet, the stakes are high and getting higher. Drug-traffick-
ing has become the main source of revenue for organized 
crime, as well as to terrorists and insurgents: in other 
words, drug-related illegality has become a threat to 
nations in so many theatres around the world. Recent 
developments in West Africa, the Sahel, and parts of 
Central America show the very real dangers of narco-
trafficking to security, even the sovereignty of states. 
So grave is the danger that the issue is now periodically 
on the agenda of the Security Council. Unless we deal 
effectively with the threat posed by organized crime, our 
societies will be held hostage – and drug control will be 
jeopardized, by renewed calls to dump the three UN 
drug conventions that critics say are the cause of crime 
and instability. This would undo the progress that has 
been made in drug control over the past decade, and 
unleash a public health disaster. 
Human rights
Above all, we must move human rights into the main-
stream of drug control. Around the world, millions of 
people (including children) caught taking drugs are sent 
to jail, not to treatment. In some countries, what is sup-
posed to be drug treatment amounts to cruel, inhuman 
or degrading punishment – the equivalent of torture. In 
several Member States, people are executed for drug-re-
lated offences. In others, drug traffickers are gunned 
down by extra-judicial hit squads. As human beings, we 
have a shared responsibility to ensure that this comes to 
an end. Just because people take drugs, or are behind 
bars, this doesn’t abolish their right to be a person pro-
tected by the law – domestic and international. 
The global perspective offered by 
the World Drug Report 2010 
In conclusion, this World Drug Report shows the various 
components of the drug market, and explains the 
dynamics that drive them. It confirms that drug policy 
must stay the course we have promoted at UNODC 
over the past years, focussed on the four basic rights of 
health, development, security and human rights.
 
Antonio Maria Costa 
Executive Director 
United Nations Office on Drugs and Crime
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Drug control has been on the global agenda for more 
than a century. As documented in the World Drug Report 
2008, the Chinese opium epidemic in the early twenti-
eth century spurred concerted international action, 
chiefly in the form of a series of treaties passed over 
several decades. These treaties, in particular the 1961 
Single Convention on Narcotic Drugs, the 1971 Con-
vention on Psychotropic Substances, and the 1988 Con-
vention against the Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances, continue to define the interna-
tional drug control system. The United Nations Office 
on Drugs and Crime (UNODC) is the guardian of these 
treaties and the United Nations lead agency on drug 
control.
In March 2009, Member States committed to elimina-
tion or significant reduction in the global illicit drug 
supply and demand by 2019 and emphasized that 
research, data collection and analysis were essential to 
support and monitor the efforts required to reach that 
objective. UNODC has provided comprehensive assess-
ments of the global drug problems and their evolution 
annually since 1999, and will continue to fulfil its man-
date this year with the publication of the World Drug 
Report 2010.
In order to prepare the World Drug Report, UNODC 
relies on Member States to provide data, primarily 
through the Annual Reports Questionnaire (ARQ). The 
ARQ was distributed to 192 Member States, and 
UNODC received 110 replies to the drug abuse section 
and 114 replies to the illicit supply of drugs section from 
Member States (and territories). In general, most coun-
tries’ ability to provide information on illicit drug supply 
is significantly better than their ability to provide 
demand-related data. Despite commendable progress, 
for example in the area of prevalence estimates, far more 
remains to be done to provide a solid, reliable basis for 
trend and policy analysis.  
The report includes in-depth and cross-sectoral analyses 
of transnational drug markets (chapter 1) as well as the 
latest statistical data and trends regarding the world drug 
situation (chapter 2). This year, the report also discusses 
the impact of transnational drug trafficking on transit 
countries (chapter 3).
8Types of drugs:
ATS – Amphetamine-type stimulants (ATS) are a group 
of substances comprised of synthetic stimulants from 
the amphetamines-group of substances, including 
amphetamine, methamphetamine, methcathinone and 
the ecstasy-group substances (MDMA and its ana-
logues). In cases where countries report to UNODC 
without indicating the specific ATS they are referring to, 
the term non-specified amphetamines is used. In cases 
where ecstasy is referred to in enclosed brackets (‘ecstasy’), 
the drug represents cases where the drug is sold as ecstasy 
(MDMA) but which may contain a substitute chemical 
and not MDMA.
Coca paste (or coca base) - An extract of the leaves of the 
coca bush. Purification of coca paste yields cocaine (base 
and hydrochloride). The term ‘cocaine (base and salts)’ 
is used to refer to all three products in the aggregate.
Crack (cocaine) - Cocaine base obtained from cocaine 
hydrochloride through conversion processes to make it 
suitable for smoking.
Heroin HCl (heroin hydrochloride) – Injectable form of 
heroin, sometimes referred to as ‘Heroin no. 4’.
Heroin no. 3 – A less refined form of heroin suitable for 
smoking.
Poppy straw - All parts (except the seeds) of the opium 
poppy, after mowing.
Terms: Since there is some scientific and legal ambiguity 
about the distinctions between drug 'use', 'misuse' and 
'abuse', this report uses the neutral terms, drug 'use' or 
'consumption'.
Annual prevalence refers to the total number of people of 
a given age range who have used a given drug a least 
once in the past year, divided by the number of people 
of a given age.
Maps: The boundaries and names shown and the desig-
nations used on maps do not imply official endorsement 
or acceptance by the United Nations. A dotted line rep-
resents approximately the line of control in Jammu and 
Kashmir agreed upon by India and Pakistan. The final 
status of Jammu and Kashmir has not yet been agreed 
upon by the parties. Disputed boundaries (China/India) 
are represented by cross hatch due to the difficulty of 
showing sufficient detail. 
Population data: The data on population used in this 
report comes from: United Nations, Department of Eco-
nomic and Social Affairs, Population Division, World 
Population Prospects: The 2008 Revision, 2009. 
Regions: In various sections, this report uses a number 
of regional designations. These are not official designa-
tions. They are defined as follows:
East Africa: Burundi, Comoros, Djibouti, Eritrea,  •
Ethiopia, Kenya, Madagascar, Mauritius, Rwanda, 
Seychelles, Somalia, Tanzania (United Republic of ) 
and Uganda.
North Africa: Algeria, Egypt, Libyan Arab Jamahiri- •
ya, Morocco, Sudan and Tunisia.
Southern Africa: Angola, Botswana, Lesotho, Ma- •
lawi, Mozambique, Namibia, South Africa, Swazi-
land, Zambia and Zimbabwe.
West and Central Africa: Benin, Burkina Faso, Cam- •
eroon, Cape Verde, Central African Republic, Chad, 
Congo (Democratic Republic of ), Congo (Republic 
of ), Côte d’Ivoire, Equatorial Guinea, Gabon, Gam-
bia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, 
Mauritania, Niger, Nigeria, Sao Tome and Principe, 
Senegal, Sierra Leone and Togo. 
Caribbean: Antigua and Barbuda, Bahamas, Barba- •
dos, Cuba, Dominica, Dominican Republic, Gre-
nada, Haiti, Jamaica, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines and Trini-
dad and Tobago.
Central America: Belize, Costa Rica, El Salvador,  •
Guatemala, Honduras, Nicaragua and Panama.
North America: Canada, Mexico and the United  •
States of America. 
EXPLANATOrY NOTES
9South America: Argentina, Bolivia (Plurinational  •
State of ), Brazil, Chile, Colombia, Ecuador, Guy-
ana, Paraguay, Peru, Suriname, Uruguay and Ven-
ezuela (Bolivarian Republic of ).
Central Asia and Transcaucasia: Armenia, Azerbai- •
jan, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, 
Turkmenistan and Uzbekistan.
East and South-East Asia: Brunei Darussalam, Cam- •
bodia, China (including Hong Kong, Macao, and 
Taiwan Province of China), Indonesia, Japan, Korea 
(Democratic People’s Republic of ), Korea (Republic 
of ), Lao People’s Democratic Republic, Malaysia, 
Mongolia, Myanmar, Philippines, Singapore, Thai-
land, Timor-Leste and Viet Nam. The Greater Me-
kong Subregion (GMS) comprises Cambodia, the 
Lao People’s Democratic Republic, Myanmar, Thai-
land, Viet Nam and Yunnan and Guangxi provinces 
in China.
Near and Middle East/South-West Asia: Afghani- •
stan, Bahrain, Iran (Islamic Republic of ), Iraq, Is-
rael, Jordan, Kuwait, Lebanon, Oman, Pakistan, 
Qatar, Saudi Arabia, Syrian Arab Republic, United 
Arab Emirates and Yemen. The Near and Middle 
East refers to a subregion which includes Bahrain, 
Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, 
Saudi Arabia, the Syrian Arab Republic, the United 
Arab Emirates and Yemen.
South Asia: Bangladesh, Bhutan, India, Maldives,  •
Nepal and Sri Lanka. 
East Europe: Belarus, Moldova (Republic of ), Rus- •
sian Federation and Ukraine.
South-East Europe: Albania, Bosnia and Herzegovi- •
na, Bulgaria, Croatia, the former Yugoslav Republic 
of Macedonia, Montenegro, Romania, Serbia and 
Turkey.
West and Central Europe: Andorra, Austria, Bel- •
gium, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Ice-
land, Ireland, Italy, Latvia, Liechtenstein, Lithuania, 
Luxembourg, Malta, Monaco, Netherlands, Nor-
way, Poland, Portugal, San Marino, Slovakia, Slov-
enia, Spain, Sweden, Switzerland and the United 
Kingdom. 
Oceania: Australia, Fiji, Kiribati, Marshall Islands,  •
Micronesia, Nauru, New Zealand, Palau, Papua 
New Guinea, Samoa, Solomon Islands, Tonga, Tu-
valu, Vanuatu and other small island territories.   
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EXPLANATOrY NOTES
AIDS Acquired Immune-Deficiency  
Syndrome
ARQ UNODC annual reports questionnaire
ATS amphetamine-type stimulants
CICAD Inter-American Drug Abuse Control 
Commission
CIS Commonwealth of Independent States
COP Colombian peso
DAINAP Drug Abuse Information Network for 
Asia and the Pacific
DEA United States, Drug Enforcement 
Administration
DELTA UNODC Database on Estimates and 
Long Term Trend Analysis
DIRAN Colombian National Police  
– Antinarcotics Directorate
DUMA Drug Use Monitoring in Australia
EMCDDA European Monitoring Centre for 
Drugs and Drug Addiction
ESPAD European School Survey Project  
on Alcohol and other Drugs
EUROPOL European Police Office
F.O. UNODC Field Office
GAP UNODC Global Assessment  
Programme on Drug Abuse
Govt. Government
HIV Human Immunodeficiency Virus
HONLEA Heads of National Drug Law  
Enforcement Agencies
IDS UNODC individual drug seizures 
database
IDU injecting drug use
INCB International Narcotics Control Board
INCSR International Narcotics Control Strat-
egy Report (United States Department 
of State)
INTERPOL/
ICPO
International Criminal Police  
Organization
LSD lysergic acid diethylamide
MDA 3,4-methylenedioxyamphetamine 
(tenamfetamine)
MDE 3,4-methylenedioxyethylamphetamine
MDMA 3,4-methylenedioxymethamphetamine
NGO Non-governmental organization
NIDA National Institute of Drug Abuse 
(USA)
OECD Organization for Economic  
Co-operation and Development 
ONDCP Office of National Drug Control  
Policy (USA)
P-2-P 1-phenyl-2-propanone (BMK)
SACENDU South African Community  
Epidemiology Network on Drug Use
SAMHSA Substance Abuse and Mental Health 
Services Administration (USA)
SRO safrole-rich oils
THC tetrahydrocannabinol
UNAIDS Joint United Nations Programme on 
HIV/AIDS
UNODC United Nations Office on Drugs and 
Crime
WCO World Customs Organization
WDR
WHO 
World Drug Report
World Health Organization
3,4-MDP-2-P 3,4-methylenedioxyphenyl-2-pro-
panone (PMK)
 Weights and measurements:
l litre
g gram
mg milligram
kg kilogram
mt metric ton
The following abbreviations have been used in this Report:
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In 1998, a special session of the UN General Assembly 
decided to work towards the “elimination or significant 
reduction” of illicit drug production and abuse by 2008, 
and adopted a series of sectoral plans to reach that objec-
tive.1 Gathered at the end of the 10-year period, Member 
States were not satisfied with the results and declared 
that they were still “gravely concerned about the grow-
ing threat posed by the world drug problem.”2 The deci-
sion was taken to continue the effort over the following 
decade.
Can overall drug supply and demand be “eliminated or 
significantly reduced” by 2019, as called for by the 
Member States? At the national level, one can hope that 
many countries will be able to significantly improve 
their drug control situation within a decade. Will these 
local successes translate into an overall improvement at 
the global level? 
A clear lesson from the history of drug control is that the 
mere sum of uncoordinated national and sectoral efforts, 
even successful ones, cannot result in a global success. 
Another lesson is that countries with limited means 
cannot resist, and counter the impact of, powerful trans-
national trafficking flows on their own. 
To achieve the 2019 objectives, the international com-
munity needs to interweave drug supply and demand 
reduction interventions and integrate national efforts in 
the framework of renewed international strategies on the 
scale of the drug markets. To do so, it is urgent to 
improve our understanding of how illicit transnational 
drug economies operate. This World Drug Report is a 
contribution toward this objective.
This year’s World Drug Report opens with an analytical 
discussion of three key transnational drug markets: the 
markets for heroin, cocaine and amphetamine-type 
stimulants (ATS). Cannabis is not covered here because 
it is increasingly produced within the country of con-
sumption and often dealt informally through social 
1 United Nations General Assembly Special Session on the World Drug 
Problem (UNGASS), New York, 8-10 June, 1998 (A/S-20/4, chapter 
V, section A).
2 High-level Segment to the 2009 United Nations Commission on 
Narcotic Drugs, Political Declaration and Plan of Action on Inter-
national Cooperation towards an Integrated and Balanced Strategy 
to Counter the World Drug Problem, March 2009 (E/2009/28 - E/
CN.7/2009/12).
channels. Though cannabis is the world’s most popular 
illicit drug, it is less subject to a transnational market 
analysis than the other three drug classes.
The market discussion is followed by a presentation of 
statistical trends for all four major drug classes, includ-
ing cannabis. The latest information on drug produc-
tion, seizures and consumption is presented and the 
limitations of this knowledge are clearly articulated. 
While also drawing on other sources where relevant, the 
statistics presented were mainly gathered through the 
Annual Reports Questionnaire and the illicit crop sur-
veys that UNODC produces in cooperation with 
Member States.
Finally, there is a chapter on a topic of growing concern 
for the international community: the relationship 
between drug trafficking and instability. This chapter 
focuses on the impact that the drug trade has on levels 
of violence and corruption in transit countries, particu-
larly in Latin America, the Caribbean and West Africa. 
This executive summary does not parallel the report, 
however. For the purpose of clarity, a global overview of 
changes in the world drug markets is presented first. 
This is followed by an integrated discussion of the world 
drug markets, including both the market analysis and 
the trend data. In closing, the discussion on the impact 
of drug trafficking on transit countries is summarized.
Global developments in illicit drug  
production, trafficking and consumption
Production 
There have been a number of encouraging develop-
ments in global cocaine and heroin markets recently: 
The global area under opium poppy cultivation de- ?
clined to 181,400 hectares (ha) in 2009 (15%) or by 
23% since 2007. 
In line with declines in the area under cultivation,  ?
global opium production fell from 8,890 metric tons 
(mt) in 2007 to 7,754 mt in 2009 (-13%), and poten-
tial heroin production declined from 757 mt in 2007 
to 657 mt in 2009. 
The global area under coca cultivation declined to  ?
158,800 ha in 2009 (5%), by 13% since 2007 or by 
28% since 2000. 
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The estimated global cocaine production fell from  ?
1,024 mt in 2007 to 865 mt in 2008 (-16%). Global 
fresh coca leaf production fell by 4% in 2009 (by 
14% between 2007 and 2009).
The recent successes, however, must be considered in the 
context of the long-term challenge. Since 1998, the year 
of the last UN General Assembly Special Session 
(UNGASS) devoted to the drug problem, global poten-
tial opium production has increased by 78%, from 4,346 
mt to 7,754 mt in 2009. Fortunately, these production 
increases do not correspond to consumption increases, 
as it appears that large amounts of opium have been 
stockpiled in recent years. This means, however, that 
even if production were completely eliminated today, 
existing stocks could supply users for at least two years.
The increase in global potential cocaine production over 
the 1998-2008 period seems to have been more moder-
ate (5%), from 825 mt to 865 mt, although there remain 
uncertainties around coca yields and production effi-
ciency. Nonetheless, available data are sufficiently robust 
to state that global cocaine production has declined 
significantly in recent years (2004-2009). 
In contrast to heroin and cocaine, only very broad pro-
duction estimates can be given for cannabis and amphet-
amine-type stimulants (ATS). Due to the decentralization 
of production, it is difficult to track global trends in 
either of these markets. Between 13,000 and 66,100 mt 
of herbal cannabis were produced in 2008, as were 
2,200 to 9,900 mt of cannabis resin. Manufacture of the 
amphetamines-group of ATS (amphetamine, metham-
phetamine, methcathinone and related substances) was 
in the range of 161 to 588 mt in 2008. Manufacture of 
drugs marketed as ‘ecstasy’ ranged from 55 to 133 mt. 
Trafficking 
Most of the long-distance trafficking involves cocaine 
and heroin, although some cannabis resin and ecstasy 
are also smuggled between regions. Much of the canna-
bis herb, methamphetamine and amphetamine con-
sumed in the world is produced locally. 
Global cocaine seizures have stabilized over the last few 
years. Seizures have declined in North America and 
Europe, but have risen in South and Central America. 
Trafficking through West Africa, which increased rap-
idly between 2004 and 2007, appears to have declined 
in 2008 and 2009, but this situation may change and 
needs to be monitored carefully.
Opiate seizures continue to increase. This applies to 
both opium and heroin seizures. Morphine3 seizures, in 
contrast, declined in 2008. The largest seizures continue 
3 Morphine represents an intermediate step in the processing of opium 
to heroin, and is rarely consumed as a drug in its own right.
to be reported from the countries neighbouring Afghani-
stan, notably the Islamic Republic of Iran and Paki-
stan. 
Tracking global ATS seizures is more complicated, 
because there are several products involved that appeal 
to different markets, including amphetamine, metham-
phetamine and ‘ecstasy’. After tripling in the early years 
of this decade, ATS seizures have remained stable since 
2006. Ecstasy seizures showed a marked decline in 2008 
compared to a year earlier. Global seizures of ampheta-
mine and methamphetamine remained largely stable at 
very high levels in 2008. 
Global cannabis herb seizures increased over the 2006-
2008 period (+23%), especially in South America, 
reaching levels last reported in 2004. Global cannabis 
resin seizures increased markedly over the 2006-2008 
period (+62%) and clearly exceeded the previous peak of 
2004. Large increases in cannabis resin seizures in 2008 
were reported from the Near and Middle East region, as 
well as from Europe and Africa. 
Consumption
Globally, UNODC estimates that between 155 and 250 
million people (3.5 to 5.7% of the population aged 
15-64) used illicit substances at least once in 2008. Glo-
bally, cannabis users comprise the largest number of 
illicit drug users (129 - 190 million people). Ampheta-
mine-group substances rank as the second most com-
monly used drug, followed by cocaine and opiates. 
At the core of drug consumption lie the ‘problem drug 
users’: those who inject drugs and/or are considered 
dependent, facing serious social and health consequences 
as a result. Based on the global estimates of the number 
of cannabis, opiate, cocaine and ATS users, it is esti-
mated that there were between 16 and 38 million prob-
lem drug users in the world in 2008. This represents 
10% to 15% of all people who used drugs that year. It 
can be estimated that in 2008, globally, between 12% 
and 30% of problem drug users had received treatment 
in the past year, which means that between 11 and 33.5 
million problem drug users did not receive treatment 
that year.
The lack of data in many countries still limits the under-
standing of the drug use problem in many countries, 
particularly in Africa, some parts of Asia and the Pacific 
Islands. The broad range of the estimates reflects the 
uncertainties in the available global data. 
Data on the delivery of treatment services for problem 
drug users can provide valuable information on varia-
tions in drug use problems across regions. The share of 
treatment services delivered to users of different drugs 
varies markedly in different regions of the world. In 
Europe and Asia, most of the treatment demand is for 
13
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opiates. In the Americas, it is cocaine, and in Africa and 
Oceania, it is cannabis. These ratios have changed over 
time. As compared to a decade ago, treatments related 
to cannabis have increased in Europe, South America 
and Oceania, suggesting that an increased proportion of 
cannabis use can become problematic. Over the same 
period of time, cocaine treatment demand has been 
declining in the Americas, especially in North America, 
while it has increased in Europe. The relative impor-
tance of opiates for drug treatment, on the other hand, 
has declined in Europe, Asia and (in particular) Ocea-
nia, while it rose in Africa. ATS are commanding a 
growing share of treatment services globally. 
Estimates of the sizes of the user populations in various 
parts of the world are derived from household and school 
surveys and indirect methods. Unfortunately, popula-
tion-based surveys are conducted very irregularly in 
most countries, so there remain significant gaps in the 
knowledge of the extent of drug use in some parts of the 
world.
Cannabis remains the most widely consumed drug 
worldwide. Global annual cannabis use prevalence is 
estimated between 2.9% and 4.3% of the population 
aged 15-64. The highest is in Oceania (9.3% to 14.8%), 
followed by the Americas (6.3% to 6.6%). There are an 
estimated 15 – 19.3 million annual cocaine users (annual 
prevalence of 0.3% to 0.4%) in the world. North Amer-
ica (2%), Oceania (1.4% to 1.7%) and West Europe 
(1.5%) are the regions with the highest prevalence rates. 
Between 12.8 and 21.8 million people (0.3% to 0.5% 
of the world population aged 15-64) used opiates in 
2008. More than half of the world’s opiate users are in 
Asia. UNODC estimates that between 13.7 and 52.9 
million people aged 15 to 64 had used an amphetamine-
type substance in the past year (0.3% to 1.2% of the 
population), including 10.5 to 25.8 million ecstasy users 
(0.2% to 0.6% of the population). Oceania, East and 
South-East Asia, North America, and West and Central 
Europe are the regions with the highest prevalence rates 
of ATS use.
In addition to the drugs mentioned above, the misuse of 
prescription drugs, such as synthetic opioids, benzodiaz-
epines or synthetic prescription stimulants, is a growing 
health problem in a number of developed and develop-
ing countries. 
Illicit drug use at the global level, 2008
Number of people who inject drugs
aged 15-64 years : 11-21 million persons
Number of "problem drug users" 
aged 15-64 years : 16-38 million persons
Number of people who have used drugs
at least once in the past year aged 
15-64 years : 155-250 million persons
Total number of people aged 15-64 years
in 2008: 4,396 million persons
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The main drug markets 
The global illicit opiate and cocaine markets represent 
two of the biggest transnational drugs and crime threats 
of our time. They appear at the same time as persistent 
problems from a previous era of drug control, priorities 
for interventions due to the severity of their impacts on 
affected societies and good candidates for a global solu-
tion within a reasonable time frame. Since they are both 
sourced from relatively concentrated production areas, 
most of their components are directly or indirectly 
linked to one another. 
In addition, ATS have gained a large share of the global 
drug market over the last two decades and have come to 
represent a major and evolving threat for present and 
future drug control efforts. Since 1990, there has been a 
spread in ATS manufacture with more than a third of 
Member States having reported ATS-related manufac-
ture activity to date. Moreover, the global number of 
ATS users is likely to exceed the number of opiate and 
cocaine users combined. 
Cocaine 
The global area under coca cultivation decreased by 5% 
last year, from 167,600 ha in 2008 to 158,800 ha in 
2009. This change is mainly due to a significant decrease 
in Colombia, not offset by increases in Peru and the 
Plurinational State of Bolivia. The global area under 
coca cultivation declined by 28% over the 2000-2009 
period. In 2009, Colombia represented about 43% of 
global cultivation, with Peru contributing 38% and the 
Plurinational State of Bolivia 19%.
The areas where cocaine is produced, trafficked and 
consumed have varied substantially over time. 
While Colombian traﬃckers have produced most of  ?
the world’s cocaine in recent years, between 2000 and 
2009, the area under coca cultivation in Colombia 
decreased by 58%, mainly due to eradication. At the 
same time, coca cultivation increased by 38% in Peru 
and more than doubled in the Plurinational State of 
Bolivia (up 112%), while traﬃckers in both countries 
increased their own capacity to produce cocaine.
Demand for cocaine in the United States has been in  ?
long-term decline: in 1982, an estimated 10.5 million 
people had used cocaine in the previous year; in 2008, 
the ﬁgure was 5.3 million, about half as many. In the 
last decade, however, the number of cocaine users in 
Europe doubled, from 2 million in 1998, to 4.1 mil-
lion in the EU-EFTA countries in 2008. By 2008, the 
European market (US$34 billion) was almost as valu-
able as the North American market (US$37 billion). 
The value of the global cocaine market is estimated at 
around US$88 billion (estimates range from US$80 
to US$100 billion).
These shifts, combined with interdiction eﬀorts, have  ?
also aﬀected traﬃcking patterns. As the Colombian 
Government has taken greater control of its territory, 
traﬃckers are making more use of transit countries in 
the region, including the Bolivarian Republic of Vene-
zuela and Ecuador. Mexican drug cartels emerged over 
the last 10 to 15 years as the primary organizers for 
shipments of cocaine into the United States, largely 
replacing the previously dominant Colombian groups. 
In response to Mexican enforcement eﬀorts, Central 
American countries are increasingly being used as 
transit countries. West Africa started to be used as a 
way station to Europe around 2004. The situation 
remains ﬂuid, and the impact on transit countries can 
be devastating.
In 2008, the potential production of pure cocaine 
amounted to some 865 mt. This is considerably less 
than four years previously, when almost 1,050 mt were 
generated. Most of these drugs are destined for consum-
ers in North America (6.2 million users in 2008) and 
Europe (4 to 5 million users). These two regions, with 
70% of the demand and 85% of the total value, play the 
main role in shaping the evolution of the global cocaine 
market. Another 2.7 million users are found in South 
America, Central America and the Caribbean.
The largest cocaine market: North America
North America is the largest regional cocaine market, 
with close to 40% of the global cocaine-using popula-
tion. In 2008, it appears that 196 mt of pure cocaine 
were required to satisfy North American demand. To get 
this amount to the consumer (accounting for seizures, 
Global coca bush cultivation (ha), 1990-2009
Source: UNODC
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As a whole, the retail value of the United States cocaine 
market declined by about two thirds in the 1990s, and 
by about another quarter in the last decade. About 70% 
of the profits made off the cocaine trade in the United 
States accrue between mid-level dealers and the con-
sumer. Farmers and traffickers in Colombia keep less 
than 3% of the retail sales value of the cocaine they 
produce. 
The second largest cocaine market: Europe
The world’s second largest flow of cocaine is directed 
towards Europe, and this flow has been growing rapidly. 
The largest national cocaine market within Europe is the 
United Kingdom, followed by Spain, Italy, Germany 
and France. Cocaine use prevalence levels are higher in 
the United Kingdom and Spain than in the United 
States.
Recent data suggest that the rapid growth of the Euro-
pean cocaine market is beginning to level off in some of 
the biggest national markets such as Italy, Spain and 
Germany. Consumption is still growing in the United 
Kingdom and in some of the smaller European markets, 
however. In 2008, an estimated 124 mt of cocaine were 
consumed in Europe. To supply this demand, an esti-
mated 212 mt departed South America toward Europe, 
about one quarter of total production. A greater share of 
this quantity comes from Peru and the Plurinational 
State of Bolivia than in the case of the United States.
Average of all cocaine purchase prices in the United States, January 2006-September 2009
Source: US Drug Enforcement Agency
Distribution of gross proﬁts (in %) of the US$35 
billion US cocaine market, 2008
Source: UNODC
National share of the cocaine user population  
in Europe in 2007/2008
Sources: UNODC ARQ; Government reports; UNODC, 2009 
World Drug Report; EMCDDA, Statistical Bulletin 2009
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1 Qtr 2 Qtr 3 Qtr 4 Qtr 1 Qtr 2 Qtr 3 Qtr 4 Qtr 1 Qtr 2 Qtr 3 Qtr 4 Qtr 1 Qtr 2 Qtr 3 Qtr
2006 2007 2008 2009
Farmers in the Andean 
countries,1.5% 
(US$0.5 bn)
Traffickers in the 
Andean countries,1% 
(US$0.4 bn)
International traffickers, 
Colombia to the 
US,13%
(US$4.6 bn)
US-wholesalers to US-
mid-level dealers,15%
(US$5.3 bn)
US-mid-level dealers to 
US-consumers, 70%
(US$24.2 bn)
EFTA countries,  2%
Other European 
countries,  8%
UK,  23%
Spain, 21%
Italy, 19%
Germany, 9%
France, 5%
Other EU countries, 
13%
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The primary countries of entry to the European market 
are Spain and the Netherlands. Most of the trafficking is 
maritime. Significant transit routes flow from former 
colonies or overseas territories of the European nations 
to their counterparts on the continent. Flows through 
West Africa appear to have declined since 2007, but 
could resume in the near future.
While the volumes are lower, the value of the European 
cocaine market (US$34 billion) is almost as high as in 
the case of the North American market (US$37 billion), 
because purity-adjusted cocaine retail prices are higher 
in Europe. European street prices in 2008 are about half 
what they were in 1990, but purity has declined and the 
dollar has weakened against the euro. In dollar terms, 
the purity-adjusted price of cocaine in Europe has 
increased since 2002.
As in the North American market, only a fraction of the 
retail value goes to those who produce the drug. The 
intercontinental traffickers receive a larger share than in 
the North American case, but more than half of the 
retail value still accrues to wholesalers and retailers 
within Europe.
Heroin
Heroin is the most widely consumed illicit opiate in the 
world. It is derived from opium, which itself can have an 
illicit use. Of the opium that is not converted into 
heroin, two thirds is consumed in just five countries: the 
Annual prevalence of cocaine use among the adult population in selected European countries
Sources: UNODC ARQ and EMCDDA, Statistical Bulletin 2009
Annual prevalence of cocaine use in the EU and EFTA countries, 1998-2008
Sources: UNODC ARQ; Government reports; UNODC, 2009 World Drug Report; EMCDDA, Statistical Bulletin 2009
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Islamic Republic of Iran (42%), Afghanistan (7%), Paki-
stan (7%), India (6%) and the Russian Federation (5%). 
Other opiates are also abused, including various poppy 
straw concoctions and prescription opiods, but heroin 
remains the most problematic opiate internationally.
With the exception of 2001, when there was hardly any 
opium poppy cultivation in Afghanistan, global opium 
production expanded remarkably in the first decade of 
the twenty-first century until 2007, apparently with no 
commensurate expansion in demand. Opium produc-
tion subsequently declined over the 2007-2009 period 
(from 8,890 to 7,754 mt), though remaining signifi-
cantly above estimated global demand (some 5,000 mt 
for consumption and seizures). The declining farm-gate 
price of opium in Afghanistan in recent years has been 
more pronounced than the decline in heroin prices. This 
may reflect a number of factors, including rising prices 
for heroin precursors (particularly acetic anhydride) in 
that country and a build-up of stocks of opium not 
processed into heroin.
Although Afghanistan is the source of most of the world’s 
illicit opiates (6,900 mt of opium or 89% of the world 
total in 2009), significant quantities are also produced 
in Myanmar (330 mt) and Latin America (notably in 
Mexico and Colombia). Since 2003, Mexico has been 
the world’s third largest source of opium, and the quan-
tities produced in 2008 (325 mt) came close to the 
quantities produced in Myanmar in 2009. 
There are indications that the downward trend in global 
opium production over the 2007-2009 period will con-
tinue in 2010. Early indications for 2010 (as revealed in 
UNODC’s Afghanistan Opium Winter Rapid Assessment) 
suggested that the area under opium cultivation in 
Afghanistan could remain basically stable, but yields will 
likely decline due to a blight. 
Both opium and heroin seizures continued to increase in 
2008. Morphine seizures, however, continued the declin-
ing trend started in 2007. Although heroin seizures have 
followed a generally increasing trend since 2002, they 
have been outpaced by the growth in global opium sei-
zures, possibly reflecting difficulties faced by Afghan 
laboratory operators to obtain sufficient precursor 
chemicals to transform the large quantities of harvested 
opium into heroin. Most of the opium seizures continue 
to be made in the Islamic Republic of Iran, neighbour-
ing Afghanistan. The global rise in opium seizures thus 
largely reflected the growing opium seizures made by the 
authorities in the Islamic Republic of Iran. 
The world’s two largest markets for Afghan opiates are 
the Russian Federation and West Europe, which together 
consume almost half the heroin produced in the world. 
About 340 mt of heroin is estimated to have been con-
sumed globally in 2008. To meet this demand, account-
ing for seizures, some 430 mt would have had to be 
produced. UNODC estimates suggest that about 380 
mt were produced out of Afghan opium that year, sup-
plying the bulk of global demand. 
The largest heroin market: West Europe
The world’s largest heroin market is West Europe, and 
about half of this market is contained in just three coun-
tries: the United Kingdom, Italy and France. Heroin use 
appears to be decreasing in most West European coun-
tries, although the harms associated with heroin use seem 
to be increasing, as reflected in heroin-induced deaths.
Global potential opium production (mt),  
1995-2009
Note: The 2009 estimate for ‘rest of the world’ is provisional as limited 
information was available for some countries and regions.
Source: UNODC
Global opiate seizures in heroin equivalents, 
1990-2008
Source: UNODC ARQ/DELTA
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Republic of Macedonia (26 kg), Hungary (28 kg), Alba-
nia (75 kg), Austria (104 kg), Slovenia (136 kg), Croatia 
(153 kg) and Serbia (207 kg).
Wholesale prices of heroin (not adjusted for purity) 
increase along the trafficking route from South-West 
Asia to Europe. In 2008, wholesale prices ranged from 
less than US$3,000 per kg in Afghanistan to US$10,300-
US$11,800 per kg in Turkey and an average of 
US$44,300 per kg in West and Central Europe.
The second largest heroin market: the Russian  
Federation
Some 25% of all Afghan heroin (95 mt) is trafficked 
each year from Afghanistan into Central Asia to meet a 
demand of some 70 mt in the Russian Federation, along 
the ‘Northern Route’. The number of opiate users in the 
Russian Federation is estimated at between 1.6 and 1.8 
million people, equivalent to a prevalence rate of 1.6% 
of the population aged 15-64. There is a very high 
prevalence of HIV among drug users (some 37%). 
To exit Afghanistan on the way to the Russian Federa-
tion traffickers can choose between three countries: 
Tajikistan, Uzbekistan and Turkmenistan. Most of the 
flow appears to proceed through Tajikistan to Osh in 
Kyrgyzstan, before transiting Kazakhstan to the Russian 
Federation. Trafficking is conducted mostly in private 
and commercial vehicles, often in relatively small 
amounts. Of 45 heroin seizures above 500 grams (a 
commercial quantity) made in Tajikistan between 2005 
and 2007, 80% amounted to 10 kg or less, and of these, 
the average size was 2.6 kg. This is a rather small amount 
per seizure when compared to other regions, suggesting 
that small-scale trafficking operations are the rule rather 
than the exception. 
While total seizures remained essentially stable in 
Tajikistan in 2008 (1.6 mt), seizures in Uzbekistan and 
Kazakhstan reached the highest levels on record, at 1.5 
mt and 1.6 mt, respectively. In the Russian Federation, 
seizures have followed an upward trend, from 2.5 mt in 
2006, to 2.9 mt in 2007 and to 3.4 mt in 2008. 
Trafficking through Pakistan
Some 150 mt (40%) of Afghan heroin/morphine are 
trafficked to Pakistan, particularly to Balochistan prov-
ince and the Federally Administered Tribal Areas, which 
both share long borders with Afghanistan. While some 
of the drugs are consumed or seized in Pakistan, most 
are trafficked to other countries. Major destinations for 
heroin trafficked through Pakistan include the Islamic 
Republic of Iran (35 mt, most for onward shipment to 
Europe), various countries in Asia (25 mt), Africa (some 
20 mt) and the United Arab Emirates (11 mt for onward 
shipment to China and East/Southern Africa). Pakistani 
traffickers also operate numerous air (and sea) traffick-
ing routes to Europe, mostly to the United Kingdom 
and the Netherlands, shipping an estimated 5 mt annu-
ally via these direct connections.
Amphetamine-type stimulants
Amphetamine-type stimulants (ATS) refer to a group of 
synthetic substances comprised of amphetamine-group 
(primarily amphetamine, methamphetamine and meth-
cathinone) and ecstasy-group substances (MDMA and 
its analogues). ATS can be made anywhere the precur-
sors can be found, so manufacturing tends to happen 
close to the main consumer markets. More than one 
third of the countries reporting to UNODC have 
detected ATS manufacture in their territories.
The number of ATS-related clandestine laboratories 
reported increased by 20% in 2008, and, for the first 
Distribution of the heroin market on the Northern route, 2000-2008
Source: UNODC
Opiate consumption, seizures and trafficking (mt)
Heroin trafficking from Russia to 
Europe per year, 4 tons
Annual heroin consumption in 
Central Asia, 11 tons
Average annual heroin seizure 
in the Russian Federation,
3 tons
Average annual heroin seizure 
in Central Asia, 5 tons
Heroin trafficking from Central 
Asia to Caucasus & China per 
year, 3 tons
Annual heroin consumption in 
the Russian Federation, 
70 tons
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time, revealed the existence of laboratories in Argentina, 
Brazil, Guatemala, the Islamic Republic of Iran and Sri 
Lanka. Information on the 8,432 detected laboratories 
came from 31 countries, with the largest numbers 
reported from the United States, the Czech Republic, 
Australia, China,4 Slovakia, New Zealand, the Nether-
lands, Canada and Mexico. However, the number of 
laboratories is not representative of their output, as 
many countries with lower total counts report only 
laboratories with large-scale outputs.
Traditionally, different regions have had problems with 
different ATS. ‘Ecstasy’ has been associated with the 
dance club scene, initially located primarily in the 
Anglophone countries, but later expanding throughout 
Europe, the Americas, the Oceania region and many 
parts of East and South-East Asia. Methamphetamine 
has been problematic in East Asia and South-East Asia 
over the last decade, as well as in North America and 
Oceania. Amphetamine was found primarily in Europe, 
though in recent years, the Middle East has emerged as 
a major new market, with demand for pills called Capta-
gon. This was a brand-name for a discontinued product 
that contained fenethylline, but these pills today mostly 
consist of amphetamine and caffeine. Pharmaceutical 
stimulants are widely misused in South America and in 
Africa.
Trends and associations with these substances are also 
changing: 
North America struggled with a rash of methampheta- ?
mine use, gradually moving from the west towards the 
east coast. Successes in precursor control, however, 
4 In 2008, China reported 244 unspecified clandestine laboratories. 
However, this figure is also known to included some opium dens and 
was therefore not included in the ATS totals.
seem to have reduced this threat, though seizures in-
creased in 2009. 
‘Ecstasy’ is becoming important in many parts of the  ?
developing world, including Asia, while it seems to 
be levelling oﬀ or declining in Europe. The situation 
remains dynamic with illicit ecstasy manufacturing 
emerging in new locations around the world, while 
European and other markets are increasingly discover-
ing synthetic substitution psychotropic substances in 
tablets sold as ecstasy. Piperazines, ketamine and other 
substitutes, either marketed as ‘ecstasy’ or under their 
own name, have grown in popularity as club drugs. 
With these changes in demand, the location of manu-
facturing operations has changed. In the past, most 
of the pills sold as ‘ecstasy’ were manufactured in Eu-
rope, but this does not seem to be the case any longer. 
Manufacture of ‘ecstasy’ has increased in North Amer-
ica (notably in Canada) and in several parts of Asia. 
In line with the increases in manufacture in Canada, 
there are now also early signs that the strong down-
ward trend in ecstasy use in North America after the 
year 2000 could be reversed.
ATS are seized in a wider range of countries and greater 
volumes than ever before. A key component of the 
volume increase is the growth in the seizures of pills 
branded as Captagon. In the more mature markets, how-
ever, ATS use appears to have stabilized or declined, and 
seizures of tablets containing ecstasy-group substances in 
Europe have plummeted since 2006.
These broad trends mask a number of important regional 
developments. Manufacture of methamphetamine for 
the United States market, for example, underwent a dra-
matic transformation in response to domestic precursor 
controls implemented in 2005. Manufacturing was dis-
placed over the border to Mexico. This displacement was 
ATS laboratories (all sizes) reported to UNODC, by type, 1999-2008
Source: UNODC ARQ
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the two, with total seizures reaching 6,587 mt, whereas 
the resin seizure total was 1,637 mt in 2008. Cannabis 
herb seizures appear to be growing most strongly in 
South America; in particular in the Plurinational State 
of Bolivia. For resin, the growth is strongest in South-
West Asia. The year 2008 saw what may be the single 
largest drug seizure in history: 236.8 mt of cannabis 
resin seized by the Afghan authorities in Kandahar prov-
ince in June.
Prices of cannabis herb vary noticeably across different 
countries and regions, even when adjusted for purchas-
ing power parity. Some regions revealed intra-regional 
consistency, although comparisons across countries 
should be considered with caution since prices may 
relate to different product types. Very high retail prices 
were reported by Japan, Singapore and two territories in 
Eastern Asia (Hong Kong and Macao, China). The high 
price in Japan may be due to the fact that cannabis herb 
is mainly imported, which is contrary to the prevalent 
pattern in most other countries. Cannabis herb prices in 
Europe were also relatively high. The lower end of the 
scale was occupied mainly by countries in Africa, South 
America and East, South-East and South Asia.
Cannabis remains the most widely used illicit substance 
in the world. Globally, the number of people who had 
used cannabis at least once in 2008 is estimated between 
129 and 191 million, or 2.9% to 4.3% of the world 
population aged 15 to 64. Cannabis use appears to be in 
long-term decline in some of its highest value markets, 
including North America and parts of West Europe. 
Increasing use has been reported in South America, 
although annual prevalence rates remain far lower than 
in North America. Although there is a lack of scientifi-
cally valid data on cannabis use for both Africa and Asia, 
national experts in both continents perceive an increas-
ing trend.
Drug trafficking and instability  
in transit countries
There are two ways that drug trafficking can pose a threat 
to political stability. The first involves countries where 
insurgents and illegal armed groups draw funds from 
taxing, or even managing, drug production and traffick-
ing. The second concerns countries that do not face such 
a situation, but where the drug traffickers become power-
ful enough to take on the state through violent confron-
tation or high-level corruption. This chapter focuses on 
the second category, and discusses the impact of cocaine 
trafficking on transit countries.
Between 2006 and 2008, over half the maritime ship-
ments of cocaine to Europe detected came from the 
Bolivarian Republic of Venezuela. Ecuador has also been 
affected by an increase in transit trafficking, and both 
countries are experiencing increasing problems with 
violence. 
The decline of the US cocaine market and the rise of the 
European one have also contributed to violence in the 
Caribbean. In some cases, this is due to new cocaine 
flows, in others, to the loss of cocaine trafficking as a 
revenue source for local criminals. It appears that any 
dramatic changes in trafficking can have a destabilizing 
effect, resulting in violence.
The region worst affected at present is the Northern 
Triangle of Central America: Guatemala, Honduras and 
El Salvador. Here, intense drug-related violence has 
posed a serious challenge to governance. While all these 
countries have had problems with violence in the past, 
Global cannabis herb seizures (mt), 1999-2008
Source: UNODC ARQ
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the murder rate is highest not in the largest urban areas 
but in those parts of the country particularly affected by 
the drug trade, including some ports and border areas.
Much has been made of drug-related violence in Mexico, 
but murder rates are considerably lower and the Govern-
ment is far stronger in Mexico. The crackdown on the 
Mexican cartels has inflamed violence, as it did in 
Colombia, but this phase may be necessary to dismantle 
organized crime groups that have begun to challenge the 
state. It appears to have disrupted the cocaine supply to 
the United States, but more importantly, it has uprooted 
widespread corruption and reasserted Government con-
trol over the entire territory of the country. Since much 
of the drug violence in Central America is tied to these 
same cartels, progress in Mexico should also aid the 
countries to the south.
On the other side of the Atlantic, large-scale cocaine 
trafficking has been a problem in West Africa since 
around 2004. While data on violence are sparse in West 
Africa, it is unlikely that the flow of drug money will 
precipitate the kind of feuds that have been recently seen 
in Latin America, because the traffickers have been able 
to co-opt top figures in some authoritarian societies. 
The best known example is Guinea-Bissau, where the 
prime minister was recently detained and threatened by 
soldiers so that the chief of staff of the military could be 
removed. The man who engineered this ‘coup’ has 
assumed the role of deputy chief. He has also been 
widely accused of involvement in drug trafficking. While 
the flow of cocaine through this region declined sharply 
after political turmoil in Guinea-Bissau and Guinea in 
2008/2009, these recent developments suggest it may 
resume in the near future.
Measures must be taken to assure that transnational 
organized crime does not contribute to instability, 
including, when relevant, building crime prevention 
into international efforts to foster peace and the rule of 
law. Since most transnational trafficking flows are inter-
continental, however, planning of integrated drug con-
trol strategies at the global level is required to address 
them, and the United Nations can help to coordinate 
this endeavour.
Murders and cocaine seizures in Trinidad  
and Tobago, 1992-2005
Source: UNODC International Homicide Statistics and DELTA
Murder rate trends in Central America  
(per 100,000 inhabitants), 2003-2008
Source: UNODC International Homicide Statistics
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1. TRANSNATIONAL DRUG MARKET ANALYSIS

1.1 Introduction
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Since the 1960s, and in a context of rapid and deep 
socioeconomic changes throughout the world, the inter-
national drug control system has succeeded in contain-
ing the spread of annual illicit drug use to around 200 
million people, or 5% of the world population aged 
15-64. This compares very favourably with the much 
higher prevalence of tobacco use, which causes 5.4 mil-
lion deaths per year.1  
The system was set up to restrict the use of controlled 
drugs to medical and scientific purposes and, while con-
tainment of illicit use to relatively low levels is already a 
remarkable achievement, Member States have always 
had a more ambitious goal in mind.
In 1998, 37 years after the 1961 Single Convention, a 
special session of the UN General Assembly (UNGASS) 
decided to work towards the “elimination or significant 
reduction” of illicit drug production and abuse by 2008,2 
and adopted a series of sectoral plans to reach that objec-
tive. Gathered at the end of the 10-year period, Member 
States were not satisfied with the results and declared 
that they were still “gravely concerned about the grow-
1 WHO, Tobacco key facts (see: http://www.who.int/topics/tobacco/
facts/en/index.html).
2 United Nations General Assembly Special Session on the World Drug 
Problem (UNGASS), New York, 8-10 June, 1998 (A/S-20/4, chapter 
V, section A).
ing threat posed by the world drug problem.”3 There is 
no single measure of the year-on-year evolution of the 
world drug problem. There is not even a clear definition 
of what is meant by the expression the ‘world drug prob-
lem’.  Since public health is at the heart of the interna-
tional drug control system, the prevalence of illicit drug 
use is generally considered a central, though imperfect, 
indicator of the status of the problem. Illicit drug use is 
a multifaceted issue, however. In particular, different 
drugs produce different effects and present different 
risks to users. At the international level, annual preva-
lence of drug use, by drug category, has thus become the 
most standardized indicator to monitor the evolution of 
illicit drug use. Unfortunately, only a minority of coun-
tries have adequate national prevalence monitoring sys-
tems in place. Producing a precise, reliable and sensitive 
measure of the evolution of the world drug problem 
over the last decade on that basis is therefore very diffi-
cult. Data on illicit drug supply can help fill the infor-
mation gap, at least for some drugs. The bulk of cocaine 
and opium production is concentrated in a few locations 
and successful efforts to develop annual surveys in the 
3 High-level Segment to the 2009 United Nations Commission on 
Narcotic Drugs, Political Declaration and Plan of Action on Inter-
national Cooperation towards an Integrated and Balanced Strategy 
to Counter the World Drug Problem, March 2009 (E/2009/28 - E/
CN.7/2009/12).
Global potential opium production, 1980-2009Fig. 1: 
Source: UNODC
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context of the 1998 Plan of Action have provided a 
coverage that is systematic enough to closely follow the 
evolution of the global opiate and cocaine markets from 
the supply side.
Data on illicit opiates supply, arguably the most prob-
lematic drug category and always a core preoccupation 
of the international drug control regime, show that 
global opium production increased by close to 80% 
between 1998 and 2009. Increases in Afghanistan more 
than offset remarkable declines in South-East Asia 
during that period. There were encouraging declines in 
the last three years, but Afghan production was still 
more than 150% higher in 2009 than in 1998. With 
strong increases after 2005, production seems to have 
well exceeded world demand and led to the creation of 
large stockpiles, but it is clear that the global opiate 
market has not been eliminated, or significantly reduced, 
since 1998.
The evolution of cocaine production has not been as 
dramatic as in the case of opium during the same decade. 
Contrasting trends were recorded in various locations, 
including a long-term decline of use in North America 
but an increase in Europe, reductions in production in 
Colombia and increases in Peru or the Plurinational 
State of Bolivia. At the global level, these changes essen-
tially amounted to geographical shifts and displacements 
in supply and demand. As a whole, the market has not 
been eliminated or significantly reduced over the last 
decade.
Data on cannabis and amphetamine-type stimulants are 
too patchy to allow year-on-year monitoring of the 
global market, but there were no indications of large 
reductions at the global level for these substances 
either.
Member States have decided to continue their efforts to 
achieve the initial UNGASS objective. Accordingly, 
illicit drug supply and demand should be “eliminated or 
significantly reduced” by 2019. Their decision was made 
in a context of renewed criticism from some parts of 
civil society against the international drug control system 
and its perceived inefficacy, but governments were 
remarkably unanimous in their perception of the world 
drug problem, in the renewal of their political commit-
ment to the international policy framework, and in their 
resolve to address shortcomings and obtain better 
results.  
Can overall drug supply and demand be “eliminated or 
significantly reduced” by 2019, as called for by the 
Member States? At the national level, one can hope that 
many countries will be able to significantly improve 
their drug control situation within a decade. There are a 
number of encouraging developments in this respect. 
Will these local successes translate into an overall 
improvement at the global level? 
The increase in world population alone (by some 0.8 
billion people, or 11%) during the next decade should 
automatically increase the size of world drug markets, 
even if drug use prevalence rates remain constant. The 
potential impact of other risk factors such as urbaniza-
tion (+20% during the next decade) and the growth of 
mega-cities in the developing world could make matters 
worse, as drug use is typically higher in urban than in 
rural areas.  
As regards cannabis, there is no global market per se to 
control and monitor. The global picture is made up of a 
patchwork of multiple and distinct submarkets, typically 
national or regional in nature. Monitoring their evolu-
tion and addressing them as a whole may thus neither 
be the easiest, nor necessarily the most useful, thing to 
Global potential cocaine production (mt), 1990-2008Fig. 2: 
Source: UNODC
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1. Transnational drug market analysis Introduction
do. Monitoring systems are largely missing, and current 
methods used to estimate the size and evolution of the 
global cannabis problems are not sensitive. That creates 
a serious technical problem for any attempt to closely 
monitor, guide and measure a global elimination 
approach. There are additional obstacles. Cannabis pro-
duction and -consumption are found everywhere and 
there is no longer a clear consensus among national 
authorities on how to tackle the issue. Under these con-
ditions, a significant reduction of the aggregate cannabis 
problem at the global level by 2019 would more likely 
be a matter of coincidence than the result of internatio- 
nally concerted action. Even if such a reduction were to 
occur, it would be difficult to detect and reliably meas-
ure it, given the lack of a clear baseline and persistent 
data gaps. 
Unlike for cannabis, there is a clear political consensus 
on heroin, cocaine and, to a large extent, amphetamine-
type stimulants (ATS). In the case of ATS, because of the 
existence of independent, mostly regional or even 
national, supply and demand markets, as well as the 
ease, discretion and changing nature of synthetic drugs 
manufacture, the problem also tends to defy a global 
approach and overall predictions over the period consid-
ered. Nevertheless, ATS have gained a large share of the 
global drug market over the last two decades and have 
come to represent a major and evolving threat for present 
and future drug control efforts. Since 1990, ATS manu-
facture has spread, with more than a third of Member 
States reporting this activity on their territory. Moreover, 
the global number of ATS users is likely to exceed the 
number of opiate and cocaine users combined. These 
drugs require international vigilance, the adoption or 
strengthening of specific regulations and control meas-
ures at the global level, and the development of strong 
regional strategies.
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Cannabis
is - by far - the most widely produced, seized and 
consumed drug worldwide, causing increased health 
problems in many countries, linked to its spread and 
rising potency in several (mostly developed) coun-
tries over the last decade. Deaths related to cannabis 
use are rare, however, and dependency tends to 
emerge only after long periods of use. As cannabis 
production is widespread, most of its production is 
intended for local or regional consumption. Over-
seas trafficking in cannabis is less frequent and 
appears to have further lost importance with the 
development of high-potency cannabis production 
in greenhouses in the industrialized countries. The 
role of transnational organized crime groups in the 
cannabis market is thus more limited than for other 
drugs, and so are the security threats related to its 
production, trafficking and consumption.  
Estimated annual value of some global Fig. 4: 
criminal markets in the 2000s
Source: UNODC
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The impact of illicit opiates, cocaine and ATS
Opiates are the most severe problem drugs worldwide, notably in Asia and Europe. Their use can lead to severe 
dependence and is often associated with IDU-related HIV/AIDS and hepatitis B and C, as well as high mortality 
rates. The mortality rate for dependent heroin users is between 6 and 20 times that expected for those in the general 
population of the same age and gender, as the difference between a ‘recreational dose’ and a ‘fatal’ one is small, and 
variations in street drug purity can result in overdoses. Thus, in most countries, opiates consumption constitutes the 
main cause of drug-related deaths. In addition, the processing and trafficking of opiates constitute significant sources 
of income for insurgents in some opium-producing countries such as Afghanistan and Myanmar. In Afghanistan, a 
conservative estimate suggests that Taliban insurgents generated some US$125 million per year in profits from the 
local opiate trade alone in the past several years. In Pakistan, Taliban allies such as al-Qaida and other like-minded 
groups have bases along the main heroin/opium trafficking routes and are well located to benefit from trafficking. 
Elsewere in the world, other militant groups also seem to be financing themselves at least partly from the illicit opiate 
trade.
Similarly, cocaine use constitutes, first of all, a major health problem. Almost a fifth (18%) of the persons who used 
cocaine in the previous year at least once were found to be dependent on it in the world’s largest cocaine market 
(United States), a higher proportion than for any other drug, except heroin. Cocaine use also results in tens of 
thousands of deaths each year worldwide. While cocaine was involved in close to 40% of all drug deaths in the 
United States in 2008, the proportion is still far smaller in Europe (8% in the EU/EFTA countries). After the opi-
ates, cocaine is the most problematic drug worldwide, notably in the Americas. While the share has declined, almost 
half (46%) of all people entering drug treatment in the Americas do so due to cocaine. The share in Europe increased 
from 3% in 1997/1998 to 10% in 2008, rising to almost 15% in West Europe. Proportions are far lower in Africa 
(6%), Oceania (0.5%) and Asia (0.5%), possibly due to the high availability of amphetamine-type stimulants in 
these regions. There is also a clear link between cocaine use (notably crack-cocaine use)  and crime. While 11% of 
arrestees in the United Kingdom in 2005/2006 were found to have used crack-cocaine in the month prior to their 
arrest, the proportion of crack-cocaine use in the general population was far lower (0.1% in that year). Similarly, 
between 29% and 35% of the male arrestees in the United States were found to have used cocaine in the previous 
month in recent years (29% in 2008), far more than the corresponding rates among males in the general US popu-
lation (1% in 2008). With cocaine use falling strongly since the late 1980s (-56% in past month prevalence rates 
between 1988 and 2008), overall crime also saw a marked decline in the United States, ranging from -29% for 
property crime rates to -43% for murder rates over the 2000-2008 period. Cocaine trafficking is also linked to cor-
ruption. Trafficking of cocaine has contributed to increasing corruption in transit countries, including in West 
Africa. Moreover, cocaine trafficking constitutes a major security threat, financing organized crime and insurgencies 
in a number of countries, including the FARC in Colombia and the Shining Path in Peru. 
Like for the other drugs, the impact of ATS use is primarily on the health side. The proportion of people requiring 
treatment for ATS abuse is 5% of all drug-related treatment demand in Africa, 10% in Europe and 12% in the 
Americas. It is particularly high in Oceania (20%) and Asia (21%), reaching 36% in East and South-East Asia with 
proportions exceeding 50% in Japan, the Republic of Korea, Thailand, Cambodia and the Philippines, as well as in 
Saudi Arabia in the Near and Middle East. In particular, methamphetamine use constitutes a major health risk where 
it occurs. Data for the United States suggest that the use of methamphetamine may constitute similar threats to 
health as the abuse of crack-cocaine, exceeding for the individuals concerned even the risks related to the consump-
tion of cocaine HCl. Organized crime is involved in the diversion of precursor chemicals, and in the manufacture 
of ATS, as well as its distribution. ATS manufacture has a major negative impact on the environment, which is 
reflected in the difficulties to dismantle clandestine ATS labs. There is clearly involvement of organized crime groups 
in ATS production, particularly in East and South-East Asia, as well as in North America. Less is known with regard 
to financing of insurgencies (this seems to occur mainly in Myanmar) and violence related to its trafficking.
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The global illicit opiate and cocaine markets represent 
two of the biggest transnational drugs and crime threats 
of our time. Tens of thousands of the millions of opiate 
users worldwide die every year. Opiates are at the origin 
of two thirds of all drug treatment demand in Europe 
and Asia. The opiate market generates an annual turn- 
over of up to US$65 billion, of which some US$ 55 
billion for heroin alone. Moreover, the opiate market is 
interlinked with severe national and international secu-
rity problems, particularly in Afghanistan and Pakistan. 
In terms of health impact, cocaine comes next, and rep-
resents as big a transnational organized crime threat as 
heroin. Estimates suggest that the global retail sales 
figure (some US$88 billion) is even higher than for opi-
ates, and the impact of the cocaine trade on stability can 
also be severe in some places.
The global heroin and cocaine markets appear simulta-
neously as persistent problems from a previous era of 
drug control, priorities for interventions due to the 
severity of their impacts on affected societies and good 
candidates for a global solution within a reasonable 
time-frame. Since they are both sourced from relatively 
concentrated production areas, most of their compo-
nents are directly or indirectly linked. The resulting 
transnational drug economies they form, from produc-
tion to trafficking and consumption, can thus be 
addressed as a whole and be affected by shocks and 
ripple effects. Not only are holistic market control 
approaches possible in these two cases, but, as shown by 
history, they are also a necessity. Local successes against 
illicit cultivation in the past – there were many – have 
always been offset by displacements to other locations, 
and closed trafficking routes replaced by new ones.  
Illicit production is presently largely entrenched in rural 
areas that are difficult to control. On the demand side, 
increases in cocaine consumption in Europe have ten-
eded to compensate reductions in North America, and 
the stabilization of heroin use in West Europe has been 
offset by a deterioration of the situation in the Russian 
Federation. Meanwhile, the size and concentration of 
the trafficking flows to these main destination markets 
have often created havoc in vulnerable production and 
transit areas by overwhelming local law enforcement 
capacities, generating corruption, fuelling violence and 
instability, and spreading addiction. 
A clear lesson from the history of cocaine and heroin 
control is that the mere sum of uncoordinated national 
and sectoral efforts, even successful ones, cannot result 
in global success. Another lesson is that countries with 
limited means cannot resist, and counter the impact of, 
powerful transnational trafficking flows on their own.  
With the benefit of experience, success against these two 
markets appears to be within reach and would result in 
the removal of a large chunk of the world drug problem 
and many of its associated ills. As regards the availability 
of tools and data to guide interventions and monitor 
their impact, the situation is much better than in the 
case of other drugs.  Production is already measured on 
a yearly basis and national data on trafficking is well 
reported by Member States. There is relatively good 
demand data from OECD countries, and gaps in other 
important consuming countries, particularly for heroin, 
could relatively easily be remedied by prevalence surveys 
for cocaine or by indirect measures, such as treatment 
multiplier methods, for heroin.  
Global opium production and global coca production 
have grown by a factor of 6 (cocaine) and 7 (opium) 
during the last three decades. Eliminating or signifi-
cantly reducing the world heroin and cocaine markets 
will thus require more effective approaches than in the 
past. What can be done? The first thing is to remedy the 
biggest shortcomings of previous approaches. Member 
States have recognized an essential one: a lack of integra-
tion.  In the 2009 Political Declaration,4 Member States 
acknowledged “the importance of promoting, in order 
to enhance the effectiveness of drug control measures, 
an integrated approach in drug policies” (art. 31).  This 
call is echoed in the new Plan of Action, notably in its 
Art. 27, under the title “Addressing supply and demand 
reduction together”: “While drug trafficking is a multi-
faceted issue than can be effectively tackled only by 
reducing both supply and demand, this interlinkage is 
often not taken into account.”   
To achieve the 2019 objectives, the international com-
munity needs to interweave drug supply and demand 
reduction interventions and integrate national efforts 
into the framework of renewed international strategies 
on the scale of the cocaine, heroin and ATS markets. To 
do so, it is urgent to improve our understanding of how 
these illicit transnational drug economies operate. 
UNODC has intensified research efforts on the topic. 
Preliminary results are presented in this chapter.  
4 High-level Segment to the 2009 United Nations Commission on 
Narcotic Drugs, Political Declaration and Plan of Action on Inter-
national Cooperation towards an Integrated and Balanced Strategy 
to Counter the World Drug Problem, March 2009 (E/2009/28 - E/
CN.7/2009/12).
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Worldwide, more than 15 million people consume illicit 
opiates1 (opium, morphine and heroin). The large 
majority use heroin, the most lethal form. More users 
die each year from problems related to heroin use, and 
more are forced to seek treatment for addiction, than for 
any other illicit drug. Among illicit narcotics, opiates are 
also the most costly in terms of treatment, medical care 
and, arguably, drug-related violence. In addition, heroin 
is the drug most associated with injection, which brings 
about a host of acute and chronic health problems, 
including the transmission of blood-borne diseases such 
as HIV/AIDS and Hepatitis C. In Central Asia, Ukraine 
and the Russian Federation, injecting opiates is linked to 
nearly 60-70% of all HIV infections.2 
Beyond its health impact, the illicit opiate industry also 
has a detrimental effect on stability and security in a 
number of places, including through the funding it pro-
vides for insurgents in production areas, particularly in 
Afghanistan. In 1998, the United Nations General 
Assembly Special Session on drugs already expressed 
‘deep concern about links between illicit drug produc-
tion, trafficking and involvement of terrorist groups, 
criminals and transnational organized crime.’3 In some 
1 Opiates are a group of psychoactive substances derived from the 
poppy plant, which includes opium, morphine, codeine and some 
others. The term ‘opiate’ is also used for the semi-synthetic drug 
heroin that is produced from poppy compounds.
2 Mathers B., Degenhardt L., Phillips B., Wiessing L., Hickman M., 
Strathdee A., Wodak A., Panda S., Tyndall M., Toufik A. and Mattick 
R, on behalf of the Reference Group to the United Nations on HIV 
and Injecting Drug Use, “Global epidemiology of injecting drug use 
and HIV among people who inject drugs: a systematic review,” The 
Lancet, 2008; 372:1733-1745.
3 United Nations General Assembly Special Session on the World Drug 
Problem (UNGASS), New York, June 8-10, 1998. 
regions, the nexus of illicit drugs, organized crime and 
instability has taken the form of growing infiltration of 
state institutions by drug trafficking groups. 
Getting opiates from producer to consumers worldwide 
is a well-organized and, most importantly, profitable 
activity. The most lucrative of illicit opiates, heroin, 
presently commands an estimated annual market value 
of US$55 billion. When all opiates are considered, the 
number may reach up to US$65 billion. Traffickers, 
essential to the transportation of drugs from production 
areas to lucrative end-user markets, pocket most of the 
profits of this trade. A rough estimate of the number of 
traffickers involved in moving this illegal commodity 
across countries and regions would likely stand at well 
above 1 million people.4
The problem is not new and tremendous efforts have 
been made by governments over the past decades to stem 
the flow of illicit opiates. Many successes have been 
obtained. Most of them have been local, however, and 
over the long term, global illicit opiate production has 
increased. 
The supply source for this huge underground economy 
is now concentrated in three areas: Afghanistan, 
South-East Asia (mostly Myanmar) and Latin America 
(Mexico and Colombia). Together, they supply nearly all 
the world’s illicit opium and heroin, but Afghanistan 
stands out among this group, accounting for around 
90% of global illicit opium production in recent years. 
 
4 Based on the annual number of arrests for heroin trafficking reported 
and a tentative, but very high, arrest ratio of 20% (1 in 5 traffickers 
arrested, which is most certainly well above the real number).
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By itself, Afghanistan provides 85% of the estimated 
global heroin and morphine supply, a near monopoly.
In a 2009 Political Declaration reviewing drug control 
achievements over the previous decade, UN Member 
States recognized that ‘the supply of opiates originating 
in Afghanistan continues to pose serious challenges to 
the international community.’5 On that occasion, 
Member States also decided to redouble their efforts and 
to obtain decisive results against illicit supply and 
demand by 2019. Obtaining such results will require 
clear improvements in the efficacy of the response pro-
vided so far by the international community. A first 
obstacle stands in the way of designing a reinvigorated 
strategy. Our understanding of the transnational illicit 
opiate economy, as well as of its links with other socio-
economic and political issues, remains fragmented and 
relatively superficial. Designing the international 
response that would solve this decades-old problem 
within the next 10 years thus requires a particular effort 
to fill knowledge gaps. 
Dimensions of the global  1.2.1 
opiate market
Estimating demand and supply
As with any other commodity, the laws of supply and 
demand apply to the trade in illicit opiates. However, 
unlike most commodities, information on supply and 
demand is not always readily available due to the illicit 
nature of the trade. Supply and demand depend on one 
another in multiple ways; there is no simple link between 
them. For example, a significant drug supply in traffick-
5 United Nations, Commission on Narcotic Drugs (CND), Fifty-
second session, Vienna, 11-20 March 2009 (UN document number 
E/CN.7/2009/Res. 52/2).
ing transit regions appears to encourage demand in 
places where there was previously none.
Estimates presented in this chapter draw heavily on the 
data reported by UNODC surveys (for example, in 
Central Asia, the Russian Federation and Pakistan), 
annual reports from governments to UNODC, referred 
to as the Annual Reports Questionnaire (ARQ) and 
UNODC estimates. The UNODC Illicit Crop Moni-
toring Programme, which collects data on global opium 
poppy cultivation, was used as the main source of pro-
duction data.6 Other indicators examined included the 
heroin seizure databases of the World Customs Organi-
zation (WCO) and UNODC. A trend analysis of both 
opiate use and seizures data for the 2000-2008 period 
was carried out by UNODC over the past year to iden-
tify the patterns and estimate the magnitude of opiate 
flows throughout the world. 
One important caveat that must be borne in mind is 
that while the estimates presented are the best currently 
available, they are not always based on direct research. 
In the case of demand, indirect methods must some-
times be used, due to the absence - for most countries 
- of any robust data collection system to arrive at scien-
tifically sound per capita consumption estimates. Only 
35% of all countries and territories (76 out of 217) 
provided data on opiate prevalence rates in the 2008 
ARQ; 141 (65%) did not provide data. Out of this total, 
UNODC used other available sources to calculate drug 
use prevalence for 55 countries (25%).
Further analysis of information gaps reveals that in 
2008, UNODC received no information on opiate 
6 The details of this methodology can be found in UNODC’s Addic-
tion, crime and insurgency: the transnational threat of Afghan opium, 
2009, pp.36-37. They can also be found in the online methodology 
section of the World Drug Report.
Global potential opium production, 1980-2009Fig. 5: 
Source: UNODC World Drug Report (figure for 2009 based on 2009 Survey results for Afghanistan and 2008 data for the rest of the 
world)
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1. Transnational drug market analysis The global heroin market
abuse prevalence from 30 countries in Africa, 20 coun-
tries in the Americas, 51 countries in Asia, 5 countries 
in Europe and 17 countries in Oceania (most of which 
are small islands).7 Essentially, a majority of countries do 
not provide domestic drug abuse data in ARQs which 
complicates efforts to generate global and/or country-
level consumption and consumer figures. Other valuable 
indicators such as data on opiate purity and prices are 
even more scarce, but this has much to do with local 
capacity. As a result, less is known about opiate demand 
than about opiate supply. All the estimations given in 
this chapter are therefore based on the limited data avail-
able to UNODC and may change or be updated as more 
data is provided by Member States. 
Apart from ARQs, estimates presented in this chapter 
also relied on indirect methods (mostly treatment mul-
tiplier and capture-recapture methods) which usually 
represent the best evidence available to estimate national 
demand for opiates. For some countries, household 
survey data is also available. This tends, however, to be 
less reliable for the use of drugs such as heroin, which is 
highly stigmatized and where many users no longer live 
in a ‘normal’ household. 
The global number of opiate users can be estimated at 
more than 15 million in the recent period. Around a 
quarter of them consume some 1,100 mt of opium in 
raw form.8 The rest use heroin and consume approxi-
mately 340 mt of pure heroin per year.9 In opium 
equivalents,10 opiate demand could be estimated at 
3,700 mt worldwide. 
7 Many of these gaps are due to the lack of well-developed data collec-
tion systems in many countries.
8 Some users consume both heroin and opium, but the overlap between 
the two categories is difficult to quantify. For the purpose of simplic-
ity, calculations did not take it into account.
9 Throughout this report, the term ‘heroin’ refers to a product with the 
purity of heroin produced at the main source, Afghanistan (70%).
10 Taking into account the distribution of production between Afghani-
stan and the rest of the world, volumes expressed in terms of opium 
equivalents in this chapter use a conversion factor of 7.5:1. 
Demand for opium
There are an estimated 4 million opium consumers 
worldwide. Unlike heroin demand, which is more evenly 
distributed around the world, opium consumption is 
concentrated in Asia, where it has a long tradition of 
use. Over the past century, opium gradually ceded its 
place to heroin, but it still maintains important markets 
in countries like the Islamic Republic of Iran, India and 
Pakistan. 
Afghanistan is the world’s largest opium producer and 
exporter but it is also an important consumer. The 
country accounted for 7% of total world demand, or 80 
mt a year, for an estimated 150,000 users in 2008 (rising 
to 200,000-250,000 in 2009).11 A large volume of 
opium is consumed in the Islamic Republic of Iran, 
approximately 450 mt, according to UNODC esti-
mates. But all of Afghanistan’s neighbours report worry-
ing levels of opium use. Excluding China, consumption 
in the countries bordering Afghanistan (the Islamic 
Republic of Iran, Pakistan, Tajikistan, Uzbekistan and 
Turkmenistan) is estimated at 650 mt per year; 60% of 
global consumption. Although small-scale cultivation 
occurs in these countries, such as in Pakistan and Cen-
tral Asia,12 the main supply source for the region’s opium 
consumers is Afghanistan.
Other parts of the world are affected as well. In the Rus-
sian Federation, over 58 mt of opium are consumed 
annually,13 while the Middle East absorbs some 16 mt 
per year. In the Americas, opium consumption is mainly 
reported in Mexico. The level of opium consumption (if 
11 UNODC, Afghanistan drug use survey 2005, 2006.
12 As the UNODC Illicit drugs trends in Central Asia (2008) report 
notes “Given the 2006 regional total of 2.22 hectares of reported 
cultivation, this is equivalent to a potential output of 90 kg of opium, 
a minute fraction of the amount produced in Afghanistan.”; see 
UNODC “Illicit drug trends in Central Asia”, April 2008, p.8. 
13 Of note, some of these users consume only “kompot” (a poppy straw 
solution that is usually injected), which is generally sourced locally.
Data on prevalence of  
opiate abuse available  
(number of countries/territories)
Data on prevalence of opiate abuse 
not available from any source 
(number of countries/territories)
Continent Data provided through ARQ UNODC estimation
Number of  
countries/territories
Share of  
countries/territories Total
Africa 4 21 30 55% 55
Americas 12 13 20 44% 45
Asia 20 17 14 27% 51
Europe 38 4 5 11% 47
Oceania 2  N/A 17 89% 19
Total 76 55 86 40% 217
Availability of data on opiate abuse prevalence, by regionTable 1: 
Source: UNODC
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any) in other Latin American countries remains unknown 
due a dearth of data for nearly half of all Latin American 
countries.
India has traditionally been an important consumer of 
opium.14 Based on the ARQs provided by the Govern-
ment, current opium consumption in India is estimated 
at some 65-70 mt per year. The Government reports also 
show that foreign-sourced opium has neither been seized 
nor reported as trafficked into India. Consequently, 
such a consumption level (6% of the estimated global 
total) would require the illicit cultivation of some 1,500 
- 2,000 hectares of opium poppy on Indian territory. 
Diversion from licit cultivation could also be a source of 
supply, but Indian authorities now consider this possi-
bility less likely given the limited size of licit cultivation 
14 UNODC, A century of international drug control, 2008, p.15.
(6,000 ha in 2009) and the strict controls in place. 
Opium is also consumed in neighbouring countries, 
such as Bangladesh and Nepal. But there also, Afghani-
stan (or Myanmar) does not appear to be the source. 
Government reports and recent field research have con-
firmed the existence of (limited) illicit opium poppy 
cultivation in Nepal, as well as in the border areas of 
Bangladesh and India,15 which could be the source for 
consumption in these countries. Until now, it was gener-
ally assumed that these markets were captured by Myan-
mar and Afghan suppliers, but the possibility of an 
emerging regional source of supply cannot be discounted 
and needs to be studied further.
The main African country to have reported opium 
15 UNODC mission report to South Asia, information provided by 
Bangladesh, Nepalese and Indian counter-narcotics officials, March 
2009. 
Estimated opium and heroin consumption, 2008Table 2: 
Source: UNODC
Region/ 
country
Heroin 
users
Opium 
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Myanmar 66,000 67,000 1.3 7.0 20.1
China 2,254,000 119,000 45.0 12.0 458.2
India 871,000 674,000 17.0 67.0 239.8
Oceania 32,500 52,000 2.0 5.0 23.4
Asia  
(except India, 
China, Myanmar)
852,000 1,118,500 17.0 75.0 245.0
Sub total 4,075,500 2,030,500 82 166 986.6
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Afghanistan 47,000 146,000 2.0 80.0 91.8
Pakistan 547,000 145,000 19.0 80.0 213.8
I.R. of Iran 391,000 531,000 14.0 450.0 547.0
Central Asia 283,000 60,000 11.0 33.0 112.2
Russian  
Federation 1,490,000 166,000 70.0 58.0 548.6
Turkey 25,000 25,000 0.8 9.0 14.4
Europe  
(except Turkey and  
Russian Federation)
1,614,000 271,000 88.0 95.0 711.0
Americas 1,538,000 82,000 26.0 29.0 212.0
Middle East and 
South Asia  
(except I.R. of Iran, 
Pakistan and 
Afghanistan)
63,500 491,000 1.6 16.0 27.2
Africa 1,240,000 172,000 25.0 60.0 235.0
Sub total 7,238,500 2,089,000 257 910 2,713
Total 11,314,000 4,119,500 340 1,075 3,700
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consumption is Egypt. As in India, there are no reports 
or data to indicate that the opium consumed in Egypt 
(estimated at 60 mt)16 is trafficked from another coun-
try. This may suggest the existence of illicit cultivation 
of some 1,000 ha of opium poppy in Egypt. Raw opium 
may also be consumed in other African countries, but 
until comprehensive drug use surveys are conducted or 
other data is made available to UNODC, much uncer-
tainty will remain in this area.
Although it reportedly consumed an extraordinary 
26,690 mt of opium a century ago,17 consumption in 
China now appears to be limited to some 12 mt annual-
ly.18 The opium consumed in South–East and East Asia 
originates mainly in Myanmar and to a much lesser 
extent in the Lao People’s Democratic Republic. There 
may be some local production in other East and South-
East Asian countries, since the amount of opium seized 
there (0.3 mt in 2008) is not proportional, compared 
with other regions, to the estimated level of consump-
tion (75 mt). Moreover, there is little evidence of opium 
trafficking from Myanmar or the Lao People’s Demo-
cratic Republic to these countries.
Demand for heroin
Heroin is a more potent and addictive derivative of 
opium. It may be smoked or injected. In recent years, it 
is estimated that some 340 mt of the substance have 
been consumed worldwide each year. 
16 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009.
17 UNODC, A century of international drug control, 2008, p.91.
18 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009, p.27.
Two markets, Europe19 and the Russian Federation, cur-
rently account for nearly half of global heroin consump-
tion. With 70 mt of heroin consumed per year, the 
Russian Federation is estimated to be the country with 
the highest national level of consumption. The com-
bined level of heroin consumption in European coun-
tries is estimated at around 85-90 mt.20 Within Europe, 
four countries dominate, namely the United Kingdom 
(some 19 mt), Italy (about 18 mt), France (an estimated 
10 mt) and Germany (approximately 7 mt). Afghan 
opium is now the only known source of heroin con-
sumed in Europe and the Russian Federation. 
In 2008, available data suggest that around 20 mt of 
heroin were consumed in the United States of America, 
1.3 mt in Canada and 5 mt in Latin America. According 
to US Government reports, the majority of the heroin 
consumed in the country comes from Latin America and 
Mexico. The rest is trafficked from Afghanistan via 
Europe and Africa. Opium production in Mexico was 
reported to have sharply increased that year (by 120%), 
amounting to 325 mt of raw opium, from which 30-40 
mt of heroin could potentially be produced.
In contrast to its high opium consumption levels and 
despite its proximity to the world’s largest heroin pro-
ducer, official reports indicate that heroin consumption 
is relatively low in the Islamic Republic of Iran (14 mt 
for an estimated 391,000 users). Afghanistan’s other 
neighbour, Pakistan, has approximately 500,000 heroin 
users, estimated to have consumed around 19 mt of 
heroin in 2008. At the source, in Afghanistan, domestic 
consumption is estimated at around 2 mt per year (2008) 
19 For the purpose of analysis in this chapter, "Europe" excludes Turkey 
and the Russian Federation.
20 Ibid. 
Estimated global opium consumption Fig. 6: 
in 2008
Source: UNODC
Global heroin consumption (340 mt), Fig. 7: 
2008
Source: UNODC
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among 50,000 users (this increased to 100,000-135,000 
in 2009. 
At an estimated 17 mt in 2008, India has the highest level 
of heroin consumption in South Asia. The estimated 
amount of heroin consumed in neighbouring Bangladesh 
was also considerable, amounting to 4 mt in the same 
year. In Nepal, heroin consumption appears to have 
increased in recent years and is currently estimated at 
around 800 kg. As already noted, there appears to be a 
certain level of heroin production – and illicit opium 
poppy cultivation- in India. According to official reports 
from the Governments of Nepal and Bangladesh, almost 
all the heroin consumed in those countries originates in 
India.
China’s 2.2 million heroin users, the largest population 
in absolute terms, were estimated to consume some 45 
mt of heroin in 2008. Most of the supply for China is 
sourced in Myanmar, although Afghan heroin appears to 
be gaining market shares. In other South-East and East 
Asian countries, heroin consumption was estimated at 
around 18 mt. The main sources of the heroin con-
sumed in this region are Myanmar and the Lao People’s 
Democratic Republic, followed by processed Afghan 
opium. In Australia and New Zealand, the annual heroin 
consumption was estimated at 1.8 mt, sourced from 
both Afghanistan and Myanmar. 
Nearly all of Africa’s opiate users are reportedly consum-
ing heroin.21 Although estimates for that region are not 
very reliable, approximately 25 mt of heroin would be 
needed to supply Africa’s addict population,22 tenta-
tively estimated at 1.2 million individuals. Most of this 
21 UNODC, 2006 World Drug Report, p. 74.
22 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009, p. 13.
market appears to be supplied by Afghan heroin traf-
ficked via Pakistan, India and a number of countries 
along the Arabian peninsula.
Value of the trade
At retail level, the total value of the heroin market is 
substantial at an estimated US$55 billion. The size of 
the annual opium market is a more ‘modest’ US$7-10 
billion. Consequently, the combined total opiates 
(heroin/opium) market could be worth up to US$65 
billion per year. This amount is higher than the GDPs of 
many countries. In economic terms, nearly half of the 
overall opiate market value is accounted for by Europe 
(some US$20 billion) and the Russian Federation 
(US$13 billion). Other lucrative markets include China 
(US$9 billion) and the United States and Canada (US$8 
billion). Most profits are generated downstream, leaving 
Afghan producers with only a fraction of the profits. The 
farm-gate value to the farmer for cultivation and imme-
diate sale of opium was estimated at US$0.4 billion in 
2009. When adjusted to include the profits derived from 
trafficking of opium and the conversion of opium to 
morphine and/or heroin, the value to the Afghan opium 
economy was estimated at US$2.4 billion (2009) or only 
about 3.5% of the total value of the opiate industry.
Global volume and distribution
To estimate the quantity of opiates required to supply 
world illicit demand, one must add reported seizures to 
estimated levels of consumption. Some 646 mt of opium 
and 91 mt of heroin/morphine were seized in 2008. 
Around 5,000 mt of opiates (heroin, morphine and 
opium combined and expressed in opium equivalents) 
would have needed to enter the market to satisfy global 
demand in 2008. 
For heroin only, world consumption (some 340 mt in 
2008) combined with reported seizures (91 mt in 2008), 
would indicate an annual flow of about 430 mt of heroin 
into the global market. 
The distribution of opium production
Production in Afghanistan increased from around 200 
mt in 1980 to 3,300 mt in 2000, reaching a peak of 
8,200 mt in 2007, before dropping slightly to 7,700 mt 
in 2008 and again to 6,900 in 2009. Expressed as a pro-
portion of the global illicit opium production, Afghani-
stan’s share rose from around 20% in 1980 to 70% in 
2000, and to more than 90% since 2006. This is directly 
related to decreased output in the ‘Golden Triangle’, 
encompassing Thailand, the Lao People’s Democratic 
Republic and Myanmar, the world’s leading opium pro-
ducer in the 1970s and 1980s. Between 2003 and 2008, 
opium production in Myanmar fell by 59%, from 810 
to 410 mt. Production in the neighbouring Lao People’s 
Global heroin/opium market  Fig. 8: 
distribution (US$ 65 billion) in 2008
Source: UNODC
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Democratic Republic also declined dramatically, from 
more than 120 mt in the 1990s to around 10 mt in 
recent years. Thailand’s production is negligible; it has 
not reported any significant cultivation since 2003. 
Although Afghanistan’s potential opium production 
decreased by 10% from 2008 to 2009, it is still well 
above the average annual production recorded during 
the 1990-2006 period. Data do not show a correspond-
ing increase in world demand and UNODC has not 
registered any unusual price declines or dramatic 
increases in the purity of the heroin seized worldwide. 
On that basis, and taking into account uncertainties as 
regards the exact level of world demand, a potential 
over-production of some 12,000 mt during that period 
presents a supply-demand riddle that deserves atten-
tion. 
Turning to the Americas, the average amount of opium 
estimated to be produced in Latin America and Mexico 
was around 130 mt per year until 2006. In 2008, a 
reported 120% increase in opium production in Mexico 
made it the third biggest opium producing country after 
Myanmar with 325 mt potentially produced in 2008. 
Heroin and 
morphine 
(mt)
Heroin and  
morphine in 
opium  
equivalent (mt)
Opium (mt)
Total opium 
equivalents 
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Myanmar 0.3 3.0 3.9 7
Prov. of China 4.3 43.0 1.4 44
India 1.1 11.0 2.0 13
Oceania 0.1 0.8 0.0 1
Asia (except India,  
China, Myanmar) 1.0 10.0 0.3 10
Sub total (rounded) 7 68 8 76
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Afghanistan 3.3 23.1 43.0 66
Pakistan 9.2 64.4 27.0 91
I. R. of Iran 32.0 224.0 561.0 785
Central Asia 5.3 37.1 4.8 42
Russian Federation 3.4 23.8 0.4 24
Turkey 15.5 108.5 0.5 109
Europe (except Turkey and 
Russian Federation) 10.4 72.8 0.3 73
Americas 3.6 25.2 0.8 26
Middle East and South Asia 
(except I. R. of Iran, Pakistan 
and Afghanistan)
0.8 5.6 0.1 6
Africa 0.3 2.2 0.1 2
Sub total (rounded) 84 587 638 1,225
World total (rounded) 91 655 646 1,301
Opiate (opium, heroin and morphine) seizures, 2008Table 3: 
Source: UNODC
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Some data also suggest that limited illicit cultivation 
takes place in other countries, such as Egypt and India. 
At the time of writing, no information was available on 
the quantities cultivated and produced, which, in the 
case of Egypt, may be negligible. Algeria reports the 
eradication of approximately 80,000 opium poppy 
plants every year, but this production appears to be lim-
ited to supplying the local market.23 Finally, there is 
illicit cultivation in some CIS countries. Ukraine, the 
Republic of Moldova and the Russian Federation for 
example seem to be self-supplied for their own local 
market of poppy straw derivative solution (Kompot).
The distribution of heroin production
In 2008, approximately 2,700 mt of Afghanistan’s opium 
were refined into an estimated 380 mt of heroin to 
supply the global market. Placing a distant second is 
Myanmar and the Lao People’s Democratic Republic 
production which yielded some 40 mt of heroin in 
2008; all processed in Myanmar. The remainder, some 
30-40 mt in 2008, is shared among mostly Latin Amer-
ican countries (including Colombia and Mexico). 
Processing Mexico’s opium output alone would poten-
tially yield some 38 mt of pure heroin in 2008. Lastly, 
lower levels of heroin production continue to exist in 
places like India.
Through a relatively simple chemical process, opium is 
used as the raw material for the extraction of morphine 
base, an intermediary product. A crucial precursor 
chemical, acetic anhydride, is then used to convert mor-
phine base into heroin.24 In terms of quantities, each kg 
23 INCB, Report of the International Narcotics Control Board for 2009, 
February 2010.
24 Other chemicals are required but most of these are anyway not 
restricted under international conventions.
of Afghan heroin requires approximately 7 kg of Afghan 
opium to produce. Afghan opium generally has a higher 
morphine content than the opium produced in Myan-
mar which requires approximately 10 kg of opium for 
each kg of heroin processed. Laboratories refining 
Afghan opium therefore face somewhat lower processing 
costs in the initial phases of heroin production.
Acetic anhydride costs approximately US$1-2 per litre in 
licit trade but (illicit) prices in Afghanistan have shot up 
over the past decade from US$24 to US$350 per litre, 
either due to more effective interdiction or increased 
demand. Since acetic anhydride is not produced in 
Afghanistan, it must be diverted from licit trade and 
smuggled into the country. In order to produce the 
required volumes of heroin (380 mt), as much as 1,000 
tons of acetic anhydride needed to be smuggled into 
Afghanistan (or other countries where processing poten-
tially takes place) in 2008. The interdiction of 14,233 
litres in Afghanistan in 2008, while an increase over 
2007, remains marginal at a ratio of approximately 1%.
Generally speaking, there is a geographical overlap 
between regions of opium production and heroin process-
ing (Afghanistan, Myanmar). It is established that there 
is a considerable number of heroin laboratories in 
Afghanistan. This is evidenced by reports from the 
Afghan authorities on the destruction of 69 facilities in 
Potential pure heroin production in Fig. 10: 
Mexico, in metric tons, 2004-08
Source: National Drug Intelligence Center, National Drug 
Threat Assessment 2010
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200825 (against 57 in 2007) while UNODC surveyors 
identified 97 laboratories that same year. By way of com-
parison, Myanmar authorities dismantled 24 heroin 
laboratories over the 2006-2008 period.26
In Afghanistan, processing (and cultivation) are concen-
trated in the southern provinces, such as Hilmand, Kan-
dahar and Nimroz, where the insurgency and lack of 
government control provide the ideal cover. Notably, 
Kandahar’s Spin Boldak district was the location of the 
largest acetic anhydride seizure in 2008, with 7,500 litres 
(enough for over 3.5 mt of heroin) confiscated in a single 
incident. But Hilmand province is at the core of the 
global trade in Afghan opiates. As well as its vast produc-
tion of opium, it is also the location of large, fixed heroin 
processing facilities. In 2008, Hilmand province alone 
accounted for almost 50% of Afghanistan’s opium sei-
zures.27 Of the known district locations, Dishu in the 
south and Nad Ali in the centre saw the greatest seizure 
25 UNODC Afghanistan country office, Analysis of Opiate and Precur-
sor Seizures in Afghanistan in 2008, 2009, p.13; see UNODC 2009 
World Drug Report, p.37.
26 UNODC, Patterns and Trends of Amphetamine-Type Stimulants and 
Other Drugs in East and South-East Asia (and neighbouring regions), 
November 2009, pp 86-91.
27 UNODC Afghanistan country office, Analysis of Opiate and Precur-
sor Seizures in Afghanistan in 2008, 2009, p.13; see UNODC 2009 
World Drug Report, p.37.
volumes. The latter district is a major opium poppy cul-
tivation area on the Hilmand river, while Dishu is a 
processing district and a hub for trafficking into Pakistan. 
However, all of the laboratories dismantled in Hilmand 
in 2008 were in central and northern districts. Well-
known opiate bazaars in places such as Lashkar Gah, 
Baramcha and Girishk continue to operate, although 
they were the scene of several seizures in 2008. 
At the same time, there is also the possibility that not all 
Afghan opium is processed into heroin in Afghanistan. 
If this is the case, Afghanistan needs to export opium 
(and/or morphine) for this purpose, which, in the case 
of opium, increases the chance of detection. There are 
no reports, however, of Afghan opium being trafficked 
to the Americas, Africa, South Asia (except Pakistan) 
and South-East Asia. Only a trivial amount is thought 
to be shipped to Gulf countries and is limited to local 
consumption. Between 2000 and 2008, seizure data 
provided to UNODC indicated negligible opium and 
morphine seizures in European countries (including 
Turkey). There were, however, sizeable opium seizures 
reported by countries north of Afghanistan. In 2008, 
approximately 4.5 mt of opium were seized in Central 
Asian countries but the regional market (34 mt) likely 
absorbed most of the flow. Moreover, there is a general 
absence of morphine seizures in this region.
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The highest volumes of morphine and opium seizures 
were reported by Pakistan and the Islamic Republic of 
Iran, Afghanistan’s immediate neighbours. In 2008, 
Pakistan (7.3 mt) and the Islamic Republic of Iran (9 
mt) seized a combined 16.3 mt of morphine, a stagger-
ing 95% of global morphine seizures. In contrast, 
Afghanistan only seized 479 kg that same year. Most 
Iranian and Pakistani morphine seizures occurred close 
to the Afghan border, perhaps suggesting that if large-
scale processing is taking place outside Afghanistan, it is 
staying close to the source. Both Pakistan (27 mt) and 
the Islamic Republic of Iran (573 mt) effected more 
than 90% of global opium seizures, but demand for the 
substance is high in both countries while that of mor-
phine is negligible. Referring to these numbers, the 
2008 World Drug Report concluded that such high mor-
phine and opium seizures indicated that ‘important 
amounts of heroin might be produced outside Afghani-
stan, as morphine does not have a large user base.’ This 
possibility needs to be further researched.
Distribution of trafficking flows
As mentioned earlier, there is no strict division between 
regions of supply and demand. The same caution is war-
ranted in examining ‘transit’ regions, which very often 
are also regions of consumption and possibly add to 
supply. The following estimate of global opiate flows 
uses a methodology combining both supply-side and 
demand-side analyses from production, consumption 
and seizure data.28 
At first sight, there are distinct patterns of distribution, 
as production in Latin America and Myanmar is mostly 
dedicated to the US and Chinese markets, respectively. 
Altogether, these two regions constitute around 15% of 
total heroin flows in the world. Afghanistan accounts for 
an estimated 85% of global heroin and morphine 
exports, often overlapping with both Latin America and 
Myanmar, including in the case of the United States and 
Chinese markets, respectively.
From Afghanistan
Of the estimated 380 mt of heroin produced in Afghan-
istan, approximately 5 mt stay in the country for local 
consumption or is seized by local law enforcement.29 
The remaining 375 mt are exported to the world via 
routes flowing into and through the neighbouring coun-
tries of Pakistan (150 mt), the Islamic Republic of Iran 
(105 mt) and the Central Asian countries of Tajikistan, 
Uzbekistan and Turkmenistan (95 mt) towards their 
28 Available demand data was the key variable used to estimate the size 
of the heroin/opium flows. Total heroin consumption was estimated 
for each country, then combined with official seizure data and bal-
anced against total production.
29 The country seized less than three mt of heroin in 2008, a seizure rate 
of less than 1%.
final destinations in Europe, the Russian Federation and 
Asia.30
About a third of the heroin produced in Afghanistan 
travels to Europe (110 mt) while a quarter goes north to 
Central Asia and the Russian Federation. Afghan heroin 
is also increasingly meeting a rapidly growing share of 
Asian, mainly Chinese, demand. Approximately 15-20 
mt are estimated to be trafficked to China while another 
35 mt are trafficked to other South and South-East 
Asian countries. 31 Perhaps 35 mt are shipped to Africa, 
while the remainder supplies markets in other parts of 
Asia, North America and Oceania. 
In addition to heroin, Afghanistan also exports some 
1,000 mt of opium annually to its immediate neigh-
bours (the Islamic Republic of Iran, Pakistan and Cen-
tral Asia) and further to a global market of some 4 
million opium consumers - most of which are in Asia.32 
With the exception of South and Central America, 
Afghan opiates are now trafficked and sold in virtually 
every corner of the globe.
From Myanmar
More than three quarters of Myanmar’s production 
(some 40 mt of heroin) supplies the local and regional 
markets, primarily Chinese. The remainder goes to other 
South-East Asian countries and Oceania. 
From Latin America (Colombia and Mexico)
In 2008, it is estimated that some 30-40 mt of heroin 
were potentially produced in Latin America (mainly 
Mexico and Colombia). Producers in Colombia and 
Mexico supply all of the Americas, although the major-
ity goes to the north.
Flow interception (seizures)
Interception rates vary widely between regions; however, 
estimated global interception rates are approximately 
20% of the total heroin flow worldwide in 2008. The 
Islamic Republic of Iran leads all countries with 23% of 
all heroin interceptions. Turkey comes next with 16%, 
followed by the United States and China, which come 
in third and fourth with 9 and 8% respectively. Heroin 
seizures decreased sharply in Pakistan compared to the 
average level observed between 2000 and 2006 (26 mt). 
30 The destination of the remaining 20 mt is unknown. It might be 
sourced from Afghanistan via Pakistan and/or other routes and/or be 
produced in India (diverted from the licit to the illicit market). In 
order to clarify this, an in-depth heroin consumption and trafficking 
study should be carried out in India.
31 There are approximately 20 mt of heroin unaccounted for which can 
potentially be trafficked to India (see UNODC, Addiction, crime and 
insurgency: the transnational threat of Afghan opium, 2009) but this 
remains a hypothesis until further evidence is produced.
32 See UNODC, Addiction, crime and insurgency: the transnational threat 
of Afghan opium, 2009, p. 11.
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Interdiction rates continued to remain very low in the 
main production centres of Afghanistan (1%) and 
Myanmar (1%), in African countries (1%), the Balkans 
(3%) and India (3%). In 2008, there were also substan-
tial decreases in heroin seizure volumes in Western and 
Central Europe (7.6 mt), compared to the level observed 
between 2000 and 2006 (9 mt). 
Global impact
The opium economy is deeply entrenched and its reach 
extends far beyond the borders of the few source coun-
tries. Whether one looks at the damages to the health of 
communities, the rise in criminal activity, the loss of 
economic productivity, the impact on global security or 
the more insidious corruption of government institu-
tions, it is fair to say that illicit opiates leave very few 
nations untouched. 
The cost of opiate use to individual users and to society 
as a whole is high. Studies indicate that more users die 
each year from problems related to heroin use and more 
are forced to seek treatment for addiction than for any 
other illicit drug. Users develop both tolerance and 
physical dependence, which means that their bodies 
adjust to the presence of heroin over time, requiring 
more to produce the same effect and inducing severe 
withdrawal symptoms if the drug is not taken in suffi-
cient quantities. The difference between a recreational 
dose and a fatal one is small, and variations in street drug 
purity result in many overdoses. The mortality rate for 
dependent heroin users is between 6 and 20 times that 
expected for those in the general population of the same 
age and gender.33 In addition, heroin is the drug most 
associated with injection, which brings about a host of 
acute and chronic heath problems including the trans-
mission of blood-borne diseases such as HIV/AIDS and 
hepatitis C. 
The largest national market for Afghan heroin is the 
Russian Federation; a market which has rapidly expanded 
since the dissolution of the Soviet Union. It is there that 
heroin is currently doing some of its worst damage, 
including through the spread of HIV. In neighbouring 
Central Asia, the past 10 years have witnessed both the 
highest increase in prevalence of drug abuse worldwide 
and similarly alarming levels of HIV/AIDS. Both these 
regions are good examples of the speed and extent of the 
33 WHO/UNODC/UNAIDS position paper: “Substitution mainte-
nance therapy in the management of opioid dependence and HIV/
AIDS prevention”.
Country/region
Estimated amount of 
heroin + morphine 
flow (mt)
Average  
heroin + morphine  
seizures (mt)
Percent of estimated 
flow intercepted
Afghanistan 380 3.30 1%
Pakistan 150 9.20 6%
I. R. of Iran 140 32.00 23%
Turkey 95 15.50 16%
South-East Europe  
(Bulgaria, Greece,  
Albania, Romania, Serbia, 
FYR Macedonia, Bosnia, 
Croatia, Montenegro)
90 2.8 3%
Rest of Europe (except  
Russian Federation) 105 7.60 7%
Midde East& Gulf  
countries (except I. R. of Iran) 14 0.80 6%
Central Asia 95 5.30 6%
Russian Federatioin 77 3.40 4%
Africa 35 0.31 1%
Myanmar 60 0.30 1%
India 37 1.10 3%
China 55 4.30 8%
Rest of S, E & SE Asia 30 1.00 3%
Oceania 2 0.08 4%
USA and Canada 24 2.1 9%
Heroin ﬂow and interdiction, 2008Table 4: 
Source: UNODC
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damage a sudden increase in heroin transit can do. On 
the Balkan route, the ravages of opiate consumption in 
the Islamic Republic of Iran have been well documented, 
that country having one of the largest opium user popu-
lations in the world. In Africa, an emerging destination 
for Afghan heroin, a rise in injecting drug use34 could 
worsen an already severe HIV/AIDS epidemic.35 In 
Afghanistan itself, while most of the lethal crop is 
exported, enough is left behind to create addiction. In 
2005, UNODC estimated the entire opiate-using popu-
lation to be 200,000. Since then, recurring anecdotal 
information appears to indicate increased addiction rates, 
sometimes affecting and debilitating entire villages. 
In 2008, 285,000-360,000 opiate users were found in 
Afghanistan. In addition to creating health problems, 
the opiate trade has implications for global security. 
Previous UNODC research highlighted the role of drugs 
(including opiates) as precursors or perpetuators of 
instability worldwide.36 One early example was the 
Soviet invasion in 1979, which triggered the mass pro-
duction of opiates in Afghanistan. Global drug produc-
tion is increasingly being concentrated in a few unstable 
areas and conflict zones. In the case of opiates, insurgent 
groups operating in various theatres are thought to par-
tially fund their operations from the taxing of produc-
tion and trafficking. In Afghanistan, a conservative 
estimate placed the figure at US$125 million/year in 
profits for Taliban insurgents. Across the border, in Paki-
stan’s tribal areas, Taliban allies such as al-Qaida and 
other like-minded groups (for example, the Islamic 
Movement of Turkestan and the Tehrik-e-Taliban Paki-
stan) have bases along the main heroin/opium traffick-
ing routes and are ideally located to benefit from 
trafficking. In other parts of the world, militant groups 
such as the Kurdistan Workers’ Party (PKK) or rebels in 
India’s north-east may also be benefiting from the illicit 
opiate trade. Illicit opiates thus potentially feed a chain 
of insecurity stretching across Asia and Europe. 
Transnational crime generates money and power. This 
power is not sufficient to threaten the stability of devel-
oped states, but in Afghanistan, and some vulnerable 
countries on the Balkan and Northern routes, money 
generated from opiates compares well with GDPs. The 
amount of money that the trade brings to bear on these 
countries’ political systems and societies poses a threat to 
their development and some nations may be at risk of 
‘drug dependence’. Countries like Afghanistan (48% of 
34 One of the indicators of that trend is the rise in the number of heroin 
users, which appears to have increased by 54% between 2004 and 
2008 in Africa.
35 Sub-Saharan Africa, is home to two-thirds (67%) of people living 
with HIV/AIDS or 22 million people; see UNAIDS, Report on the 
Global AIDS epidemic 2008, August 2008.
36 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009; see also UNODC, Crime and instability: case 
studies of transnational threats, February 2010.
GDP in 2007, 33% in 2008 and 26% in 2009), are in 
a sense dependent on the illicit opiates industry. In the 
case of Tajikistan, the industry may amount to as much 
as 30% of the recorded GDP.37 This situation is exploited 
by powerful criminal organizations, which have in some 
cases infiltrated the highest levels of government. These 
groups, which generate vast profits through drug traf-
ficking and other illicit activities, are able to corrupt 
governmental officials, reduce the effectiveness of law 
enforcement and derail the march towards instituting 
the rule of law in newly-formed states in the Balkans, 
transition states in Central Asia and vulnerable states in 
Africa. Of course, corruption can emerge at any part of 
the chain, which means that corruption is not limited to 
transit (or source) countries.
Northern route1.2.2 
Unlike other major routes out of Afghanistan which 
have existed for decades, the Northern route through 
Central Asia and into the Russian Federation is a rela-
tively recent phenomenon, only taking shape in the 
mid-1990s. In this region, both the nature and extent of 
drug trafficking have been strongly shaped by the dis-
solution of the USSR, whereby newly-formed states had 
to suddenly police borders previously administered cen-
trally. These new borders remained virtually open until 
new national customs services were created in 1993–
1994.38 
Routes and volumes
UNODC estimates that 25% of all Afghan heroin -or 
95 mt- are trafficked each year from Afghanistan into 
the Central Asian Republics (CARs) towards the Rus-
sian Federation.39 This total includes heroin that is 
consumed en route or at destination, seized by law 
enforcement or to a limited extent, trafficked onward to 
Europe. The Russian market is estimated to consume 
approximately 70 mt of heroin annually while Central 
Asian demand stands at 11 mt; the rest is either seized 
or continues onwards. 
In addition to heroin, some 120-130 mt of opium are 
smuggled into the region each year, mostly for con-
sumption in the CARs and the Russian Federation. 
There is no evidence of morphine being shipped in large 
quantities through this route. Transformed into opium 
equivalents, approximately 780-800 mt of opiates are 
trafficked annually along this route. 
37 Letizia Paoli et al., “Tajikistan: the rise of a narco-state”, The Journal 
of Drug Issues, 2007, p.951.
38 Martha Brill Olcott et al.; “Drug trafficking on the great Silk road: 
the security environment in Central Asia”, Carnegie Endowment 
working papers, 2000.
39 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009.
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From Afghanistan to the north, traffickers are offered a 
choice of three countries: Tajikistan, Uzbekistan and 
Turkmenistan. These northern borders span a length of 
some 2,600 km. The Uzbek and Tajik borders are 
marked by the Amu Darya River, while the Turkmen 
border is mostly desert. Although there is no shortage of 
possibilities for clandestine crossings, it appears that 
most of the trafficking occurs along established trade 
and transit routes. There are nine official crossings 
between Afghanistan and Central Asia, including two 
river ports, one on the Uzbek border and one on the 
Tajik border. These river ports are the primary conduit 
for legitimate trade, and also, it appears, for trafficking. 
They are:
Hayraton (Afghanistan’s Balkh province -   ?
Sukhandaraya province of Uzbekistan); 
Ninji Pianj (Afghanistan’s Kunduz province -   ?
Khatlon Province, Tajikistan).
Uzbekistan’s border with Afghanistan is short (137 km) 
and well-policed. While armed attempts at night cross-
ings still occur, traffickers generally prefer to avoid this 
border in favour of easier alternatives such as the Tajik 
border. It appears instead that most opiates that do enter 
Uzbekistan first transit Tajikistan and to a lesser extent 
Kyrgyzstan. What cannot be excluded, however, is that 
larger, long-distance shipments by well-protected net-
works may find it convenient to use the better-developed 
infrastructure of Hayraton when aiming for the Russian 
market, or even to import precursor chemicals, as evi-
denced by a 2008 seizure of 1.5 mt of acetic acid.40
Afghanistan’s border with Turkmenistan is lengthy (744 
km) and mostly desert. There is some lab activity in the 
border areas of adjoining Afghan provinces (such as 
Badghis), which is of concern since traffickers generally 
export opiates over the closest border. The Turkmen 
route is facilitated by the presence of approximately 1 
million ethnic Turkmens in Hirat, Badghis and Faryab 
provinces. Turkmenistan also shares a 992 km border 
with the Islamic Republic of Iran where an equal number 
of Turkmens reside, mainly in the Mazanderan and 
Khorassan provinces, close to the border. Turkmenistan 
borders the Caspian Sea for a length of 1,768 km and its 
coastal port of Turkmenbashi was long viewed as an 
important heroin route across the Caspian to Azerbaijan 
and further to Europe. Although the Caspian is undoubt-
edly used for opiate trafficking, recent UNODC field 
research suggests that trafficking through this particular 
seaport may have fallen into disuse. Seizure data also 
appears to indicate limited direct trafficking from 
Afghanistan into Turkmenistan. Other routes may how-
ever be used. Recent data from the Central Asia Regional 
Information and Coordination Centre (CARICC) indi-
40 Acetic acid is not a controlled substance but as been cited as a possible 
alternative to acetic anhydride in processing.
cates the emergence of a new route through Turkmeni-
stan: From Afghanistan to the Islamic Republic of 
Iran-Turkmenistan-Kazakhstan-Russian Federation/CIS 
countries-Europe.41 Not enough information is availa-
ble on this route to estimate its importance, however. 
Turkmenistan was a leading country in precursor chem-
ical seizures in the late 1990s,42 but no movements have 
been detected in the past decade.
From a law enforcement perspective, control of the 
Tajik-Afghan border (1,387 km) is becoming more and 
more elusive. Outside fixed border points, traffickers 
continue to swim, wade or cross the Amu Darya river by 
boat, with the majority reportedly crossing undetected. 
Once in Tajikistan, the loads are then broken down into 
smaller quantities to be shipped across the border by 
land, rail and air. The larger portion of opiates travels 
north through Kyrgyzstan toward Kazakhstan. In Kyr-
gyzstan, the southern city of Osh has consistently been 
identified as a regional hub of trafficking activity. As 
noted, a smaller flow veers east into Uzbekistan and 
further to Kazakhstan. 
The building of new bridges across the Amu Darya river, 
while crucial for the development of regional trade, is 
misused by traffickers. According to law enforcement 
sources, opiate traffickers, in collusion with corrupt 
officials, reportedly use the cover provided by legitimate 
cross-border commerce to traffic growing quantities of 
heroin into Tajikistan.43 These developing corridors can 
also be potentially misused for precursor conveyance 
destined for laboratories in north-eastern Afghanistan.44 
In 2007, a seizure of 10 mt of acetic anhydride in the 
Russian Federation was to be shipped by truck to 
Afghanistan, by way of Tajikistan.45 
In all, 95 mt of heroin are estimated to be trafficked 
across these three borders. Estimates suggest that the 
largest proportion of the Central Asian flow runs through 
Tajikistan. Once in Central Asia, traffickers have access 
to a number of transportation options, including a well-
developed road and rail network. Based on seizure fig-
ures, most trafficking appears to be conducted in private 
and commercial vehicles, often in relatively small 
amounts. Of 45 heroin seizures above 500 grams (a 
commercial quantity) made in Tajikistan between 2005 
41 UNODC Regional office for Central Asia, “Compendium 2010”.
42 In 1997-1998, 78% of heroin seized in Central Asia was apprehended 
in Turkmenistan while in 1995-2000, more than 198 mt of precursor 
chemicals were seized in the country, mostly acetic anhydride; see 
UNODC ROCA, “The Drug and Crime Situation in Central Asia: 
Compendium”, 2003.
43 Interview, Tajikistan, November 2009.
44 UNODC surveyors identified 24 laboratories (13 morphine, 11 
heroin) in north-eastern Afghanistan, see UNODC Afghanistan 
country office, Analysis of Opiate and Precursor Seizures in Afghanistan 
in 2008, p 13.
45 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009, p.73.
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and 2007, 80% amounted to 10 kg or less, and of these, 
the average size was 2.6 kg. The largest seizure, made in 
2005, was 119 kg. This is a large seizure, but it would 
take hundreds of similar shipments to accommodate the 
95 mt estimated to be trafficked through the region.46 
There appears to be a recent trend toward larger seizures, 
however, suggesting increasingly well-resourced organi-
zations. While it was rare to find a seizure of over 100 
kg of heroin in Central Asia (or the Russian Federation) 
prior to 2008, at least 14 such seizures have been made 
since that time, including in Kazakhstan (537 kg), 
Tajikistan (100 kg twice), Uzbekistan (133 kg and 568 
kg) and the Russian Federation (330 kg). A similar trend 
was observed with opium, where larger than usual con-
signments were seized in Tajikistan (400 kg), Turkmeni-
stan (200 kg) and Uzbekistan (155 kg and 190 kg) in 
2008. Of course, it remains unclear whether these trends 
reflect changes in the nature of the trafficking or in the 
nature of enforcement.
Reversing a previous downward trend that started in 
2005, heroin seizures sharply increased in 2008 and 
made up the largest proportion of opiates seized in Cen-
tral Asia. In all, 5.3 mt of heroin (60% more than in 
2007) and 4.5 mt of opium (28% less than in 2007) 
were seized in Central Asia in 2008. Tajikistan has tra-
ditionally led Central Asia in heroin seizures, and on a 
per capita basis, probably leads the world in opiate sei-
zures.47 Turkmenistan’s seizures are dominated by opium 
46 In contrast, large cocaine seizures are typically multiple mt, and the 
wholesale value of these drugs is about the same in their primary 
destination markets.
47 According to UNODC data, three of the Central Asian countries 
were listed among the top 25 opium seizing countries in 2007. In 
terms of global heroin seizures, Tajikistan ranked 7th; Kazakhstan – 
19th; and Uzbekistan – 21st. 
while other Central Asia countries appear more bal-
anced. In 2008, Uzbekistan’s heroin seizures (1,472 kg) 
more than tripled compared to 2007 (480 kg). 
Although most opiates are reported trafficked by road, 
traffickers can also move their product by air, including 
via direct routes into the Russian Federation. A common 
method involves internal body carry or 'swallowers'; 
most start their journey in Tajikistan. Air routes from 
Central Asia carry smaller shipments of opiates than 
land routes, but on aggregate, they likely amount to 
significant quantities with higher profit margins. Accord-
ing to official reports from the Russian Federation, more 
than 20% of seized heroin enters the Russian Federation 
through commercial airliner.48 A smaller proportion, 
approximately 12%, is reportedly trafficked northward 
by passenger train. Here again, internal body carry 
appears to be a common method. UNODC estimates 
that approximately 25 mt of heroin are trafficked by air/
rail, while the bulk, some 50-55 mt, is trafficked using 
the regional road network, mainly via Kazakhstan.49 
Although Kazakhstan is the inescapable heroin gateway 
to the Russian Federation if travelling by land, it seized 
only about 3% of the heroin flow estimated to cross its 
territory in 2008, despite a three-fold increase in heroin 
seizures over previous years. Kazakhstan is also last in 
regional opium seizures despite an annual consumption 
estimated at 18 mt. This anomaly is difficult to explain. 
It is true that due to their length, Kazakhstan’s borders 
are the most challenging of all the CARs. A country 
roughly the size of Western Europe, Kazakhstan must 
police some 12,000 km of land borders (including the 
7,000 km border with the Russian Federation) and 
1,900 km of Caspian Sea coastline. Conversely, Kaza-
khstan is probably the best equipped Central Asian state 
to handle the drug threat as it has the largest financial 
resources. A 2008 report from the Central Asian Regional 
Information and Coordination Centre (CARICC) 
starkly concluded: “If drugs reach the territory of Kaza-
khstan then the probability of safe shipping to the Rus-
sian Federation can be around 95%.” Once the heroin 
reaches Kazakhstan, most passes through the north-
western borders into the populated areas of south-west-
ern Russia and western Siberia.
In addition to losses en route such as seizures and local 
consumption, not all heroin is destined for the Russian 
Federation. One small stream (approximately 1 mt) 
veers east towards China’s Xinjiang province to supply 
the Chinese market. Based on anecdotal reports, this 
route may have grown in significance although it is 
unclear if one or all of Central Asia’s borders with China 
48 ARQ, Russian Federation 2008. 
49 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009, p.50.
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are used for trafficking.50 Another two mt are estimated 
to be shipped from Central Asia to the Caucasus region 
every year. The remainder, approximately 75-80 mt of 
heroin, enters the Russian Federation. Some 70 mt is 
annually consumed by heroin users in the Russian Fed-
eration and an average of 3 mt of heroin is seized annu-
ally. This leaves an estimated 4 mt of heroin to exit into 
Ukraine, Belarus, the Baltic countries and the Nordic 
countries. 
How does the market operate?
The dissolution of the USSR influenced the dynamics 
and structures of organized crime in the region. Firstly, 
it permitted the re-activation of dormant cross-border 
trade, ethnic and family ties with Afghanistan. Second, 
the Central Asian states inherited a well-established air 
and road communication system that links them to the 
Russian Federation and Europe, a boon for opiate traf-
fickers seeking new markets and alternate routes to 
Europe. Third, these new states are mostly poor and 
some have had problems with political insurgencies. 
Under-resourced and struggling to find their feet, 
addressing heroin trans-shipment was not an early prior-
ity. During the early transition years, Afghan groups 
quickly expanded their operations into Central Asia. 
The civil war in Tajikistan (1992-1997) was a facilitator, 
creating a lawless climate and further impoverishing the 
least developed of all post-Soviet states. In the post-war 
period, some warlords and criminal elements were left to 
consolidate their position. Over time, Tajik and other 
50 According to some reports, the level of heroin trafficking from Cen-
tral Asia (especially from Tajikistan) to China may be higher than 
currently estimated. Given the paucity of information, it is currently 
difficult to estimate the importance and extent of this relatively new 
phenomenon.
Central Asian groups would traffic increasingly large 
loads into a rapidly expanding Russian market. Net-
works became entrenched and relationships were 
cemented with both Russian organized crime and Afghan 
suppliers. 
On the Afghan side of the border, trafficking to Central 
Asia appears to be dominated by reportedly five major 
Afghan narcotics networks, comprised of officials, organ-
ized crime groups and warlords with sprinkled elements 
from former Mujahedin factions such as Hizb-i-Islami. 
These (sometimes overlapping) networks are often 
engaged in legitimate businesses and work alongside 
much smaller, often family-based, groups. Ethnic Tajiks 
living on both sides of the Tajik-Afghan border and their 
common language are important in this respect. 
Although there are some laboratories active in the adja-
cent north-eastern Afghan provinces (Takhar, Kunduz 
and Badakhshan)51 bordering Tajikistan, most Central 
Asian heroin is processed in and trafficked from south-
ern Afghanistan. Pashtun networks based in the south 
ship narcotics across the country to Uzbek and Tajik 
groups for further shipment. Although groups are gener-
ally organized along ethnic lines in Central Asia, mixed 
ethnic membership is also found in some regions. This 
is most obvious in Tajikistan where some networks are 
composed of nationals from Afghanistan and Tajikistan. 
This facilitates trafficking operations and ensures smooth 
lines of supply. 
Based on customs seizures, there is plenty of evidence of 
transnational activity, but no national groups appear to 
dominate regional trafficking. Russian nationals com-
prise a large share of arrestees in Kazakhstan and Kyr-
51 There are also laboratories active in Nangarhar (eastern Afghanistan) 
and a portion of their production reportedly moves north. 
Distribution of the heroin market on the Northern route, 2000-2008Fig. 12: 
Source: UNODC
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gyzstan, but a much smaller share among countries that 
span the Afghan border. Conversely, a small number of 
Afghans are arrested in Tajikistan, but usually not fur-
ther afield. Tajiks appear to be major players in a number 
of countries, including the Russian Federation, but are 
detected in much smaller numbers in Kazakhstan. 
According to Western law enforcement sources in the 
region, Russian-based organized crime groups generally 
place orders with Tajik-based groups who arrange for 
trans-shipment of the drugs from Afghanistan through 
Tajikistan. The drugs are then moved through the region 
and into the Russian Federation. It is possible that the 
Tajik groups who source the drugs then pass the con-
signments on to Russian groups in Kazakhstan but it 
seems more likely that the drugs change hands several 
times before reaching the consumer. 
Outside these ‘regional’ nationalities, West Africans, 
especially Nigerians, have also been reported, particu-
larly in Tajikistan. In some instances, they may act as 
simple couriers, as demonstrated with the 2006 attempt 
by a Nigerian group to have one of their own cross the 
Kazakh-Chinese border with heroin. There is a distinct 
possibility that firmer ties across borders will occur 
between Central Asian groups and networks that origi-
nate outside the region. Increased cross-border commer-
cial ties and a re-establishment of ethno-cultural linkages 
with the western Chinese province of Xinjiang could 
facilitate supply to a growing heroin market in that part 
of China.
Heroin trafficking in some Central Asian countries also 
appears increasingly complex and professional. Large 
seizures in recent years may indicate an organized traf-
ficking business, while arrest statistics seem to suggest a 
trend towards regionalization. Although they are still 
numerically important, individual entrepreneurs and 
smaller groups united by family ties or kinship may have 
become fewer in number. There is also evidence that 
traffickers are increasingly resorting to violence in order 
to protect shipments. Armed clashes used to occur 
mostly on the Tajik-Afghan border, but Uzbek and 
Turkmen border guards are reporting incidents as 
well.52 
Heroin increases in value as it distances itself from the 
source. The estimated value of opiates (at the borders) 
trafficked through the Afghanistan/Central Asia border 
area is US$350-400 million53 annually. The portion 
that eventually reaches the Russian Federation will be 
worth 30 times this amount. In the Russian Federation, 
retail distribution of heroin and other drugs is carried 
out by a variety of criminal groups typically organized 
along ethnic lines with Central Asian, Caucasian, Rus-
sian/Slavic and Roma groups all active in drug traffick-
ing.54
Impact of this flow
In terms of absolute numbers, the Russian Federation is 
particularly affected with its 1.5 million addict popula-
tion. The hugely damaging threat of HIV/AIDS is 
directly related to heroin injection. To date, there are 
over a quarter of a million registered HIV cases (although 
the number of unregistered cases is estimated to be 
much higher than this) in the Russian Federation. Of 
these, over 80% are intravenous drug users. In the CARs, 
nearly 15 years of continuous heroin transit has created 
52 Interview Uzbek Chief of Border Guards, Tashkent, Uzbekistan, 
November 2009; Interview Deputy Chief Turkmen border guards, 
Ashghabat, Turkmenistan, November 2009.
53 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009.
54 International Narcotics Control Strategy Report - 2007.
Distribution of nationalities of arrested heroin trafﬁckers at customs, 2000-2008Fig. 13: 
Source: World Customs Organization
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a local market of 282,000 heroin users, consuming 
approximately 11 mt of heroin annually. Local opium 
consumption is estimated at approximately 34 mt 
(although demand in Turkmenistan may be underesti-
mated). This puts some Central Asian states on par with 
countries with the highest global opiate abuse preva-
lence.55 As in the Russian Federation, heroin use in 
Central Asia has led to a jump in HIV cases, spreading 
predominantly among male injecting drug users of the 
most productive age (20 to 49 years).56 Another statistic 
completes this grim picture: the total number of offi-
cially registered HIV cases in Central Asia has increased 
19-fold in the last decade: from 1,641 cases in 2000 to 
30,993 cases57 in late 2008.58
The total value of the opiate market is estimated to be 
around US$13-15 billion per year in both Central Asia 
and the Russian Federation.59 By virtue of this financial 
weight alone, organized crime in the region contributes 
substantially to problems of corruption and undermines 
governance. Drug traffickers are able to offer substantial 
bribes to poorly paid local police, border guards and 
customs to turn a blind eye to suspicious shipments. In 
Central Asia, both Tajikistan and Kyrgyzstan are par-
ticularly vulnerable, and both have very high levels of 
corruption. 
55 Current annual prevalence of opiate abuse is estimated to be around 
1% of the adult population (between 15 – 64 years) in the region.
56 UNODC Regional Office for Central Asia, Compendium of Drug 
Related Statistics. 1997-2009, 2009, p.7.
57 In 2008, 6,664 officially registered persons with HIV/AIDS were 
identified in Central Asia. 
58 UNODC Regional Office for Central Asia, Compendium of Drug 
Related Statistics. 1997-2009, 2009, p.7.
59 These figures are necessarily imprecise, particularly due to the lack 
of data on heroin purity levels in Central Asia and lack of certainty 
regarding the size of the Russian heroin using population.
Balkan route1.2.3 
The Balkan route to West and Central Europe runs from 
Afghanistan via the Islamic Republic of Iran, Turkey and 
south-east European countries. This route and its vari-
ous branches form the artery that carries high purity 
Afghan heroin into every important market in Europe. 
UNODC estimates that 37% of all Afghan heroin or 
140 mt is annually trafficked into the Islamic Republic 
of Iran, from Afghanistan and Pakistan, towards the 
European market. 
Routes and volumes
The Islamic Republic of Iran’s eastern border with 
Afghanistan and Pakistan is 1,845 km long and consists 
of mainly mountainous or harsh desert terrain. There 
are obvious challenges to achieving even partial control 
over this area, although 12,000 anti-narcotics police and 
border guards are reportedly deployed at these long bor-
ders.60 The Balkan route begins in Afghanistan’s south-
ern and western provinces, with shipments destined for 
both the Afghan-Iran border and the Afghan-Pakistan 
border. 
Most of the heroin flow moves through the Iran-Afghan 
border. Every year, approximately 105 mt of heroin are 
smuggled from the Afghan provinces of Nimroz, Hirat 
and Farah into eastern Islamic Republic of Iran. Possibly 
due to increased law enforcement efforts at that border, 
Afghan traffickers are thought to increasingly rely on the 
Afghanistan-Pakistan-Iran route, estimated to handle an 
additional 35 mt of heroin. To do this, they must first 
cross into the Pakistani province of Balochistan and veer 
60 UNODC project document, “Integrated Border Control in the I.R. 
of Iran (IRNI50). 
Country
Number of  
estimated heroin 
users
Estimated level  
of heroin  
consumption (mt)
Number of  
estimated raw 
opium users
Estimated level  
of opium  
consumption (mt)
Tajikistan 20,300 1 4,700 3
Turkmenistan 31,200 1 1,400 1
Uzbekistan 118,600 5 13,800 8
Kyrgyzstan 25,900 1 9,600 5
Kazakhstan 86,000 3 33,000 18
Total (rounded) 282,000 11 62,500 34
Russian  
Federation 1,500,000 70 160,000 58
Heroin users and consumption in the Russian Federation and Central AsiaTable 5: 
Source: UNODC
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east into the Islamic Republic of Iran. Once in the 
Islamic Republic of Iran, only two borders separate 
Afghan opiates from mainland Europe.
In all, approximately 1,000 mt of opium and 140 mt of 
heroin flow into the Islamic Republic of Iran via these 
borders. Most of the heroin, around 30% (105-110 mt) 
of Afghanistan’s total production, continues to move 
west/south-west into the Islamic Republic of Iran 
towards Turkey and further to Europe. This total includes 
heroin that is consumed within Europe, seized by law 
enforcement or trafficked onward to destinations like 
the United States. The bulk of the supply (at least 80%, 
or 85 mt) travels the traditional overland Balkan route. 
An additional 10 mt reach Europe by air or sea from 
various points of departure. 
The so-called ‘northern Balkan route’ is a relatively 
recent variant on the Balkan route which transits the 
Caucasus rather than Turkey. Every year, approximately 
9 mt of heroin are estimated to be trafficked from the 
Islamic Republic of Iran along this route. Joining this 
flow is a smaller volume of about 2 mt from Central Asia 
(not shown on map). In all, 11 mt of heroin are esti-
mated to enter the Caucasus. Some 4 mt are either 
consumed or seized. The remainder, around 7 mt,61 is 
thought to be trafficked to Europe. Through one branch 
of this route, an estimated 6 mt are shipped from Geor-
gia and then to Europe (Bulgaria) via the Black Sea.62 A 
smaller flow of 1 ton also travels through Georgia, but 
moves northward across the Black Sea to the Ukraine.63 
61 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009, p.49.
62 Ibid., p.39.
63 Ibid., p.39.
Some of the identified routes running through the 
Caucasus are:
Islamic Republic of Iran – Azerbaijan – Georgia – 1. 
Black Sea – Ukraine and/or Bulgaria;
Islamic Republic of Iran – Caspian Sea – Russian 2. 
Federation/Caucasus – Black Sea – Ukraine and/or 
Bulgaria;
Afghanistan – Central Asia – Caspian Sea 3. 
– Azerbaijan/Caucasus.
Other, smaller routes include trafficking from the Islamic 
Republic of Iran into Azerbaijan and onward to Dag-
estan in the Russian Federation, and a small heroin flow 
originally shipped to the Ukraine via the Caucasus 
region for transport to Romania and beyond to West 
Europe. An extension of the Northern route, perhaps 4 
mt per annum (4%), is also reported to reach Europe via 
the Russian Federation.
Heroin crosses from the Azarbaycan-e-Khavari province 
of the Islamic Republic of Iran into Turkey and traverses 
Turkey’s Hakkari and/or Van districts. An estimated 95 
mt of heroin are shipped across Turkey’s borders every 
year along the following routes:
Hakkari/Van – south-eastern cities – central Anatolian  ?
cities – Istanbul – Edirne to Bulgaria/Greece.
Hakkari/Van – south-eastern cities – southern/western  ?
Anatolian cities and onward to Greece/Cyprus by sea.
Hakkari/Van – south-eastern cities – central Anatolian  ?
cities – northern Anatolian cities – Ukraine. 
From Turkey, around 80-85 mt of heroin flow towards 
West Europe (particularly Germany, the Netherlands 
Italy and the UK) along several routes: 
The Northern and Balkan routesMap 3: 
Source: UNODC
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To Italy ? : Approximately 20-25 mt64 of heroin are 
traﬃcked towards Italy (mostly by sea) and Switzer-
land. Most of that amount is thought to be traﬃcked 
via Bulgaria, Greece, the former Yugoslav Republic of 
Macedonia and Albania for onward transportation to 
64 This amount is equivalent to the estimated quantity of heroin con-
sumed in Italy and Switzerland.
Italy. A smaller route proceeds directly from Greece 
by sea towards Italy. Some heroin also ﬂows via the 
former Yugoslav Republic of Macedonia to Serbia, 
Bosnia and Herzegovina, Croatia and Slovenia and 
further north. In addition, an undetermined amount 
of heroin is traﬃcked via sea and air from Turkey to 
Italy. 
Route
Size of flows 
(mt)
Percentage 
(rounded)
Balkan route (Afghanistan-I. R. of Iran-Turkey-Southern Europe-Rest of Europe) 85 80%
Northern route (Afghanistan-Central Asia-Russian Federation-East Europe) 4 4%
Northern Balkan route (Afghanistan-I. R. of Iran-Caucasus-Southern Europe) 7 7%
Directly from Pakistan to West and Central Europe 5 5%
Through Africa to Western and Central Europe 2 2%
Directly from South and South-East Asia (except India)  
to West and Central Europe 1 1%
Through the Middle East and the Gulf area to West and Central Europe 1 1%
Directly from India to West and Central Europe 1 1%
Total 106 100%
Breakdown of heroin ﬂows to EuropeTable 6: 
Source: UNODC
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To the Netherlands and Germany ? : The bulk of the 
heroin traﬃcked along this route (approximately 55 
to 60 mt) travels to Germany and the Netherlands 
through Bulgaria, Serbia, Hungary and Austria, or 
through Bulgaria, Romania, Hungary, Slovakia and 
Austria. From Germany and the Netherlands, heroin 
shipments are traﬃcked onwards to larger markets in 
France, the United Kingdom and Spain. 
Because of its central position along the Balkan route, 
Austria plays an important transit role for much Germa-
ny-bound heroin. Heroin flows to Austria through its 
borders with Slovenia and Hungary. However, some 
heroin destined for the German market is trafficked 
through Bulgaria, Romania, Hungary, Slovakia and the 
Czech Republic, thereby bypassing Austria. Controls at 
Schengen borders are limited or non-existent. 
Other routes include:
To East Europe: A limited amount of heroin is traf- ?
ﬁcked directly from Turkey to Ukraine by sea. 
Direct shipments to West and Central Europe: An  ?
undetermined amount of heroin is traﬃcked directly 
from Turkey to Western and Central European coun-
tries such as Germany, the Netherlands, Belgium, 
France and the United Kingdom by sea and air. 
How does the market operate?
Considerable quantities of heroin are trafficked to 
Europe by sea and air, but the Balkan route resembles 
the Northern route in that the bulk of the flow proceeds 
by land. Most of the heroin headed for West European 
markets leaves Afghanistan into the Islamic Republic of 
Iran, Pakistan and Turkey, which collectively seize most 
of the heroin interdicted in the world (40% of the esti-
mated flow intercepted in 2008). Despite these remark-
able enforcement efforts, traffickers nevertheless succeed 
in getting sufficient volumes through, so that most of 
the heroin consumed in Europe in recent decades has 
passed through these countries. 
Drug smuggling along the Balkan route is systematic 
and seems to involve groups with ample resources and 
consignments much larger than those found on the 
Northern route (in Central Asia). On the Balkan route, 
the average amount of heroin seized is approximately 10 
kg, which is twice the average amount seized on the 
Northern route. Consignments very rarely travel the 
whole way from Afghanistan to Europe in a single 
unbroken journey. Normally, they will be bought and 
sold by different groups along the route, the mode of 
transport will change, and loads will be split and merged 
as they are moved westward. Seizures are especially large 
up to Turkey, at which point consignments appear to be 
broken down into smaller quantities. 
The logistics of the trade summarized above necessitates 
the involvement of well-organized trafficking groups 
with international connections. For such profit-driven 
organizations, the lure of Afghan opiates is obvious 
given the huge mark-ups that arise with distance from 
the source. One kg of heroin is worth around US$2,000-
2,500 in Afghanistan, but rises to US$3,000 on the 
Afghanistan-Pakistan border and to US$5,000 on the 
Iran-Afghanistan border. It increases yet again by around 
60%, to approximately US$8,000, at the Iran-Turkey 
border. Based on the estimated flows via this route, Ira-
nian crime groups organizing heroin trafficking from 
the Afghanistan-Iran border to the Turkey-Iran border 
stand to pocket some US$450-600 million per year. In 
addition to heroin, raw opium (some 1,000 mt in 2008) 
also flows from Afghanistan to the Islamic Republic of 
Iran via the above-mentioned routes to feed an estab-
lished Iranian market. An estimated total of 450 mt65 of 
opium is consumed each year in the Islamic Republic of 
Iran. The annual street value of opium consumed in that 
country is around US$900,000. 
Given the huge sums involved and the serious penalties 
if caught,66 traffickers along the Iran-Afghanistan bor-
ders are generally well-organized and well-armed. Deadly 
clashes between Iranian troops and traffickers are com-
monplace, as demonstrated by the thousands of casual-
ties sustained by the Iranian border guards in the past 
three decades. Depending on the border region, smug-
glers may be Baluchi tribesmen or Kuchi nomads. If 
opiates are trafficked through Balochistan - via the 
largely uncontrolled borders of the Nimroz, Hilmand 
and Kandahar provinces of Afghanistan - Taliban insur-
gents are known to provide security to drug convoys up 
to the border. Balochistan-based organized crime groups 
then transport the heroin to the Iran-Pakistan border. 
Once the heroin enters the Islamic Republic of Iran, 
drug trafficking groups based in that country facilitate 
onward trafficking to the Turkish border. This is sup-
ported by the official statistics of the Islamic Republic of 
Iran which show that most traffickers are Iranian nation-
als, with few Pakistanis arrested in the Islamic Republic 
of Iran (similar proportions are observed for Iranian 
arrestees in Pakistan). These numbers and other reports 
suggest that the involvement of Pakistani organized 
crime groups may not extend far inside the borders of 
the Islamic Republic of Iran. 
Once Iranian criminal groups receive the shipments, the 
majority is forwarded westward towards Turkey. As pre-
viously noted, a portion of the flow veers north and 
transits the Caucasus towards Europe. The presence of 
12 to 20 million ethnic Azeris in northern Islamic 
Republic of Iran can facilitate direct traffic into Azerba-
ijan. Also hindering drug law enforcement over Azerba-
65 UNODC, Addiction, crime and insurgency, 2009, UNODC.
66 Drug control in 2009, Annual Report, Islamic Republic of Iran. 
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ijan’s 132 km long border with the Islamic Republic of 
Iran is the existence of uncontrolled territories due to an 
unresolved conflict. In fact, the entire Caucasus region 
hosts several breakaway republics and disputed zones, 
over which no recognized national authority has control. 
The recent conflict in Georgia, for example, has report-
edly led to an increase in the volume of heroin traffick-
ing from that country to Europe via the Black Sea. 
On the main route to Turkey, ethnic Kurdish groups, 
with large border populations in the Islamic Republic of 
Iran, Iraq and Turkey, may be responsible for border 
crossings. These groups may resell these drugs in Turkey 
or traffic them to Europe through their own networks. 
The United Kingdom’s Serious Organised Crime Agency 
argues that in 2009, 138 Turkish networks continued to 
control the heroin supply to Europe.67 According to 
WCO seizure statistics between 2000 and 2008, the 
majority of drug traffickers arrested in Turkey were 
Turkish nationals. This might suggest that Turkish 
groups are organizing the heroin trafficking all through 
Turkey up to the borders with Bulgaria and Greece 
where Balkan-based groups take over. 
Once heroin leaves Turkish territory, interception effi-
ciency drops significantly. In the Balkans, relatively little 
heroin is seized, suggesting that the route is exceedingly 
well organized and lubricated with corruption.68 In 
2008, the countries and territories that comprise South-
East Europe (a total of 11 countries, including Greece 
and Cyprus) seized 2.8 mt of heroin in 2008. This is in 
sharp contrast to what is seized upstream in Turkey 
(15.5 mt in 2008) and the Islamic Republic of Iran (32 
mt in 2008) every year. In other words, for every kg 
seized in the South East Europe, nearly 6 are seized in 
Turkey and 11 in the Islamic Republic of Iran. Given 
that approximately 85-90 mt travel through this region, 
this suggests inadequate controls and poor cooperation 
in a region where high levels of unemployment and low 
salaries also create incentives for corruption.
The total quantity of heroin seized in West and Central 
Europe, as reported by some 45 countries, was around 7.6 
mt in 2008, which again is only a fifth of the total amount 
seized in Turkey and the Islamic Republic of Iran in 2008. 
In all, three countries - the United Kingdom (18%), Italy 
(14%) and Bulgaria (13%) – accounted for almost half of 
the total amount seized in the EU and EFTA countries in 
2008. Across Europe, many countries directly straddling 
the main heroin trafficking routes report rather low levels 
of heroin seizures, such as Montenegro (18 kg in 2008), 
Bosnia and Herzegovina (24 kg), the former Yugoslav 
Republic of Macedonia (26 kg), Hungary (28 kg), Alba-
67 Serious Organised Crime Agency, The United Kingdom Threat Assess-
ment of Organized Crime, October 2009, p.26.
68 Interception rates in the Balkan region are very low (3%), especially 
when compared with Turkey (16%) and the Islamic Republic of Iran 
(23%).
nia (75 kg), Austria (104 kg), Slovenia (136 kg), Croatia 
(153 kg) and Serbia (207 kg). 
Organized crime in the Balkans involves a large variety 
of criminal activities and as such, heroin is but one, 
albeit among the most lucrative, commodities illicitly 
trafficked through this region. The profits accrued as the 
opiates move downstream are substantial. Organized 
crime groups managing heroin trafficking between the 
Islamic Republic of Iran and Turkey and on to the Bal-
kans are estimated to earn around US$8,000 per kg of 
heroin or a total of US$600-700 million per year. The 
routes through this region also operate in the reverse 
direction with cocaine, precursor chemicals and amphet-
amine-type stimulants (ATS) moving eastward into 
Turkey and beyond. Organized crime groups controlling 
these corridors thus have comparatively better access to 
more numerous and diversified crime markets than their 
Northern route counterparts. Thus, many tend to be 
poly-drug (heroin, cannabis et cetera) and poly-crime 
(trafficking in human beings, weapons and stolen vehi-
cles, to name but a few). 
Another notable feature of the Balkan route is that some 
important networks have clan-based and hierarchically 
organized structures. Albanian groups in particular have 
such structures, making them particularly hard to infil-
trate. This partially explains their continued involvement 
in several European heroin markets. Albanian networks 
continue to be particularly visible in Greece, Italy and 
Switzerland. Italy is one of the most important heroin 
markets in Europe, and frequently identified as a base of 
operation for Balkan groups who exploit the local 
diaspora. According to WCO seizure statistics, Albanians 
made up the single largest group (32%) of all arrestees 
for heroin trafficking in Italy between 2000 and 2008. 
The next identified group was Turks followed by Italians 
and citizens of Balkan countries (Bulgaria, Kosovo/
Serbia, the former Yugoslav Republic of Macedonia and 
to some extent Greece). A number of Pakistani and Nige-
rian traffickers were arrested in Italy as well. 
Most of the Balkan heroin first passes through Bulgaria, 
a country which has reported some fairly large heroin 
seizures in the past, but where figures have been erratic, 
despite little evidence of fluctuation in the flows. In 
2008 for example, Turkey seized some 15 mt of heroin 
while Bulgaria, despite being the recipient of most of the 
Balkan route flow, seized 1.1 mt. In Bulgaria, most of 
the arrested heroin traffickers are nationals of that coun-
try. However, the proportion of Turkish nationals also 
stands out. The other main nationalities are citizens of 
the Balkans such as Serbs and Macedonians. Notably, 
Albanians are near-absent. 
The Netherlands is a hub for heroin trafficking to 
France, the United Kingdom, Belgium, as well as Ger-
many. In the Netherlands, the total number of arrests 
made by customs authorities is limited. Dutch, Nigerian 
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and Turkish nationals are nearly equally represented, 
while Balkan nationals are conspicuously absent. 
In Germany, the number of Turks arrested for heroin 
trafficking outnumbers all other nationalities except 
Germans. Dutch citizens represent 5% of all heroin traf-
ficking arrests and generally enter the trafficking chain 
only after the heroin has arrived in Germany or in traf-
ficking the heroin from the Netherlands back into Ger-
many. Balkan nationalities make up a minority of 
arrestees in Germany, followed by Nigerian nationals.
In the United Kingdom, British citizens predominate, 
but a considerable number of Dutch citizens also show 
up in arrest statistics. The proportion of arrested Turk-
ish, German, Pakistani and Belgian nationals was con-
siderably smaller than Dutch or British nationals between 
2000 and 2008. Here too Balkan nationalities com-
prised a negligible percentage of all heroin trafficking 
arrests.
Heroin trafficking from the Turkey-Bulgaria and Tur-
key-Greece borders to the main heroin markets in the 
United Kingdom, France, Germany and the Nether-
lands is organized by multi-ethnic groups. Locally-based 
organized crime groups generally traffic heroin within 
the destination (main consumer) countries. In Germany 
and the United Kingdom, for example, German and 
British groups, respectively, operate heroin distribution 
networks. In transit countries, south-east European and 
Turkish organized crime groups cooperate. The involve-
ment of local groups in transit countries varies from 
country to country. In Austria, for example, the number 
of Austrians arrested for heroin trafficking between 2000 
and 2008 was negligible, with most arrestees holding 
Turkish, Hungarian, Nigerian or Iranian citizenship. In 
Nationality of heroin trafﬁckers  Fig. 14: 
arrested in Italy, 2000-2008
Source: World Customs Organization
Nationality of heroin trafﬁckers  Fig. 15: 
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 Source: World Customs Organization
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neighbouring Hungary, by contrast, the number of 
Hungarian nationals arrested for heroin trafficking 
during the same period was comparable to that of other 
nationalities. 
Shared ethnicity and language undoubtedly helps smug-
glers to facilitate opiate trafficking from the source, 
through the Iran-Pakistan and Afghanistan-Pakistan 
borders all the way to the Turkish border and beyond. 
At the same time, different ethnic groups cooperate 
seamlessly. This includes Kurdish and Turkish groups as 
well as Bosnian, Serb, Albanian and Croat groups fur-
ther downstream. The 2010 US International Narcotics 
Control Strategy Report argues, regarding trafficking in 
the Balkans, that ‘elements from each ethnic group and 
all major crime “families” are involved in the narcotics 
trade, often collaborating across ethnic lines.’ 
Impact of this flow
The first and most direct impact of opiates is on health, 
including heroin-related deaths. Opiates (including syn-
thetics) account for 35% to almost 100% of all drug-
related deaths in the 22 European countries that have 
provided data, and over 85% in 11 of those countries.69 
In addition, heroin abuse by injection contributes to 
high rates of serious diseases such as hepatitis B, hepati-
tis C and HIV.70 The HIV epidemic among injecting 
drug users continues to develop at varying rates across 
Europe. In the countries of the European Union, the 
rates of reported newly diagnosed cases of HIV infection 
69 European Monitoring Center for Drugs and Drug Addiction 
(EMCDDA), Drug situation in Europe: Drug-related infectious diseases 
and drug-related deaths, November 2009.
70 Hepatitis C (HCV) is more prevalent than HIV among injecting drug 
users across Europe. HCV antibody levels among national samples of 
injecting drug users in 2006 and 2007 vary from 18% to 95%, with 
half of European countries reporting levels in excess of 40%.
among injecting drug users are mostly at stable and low 
levels, or in decline. However, in post-soviet European 
countries such as Ukraine, Belarus and the Republic of 
Moldova, those rates increased in 2007.71 Finally, the 
term ‘transit country’ may not adequately apply to the 
Islamic Republic of Iran, given the ravages of opiates in 
the country. There are around 1 million opiate users in 
the Islamic Republic of Iran and approximately 14 mt of 
heroin and 450 mt of opium are consumed in-country.72 
The Islamic Republic of Iran appears to have one of the 
highest rates of heroin addiction per capita in the world: 
20% of Iranians aged 15 to 60 are involved in illicit drug 
use, and 9% - 16% inject drugs.73 But the lethality of 
heroin is even more direct on the Islamic Republic of 
Iran’s borders where 3,500 casualties among the border 
guards are a reminder of the risks taken by law enforce-
ment officials to stem this deadly flow.
Europe is the most important market in terms of volume 
and turnover for Afghan heroin, with around 250 kg of 
heroin (of 70% purity) consumed on a daily basis. 
Annually this represents some 85-90 mt of heroin and a 
value of some US$20 billion. Most of it, approximately 
80 mt, is thought to be consumed in Western and Cen-
tral European countries. The European market is far 
from homogenous as four main national markets, the 
United Kingdom (21%), Italy (20%), France (11%) and 
Germany (8%) together account for about 60% of con-
sumption in Europe. 
Opiate trafficking also fuels corruption and all countries 
on the Balkan route are affected. The combined GDP of 
Kosovo/Serbia, the former Yugoslav Republic of Mace-
donia and Albania at US$20 billion is equivalent to the 
value of West-Europe’s heroin market. The opiate trade 
is a serious threat to the Balkans; particularly vulnerable 
71 European Monitoring Center for Drugs and Drug Addiction 
(EMCDDA), Drug situation in Europe: Drug-related infectious diseases 
and drug-related deaths, November 2009.
72 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, 2009, p.25.
73 Razzaghi E, Movaghar A, Green TC, Khoshnood K. 2006. “Profiles 
of risk: a qualitative study of injecting drug users in Tehran, Iran.” 
Harm Reduct J, Vol. 3, No. 12, doi:10.1186/1477-7517-3-12 in 
“Mapping and Situation Assessment of High-Risk Key Populations 
in Three Cities of Afghanistan”, World Bank, September 2007, p.4.
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are Kosovo/Serbia, Bosnia, the former Yugoslav Repub-
lic of Macedonia and Albania. A number of unresolved 
conflicts and/or remaining inter-ethnic tensions along 
sections of this route continue to prevent the emergence 
of effective regional counterdrug cooperation and to 
facilitate trafficking. 
The Southern route1.2.4 
Unlike the Northern or Balkan routes, which are mostly 
dedicated to single destination markets, the southern 
route serves a number of diverse destinations, primarily 
Europe, Africa and Asia, and even a limited quantity 
going to the United States and Canada. In truth, the 
only opiate destination market seemingly not targeted 
through this route is the Russian Federation. It therefore 
seems more accurate to talk about a vast network of 
routes rather than one general flow direction. 
Routes and volumes
Pakistan is geographically vulnerable to opiate traffick-
ing; UNODC estimates that approximately 40% of 
Afghanistan’s heroin/morphine (150 mt) transits or is 
consumed in Pakistan. More Afghan opiates pass through 
Pakistan than any other country bordering Afghanistan. 
Controlling this border is a major challenge; the long, 
thinly guarded boundary (2,500 km) follows a chain of 
mountains with long sections reaching altitudes of more 
than 4,000 metres gradually ceding to open plains and 
dunes in Balochistan province facing southern Afghani-
stan. The most important points for all trade, both licit 
and illicit, on the Pakistan-Afghanistan border are the 
Torkham crossing in the Federally Administered Tribal 
Areas (FATA) and the Chaman checkpoint in Balo-
chistan province. In addition to these, there are hun-
dreds of natural passes and desert roads coursing across 
the entire border, most of which are unmanned and 
unsupervised. 
In recent years, a cross-border insurgency has precluded 
effective law enforcement work in much of the FATA and 
in parts of Balochistan province. The biggest vulnerabil-
ity, however, is Pakistan’s immediate proximity to heroin 
processing zones in Afghanistan, notably the adjoining 
provinces of Hilmand, Nimroz and Kandahar. Every day, 
finished heroin is smuggled into Pakistan using multiple 
methods of transportation, including the wide usage of 
camels and pack animals. Not only heroin but unrefined 
opium and semi-refined morphine are shipped across 
these borders, as seizure data demonstrates. In 2006, 
Pakistan seized approximately 32,658 mt of morphine or 
72% of global seizures. This is a huge 18-fold increase 
over seizures in 2001, which totaled 1,825 kg.74 Since 
then, morphine seizures have dropped by two thirds in 
74 UNODC, Addiction, crime and insurgency: the transnational threat of 
Afghan opium, UNODC, p.34.
2007 (10,989) and again by a third in 2008 (7,324).75 
Seizures of opium nearly doubled from 2007 (15,369) to 
2008 (27,242) and Pakistani users consume approxi-
mately 80 mt of opium annually, most of it sourced in 
Afghanistan. A portion of heroin never leaves Pakistan, 
either due to absorption into the domestic market (esti-
mated to consume approximately 20 mt of heroin 
annually)76 or seizures (9.2 mt of heroin in 2008). 
The remaining opiates (mostly heroin) flow out of Paki-
stan in multiple directions, starting with the major con-
sumption markets next door in China, India and the 
Islamic Republic of Iran. The following are the major 
routes identified: 
From eastern Afghanistan into the FATA, opiates are  ?
traﬃcked in three main directions: 1) towards China 
via Gilgit (northern areas) by road; 2) towards India 
through the NWFP-Chakwai/Rawalpindi-Sailkot-
Wagha route; 3) towards Karachi via the North West-
ern Frontier Province (NWFP)-Rawalpindi-Chawai-
Faisabad-Mutan-Sukkur route. 
From Balochistan (mostly the cities of Dalbandin and  ?
Quetta) towards eastern Islamic Republic of Iran by 
road and rail for onward movement towards Turkey 
and Western Europe. Towards Gwadar port or the 
smaller ﬁshing ports and open areas of the Makran 
coast or the main ports of Karachi and Port Qasim 
and further to international destinations via air or sea, 
mostly using cargo containers.
Although significant quantities are shipped from East-
ern Afghanistan into FATA, the Pakistani province of 
Balochistan is the primary transit area, both for ship-
ments that exit via the Pakistani coast and those which 
travel through Pakistan to the Islamic Republic of Iran. 
This is a significant flow in itself with almost a quarter 
of the heroin flow (or 35 mt) veering west towards the 
Iranian border and blending into the Balkan flow des-
tined for Europe. 
Europe, an especially lucrative market, is also targeted by 
Pakistani traffickers who operate numerous air (and sea) 
trafficking routes from Pakistan to Europe (mostly the 
United Kingdom and the Netherlands), shipping an 
estimated 5 mt annually via these direct connections.77
Approximately 2 mt of heroin are shipped to the United 
States and Canada annually, through various routes, 
including directly in cargo planes.78 
Over the past decade, China appears to have received an 
increasing amount of Afghan opiates, approximately 7 
mt (out of an estimated total 55 mt of heroin trafficked 
75 ARQ, Pakistan, 2008.
76 UNODC, Addiction, crime and insurgency, p.25.
77 Ibid., p.34.
78 In July 2009, the Royal Canadian Mounted Police seized over 120 kg 
of heroin that had been shipped from Pakistan.
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How does the market operate?
The first stage of the route offers relatively few chal-
lenges to experienced traffickers, many of whom belong 
to ethnic groups that live on both sides of the border. In 
Balochistan, drug trafficking convoys consist mostly of 
Baloch traffickers receiving from Pashtuns in Afghani-
stan and delivering to the Islamic Republic of Iran, 
Karachi, or launches from the Balochistan coast (Gwadar 
and Pasni ports). These convoys are heavily militarized 
and intimidation/violence occurs all around their busi-
ness, including in areas of Balochistan that suffer from 
having very low penetration of government security 
forces. Many important traffickers are based in Quetta 
(Balochistan) and some are Afghans who have relocated 
there following law enforcement operations in southern 
Afghanistan. 
Trafficking from eastern Afghanistan into the FATA gen-
erally involves the use of mountain trails and pack ani-
mals. Violence is rarely reported during crossings (which 
often occur at night). The cross-border trade is under the 
control of several prominent cross-border Pashtun tribes, 
notably the Afridi and Shinwari, but also others such as 
members of the Mohmand and Waziri sub-tribes. To 
offload further in Pakistan, whether in Karachi or on the 
Makran coast, traffickers rely on high-level political pro-
tection and connections between Afghans and powerful 
people in Sindh and Punjab provinces. 
With the possible exception of Iran-bound opiates, Afri-
can traffickers – the majority West Africans - are pivotal 
to the international trafficking of heroin. Groups often 
have a large and varied pool of couriers to employ. These 
may be Filipinos, Indonesians, Pakistanis and Chinese 
nationals but also West Africans. Among West African 
groups, Nigerians are especially active as attested in 
arrest figures. These groups tend to be organized along 
tribal/ethnic lines with loose network structures.84
West African groups traffic to multiple destinations, 
including China, India and Africa. This type of traffick-
ing usually involves the use of air routes (from the air-
ports of Peshawar, Islamabad, Lahore, Karachi and 
Quetta) to transit points like Dubai and onward to 
Nigeria and other West African countries.85 The use of 
post parcels is also widely reported. 
Africa is both a market and a staging point for other 
destinations. According to ANF reports, African traffick-
ers “have created two networks: a supply network from 
Pakistan to Africa and a redistribution network from 
Africa to Europe and North America and elsewhere.”86 
In destination markets like Europe, West African net-
works rely on their respective diaspora as a base for their 
activity (importation and retail distribution of heroin). 
Recruiting European nationals as couriers to bring heroin 
by air to Europe has also been reported. 
The use of air routes is significant; over 37% of Paki-
stan’s total heroin seizures in 2006 took place at air-
ports.87 Couriers typically attempt to either conceal 
opiates in luggage or body carry them out of Pakistan. 
The extent to which African groups collaborate with 
Pakistani groups in smuggling ventures remains unclear. 
According to the US State Department INCSR 2010, 
drug trafficking organizations in Pakistan are still frag-
mented and decentralized but there is a trend towards 
specialization. Clearly, the market is not closed to out-
siders, as Nigerians alone account for fully 32% of drug 
trafficking arrests in 2008. Rather it appears that Nige-
rians (and other African groups) overlap in some cases 
with Pakistani groups, both in Pakistan and in some 
destination markets (Africa and China)
Annually, UNODC estimates that the revenue gener-
ated by Afghan opiate trafficking to and through Paki-
stan exceeds US$1 billion, while emphasizing that this 
excludes the revenue from illicit trading in associated 
precursor chemicals. In the past few years, most large 
(multi-ton) seizures have occurred at the port of Karachi 
but chemicals may also be trafficked to Pakistan in small 
lots from China and/or India, two major producers. It is 
notable that Pakistan’s acetic anhydride seizures sur-
passed Afghanistan’s in 2008.88 There is an increasing 
84 Joergen Carling, Migration, Human Smuggling and Trafficking from 
Nigeria to Europe, International Peace Research Institute, Oslo 
(PRIO), 2006.
85 Anti Narcotic Force Pakistan, Analysis of domestic seizures 2006.
86 Ibid., p.14.
87 UNODC Pakistan country office, Illicit drug trends in Pakistan, April 
2008, p.23.
88  According to information provided by the UNODC Pakistan coun-
try office, in 2008, Pakistan reportedly seized over 15,000 litres of 
acetic anhydride in three separate seizures.
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information flow on precursor trafficking through Paki-
stan and this is directly related to the country’s openness 
to observation and international cooperation. There 
remain, however, serious information gaps on precursor 
procurement networks and the illicit precursor trade in 
general. 
Impact of this flow
As with the Islamic Republic of Iran, Pakistan’s high 
levels of opium and heroin use are fuelled by the easily 
available supply. The latest assessment of drug use in 
Pakistan took place in 2006 and estimates the number of 
chronic opiate users at 628,000, of which around 500,000 
are heroin users.89 To put these numbers in perspective, 
this is twice the numbers found in Central Asia90 and ten 
times the numbers found in Afghanistan. 
A 100% increase in injecting drug use was estimated 
between 2000 and 2006. There is currently a concen-
trated, but localized, HIV epidemic among injecting 
drug users (IDUs) in Pakistan. Coupled with widespread 
risk behaviour, this could lead to an HIV epidemic 
among the wider population. Surveys in several cities of 
Pakistan have confirmed substantial epidemics of HIV 
among IDUs.91 One study in Karachi revealed an increase 
in HIV prevalence among IDUs from 1% in 2004 to 
26% in March 2005,92 while a more recent study found 
that HIV prevalence among IDUs has reached 24% in 
Quetta (along the border with Afghanistan).93 The 
increase in the number of IDUs has complicated drug 
treatment and requires trained service providers.
As in neighbouring Afghanistan, drugs in Pakistan are 
inseparably entangled with corruption and insecurity. 
Currently, Pakistan’s efforts against the trafficking of 
Afghan opiates (and the cultivation of opium poppy) are 
constrained by a major cross-border insurgency and the 
threat of violent extremism, which has monopolized the 
attention of law enforcement agencies. One example is 
the restive Federally Administered Tribal Areas (FATA) 
which was opium poppy-free for several years until 
2003/2004, but where there has been a re-expansion of 
cultivation.94 
89 According to the 2008 UNODC survey Illicit drug trends in Parkistan 
there are 482,000 heroin users in Pakistan.
90 Prevalence was revised downwards to 0.7% of the adult population. 
However, this assessment was not methodologically sound and it is 
suspected that opiate use in Pakistan is much higher than the num-
bers it returned.
91 National AIDS Control Programme of Pakistan, HIV Second Genera-
tion Surveillance in Pakistan: National Report – Round 1, 2005.
92 Emmanuel F, Archibald C, Altaf A; “What Drives the HIV Epidemic 
among Injecting Drug Users in Pakistan: A Risk Factor Analysis”, 
XVI International AIDS Conference, 13-18 August 2006, Toronto, 
Canada.
93 Achakzai M, Kassi M, Kasi PM, “Seroprevalences and Co-infections 
of HIV, Hepatitis C Virus and Hepatitis B Virus in Injecting Drug 
Users in Quetta, Pakistan”, 2007, Tropical Doctor, 37(1):43-5.
94 According to the US Government, Pakistan cultivated 1,779 ha in 
Implications for response1.2.5 
Drug control in the era of globalization faces a number 
of challenges, from a cultural shift in consuming socie-
ties - which sees some forms of drug use as increasingly 
acceptable - to the dismantling of barriers to global 
trade. The latter poses acute challenges to border con-
trols, which still require substantial strengthening, par-
ticularly in the Balkans, Central Asia, South Asia and 
along the Pakistan-Afghanistan border. The level of 
global sea, air and land transportation will continue to 
increase. As an example, according to the International 
Association of Ports and Harbours container traffic is 
expected to double by the year 2012, compared with 
1999 figures. At present, more than 220 million sea 
containers move around the globe per year with approx-
imately 90% of the world’s cargo shipped via container. 
Scanning or searching every single container, load and 
vehicle is practically impossible. Traffickers are well 
aware of these limitations and frequently target the 
busiest ports of entry. International information exchange 
and cooperation should therefore be the pillar of any 
global counter-narcotics strategy. Practically speaking, 
this should include increased support for regional infor-
mation collection and coordination bodies such as the 
Joint Planning Unit (JPU) in the Islamic Republic of 
Iran, the Southeast European Cooperative Initiative 
(SECI) centre in the Balkans and the Central Asian 
Regional Information and Coordination Centre 
(CARICC) in Central Asia, which would enhance 
capacities for expanded cooperation in the future. 
Like any other industry, the opiate market follows the 
laws of demand and supply, and also react to economic 
stimulus and pressures. The geographic concentration of 
opiate production in Afghanistan is unique. It is tempt-
ing to think that if control could be maintained over a 
few provinces in one of the poorest countries on earth, 
one of the world’s most intractable drug problems could 
be solved overnight. Experience has shown, however, that 
markets quickly adjust, and that production soon re-
emerges to meet an established demand. This perspective 
may also have led to a disproportionate focus on produc-
tion in Afghanistan, at the cost of efforts in other parts 
of the market chain. It is thus imperative that the market 
be tackled as a whole, including both supply and demand. 
The international community needs to strengthen the 
link between supply and demand reduction measures 
and to better integrate national efforts in the framework 
of an international strategy on the scale of the market. To 
do both, getting a better understanding of the transna-
tional heroin economy is a matter of urgency. 
2009 with a potential opium production of approximately 44 mt. 
The majority of this cultivation occurs in the Federally Administered 
Tribal Areas (Khyber, Bajaur, and Mohmand); see Bureau of Inter-
national Narcotics and Law Enforcement Affairs, 2010 International 
Narcotics Control Strategy Report (INCSR), March 2010.
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Cocaine has been a popular recreational drug for decades, 
and while demand appears to be on the wane in its larg-
est markets, it has gained popularity in an ever widening 
range of countries. ‘Cocaine’ comprises at least two dis-
tinct drug products: powder cocaine on the one hand, 
and a range of cocaine base products, mostly falling 
under the heading of ‘crack’, on the other. Powder 
cocaine produces a more subtle effect, is more expensive 
to use, and has become emblematic of economic success 
in some circles. Demand has emerged in many develop-
ing countries, particularly among elites. Crack is cheaper, 
more intense, and associated with prostitution and street 
crime. Traditionally, crack use was rare outside the 
United States of America and the United Kingdom, but 
this also appears to be changing, especially in Latin 
America and parts of Africa.
Starting in the 1960s and 1970s, global production, 
trafficking and consumption of cocaine rose strongly. 
Until the mid-1960s, global cocaine seizures were mea-
sured in the tens of kilograms annually. In recent years, 
they have been in the hundreds of tons. Based on seizure 
figures, it appears that cocaine markets grew most dra-
matically during the 1980s, when the amounts seized 
increased by more than 40% per year. The number of 
countries reporting cocaine seizures has also grown 
during this period, from 44 in 1980 to 87 in 1990 and 
123 in 2008.1
 
1 UNODC ARQ.
Dimensions 1.3.1 
Supply, demand and value  
The extent as well as the pattern of global cocaine pro-
duction have changed significantly over the last four 
decades. From the end of World War II until the late 
1990s, almost all the world’s coca bush (the raw material 
for the manufacture of cocaine) was grown in Peru and 
the Plurinational State of Bolivia, and since the 1970s, 
most of this output was refined into cocaine in Colom-
bia. This increased over time and, in 1997, coca cultiva-
tion in Colombia exceeded that of the traditional 
growers for the first time. 
In the twenty-first century, the pendulum has swung 
back again. Coca cultivation in Colombia decreased by 
58% between 2000 and 2009, mainly due to large-scale 
eradication. At the same time, it increased by 38% in 
Peru and more than doubled in the Plurinational State 
of Bolivia (+112%), and both of these countries have 
acquired the ability to produce their own refined cocaine. 
Despite the increases in Peru and the Plurinational State 
of Bolivia, the net decline in the global area under coca 
cultivation over the 2000-2009 period was significant, 
amounting to 28%. A far smaller area is now under coca 
cultivation than in any year of the 1990s. 
In 2008, an estimated 865 metric tons (mt) of pure 
cocaine were produced. This was the lowest level in five 
years and considerably less than a year earlier when over 
1,000 mt were produced. A further decline on a year 
earlier seems to have taken place in 2009 though final 
figures for 2009 are not yet available. In 2008, Colom-
bia appears to have been responsible for about half of 
66
World Drug Report 2010 
global production, with Peru contributing over one 
third and the Plurinational State of Bolivia making up 
the balance. 
The process of analysing the production of cocaine is 
complex, though, because the amount of cocaine that 
can be produced out of a given plot of land varies over 
time and between areas. Productivity has grown in some 
areas due to improvements in both farming and process-
ing techniques, but eradication has pushed some cultiva-
tion into less suitable areas, decreasing yields. 
Improvements in laboratory efficiency increased again 
cocaine production. In the end, the hectares of cultiva-
tion (determined through satellite and ground surveys) 
are multiplied by an average kilogram-per-hectare coca 
leaf yield figure and coca-leaf to cocaine transformation 
ratios to generate a cocaine production estimate. When 
these ratios are updated, they can create misleading year-
on-year trends (like those seen between 2003 and 2004). 
The long-term trends should be more accurate (pro-
vided the coca yields and transformation ratios were 
accurately measured). It appears that, despite radical 
changes within countries, total cocaine output has been 
fairly stable over the last decade. This perception may 
still change, however, once updated and properly veri-
fied information on the different ratios for the different 
countries (and for the various coca producing regions in 
these countries) becomes available. 
Global cocaine seizures have grown greatly over the last 
decade, suggesting that a declining amount of the drug 
is actually reaching the markets - unless there is more 
production than presently accounted for. Most of the 
increase in seizures came from South America while 
Global coca bush cultivation (ha), 1990-2009Fig. 20: 
Source: UNODC
Global cocaine production, 1990-2008 Fig. 21: 
Source: UNODC
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1. Transnational drug market analysis The global cocaine market
seizures in North America and Europe declined between 
2006 and 2008. Since 2001, Colombia has seized more 
cocaine than any other country in the world, and sei-
zures have also increased strongly in Central America.2 
Enhanced international cooperation has meant that 
many shipments are seized before they leave their source 
country, or before they reach their final destination. 
But here again, the analysis is complex because produc-
tion estimates are made on the basis of pure cocaine, and 
most seizures consist of a product of uncertain dilution. 
It appears that the purity of cocaine shipments is declin-
ing. Traditionally, they have been around 60% cocaine, 
but the average purity3 reported to UNODC declined 
to 58% in 2007 and 51% in 2008. Keeping these con-
siderations in mind, it appears that a large share of the 
cocaine produced is seized: around 42%.4 This share has 
increased dramatically from a decade ago, when the 
figure was closer to 24%. 
Once purity is accounted for and seizures deducted, it 
seems that the amount of cocaine available for consump-
tion fell from over 700 mt in the mid-1990s to around 
500 mt in 2008.5 
2 It is possible that some of this rise was due to double counting. 
Enhanced international cooperation could lead to several countries 
reporting a single cocaine seizure as their own.
3 Unweighted average of wholesale and retail purity data reported by 
Member States to UNODC in a given year. 
4 If reported purities were weighted by the amounts seized, the calcu-
lated average purity would be higher, which would result in an even 
higher interception rate. However, some of the reported seizures are 
inflated due to double counting.
5  Methods to estimate the potential cocaine production in the Andean 
region are currently under review and could lead to higher estimates 
than previously reported. While it is too early to predict the outcome 
of this exercise, it may help answer the questions raised by a decline 
of the estimated cocaine availability in recent years, while the number 
of cocaine users was increasing (though in different regions at various 
How does this tally with what is known about global 
cocaine consumption? Knowledge about cocaine con-
sumption is based on household surveys. Unfortunately, 
few countries have annual household surveys on drug 
use, and in some areas of the world (mostly in Asia and 
Africa), few such surveys have ever been conducted. In 
keeping with this uncertainty, starting last year, UNODC 
presents use rates as ranges, rather than point estimates. 
In many cases, though, the reason why a survey has not 
been undertaken is because there is good reason to 
believe that widespread drug use is unlikely. As a result, 
the best point estimates are often toward the bottom of 
the range of uncertainty. For example, it is theoretically 
possible that cocaine use is widespread in China and 
India, since no national survey data exist to establish the 
level of use in either country. But based on what is 
known about cocaine production, trafficking patterns 
and the countries themselves (derived from seizures, 
arrests, treatment and qualitative information), this is 
highly unlikely. Taking just these two countries out of 
the picture can have a dramatic effect on global use 
estimates.
Based on the best reading of the available data, the 
number of people who consumed cocaine at least once 
in the previous year may have increased by around 14% 
between the late 1990s and 2008, with the rate of annual 
cocaine use basically stable in the last decade, at about 
0.4% of the adult population (16 million people in 
2008; range: 15-19 millions).
stages of market maturity). 
Global cocaine seizures (unadjusted for purity), 1990-2008Fig. 22: 
Source: UNODC DELTA
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If the amount of cocaine making it to market has 
declined (from more than 700 mt in the late 1990s to 
around 500 mt in 2008) while the number of users 
increased over the past 10 years, then the amount used 
by each consumer must have declined significantly. 
Alternatively, one should not exclude the possibility that 
laboratory efficiency may have increased stronger than is 
currently reflected in the cocaine production estimates 
so that global cocaine availability (production less sei-
zures) may have remained stable or increased slightly 
over the last decade. 
How well does all this jell with expert opinion about 
global drug trends? One of the questions asked in 
UNODC’s Annual Reports Questionnaire (ARQ) con-
cerns perceptions about trends in each drug market. 
This allows countries who do not conduct surveys to 
highlight what they see as emerging drug issues. If these 
responses are amalgamated to create an index,6 this 
index is rising, suggesting that a growing number of 
countries indicate that cocaine is a growing problem. If 
these responses are weighted by the estimated cocaine-
using population, however, the global trend is down-
wards in recent years, in keeping with the decline in use 
in the United States, the largest national cocaine market. 
A clear divergence can be seen between the responses of 
developed (OECD) and developing countries: use is 
perceived to be declining in the former and increasing in 
the latter.
6 For ‘strong increase’ 2 points are given; for ‘some increase ‘1 point; for 
stable: 0 points; for ‘some decline’ 1 point is deducted and for ‘strong 
decline’ 2 points are deducted. The average at the global level is then 
calculated.
Cocaine production, seizures and supply to markets, 1990-2008 Fig. 23: 
Sources: UNODC World Drug Report 2009 and DELTA
Annual prevalence of cocaine use at the global level Fig. 24: 
Sources: UNODC World Drug Report 2008 and updates based on ARQ
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How has this affected the value of the global cocaine 
market? The value is most certainly lower than it was in 
the mid-1990s, when prices were much higher and the 
US market was strong. For 1995, UNODC estimated 
the retail value of the global market at US$117 billion.7 
Expressed in constant 2008 US dollars, this would be 
equivalent to US$165 billon in 2008. The correspond-
ing figure for 2008 would be US$88 billion (range: 
US$80–US$100 bn), suggesting the value has halved in 
this 13-year period. The global cocaine retail sales were 
equivalent to 0.15% of global GDP in 2008, down from 
0.4% of global GDP in 1995. Nonetheless, the value of 
global cocaine retail sales in 2008 were still higher than 
the gross domestic product (GDP) of 123 out of 184 
countries for which the World Bank provided estimates 
for the years 2007 or 2008.  
7 UNDCP, Economic and Social Consequences of Drug Abuse and Illicit 
Trafficking, Vienna 1997.
8 UNDCP, Economic and Social Consequences of Drug Abuse and Illicit 
Trafficking, Vienna 1997; World Bank, World Development Indica-
tors 2009; UNODC estimates for 2008 based on UNODC ARQ; 
UNODC, “Estimating the value of illicit drug markets” in UNODC, 
2005 World Drug Report, Volume 1: Analysis, pp. 123-143; ONDCP, 
What America’s Users Spend on Illegal Drugs, December 2001; United 
Nations Department of Economic and Social Affairs, Population 
Division, World Population Prospects: The 2008 Revision, 2009; 
SAMHSA, National Survey on Drug Use and Health, Rockville MD 
2009, and previous years; FBI, Uniform Crime Reports (2002-2008); 
ONDCP, Arrestee Drug Abuse Monitoring Program - ADAM II 2008 
Annual Report, Washington D.C, April 2009; ONDCP, “Cocaine 
Consumption Estimates Methodology”, September 2008 (internal 
paper); US State Department, International Narcotics Control Strat-
egy Report, March 2010; ONDCP, The Price and Purity of Illicit 
Drugs: 1981-2007, Report pared by the Institute for Defense Analy-
sis for ONDCP, Washington, July 2008; US Drug Enforcement 
Agency analysis of STRIDE data; Health Canada, Canadian Alcohol 
and Drug Use Monitoring Survey 2008; Instituto Nacional de Salud 
Pública, Encuesta Nacional de Adicciones, 2008; EMCDDA, Statistical 
Bulletin 2009; European Centre for Social Welfare Policy, Two Worlds 
of Drug Consumption in Late Modern Societies, Vienna 2009; UK 
Home Office, Sizing the UK market for illicit drugs, London 2001; 
Home Office, Measuring different aspects of problem drug use: meth-
odological developments, Home Office Online Report 16/06, London 
2006; and various other Government reports.
Global trends in cocaine use as  Fig. 25: 
perceived by government experts, 
1992-2008
Source: UNODC ARQ
Global trends in cocaine use, OECD Fig. 26: 
versus non-OECD countries, as per-
ceived by government experts (based 
on trends weighted by cocaine using 
population), 1992-2008
Source: UNODC ARQ
Global cocaine retail market in billion Fig. 27: 
constant 2008 US$, 1995 and 2008
Source: UNODC estimates8
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Global volume and distribution 
Although cocaine use appears to be growing in develop-
ing countries, the vast bulk of the production is destined 
for two major overseas markets: North America (6.2 
million users in 2008) and Europe (4 to 5 million users, 
of which 4.1 million were in the EU and EFTA 
countries).9 The largest emerging market in the develop-
ing world is seen in the South America, Central America 
and Caribbean region, with some 2.7 million users. 
Estimates are far less certain for use levels in Asia and 
Africa.
Current estimates suggest that about 500 mt of pure 
cocaine were available for consumption in 2008, of 
which around 480 mt were actually consumed. The rest 
was either stocked or lost in transit. Based on what is 
known about production, seizures, use levels and use 
rates, a likely global distribution of the 480 mt of cocaine 
consumed in 2008 is presented in a separate table. This 
table suggests that more than 320 mt, or around two 
thirds, is consumed in the mature cocaine markets of 
North America (41%) and West Europe (26%). Latin 
America is not far behind, however, suggesting that 
more attention should be paid to this growing market. 
9 The 27 countries of the European Union (EU) and the four countries 
of the European Free Trade Association (EFTA).
These estimates remain tentative, with substantial uncer-
tainty in Asia and Africa in particular, but they are 
generally in keeping with the distribution of global 
cocaine seizures.
Based on this distribution and what is known about 
prices and purities, it is possible to place a retail value on 
each regional market. Due to much higher purity-ad-
justed retail prices, the estimated value of the market in 
Europe (US$34 billion) is almost as large as that of 
North America (US$38 billion). Surprisingly, the third 
largest cocaine market, in economic terms, is the Oce-
ania region, worth an estimated US$6 billion, due to 
very high retail prices.
Global impact
The use of cocaine constitutes, first of all, a major health 
problem. Cocaine use results in tens of thousands of 
deaths each year worldwide. After the opiates, cocaine is 
the most problematic drug globally, and it is indisputa-
bly the main problem drug in the Americas. Out of the 
5.3 million people who used cocaine at least once in the 
United States during 2008, 1.9 million also used cocaine 
in the previous month, of which almost 1 million were 
found to have been dependent on cocaine.10 In other 
10 Substance dependence was based on the definition of the 4th edi-
Main global cocaine ﬂows, 2008Map 6: 
Source: UNODC, World Drug Report 2009, and UNODC calculations, informed by US ONDCP, Cocaine Consumption Estimates  
Methodology, September 2008 (internal paper).
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words, out of the people who used cocaine in the previ-
ous year at least once, 18% were dependent on it. This 
is a higher proportion than for any other drug except 
heroin. Figures for the year 2007 showed that out of 
1,000 people who used crack cocaine in the previous 12 
months, 116 entered treatment for substance abuse, a 
slightly higher proportion than for methamphetamine 
(102) and a significantly higher proportion than for 
drug use in general (30) or for the use of alcohol (6).13 
tion of the Diagnostic and Statistical Manual for Mental Disorders 
(DSM-IV).
11 Sources the same as for footnote 8, except UNDCP, Economic and 
Social Consequences of Drug Abuse and Illicit Trafficking, Vienna 1997; 
World Bank, World Development Indicators 2009; ONDCP, The Price 
and Purity of Illicit Drugs: 1981-2007, Report prepared by the Insti-
tute for Defense Analysis for ONDCP, Washington, July 2008; US 
Drug Enforcement Agency, based on STRIDE data.
12 Sources the same as for footnote 8, except UNDCP, Economic and 
Social Consequences of Drug Abuse and Illicit Trafficking, Vienna 1997; 
World Bank, World Development Indicators 2009; ONDCP, The Price 
and Purity of Illicit Drugs: 1981-2007, Report prepared by the Insti-
tute for Defense Analysis for ONDCP, Washington, July 2008; US 
Drug Enforcement Agency, based on STRIDE data.
13 SAMHSA, Treatment Episode Data Sets (TEDS) and SAMHSA, 
While the share has declined, almost half of all people 
entering drug treatment in the Americas do so due to 
cocaine (46%), and the share in Europe increased from 
3% in 1997/1998 to 10% in 2008. In West Europe, the 
share is almost 15%.
Trafficking in cocaine also constitutes a security threat, 
financing organized crime and insurgencies in a number 
of countries, including the FARC in Colombia and the 
Shining Path in Peru. 
Cocaine trafficking is also linked to corruption. Traffick-
ing in cocaine both thrives on corruption and breeds 
corruption. Rising trafficking of cocaine via countries 
neighbouring the cocaine production centres in the 
Andean region led to rising levels of corruption, while 
high levels of corruption in a number of West African 
countries have certainly been a facilitating factor for the 
establishment of cocaine transit traffic via this region.
National Survey on Drug Use and Health. 
Estimated number of 
users (in millions)
Grams per 
user per year
Amounts of pure cocaine 
consumed (in mt)
In %
North America 6.2 31.6 196 41%
EU/EFTA 4.1 30.2 124 26%
South America,  
Central America, Caribbean 2.7 35 95 20%
Africa 1.3 20 26 5%
Asia 0.7 20 14 3%
East and South-East Europe 0.5 26 13 3%
Oceania 0.4 25 11 2%
World (rounded) 15.9 30.1 480 100%
Amounts 
consumed 
(in mt)
Average 
retail price 
(in US$ per 
gram)
Average 
purity at 
retail level
Purity-adjusted 
prices
Value  
(in billion 
US$)
North America 196 108 56% 192 38
EU/EFTA 124 101 37% 273 34
South America,  
Central America, Caribbean 95 11 66% 17 2
Africa 26 22 34% 65 2
Asia 14 142 73% 195 3
East and South-East Europe 13 125 48% 260 3
Oceania 11 291 53% 549 6
World – total (rounded) 480 88
Tentative distribution of global cocaine consumption (purity-adjusted), 2008 Table 8: 
Source: UNODC estimates11
Tentative distribution of the global cocaine market in billion US$, 2008Table 9: 
Source: UNODC estimates12
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Cocaine from the Andean region 1.3.2 
to North America
North America is the largest regional cocaine market, 
with some 6.2 million annual users, close to 40% of the 
global cocaine-using population. The United States 
remains the single largest national cocaine market in the 
world, but this market has declined since the early 
1980s. In 1982, an estimated 10.5 million people in the 
United States had used cocaine in the previous year.15 In 
2008, the figure was 5.3 million, about half as many. 
This long-term decline occurred despite falling prices 
and can be attributed to a number of causes, including 
increased prevention, treatment (complemented by the 
14 Unweighted results are shown as for a number of developing coun-
tries data from only a few hospitals or drug treatment centers is 
available. Nonetheless, for most regions, changes in the proportion of 
treatment demand for cocaine seem to reflect rather well underlying 
actual trends in the relative importance of cocaine in total drug-
related treatment demand. The only exception is Africa. The alleged 
‘decline’ in the proportion of cocaine-related treatment demand for 
Africa between 2004 and 2008 is a statistical artifact. For this year’s 
World Drug Report all estimates older than 10 years were removed. 
This did not impact much on most regions, except Africa. It reduced 
significantly the number of country estimates available for Africa. 
The ‘decline’ for Africa is thus basically due to a different and very 
small sample of reporting African countries, but not to any actual 
decline of cocaine-related treatment demand there. On the contrary, 
in the limited number of African countries where comparable data 
are available, the proportion of cocaine in total treatment demand 
appear to have increased. 
15 US Department of Health and Human Services, Substance Abuse and 
Mental Health Services Administration (SAMHSA), 1995 National 
Household Survey on Drug Abuse, Report #18, Rockville, Maryland, 
1996.
establishment of ‘drug courts’) and ‘social learning.’ 
Crack cocaine became a stigmatized drug in the second 
half of the 1980s, and powder cocaine also became less 
fashionable. 
This long-term demand-driven decline appears to have 
been complemented by a recent, more dramatic, supply-
driven one. The annual prevalence rate of cocaine use in 
the United States fell from 3% of the adult population 
in 2006 to 2.6% in 2008.16 Recent declines have also 
been reported in Canada, with adult annual use rates 
falling from 2.3% in 2004 to 1.9% in 2008.17 House-
hold surveys in Mexico showed an increase after 2002. 
However, results from a survey in Mexico City in 2006 
suggest that cocaine use may have actually declined 
between 2006 and 2008, following a strong increase 
between 2002 and 2006.18
16 SAMHSA, Results from the 2008 National Survey on Drug Use and 
Health. The data were re-adjusted to the internationally comparable 
age group 15-64. 
17 Health Canada, Canadian Alcohol and Drug Use Monitoring Survey 
2008, Ottawa 2009. The decline from 1.9% of the population age 15 
and above in 2004 to 1.6% in 2008 is equivalent to a decline from 
2.3% to 2.0% if the numbers are re-adjusted to the internationally 
comparable age group of those aged 15-64.
18 Massive increases, followed by a decline seems to be indirectly also 
confirmed by general population household surveys conducted in 
Mexico in 2002 and 2008. While lifetime prevalence of cocaine use 
doubled, from 1.23% in 2002 to 2.4% in 2008, annual prevalence 
rose by ‘just’ 25% from 0.35% in 2002 to 0.44% in 2008.In other 
words, lifetime prevalence rose by almost 1.2 percentage points while 
annual prevalence rose by ‘just’ 0.1 percentage points. Such results 
would be only possible if large sections of society started experiment-
ing with cocaine but gave it up again at some point between 2003 
Cocaine as primary drug of abuse Fig. 28: 
among persons treated for drug  
problems* 
* unweighted regional averages.
Sources: UNODC ARQ and World Drug Report 2006;  
UNODCCP, World Drug Report 2000
Annual prevalence rates of cocaine Fig. 29: 
use in North America among the  
population aged 15-64, 2002-2008
* 2006 data for Mexico: UNODC estimates, extrapolated from house-
hold survey results in Mexico City. 
Sources: SAMHSA, Results from the 2008 National Survey on 
Drug Use and Health (and previous years); CONADIC, 
Encuesta Nacional de Adicciones 2008; Health Canada, Cana-
dian Alcohol and Drug Use Monitoring Survey 2008; UNODC, 
World Drug Report 2009 (and previous years)
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The same recent and dramatic decline can be seen in 
school surveys in the United States and Canada, where 
student use has almost halved in three years.19 In 2009, 
the perceived availability of cocaine among US students 
reached its lowest level since 1978. A strong reduction 
in availability is also confirmed by US law enforcement. 
Despite ongoing efforts to fight the drug trade, US 
cocaine seizures along the border with Mexico fell by 
40% between 2006 and 2008 and remained at the lower 
level in 2009, while heroin, marijuana and metham-
phetamine seizures all increased.20
The strong drop in cocaine use is also reflected in foren-
sic data. Cocaine positive hair tests among the US work-
force, reflecting use over the past three months, showed 
a 40% drop in just two years, from 5.3% in 2007 to 
3.2% over the first two quarters of 2009.21 The share of 
the US workforce that tested positive for cocaine, as 
detected by urine analysis (reflecting use over the last 
two to three days), showed a 58% decline between 2006 
(0.72%) and the first two quarters of 2009 (0.3%). 
and 2007. This in turn would suggest that the annual prevalence 
of cocaine use was already higher at some point between 2003 and 
2007, with a peak probably around 2006, followed by a decline in the 
most recent years. Alternatively, more than 50% of all annual cocaine 
users would have had to give up their habit every year between 2002 
and 2007, which is not very likely. Moreover, the proportion of 
cocaine in total drug treatment demand declined in recent years, 
from 37.1% in 2006 to 33.9% (UNODC ARQ). 
19 The reduction was 40% between 2006 and 2009 in the USA and 
50% in Ontario, which accounts for more than a third of Canada’s 
total population.
20 National Drug Intelligence Center, National Drug Threat Assessment 
2010, Johnstown, February 2010. 
21 Quest Diagnostics, New Hair Data Validate Sharp Downward Trend 
in Cocaine and Methamphetamine Positivity in General U.S. Workforce 
Madison, N.J, 20 November 2009 and The Medical News, Quest 
Diagnostics reports sharp downward trends in cocaine and methamphet-
amine use, 20 November 2009. 
While the forensic tests are not administered to a repre-
sentative sample of the US population, some 6 million 
people undergo these tests, almost 100 times as many as 
those interviewed in household surveys (69,000 in 
2008).22
The recent decline (since 2006) appears to have been 
mainly supply-driven, caused by a severe cocaine short-
age. This shortage is also reflected in rapidly falling 
purity levels and a consequent rise in the cost per unit 
of pure cocaine. While street prices remained fairly 
22 SAMHSA, Results from the 2008 National Survey on Drug Use and 
Health.
Annual prevalence of cocaine use among high school students in the United States and Fig. 30: 
Ontario (Canada), 1980-2009
Sources: NIDA, Monitoring the Future; OSDUH, Drug Use Among Ontario Students, 1977-2009
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stable throughout this period, purity dropped dramati-
cally, resulting in an effective doubling of the real price 
of cocaine between 2006 and 2009. 
There are several reasons for this shortage. Interdiction 
has stiffened in Colombia, Central America and Mexico. 
Cartel violence in Mexico has also disrupted supply 
routes. Perhaps most importantly, production has 
declined in Colombia, the primary source of cocaine for 
the United States market, and production in Peru and 
the Plurinational State of Bolivia continue to be directed 
towards Europe and the Southern Cone. The fact that 
the US market is almost exclusively supplied by Colom-
bian cocaine (rather than Peruvian or Bolivian) has been 
established scientifically. Forensic analyses of cocaine 
seized or purchased in the United States have repeatedly 
shown that nearly 90% of the samples originate in 
Colombia.23 
Cocaine is typically transported from Colombia to 
Mexico or Central America by sea (usually by Colom-
bian traffickers), and then onwards by land to the United 
States and Canada (usually by Mexican traffickers). The 
US authorities estimate that close to 90% of the cocaine 
entering the country crosses the US/Mexico land border, 
most of it entering the state of Texas and, to a lesser 
extent, California and Arizona, through the relative 
importance of Arizona seems to be increasing. Accord-
ing to US estimates, some 70% of the cocaine leaves 
Colombia via the Pacific, 20% via the Atlantic and 10% 
via the Bolivarian Republic of Venezuela and the Carib-
bean.24 The routes have changed over the years.
23 US State Department, Bureau for International Narcotics and Law 
Enforcement Affairs, International Narcotics Strategy Report, Vol. I, 
March 2009. 
24 National Drug Intelligence Center, National Drug Threat Assessment 
2009, December 2008.
Direct cocaine shipments from Colombia to Mexico 
have been moved by a wide variety of marine craft, 
recently including self-propelled semi-submersibles, 
often transporting several tons of cocaine (typically 
between 2 and 9 mt). In 2008, 29.5 mt of cocaine were 
seized by the Colombian navy on board semi-submersi-
bles in the Pacific Ocean, equivalent to 46% of all sei-
zures made at sea by the Colombian authorities in the 
Pacific (64.5 mt). A few semi-submersibles have been 
detected on the Atlantic side as well. The Colombian 
Government reported seizing 198 mt of cocaine in 2008; 
58% in the Pacific region and 31% in the Atlantic 
region.25 
25 UNODC and Government of Colombia, Colombia Coca Cultivation 
Survey, Bogota, June 2009.
Average of all cocaine purchase prices in the United States, January 2006-September 2009Fig. 32: 
Source: US Drug Enforcement Agency 
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In addition, the Bolivarian Republic of Venezuela has 
emerged as a prominent trans-shipment location for 
cocaine destined for Europe and the United States, 
according to Colombian, US and European sources, 
reflected, inter alia, in strong increases of Colombian 
overland cocaine shipments to the Bolivarian Republic 
of Venezuela. Cocaine transiting the Bolivarian Republic 
of Venezuela en route to the USA frequently departs by 
air from locations close to the border with Colombia for 
destinations in the Dominican Republic, Honduras and 
other Caribbean and Central American countries, as 
well as Mexico.27 
Moreover, the importance of the Central American coun-
tries as trans-shipment locations has increased in recent 
years. Most of this cocaine is destined for Mexico and the 
United States, though some is also locally trafficked. 
Routes and volumes
Calculating the amount of an illicit drug consumed in a 
country is complicated, even in a country as rich in data 
as the United States. In 2001, the US Government esti-
mated that national cocaine consumption had declined 
from 660 mt in 1988 to 259 mt in 2000.28 If these 
26 For data 1988-2000: ONDCP, What America’s Users Spend on Illegal 
Drugs, December 2001; for 2001 data: Drug Availability Steering 
Committee, Availability Estimates in the United States, December 
2002; for 2002-2008: UNODC estimates based on SAMHSA, 2008 
National Survey on Drug Use and Health, Rockville MD 2009, and 
previous years; FBI, Uniform Crime Reports (2002-2008); ONDCP, 
Arrestee Drug Abuse Monitoring Program - ADAM II 2008 Annual 
Report, Washington D.C, April 2009; ONDCP, Cocaine Consumption 
Estimates Methodology, September 2008 (internal paper).
27 US Department of State, 2010 International Narcotics Control Strat-
egy Report, March 2010. 
28 The last comprehensive attempt to measure the size the US cocaine 
market entitled What America’s Users Spend on Illegal Drugs was pub-
lished by the Office of National Drug Control Policy (ONDCP) in 
calculations were extended based on more recent annual 
prevalence data, the figure would be 231 mt for 2008. 
This simple extension, however, may not capture the 
strong decline in recent years. A simplified model, 
recently proposed by the US Government,29 results in a 
consumption range of 140 to 164 mt in 2008.30 A third 
method, suggested by a think tank, would put the figure 
at less than 175 mt.31 
2001. The report estimated the number of chronic and occasional 
cocaine users, and multiplied these numbers with a per capita expen-
diture estimate, derived from interviews with arrested persons who 
had used drugs. Based on these dollar amounts, the actual amounts 
consumed could be calculated. 
29 The simplified ONDCP model assumes that 20% of the monthly 
cocaine users consume 0.5 grams of cocaine per day while the 
remaining 80% consume 0.5 grams per week. This gives an average 
consumption of 57.3 grams of cocaine per month. Non-monthly 
annual users are assumed to consume 4 grams of cocaine per year. In 
the case of crack-cocaine it is assumed that 30% of the monthly users 
consume 0.75 grams per day and the remaining 70% consume 0.75 
grams per week. This gives, on average, 109.4 grams of crack-cocaine 
per year for monthly users. The annual excluding monthly users are 
assumed to consume 6 grams of crack-cocaine per year. (ONDCP, 
Cocaine Consumption Estimates Methodology, September 2008, inter-
nal paper). Adding cocaine HCL and crack-cocaine consumption 
estimates, the model results in overall per capita consumption of 31 
grams of cocaine per user in the USA in 2008. 
30 The problem here is that the US household survey provides estimates 
on overall cocaine use (that is, cocaine HCl and crack-cocaine) and 
then gives an estimate on the number of crack cocaine users. Assum-
ing that no crack user in the US consumes cocaine HCl, the cocaine 
HCl users can be ‘calculated’ by subtracting crack cocaine users from 
all cocaine users; assuming that all crack-cocaine users also consume 
cocaine HCl, the cocaine HCl figure would be identical to the overall 
cocaine figure. Applying the first interpretation, cocaine use would 
have amounted to 140 tons in 2008; applying the second interpreta-
tion, cocaine use would have amounted to 164 tons in 2008. 
31 Institute for Defense Analyses, History of the US cocaine market 
(supply and consumption), presentation given to the UNODC expert 
group meeting: “The evidence base for drug control in Colombia: 
lessons learned”, Bogota, 9-10 November 2009.
Estimates of cocaine consumption in the United States, 1988-2008Fig. 34: 
Sources: Multiple sources26
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There is a fourth method which makes use of new data 
to reclassify the users and calculate the amount of cocaine 
a user consumes in a year.33 Applying these figures to the 
2001 model suggests a total US consumption of 165 mt 
in 2008.34 The four methods show a range of 140 to 
231 mt, with the final method (165 mt) falling within 
this range of values.
32 ONDCP, What America’s Users Spend on Illegal Drugs, December 
2001; Drug Availability Steering Committee, Availability Estimates 
in the United States, December 2002; SAMHSA, National Survey on 
Drug Use and Health, Rockville MD 2009, and previous years; FBI, 
Uniform Crime Reports (2002-2008); ONDCP, Arrestee Drug Abuse 
Monitoring Program - ADAM II 2008 Annual Report, Washington 
D.C, April 2009; ONDCP, Cocaine Consumption Estimates Method-
ology, September 2008 (internal paper); Health Canada, Canadian 
Alcohol and Drug Use Monitoring Survey 2008 and previous years; 
CINADIC, Encuesta Nacional de Adicciones 2002, Ciudad Mexico, 
Secretaria de Desarrollo, Encuesta de Hogares, 2006; CONADIC and 
Instituto Nacional de Salud Pública, Encuesta Nacional de Adicciones, 
2008, UNODC ARQ/DELTA.
33 For example, new data are available on the number of cocaine-depen-
dent people and heavy cocaine users (using cocaine more than 100 days 
a year) identified in the National Household Survey on Drug Use and 
Health (NHSDU). There are also new data on cocaine-positive tests 
among arrestees, provided in the Arrestee Drug Abuse Monitoring 
Program (ADAM II). See ONDCP, Arrestee Drug Abuse Monitoring 
Program, ADAM II 2008 Annual Report, Washington D.C., April 
2009. This allows an updated definition and estimate of ‘chronic use.’
34 The 31 grams of pure cocaine figure is the result of a multiplication of 
the number of chronic users (2.3 million) with a per capita use of 55 
grams per year and a multiplication of the number of occasional users 
(3 million) with 14 grams per year, This yields a total at 165 tons 
for 5.3 million users, which gives 31 grams per user in 2008, down 
from 44 grams per user in 1998 and 66 grams per user in 1988. The 
per capita use figures were derived from the results of the ONDCP 
study What America’s Users Spend on Illegal Drugs, published in 2001. 
They found average per capita consumption for chronic users to have 
fallen from 141 grams in 1988 to 106 grams in 1990 and 78 grams in 
1998. The model used assumed that the downward trend continued 
as availability of treatment facilities continued to improve (67 grams 
in 2007). The downward trend was assumed to have accelerated in 
2008, as a result of falling purity levels (55 grams). The decline in per 
capita consumption for occasional users was less pronounced, from 
16 grams in 1988 to 15 grams in 1998, and was thus assumed to have 
fallen only slightly, to 14 grams in 2008.
The simplified method proposed by the United States 
can also be applied to the survey data available from 
Canada and Mexico, producing estimates of around 17 
mt of cocaine for Mexico and 14 mt for Canada in 
2008. Adding this to US consumption results in a total 
North American cocaine consumption of some 196 mt 
for the year 2008.
How much cocaine must be produced to satisfy this 
demand? Seizures along this route are substantial, 
although these shipments are not pure cocaine. In order 
to get 196 mt to the consumer, it appears that around 
309 mt of cocaine was dispatched from the Andean 
region destined for North America in 2008. This would 
represent about half of all the cocaine that leaves these 
countries, down from around 60% in 1998.
How much is this worth, and who derives the most 
money out of the supply chain? Calculating the retail 
value of the US market is a matter of applying the esti-
mated volume consumed to the price data and adjusting 
for purity. The 2001 US Government calculations, 
adjusted to constant 2008 US dollars, show a decline of 
the US cocaine market from almost US$134 billion in 
1988 to US$44 billion in 1998. Applying the new fig-
ures, it appears this value has fallen further still, to 
around US$35 billion by 2008. 
In other words, the retail value of the US cocaine market 
declined by about two thirds in the 1990s, and by about 
another quarter in the last decade. The reason the value 
did not drop even further in the last 10 years is that the 
real price (adjusted for purity) has gone up.35
35 The calculations were based on the available price data series, pro-
vided by ONDCP, ending for the year 2007. For 2008, the purity-
adjusted cocaine prices per gram, as reported by the DEA, were used. 
However, a comparison shows that the two price data series – though 
both based on STRIDE data – do not correspond, neither in absolute 
Cocaine demand (consumption and seizures), North America, 1998-2008Fig. 35: 
Sources: Multiple sources32
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Applying similar methods, the 2008 value of the Cana-
dian cocaine market can be estimated at around US$2.4 
billion. The domestic Mexican cocaine market is worth 
much less, due to far lower cocaine prices: around 
US$300 million in 2008. Adding these values, it appears 
that the North American cocaine market has declined in 
value from US$47 billion in 1998 to US$38 billion in 
2008. Between 2006 and 2008, the value of the market 
remained basically stable.
Using price data and volumes for the various points in 
values nor in trends. While the ONDCP price data are supposed to 
reflect exclusively the retail level, based on the analysis of purity-
adjusted prices for purchases of 2 grams or less, the DEA price data 
series is based on the average price for all cocaine purchases, purity-
adjusted and recalculated to represent the average price of cocaine per 
gram. Though differences in methodology can explain differences in 
the level, they do not really explain differences in trends. In fact, the 
bulk of the DEA prices concerns the retail level and the DEA prices 
should thus – primarily – reflect changes in these prices as well. The 
differences in the two data sources is not only of academic inter-
est. If the growth rates in prices, as revealed in the DEA data, were 
applied to the ONDCP price data set, starting as of 2007, the cal-
culations suggest that the overall cocaine market would have slightly 
increased, from US$33.5 bn in 2006 to US$35 bn in 2008, as the 
strong increases in prices would have more than compensated for the 
declines in consumption. Given the large number of reports suggest-
ing that strong price increases took place over the 2006-2008 period, 
the latter estimates appear to have a higher level of credibility.
36 UNODC, 2009 World Drug Report, Vienna 2009; UNODC ARQ/
DELTA; ONDCP, What America’s Users Spend on Illegal Drugs, 
December 2001; Drug Availability Steering Committee, Availability 
Estimates in the United States, December 2002; SAMHSA, National 
Survey on Drug Use and Health, Rockville MD 2009, and previ-
ous years; FBI, Uniform Crime Reports (2002-2008) and ONDCP, 
Arrestee Drug Abuse Monitoring Program - ADAM II 2008 Annual 
Report, Washington D.C, April 2009 and ONDCP, Cocaine Con-
sumption Estimates Methodology, September 2008 (internal paper), 
Health Canada, Canadian Alcohol and Drug Use Monitoring Survey 
2008 and previous years, CINADIC, Encuesta Nacional de Adicciones 
2002, Ciudad Mexico, Secretaria de Desarrollo, Encuesta de Hogares, 
2006, CONADIC and Instituto Nacional de Salud Pública, Encuesta 
Nacional de Adicciones, 2008.
the trafficking chain, the value accruing to the various 
market players can be estimated. One study, analysing 
data from the late 1990s, suggested that there are typi-
cally seven layers of actors between a coca farmer in the 
Andean countries and the final consumer in the 
USA:37
The farmer sells the coca leaf (or his self-produced 1. 
coca paste) to a cocaine base laboratory, operated by 
the farmers themselves or by various criminal traﬃck-
ing groups. Sometimes these labs have the capacity to 
reﬁne the drug further into cocaine hydrochloride. 
The cocaine base (or the cocaine hydrochloride) is 2. 
sold to a local traﬃcking organization which trans-
ports and sells the cocaine to a transnational drug traf-
ﬁcking organization. 
The drug traﬃcking organization contracts yet an-3. 
other group to do the actual shipping. 
The cocaine is shipped to traﬃckers in Mexico.4. 
The Mexican traﬃckers transport the drugs across the 5. 
US border to wholesalers. 
The wholesalers sell the cocaine to local mid-level 6. 
dealers or street dealers across the USA. 
The street dealers sell the cocaine to the consumer.7. 
The coca farmers in the three Andean countries earned 
about US$1.1 billion in 2008, down from US$1.5 bil-
lion in 2007.38 Since about half of the exports go to 
North America, about half the farmer’s income is ulti-
mately derived from the North American market. But 
the share of the value of that market which goes to the 
37 R. Anthony and A. Fries, “Empirical modelling of narcotics traffick-
ing from farm gate to street”, in UNODC, Bulletin on Narcotics, Vol. 
LVI. Nos. 1 and 2, 2004, Illicit Drug Markets, pp. 1-48.
38 UNODC, 2009 World Drug Report, Vienna 2009.
Cocaine production and demand for cocaine, North America, 1998-2008Fig. 36: 
Sources: Multiple sources36
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farmer is only about 1.5%. The other 98.5% goes to 
those who transport and deal the drug.
The farmer’s output is processed further and transported 
within the country to its point of embarkation. Those 
who take on these tasks earned around US$400 million 
from North American-bound shipments in 2008, or 
about 1% of the retail sales value. 
39 For data 1988-2000: ONDCP, What America’s Users Spend on Illegal 
Drugs, December 2001; for 2001 data: Drug Availability Steering 
Committee, Availability Estimates in the United States, December 
2002; SAMHSA, National Survey on Drug Use and Health, Rockville 
MD 2009, and previous years; FBI, Uniform Crime Reports (2002-
2008) and ONDCP, Arrestee Drug Abuse Monitoring Program 
- ADAM II 2008 Annual Report, Washington D.C, April 2009; 
ONDCP, The Price and Purity of Illicit Drugs: 1981-2007, Report 
prepared by the Institute for Defense Analyses for ONDCP, Wash-
ington, July 2008; US Drug Enforcement Agency, based on STRIDE 
data.
Out of 309 mt of cocaine that left the Andean region 
towards North America in 2008, some 208 mt arrived 
in the hands of the Mexican cartels. Most of the rest was 
seized. Trafficking from Colombia to Mexico was still 
largely in the hands of Colombian groups in 2008, 
though more recently Mexican groups have also started 
40 For data before 2000: ONDCP, What America’s Users Spend on Ille-
gal Drugs, December 2001; for 2001 data: Drug Availability Steering 
Committee, Availability Estimates in the United States, December 
2002; SAMHSA, National Survey on Drug Use and Health, Rockville 
MD 2009, and previous years; FBI, Uniform Crime Reports (2002-
2008) and ONDCP, Arrestee Drug Abuse Monitoring Program 
- ADAM II 2008 Annual Report, Washington D.C, April 2009; 
ONDCP, The Price and Purity of Illicit Drugs: 1981-2007, Report 
prepared by the Institute for Defense Analyses for ONDCP, Wash-
ington, July 2008; US Drug Enforcement Agency, based on STRIDE 
data, quoted in DEA Intelligence Division, “Cocaine Shortages in 
U.S. Markets, November 2009” and US Bureau of Labor Statistics, 
Consumer Price Index (CPI); UNODC ARQ.
Value of the US cocaine market, 1988-2008, in constant 2008 US$ Fig. 37: 
Sources: Multiple sources39
Value of the North American cocaine market in constant 2008 US$, 1998-2008 Fig. 38: 
Source: Multiple sources40
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to enter this line of business. At a wholesale price of 
US$12,500 per kg (US$15,625 per kg if purity adjusted), 
the imported cocaine in Mexico was worth some US$3.3 
billion in 2008. With a purchase price of just under 1 
billion dollars in Colombia, the total gross profits41 
accruing to those exporting the cocaine to Mexico can 
be estimated at around US$2.4 billion. 
Shipments from Mexico into the United States are pri-
marily undertaken by Mexican drug cartels. Taking 
domestic consumption, seizures and purity into account, 
Mexican cartels moved some 191 mt of pure cocaine 
across the border to the United States in 2008, valued at 
US$3 billion in Mexico. If all of this had been sold to 
wholesalers in the United States, it would have been 
worth US$6.4 billion. Border seizures reduced this value 
to US$5.8 billion. Deducting purchase costs, a gross 
profit of US$2.9 billion was generated by moving the 
cocaine across the border into the United States. Most 
of these profits were reaped by the Mexican drug 
cartels. 
The largest profits, however, are made within the United 
States. The difference between the wholesale purchase 
price and the retail value of cocaine in the US was 
US$29.5 billion in 2008. Out of these gross profits, the 
bulk is generated between the mid-level dealers and the 
consumers, generating more than US$24 billion in gross 
profits, equivalent to 70% of total US cocaine sales. 
Some Mexican groups - as well as Dominican and Cuban 
groups - are tapping into this highly lucrative market, 
but most appears to go to a large number of small 
domestic US groups.
These figures show that US dealers as a whole make the 
41 Gross profits are defined here as the difference between the sales price 
of the drugs and the original purchase price. 
most out of the market, but there are a lot of US dealers, 
so individual earnings may remain relatively small. Esti-
mates of the number of persons involved in cocaine 
trafficking in the 1990s suggested that there were some 
200 cocaine wholesalers in the United States, but some 
6,000 mid-level cocaine dealers.42 Beneath them, there 
are countless street-level dealers, many of whom are 
users themselves. Comparable figures are not available 
for the number of international traffickers, but it seems 
likely that, as individuals, they make more money than 
the thousands of dealers in the United States.
How does the market operate? 
Following the dismantling of the Medellin and Cali 
cartels in the early 1990s, the Colombian organized 
crime groups got smaller, and market competition 
increased, pushing prices down. After the Colombian 
Congress amended the Constitution in 1997 to allow 
the extradition of citizens,43 Colombian groups were 
largely relegated to the front end of the market chain. 
Better controls, first for direct flights from Colombia to 
the United States (starting in the 1980s), and later 
improved control over shipping in the Caribbean (in the 
1990s), reduced the ability of the Colombian organized 
crime groups to traffic cocaine directly to the United 
States. By 2008, Mexican organized crime groups were 
found in 230 US cities (up from 100 cities three years 
earlier) while Colombian groups controlled illicit cocaine 
and heroin distribution channels in only 40 cities, mostly 
in the north-east. 
In addition, criminal groups from Caribbean countries 
are also involved in cocaine trafficking, notably groups 
with links to the Dominican Republic. Dominican 
groups have been identified in at least 54 US  cities. They 
operate mainly in locations along the east coast, includ-
ing Florida. In addition, US-based Cuban organized 
crime groups pose a threat, because of their affiliations to 
drug traffickers in Peru, the Bolivarian Republic of Ven-
ezuela and Colombia. They are said to operate distribu-
tion networks in at least 25 US cities.44 
Only a quarter of those arrested for cocaine trafficking in 
the US are foreign, however. US citizens appear to have 
secured the most lucrative portion of the trafficking 
chain for themselves. Perhaps this is why, despite the 
importance of the US as a destination market, US citi-
zens are rarely arrested for cocaine trafficking in the 
transit or production countries. Based on data from 31 
42 Institute for Defense Analyses, History of the US Cocaine Market 
(Supply and Consumption), presentation given to the UNODC expert 
group meeting: “The evidence base for drug control in Colombia: 
lessons learned”, Bogota, 9-10 November 2009. 
43 Article 35, amended in the Colombian Constitution, A.L. No. 01, 
1997. 
44 National Drug Intelligence Center, National Drug Threat Assessment 
2009, December 2008. 
Distribution of gross proﬁts (in %) of Fig. 39: 
the US$ 35 billion US cocaine market, 
2008
Source: Original calculations based on UNODC ARQ and  
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countries in the Americas, US citizens comprised only 
0.2% of all cocaine trafficking arrestees over the 2001-
2008 period. In 2008, the share was only 0.1%.
Impact of this flow 
Large-scale cocaine imports into North America consti-
tute, first of all, a serious health problem. This is reflected 
in high levels of dependence and strong treatment 
demand for cocaine across the Americas as well as in 
high levels of drug-related deaths linked to the abuse of 
cocaine. In most countries of the Americas, cocaine is 
the main problem drug, and thus the main drug for 
which treatment is required. 
In the United States alone, almost 1 million people were 
dependent on cocaine in 2008 (see Box for the defini-
tion of ‘dependence’). Of these, 660,000 people had to 
be treated for cocaine problems, according to US house-
hold survey data. This was twice as many people as for 
heroin or stimulants (around 340,000 each). One out of 
three people treated for drug problems in the United 
States in 2008 was treated for cocaine problems,45 at a 
direct cost of around US$6 billion.46 
45 SAMHSA, Results from the 2008 National Survey on Drug Use and 
Health: National Findings, 2009. 
46 Treatment expenditure at the federal level amounted to US$3.3 bn 
or 24.5% of the federal US drug control budget in 2008. (ONDCP, 
National Drug Control Strategy: FY 2010 Budget Summary, Washing-
ton, May 2009). A previous ONDCP study put the overall health 
care costs (federal and state) at US15.7 bn in 2002 (ONDCP, The 
Economic Costs of Drug Abuse in the United States, December 2004), 
equivalent to US$18.9 bn expressed in 2008 US dollars. As the total 
number of persons treated remained largely unchanged between 2002 
and 2008 (2.0 million persons treated in 2002, rising to 2.5 million 
in 2006 before falling to less than 2.1 million in 2008; SAMHSA, 
Results from the 2008 National Survey on Drug Use and Health: 
National Findings, Sept. 2009 ), total health care costs may have still 
been close to US$ 19 bn in 2008. As cocaine accounted for close to 
a third of all persons treated in 2008, cocaine-related treatment costs 
can be estimated to amount to some US$6 bn. 
Citizenship of federal cocaine  Fig. 40: 
arrestees in the USA in 2008
Source: UNODC ARQ
The DSM-IV definition of 
‘dependence’
The definition of ‘dependence’ in the US household 
survey is based on the definition found in the 4th 
edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV). DSM-IV defines 
dependence as: a maladaptive pattern of substance 
use, leading to clinically significant impairment or 
distress, as manifested by three (or more) of the fol-
lowing, occurring at any time in the same 12-month 
period:
Tolerance, as deﬁned by either of the following:  ?
- a need for markedly increased amounts of the 
substance to achieve intoxication or desired 
effect; 
- markedly diminished effect with continued 
use of the same amount of substance. 
Withdrawal, as manifested by either of the  ?
following: 
- the characteristic withdrawal syndrome for the 
substance; 
- the same (or a closely related) substance is 
taken to relieve or avoid withdrawal symptoms.  
Use of larger amounts or over a longer period  ?
than was intended. 
There is a persistent desire or unsuccessful ef- ?
forts to cut down or control substance use.  
A great deal of time is spent in activities to ob- ?
tain the substance, use the substance, or recover 
from its eﬀects. 
Important social, occupational or recreational  ?
activities are given up or reduced because of 
substance use. 
The substance use is continued despite knowl- ?
edge of having a persistent or recurrent physical 
or psychological problem that is likely to have 
been caused or exacerbated by the substance 
(for example, continued drinking despite recog-
nition that an ulcer was made worse by alcohol 
consumption). 
 
Source: DSM-IV, Diagnostic and Statistical Manual of 
Mental Disorders, ed. 4. Washington DC: American 
Psychiatric Association (AMA), 1994.
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Cocaine also plays a significant role in drug-related 
deaths. Some 31,800 people died from drug-related 
causes in the United States in 2007, or about 10 per 
100,000 citizens.47 This is about twice the country’s 
murder rate. The 7,475 fatal poisonings due to cocaine 
in 2006 are equivalent to 2.5 deaths per 100,000 inhab-
itants, or 20% of all drug-related deaths in the USA. 
Other studies suggest that the total proportion of 
‘cocaine-related’ deaths (that is, deaths where cocaine 
was involved though not necessarily the only cause) is 
higher, at 40% of the total, equivalent to some 12,700 
people in total in 2007.48 The costs of these premature 
cocaine deaths can be estimated at some US$13 billion, 
expressed in 2008 US$.49 
Cocaine use is more common among arrestees than the 
general population. The national drug use survey indi-
cated that about 1% of US men used cocaine in the 
previous month in 2008, but urine tests of arrestees in 10 
US cities found that 28.5% of the men in custody had 
recently used the drug. In Chicago, the figure was 44%. 
The corresponding rates in the 10 US cities for opiates 
(7.7%) and methamphetamine (5.9%) were much lower 
than for cocaine.50 In line with the trends among the 
47 National Vital Statistics Reports, Deaths: Preliminary Data for 2007, 
Vol. 58, No. 1, August 2009.
48 Ibid. 
49 The overall costs related to premature deaths due to drug abuse for 
US society were estimated by ONDCP at US$ 24.6 bn for the year 
2002 (ONDCP, The Economic Costs of Drug Abuse in the United 
States, 1992-2002, Washington, November 2004), equivalent to US$ 
27 bn in 2008 US dollars. As the number of drug-related premature 
deaths actually increased by 22% between 2002 and 2007, this 
figure would come close to US$33 bn, expressed in 2008 US dollars. 
Applying a ratio of 40% to this value (share of cocaine in all deaths 
in 2007), results in an estimate for cocaine-related premature death 
of around US$13 bn. 
50 ONDCP, Arrestee Drug Abuse Monitoring Program - ADAM II, 2008 
Annual Report, April 2009. 
general population, however, cocaine use among arrestees 
has shown a clear decline in recent years. 
Of course, the fact that suspected criminals use cocaine 
does not mean that cocaine causes their criminality. Both 
drug use and the likelihood of being arrested may be 
related to a third factor, such as social marginalization. 
But the same would be true for heroin or methampheta-
mine, where the connection with crime is much weaker. 
Studies have also shown a stronger correlation between 
levels of cocaine use in a city and violent crime than for 
other drugs. Cocaine users, especially crack users, can 
consume an almost unlimited amount of their chosen 
drug, unlike heroin or methamphetamine users. Crack 
highs are short-lived, prompting users to find money for 
more by any means possible, including prostitution and 
violent acquisitive crime. High sales volumes have also 
made crack an attractive funding source for street gangs, 
whose wars over sales turf have been a major source of 
murders in the United States in the past.
This is one reason that the general decline in murders in 
the United States over the last two decades or so has been 
attributed, at least in part, to declines in cocaine use. 
Other crime rates have also fallen in the same period. 
According to national surveys, the share of people who 
used cocaine in the previous month fell by 56% between 
1988 and 2008. Between 1990 and 2008, the murder 
rate fell by 43%. During the same period, the US prop-
erty crime rate fell by 29% and the violent crime rate by 
34%.51 There are also clear links between cocaine 
and violence in the production and transit countries.
51 US Department of Justice, Federal Bureau of Investigation (FBI), 
Crime in the United States, Preliminary Semiannual Uniform Crime 
Report, January to June, December 2009. 
Drug related deaths – by drug  Fig. 41: 
category – across 40 US metropolitan 
areas, 2007 
Source: SAMHSA, Drug Abuse Warning Network, 2007: Area 
Profiles of Drug Related Mortality, 2009
Cocaine use among male arrestees in Fig. 42: 
10 US cities* and past month preva-
lence of cocaine use among males in 
the general US population, 2000-2008
* Unweighted average of results obtained from Atlanta, Charlotte, 
Chicago, Denver, Indianapolis, Minneapolis, New York, Portland, Sacra-
mento and Washington DC.  
Source: Office of National Drug Control Policy 2009
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Long-term trends: Cocaine use and changes in the crime rates in the United States Fig. 43: 
Sources: SAMHSA, 2008 Household Survey on Drug Use and Health; SAMHSA, 1998 National Household Survey on Drug Abuse; FBI, 
Uniform Crime Reports
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Cocaine from the Andean Region 1.3.3 
to Europe
The world’s second largest flow of cocaine is directed 
towards Europe. The 27 countries of the European 
Union (EU) and the four countries of the European Free 
Trade Association (EFTA) host some 90% of Europe’s 
4.5 million cocaine users. The single largest cocaine 
market within Europe is the United Kingdom, followed 
by Spain, Italy, Germany and France.
In contrast to the shrinking cocaine market in North 
America, the number of cocaine users in the EU/EFTA 
countries has doubled over the last decade, from 2 mil-
lion in 1998 to 4.1 million in 2007/2008. Recent data 
suggest, however, that the rapid growth of the European 
cocaine market is beginning to level off. The annual 
cocaine prevalence rate in the EU/EFTA region (1.2% 
of the population aged 15-64) is still far lower than in 
North America (2.1%), though individual countries, 
notably Spain (3.1% in 2007/2008) and the United 
Kingdom (3.7% in Scotland; 3.0% in England and 
Wales in 2008/2009), already have higher annual preva-
lence rates than the United States (2.6% in 2008). 
Routes and volumes 
Trafficking of cocaine to Europe is mainly by sea (often 
in container shipments), although deliveries by air and 
by postal services also occur. The World Customs 
Organization reported that 69% of the total volume of 
cocaine seized by customs authorities en route to West 
Europe was detected on board boats or vessels, con-
cealed in freight or in the vessels’ structure.52 Though 
recent years have seen a proliferation of entry points, 
including some in the Balkan region, most of the cocaine 
entering Europe does so through one of two hubs: Spain 
and Portugal in the south, or Netherlands and Belgium 
in the north. The Iberian peninsula is close to Latin 
America both geographically and culturally, and the 
Low Countries host the largest ports in Europe. Between 
them, Spain, Portugal, the Netherlands and Belgium 
accounted for close to 70% of all cocaine seized in 
Europe in 2008, though just a quarter of the ‘European 
cocaine’ was consumed in these countries.53
Despite the growth of Peruvian and Bolivian production 
capacity, the main source of the cocaine found in Europe 
52 World Customs Organization, Customs and Drugs Report 2008, Brus-
sels, June 2009. 
53 EMCDDA/Europol, Cocaine: A European Union perspective in the 
global context, April 2010.
National shares of the cocaine user Fig. 44: 
population in Europe in 2007/08
UNODC ARQ; Government reports; UNODC, World Drug 
Report 2009; EMCDDA, Statistical Bulletin 2009
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in still Colombia. Individual drug seizures reported by 
Spain suggest, for instance, that 81% of the cocaine 
originated in Colombia and its neighbouring countries 
(the Bolivarian Republic of Venezuela, Ecuador and 
Panama) in 2008. Nonetheless, shipments from Peru 
and the Plurinational State of Bolivia are more common 
for Europe than for the United States, and the relative 
importance of Colombia is declining. For 2002, the UK 
authorities reported that 90% of the cocaine seized there 
originated in Colombia; by 2008, the figure fell to 65%. 
For some of the smaller European markets, Peru and the 
Plurinational State of Bolivia seem to be the primary 
sources of cocaine already.There have also been changes 
in the routes. Shipments to Europe, particularly large 
maritime shipments, have been increasingly transiting 
the Bolivarian Republic of Venezuela in recent years.54 
In fact, for cocaine seized since 2004 where the origin 
could be determined, 41% have been traced back to the 
Bolivarian Republic of Venezuela.55 According to the 
new Maritime Analysis Operation Centre (MAOC-N), 
more than half (51%) of all intercepted shipments in the 
Atlantic over the 2006-2008 period started their journey 
in the Bolivarian Republic of Venezuela. Direct ship-
ments from Colombia accounted for just 5% of the 
total.56 
Sailing vessels, mostly travelling from the Caribbean 
to Europe, emerged in recent years as the most common 
source for seizures (43% of all seizure cases according 
to MAOC-N data), followed by freight vessels (39%) 
and other motor vessels (12%).57 Semi-submersibles, 
in contrast, do not play any significant role for traffick-
ing cocaine from South America to Europe. Only one 
has been sighted so far, in Galicia, northern Spain in 
2006.58
There are also ongoing cocaine shipments by air from 
various South American countries (Brazil, Argentina, 
Uruguay et cetera), Caribbean countries (Netherlands 
Antilles, Dominican Republic, Jamaica et cetera) and 
Central American countries (including Costa Rica) to 
destinations in Europe. 
In addition, shipments to Africa, mostly West Africa, 
gained in importance between 2004 and 2007, resulting 
in the emergence of two key trans-shipment hubs: one 
centered on Guinea-Bissau and Guinea, stretching to 
Cape Verde, Gambia and Senegal, and one centered in 
the Bight of Benin, which spans from Ghana to Nigeria. 
Colombian traffickers often transport the cocaine by 
‘mother ships’ towards the West African coast before 
54 Ibid.
55 UNODC, Individual Drug Seizures database. 
56 Maritime Analysis Operation Centre (MAOC(N), Statistical Analysis 
Report, Lisbon 2009.
57 Ibid.
58 MAOC-N, Semi-Submersible Briefing Paper, Lisbon 2008. 
offloading it to smaller vessels. Some of it proceeds 
onward by sea to Spain and Portugal while some is left 
as payment to West Africans for their assistance – as 
much as 30% of the shipment.59 The West Africans 
then traffic this on their own behalf, often by commer-
cial air couriers. Shipments are also sent in modified 
small aircraft from the Bolivarian Republic of Venezuela 
or Brazil to various West African destinations.60 Increased 
awareness, interdiction and political turmoil in the 
northern hub seem to have reduced the traffic through 
this region in 2008 and 2009, although it could quickly 
re-emerge. The decline in trafficking, affecting in par-
ticular Lusophone Africa, may also be a reason why 
Portugal experienced a sharp fall in cocaine seizures 
between 2006 and 2008, following a massive upward 
trend over the 2003-2006 period.
European cocaine seizures as a whole increased strongly 
over the 1998-2006 period, from 32 to 121 mt, before 
declining again over the 2006-2008 period to some 63 
mt. Nonetheless, overall cocaine seizures in 2008 were 
almost twice as high as in 1998. 
The largest interceptions were reported by Spain, account-
ing for 45% of all European cocaine seizures in 2008 as 
well as over the 1998-2008 period. The Spanish figures 
reflect both the strong increase and the recent decline in 
cocaine seizures in Europe. The trends are also confirmed 
in survey data on perceived cocaine availability in Spain.61 
59 Serious Organized Crime Agency (SOCA), The United Kingdom 
Threat Assessment of Organised Crime, 2009/10, London, 2009. 
60 UK Home Affairs Committee, The Cocaine Trade (see: http://
www.publications.parl iament.uk/pa/cm200910/cmselect/
cmhaff/74/7410.htm); SOCA, UK Threat Assessment of Organised 
Crime 2009/10.
61 Ministerio de Sanidad y Consumo, 2008 National Report to the 
EMCDDA by the Reitox National Focal Point, ‘Spain’ New Develop-
ment, Trends and in-depth information on selected issues, Madrid, 
Departure locations of identiﬁed drug Fig. 46: 
trafﬁcking shipments by sea from 
South America to Europe, 2006-2008
Source: Maritime Analysis Operation Centre
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Spanish cocaine seizures primarily take place in inter-
national waters (two thirds of the total in 2007) and 
about one tenth are made from containers. A much 
smaller share is seized close to the country’s beaches (2%), 
while airports account for just 6%.62
Portuguese seizures basically mirror the patterns seen in 
Spain, showing increases until 2006 and declines there-
after (from 34 mt in 2006 to 5 mt in 2008). The changes 
have been even more pronounced in Portugal, reflecting 
the strong links with trafficking via West Africa (via 
Guinea-Bissau and Cape Verde).
Dutch cocaine seizures have also sharply fallen in recent 
years. This is a result of the ‘100% control’ policy in the 
Antilles and at Schiphol airport (Amsterdam), which 
reduced the number of drug couriers from the Carib-
bean and various South American countries,63 improved 
container controls as well as growing efforts to stop ship-
ments before they arrive in the Netherlands. For exam-
ple, in 2008, the National Crime Squad arrested several 
men planning to ship 2.6 mt of cocaine from a ware-
house in Sao Paulo, Brazil, to the Netherlands. Large 
amounts of cocaine continue to be seized by the coast-
guards of the Dutch Antilles and Aruba. Out of 6.8 mt 
seized in 2008, 4.2 mt were taken by the Dutch navy 
from a cargo vessel sailing under a Panamanian flag from 
the Bolivarian Republic of Venezuela to Europe. An 
additional factor may be diversions to the port of Ant-
werp (Belgium).
2008.
62 Ministerio del Interior, Secretaria de Estado de Seguaridad, Centro 
de Inteligencia contra el Crimen Organizado, Hashish and Cocaine in 
Europe, presentation given to UNODC, Vienna, July 2008.
63 US Department of State, International Narcotics Control Strategy 
Report, March 2009. 
In 2008, for the first time, France seized more cocaine 
than any other European country besides Spain. Most of 
this cocaine (6 out of 8.2 mt) was seized at sea, mainly 
close to the French overseas territories in the Caribbean 
or close to the West African coast. Cocaine seizures that 
could be traced back to the West African countries 
themselves, however, amounted to just 0.3 mt in 2008. 
Most of the French-seized cocaine in 2008, came from 
Brazil (40% of the total) or the Bolivarian Republic of 
Venezuela (21% of total). Cocaine trafficked from Brazil 
most likely originated in Peru or the Plurinational State 
of Bolivia, reflecting the growing importance of these 
producers to Europe.64 
As in the US market, estimating the volume of cocaine 
consumed in Europe is complicated. There are good 
survey data on the share of the population that uses 
cocaine, but less information on how much they use. 
The subsequent analysis is based on four different esti-
mation methods,65 resulting in average consumption 
64 Direction Générale de la Police Nationale, Direction Générale de la 
Police Judiciare, Office Central pour la Répression du Trafic Illicite 
des Stupéfiants (O.C.R.T.I.S.), Usage et Trafic des Produits Stupéfiants 
en France en 2008, Paris, 2009. 
65 These techniques are detailed in the following documents: United 
States Office of National Drug Control Policy, Cocaine Consump-
tion Estimates Methodology, September 2008 (internal paper); Home 
Office, Sizing the UK market for illicit drugs, London 2001; Home 
Office, Measuring different aspects of problem drug use: methodologi-
cal developments, Home Office Online Report 16/06, London 2006; 
UNODC, 2005 World Drug Report, Volume 1: Analysis, Vienna 
2005; European Centre for Social Welfare Policy, Two Worlds of 
Drug Consumption in Late Modern Societies, Vienna 2009. While the 
first model, developed by ONDCP, seems reasonable, it is based on 
assumptions, not on actual empirical data from European countries. 
The second model is based on empirical data, but they refer to the 
situation in one country (UK) which is not necessarily representative 
for the rest of Europe. The third model refers to cocaine use in West 
and Central Europe, but it is again derived from a number of under-
lying assumptions (such as effectiveness of law enforcement interven-
European cocaine seizures (mt; not adjusted for purity), 1998-2008Fig. 47: 
*No data for 2008 received for Poland, Scotland, Ukraine and Belarus – assumed unchanged levels of seizures. 
Source: UNODC ARQ/DELTA
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rates of between 25 to 35 grams of pure cocaine per user. 
Multiplied by the number of users, this suggests con-
sumption of some 101 to 144 mt for the EU and EFTA 
countries in 2008. The average is 124 mt, about double 
the figure a decade before.6667
In line with the increases in the volumes of cocaine traf-
ficked into Europe since the early 1990s, prices declined. 
Expressed in constant 2008 euros,68 cocaine retail prices, 
at street purity, fell from an average of €143 in 1990 to 
€70 per gram in 2008, essentially halving in two dec-
tions and importance of regional proximity). The fourth model is 
based on empirical data from six cities in Europe, but applying the 
use rate found among marginalized users to all past month users is 
likely to result in an over-estimate. At the same time, a basic problem 
of household surveys, based on self-reports, is that they are – most 
likely – showing a substantial under-estimate of the extent of drug 
use. It remains difficult to judge to what extent these errors offset 
each other in the final calculation of the amounts consumed.
66 UNODC ARQ; UNODC, 2009 World Drug Report, Vienna 2009; 
EMCDDA, Statistical Bulletin 2009, Lisbon 2009; United Nations, 
Department of Economic and Social Affairs, Population Division, 
World Population Prospects: The 2008 Revision, 2009; European 
Centre for Social Welfare Policy, Two Worlds of Drug Consumption 
in Late Modern Societies, Vienna 2009; ONDCP, Cocaine Consump-
tion Estimates Methodology, September 2008 (internal paper); Home 
Office, Sizing the UK market for illicit drugs, London 2001; Home 
Office, Measuring different aspects of problem drug use: methodological 
developments, Home Office Online Report 16/06, London 2006; 
UNODC, 2005 World Drug Report, Volume 1: Analysis, Vienna 
2005.
67 Available data suggest that the European cocaine market doubled in 
volume terms over the 1998-2006 period, before stabilizing over the 
2006-08 period. The calculation is based on the assumption of largely 
stable per capita use levels. Given the lack of reliable quantitative or 
qualitative information, the calculations do not allow for the possibil-
ity that per capita use levels increased over the 1998-2006 period due 
to the progression from casual to problematic use, and that they may 
have fallen in terms of pure cocaine equivalents after 2006 as purity 
declined while use may have remained stable in terms of the amounts 
of street level cocaine consumed.
68 Current euro values were transformed into constant euros by apply-
ing the consumer price index for the euro zone.
ades. To understand the relative attractiveness of this 
market, however, it helps to look at these figures in con-
stant 2008 US dollars.69 Here, too, cocaine prices 
declined over the 1990-2000 period, but they increased 
over the 2000-2008 period, from US$88 to US$102, as 
the US dollar depreciated against the euro. The increase 
was most acute over the 2006-2008 period. 
These euro price declines took place in the context of 
declining purity, however.70 Taking purity into account, 
retail cocaine prices expressed in constant 2008 euros 
remained basically stable between 1998 and 2008: €183 
per pure gram in 1998 and €189 per pure gram in 2008. 
The same was true of wholesale prices. Expressed in 
constant US dollars, the purity-adjusted price actually 
increased significantly. The euro, particularly the high-
value 500 euro note, has become an important second-
ary currency for drug traffickers.
If the amounts of cocaine consumed are multiplied by 
69 Current US dollar values were transformed into constant US dollar 
values by applying the US consumer price index. 
70 The unweighted averages of reported purities for countries in West 
and Central Europe show a decline at the retail level from 59% in 
1998 (range: 25% - 75%) to 47% in 2005 and 36% in 2008 (range: 
16% - 52%). At the wholesale level the decline was from 78% (range: 
55% -90%) in 1998 to 55% in 2008 (range: 26% - 80%).
 As some of the decline could have been simply the result of specific 
countries reporting in one year, and not in another, a modified cal-
culation model was introduced. This model assumes that the results 
of non-reporting countries remained basically unchanged from the 
previous year (or a later year) for which data are available. This was 
done to avoid changes in the overall average due to the reporting 
or non-reporting of countries in specific years. Using this approach 
for missing data, changes in the overall average only reflect actual 
changes in country-specific purity data. Based on this model, the 
average cocaine purities at the retail level in West and Central Europe 
declined from 55% in 1998 to 43% in 2005 and 37% in 2008. The 
wholesale purities declined according to this model from 72% in 
1998 to 60% in 2005 and 56% in 2008.
Amounts of (pure) cocaine consumed in the EU/EFTA countries, 1998-2008Fig. 48: 
Sources: Multiple sources66
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the purity-adjusted retail prices, it appears that the value 
of the European cocaine market has more than doubled 
in the last decade (from US$14 billion in 1998 to US$34 
billion in 2008). In 2008, it was worth almost as much 
as the US market (US$35 billion), even though it was 
still significantly smaller in terms of volume. 
How much cocaine must be shipped to satisfy this grow-
ing demand? Taking seizures into account,71 some 212 
mt would have to have left South America to the Euro-
71 Based on the Annual Reports Questionnaire Data, about 55% of 
the seizures made in the Caribbean and 61% of the seizures made in 
South America excluding the Andean countries were linked to ship-
ments towards Europe in 2008, up from 47% and 46% respectively 
in 2002. For seizures made in Africa it was assumed that the bulk of 
them was linked to shipments towards Europe.
pean market in 2008.72 The growth of the European 
market has meant that a growing share of the total 
cocaine production needs to be funneled toward the 
EU/EFTA countries, increasing from 13% in 1998 to 
25% of total production in 2008. 
Where does the money go? Out of European cocaine 
sales, less than 1% goes to the Andean coca farmers. 
Another 1% goes to the processors and traffickers within 
the Andean region. About 25% of the final sales value 
accrues to the international traffickers who ship the 
cocaine from the Andean region to the main entry 
points. Shipping the cocaine from the entry points to 
the wholesalers in the final destination countries across 
72 Range: 189–232 tons.
Cocaine prices (not adjusted for purity) in West Europe* in constant currency units  Fig. 49: 
per gram, 1990-2008 
 * Average price of 18 West European countries (accounting for the bulk of cocaine consumption in Europe), weighted by population size.
Sources: UNODC, World Drug Report 2009 (and previous years) and ARQ
Purity-adjusted cocaine prices in West Europe, in constant currency units, per gram,  Fig. 50: 
1998-2008 
Sources: UNODC, World Drug Report 2009 (and previous years) and ARQ
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Europe generates a further 17% of the retail value. More 
than half (56%) of the value is, however, made within 
the destination countries, between the wholesalers and 
the consumers. As there are far more dealers at the 
national level, the per capita income of the dealers at the 
national level is (like in North America) likely lower 
than among the smaller group of international cocaine 
traffickers.
73 UNODC, Annual Reports Questionnaire Data; Government reports; 
UNODC, 2009 World Drug Report, Vienna 2009; EMCDDA, Sta-
tistical Bulletin 2009, Lisbon 2009; United Nations, Department of 
Economic and Social Affairs, Population Division. World Popula-
tion Prospects: The 2008 Revision, 2009; Home Office, Sizing the 
UK market for illicit drugs, London 2001, Home Office, Measuring 
different aspects of problem drug use: methodological developments, 
Home Office Online Report 16/06, London 2006; European Centre 
for Social Welfare Policy, Two Worlds of Drug Consumption in Late 
Modern Societies, Vienna 2009; UNODC, 2005 World Drug Report, 
Volume 1: Analysis, Vienna 2005.
How does the market operate?
Trafficking of cocaine to Europe is, to a significant 
extent, organized by Colombian organized crime groups 
that forge alliances with various criminal groups operat-
ing in Europe, notably with groups in Spain, Italy and 
the Netherlands. In most European countries, the major-
ity of those arrested for drug trafficking are local citi-
zens, but the Colombian groups act as importers and, to 
a lesser extent, as wholesalers. Their involvement in 
retail markets is limited to Spain. Between 21% and 
26% of all foreigners arrested for cocaine trafficking in 
Spain over the 2004-2007 period were Colombian 
nationals. The proportion rose to 29%, or nearly 1,000 
individuals, in 2008. 
In addition, groups from the Caribbean region play a 
role, including Dominicans in Spain, Jamaicans in the 
United Kingdom and Antilleans in the Netherlands. 
Other South Americans are also prominent, especially 
on the Iberian peninsula. In a number of countries in 
continental Europe, West Africans are active as retailers 
(as well as small-scale importers), including in France, 
Switzerland, Austria, Italy, Germany and Portugal. 
The largest proportion of non-Portuguese cocaine traf-
fickers arrested in Portugal in 2008 were from Cape 
Verde (27%) and Guinea-Bissau (19%). 
North Africans are prominent in several countries with 
a Mediterranean coastline or a large North African 
diaspora, including Spain, Italy, France and the Nether-
lands. A few groups from the Balkan region have also 
emerged as players in the international cocaine trade in 
recent years. In contrast, there is little concrete evidence 
so far to suggest that the Mexican drug cartels are play-
ing a major role in Europe.
Size of the EU/EFTA cocaine market in billions of constant 2008 US$Fig. 51: 
Sources: UNODC ARQ; Government reports; UNODC, World Drug Report 2009; EMCDDA, Statistical Bulletin 2009; European Centre 
for Social Welfare Policy, Two Worlds of Drug Consumption in Late Modern Societies
’Value-added’ of cocaine sales among Fig. 52: 
the EU/EFTA countries in 2008, billion 
US$
Sources: Multiple sources73
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In the Netherlands, criminal groups from the ‘Dutch 
Caribbean’ (Aruba, Netherlands Antilles and Suriname) 
have long been active alongside Colombians.74 In recent 
years, Nigerian groups expanded in Amsterdam, work-
ing inter alia through air couriers flying to the Nether-
lands from the Netherlands Antilles and Suriname. As 
controls improved on direct flights, they also started to 
use other transit countries such as the Dominican 
Republic, Peru and Mexico.75 Some of the traffic has 
also been displaced to Antwerp (Belgium), following 
improved controls in the port of Rotterdam (Nether-
lands). This traffic is still largely controlled by Colom-
74 Damian Zaitch, Trafficking Cocaine – Colombian Drug Entrepreneurs 
in the Netherlands (Studies of Organized Crime), The Hague 2002. 
75 US Department of State, International Narcotics Control Strategy 
Report, March 2009. 
bian groups,76 though Albanian groups, working at the 
port facilities, also seem to play a role in Antwerp. 
Most of the cocaine needed to supply the United King-
dom, Europe’s largest cocaine market, transits another 
European country, rather than being shipped directly. 
Bulk maritime shipments on merchant vessels or yachts 
from ports in Colombia or the Bolivarian Republic of 
Venezuela cross the Atlantic to the Iberian Peninsula. 
There, the cocaine is sold to local British criminals, who 
then smuggle it to the United Kingdom. To a lesser 
extent, cocaine is also imported by British criminals 
from the Netherlands. Thus, some 75% of the cocaine 
destined for the UK market is estimated to have been 
carried across the Channel, concealed in trucks, private 
cars or by human couriers (‘mules’). 
76 Ibid. 
Nationality of persons arrested in Spain for trafﬁcking cocaine into or within the country, Fig. 53: 
2008
Source: UNODC ARQ
Nationality of persons arrested in Portugal for trafﬁcking cocaine into or within the country, Fig. 54: 
2008
Source: UNODC ARQ
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In Italy, Colombian, Dominican and other Latin Amer-
ican organizations are working with Italian organized 
crime groups (notably the ‘Ndrangheta) to import 
cocaine in commercial cargo or containerized ship -
ments.7778 Italy is also one of the few European countries 
where close links between organized Mexican groups 
(the Gulf Cartel) and local organized crime groups have 
been confirmed.79 As of 2007, the Camorra, located in 
77 Sample of arrested cocaine traffickers (n = 442) for which nationality 
was identified; number of all arrested cocaine traffickers in France in 
2006: N = 2,561. 
78 Presidenza del Consiglio dei Ministri, Dipartimento Politiche Anti-
droga, Relazione Annuale Al Parlamento Sullo Stato Delle Tossicodipen-
denze in Italia 2008, Rome 2009.
79 US Department of State, op cit.
Naples, was reported to have begun trafficking cocaine 
to Italy from Spain, as well as directly from South Amer-
ica. More recently, the Sicilian mafia has also become 
involved, getting support from the ‘Ndrangheta and the 
Camorra to bring cocaine into the areas it controls.80 
West African and North African groups are active in 
retailing and small-scale import, as well as groups from 
the Balkans, in particular Albanians and Serbians. Sev-
eral West African and Albanian groups import the 
cocaine from the Netherlands to northern Italy.81 
The French cocaine market used to be rather small, 
80 Presidenza del Consiglio dei Ministri, op cit..
81 US Department of State, op cit.
Nationality of trafﬁckers arrested in Italy for trafﬁcking cocaine into or within the country, Fig. 55: 
2008
Source: UNODC ARQ
Nationality of trafﬁckers arrested in France for trafﬁcking cocaine into or within the country, Fig. 56: 
200677
Source: UNODC ARQ
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though this has started to change in recent years, partly 
due to the growing importance of Africa as a transit loca-
tion. When West Africa became a more prominent tran-
sit area after 2004, West African traffickers also became 
more prominent. In 2008, cocaine traffickers from Togo, 
Benin, Ghana, Nigeria, Senegal and the Democratic 
Republic of the Congo were arrested. North African and 
European traffickers have also been arrested.82
The bulk of cocaine traffickers in Germany were not 
born in Germany.83 The largest group of foreign traf-
82 UNODC ARQ, 2002-2008. 
83 Bundeskriminalamt, Polizeiliche Kriminalstatistik 2008, Wiesbaden 
2009; Bundeskriminalamt, Organisierte Kriminalität, Bundeslagebild 
2008, Wiesbaden 2009.
fickers in Germany were Turkish (22% of all foreign 
cocaine traffickers in 2008). This is a recent develop-
ment: Turkish traffickers have traditionally been associ-
ated with heroin. The second largest foreign group 
detected are traffickers from Italy (7%), often associated 
with the ‘Ndrangheta and other Italian mafia groups. 
Various groups from the Middle East (Lebanon and 
Morocco: 5%) and from West Africa (Sierra Leone, 
Nigeria and Guinea: 4%) were also prominent.84 Those 
arrested for ‘cocaine imports’ comprise a smaller and 
more varied group, with the top foreign nationalities 
being Dutch (13%) and Turkish (10%, typically acquir-
84 Bundeskriminalamt, Organisierte Kriminalität, Bundeslagebild 2008, 
Wiesbaden 2009.
Germany,
 225,
 37%
Foreigners
 380, 
63%
Albania, 10, 2%
Poland, 11, 2%
Morocco, 12, 2%
Jamaica, 11, 2%
Italy, 26, 4%
Nigeria, 30, 5%
Turkey, 37, 6%
Netherlands, 48, 8%
Other, 195, 32%
Nationality of those arrested for sale of cocaine in Germany, 2008Fig. 57: 
Sources: UNODC ARQ and Bundeskriminalamt, Polizeiliche Kriminalstatistik 2008, Wiesbaden 2009
Nationality of ‘cocaine importers’ arrested in Germany, 2008Fig. 58: 
Sources: UNODC ARQ and Bundeskriminalamt, Polizeiliche Kriminalstatistik 2008, Wiesbaden 2009
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ing the cocaine from the Netherlands). Nigerian (5%) 
and Italian individuals (4%) also feature prominently.85
Impact of this specific flow
The social and economic impact of the flow of cocaine 
to Europe has been – so far at least – less severe than for 
North America. Though the proportion of people in 
need of treatment in Europe for cocaine abuse has more 
than tripled over the last decade (from 3% of total drug 
treatment demand in 1997/1998 to 10% in 2007/2008), 
it is still far lower than in North America (31% in 
2007/2008). 
The number of cocaine-related deaths is also far lower in 
Europe than in North America. According to the latest 
national data, less than 700 people in the EU/EFTA 
85 Ibid. 
countries died due to cocaine use, which is less than 0.2 
deaths per 100,000 inhabitants, and only 8% of all 
drug-related deaths. As in North America, deaths from 
poly-drug use are common in Europe. German data 
show, for example, that in only 14% of all ‘cocaine-re-
lated’ death cases was cocaine the only substance 
involved.86 
Cocaine use in Europe is also less associated with vio-
lence than in North America. This is most likely because 
powder cocaine is still dominant in Europe, and it is 
crack that is most associated with violent crime. There 
does appear to be a link with acquisitive property crime, 
however. 
England and Wales conduct arrestee drug testing. These 
studies found that 13% of the arrestees in 2005/2006 
86 Bundeskriminalamt, Rauschgift, Jahreskurzlage 2008, Tabellenanhang, 
Wiesbaden 2009. 
Country Year
Cocaine-
related 
deaths
Drug 
deaths
Cocaine in 
% of drug 
deaths
 Cocaine deaths 
per 100,000 
inhabitants
Source Comments
Spain 2006 257 428 60.0% 0.58 EMCDDA overdose
United  
Kingdom 2007 246 3,359 7.3% 0.40 ARQ all deaths
Germany 2008 126 1,449 8.7% 0.15 Govt all deaths
Portugal 2007 103 314 32.8% 0.96 EMCDDA all deaths
France 2008 51 233 21.9% 0.08 ARQ all deaths
Italy 2008 37 502 7.4% 0.06 ARQ overdose
Ireland 2005 34 159 21.4% 0.77 ARQ overdose
Netherlands 2008 22 129 17.1% 0.13 ARQ overdose
Denmark 2007 5 205 2.4% 0.09 ARQ all deaths
Malta 2008 3 8 37.5% 0.74 ARQ all deaths
Finland 2007 3 229 1.3% 0.06 ARQ all deaths
Poland 2006 2 241 0.8% 0.01 ARQ all deaths
Slovenia 2005 1 85 1.2% 0.05 ARQ all deaths
Luxembourg 2002 1 35 2.9% 0.21 ARQ all deaths
Czech 
Republic 2006 1 212 0.5% 0.01 ARQ overdose
Sweden 2006 0 125 0.0% - ARQ all deaths
Romania 2007 0 23 0.0% - EMCDDA all deaths
Liechtenstein 2008 0 1 0.0% - ARQ all deaths
Hungary 2008 0 194 0.0% - ARQ all deaths
Bulgaria 2006 0 48 0.0% - EMCDDA All deaths
Iceland 2007 0 38 0.0% - ARQ all deaths
Cyprus 2007 0 22 0.0% - ARQ overdose
Total 635 7,611 8.3% 0.14
Reported cocaine related deaths in EU/EFTA countries in 2008 or latest year available*Table 10: 
* EU/EFTA countries which provide a breakdown of drug-related mortality by drug type.
Sources: UNODC ARQ; EMCDDA, Statistical Bulletin 2009; EMCDDA, National Reports
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had used cocaine powder and 11% crack-cocaine in the 
previous month.87 This is less than in the United States 
but much more than in the general population: house-
hold surveys during the same period indicate that only 
1.2% of the population had used cocaine powder and 
0.1% had used crack-cocaine in the previous month.88 
A previous arrestee survey for England and Wales 
(2003/2004) found that 68% of those arrested for shop-
lifting, 63% of those arrested for burglary, 41% of those 
arrested for ‘other theft’ and 23% of those arrested for 
assault had consumed either crack-cocaine, cocaine 
powder or heroin within the previous 12 months.89 
The consequences of trafficking and cocaine consump-
tion in Europe are dwarfed by the serious repercussions 
for the cocaine-producing countries (in terms of cocaine-
generated violence and insurgencies) and for many of 
the transit countries in South America, Central America, 
the Caribbean and Africa, notably West Africa where 
some of the smaller countries are easy targets for cocaine 
trafficking organizations that operate internationally. 
Implications for response1.3.4 
Prevention and treatment can work. The significant 
decline in cocaine use in the United States over the last 
three decades can be linked, inter alia, to increased 
spending on prevention and treatment. However, not all 
87 Home Office, The Arrestee Survey 2003-2006, 2nd edition, London, 
November 2007. 
88 Home Office, “Drug Misuse Declared: Findings from the 2005/06 
British Crime Survey, England and Wales”, Home Office Statistical 
Bulletin, October 2006. 
89 Home Office, “The Arrestee Survey Annual Report: Oct. 2003-Sept. 
2004”, Home Office Statistical Bulletin, November 2006.
prevention efforts are effective. Simplistic interventions 
can generate an interest in drugs and can lead to even 
higher use levels. Treatment of problem drug users, who 
consume the bulk of the drugs, can reduce the demand 
for drugs. But this requires time as relapse rates are usu-
ally high. Some users may never achieve abstinence. It 
also seems that treating cocaine dependence is even 
more difficult than treating other drug addictions and 
some new approaches (‘cocaine vaccinations’) are being 
explored. 
Many studies have shown that treatment is an effective 
investment to reduce drug demand, including demand 
for cocaine,90 despite its shortcomings. The fight against 
the drug cartels is a legitimate and necessary undertak-
ing, but this may not automatically reduce the cocaine 
market. History has shown that break-ups of big cocaine 
cartels may lead to the emergence of a larger number of 
smaller groups. Increased competition can produce 
lower prices, which could even encourage higher use 
levels.
90 William S. Cartwright, Cost–Benefit Analysis of Drug Treatment 
Services: Review of the Literature, The Journal of Mental Health Policy 
and Economics,J. Mental Health Policy Econ. 3, 11–26 (2000); Treat-
ment Research Institute at the University of Pennsylvania, Economic 
Benefits of Drug Treatment: A critical Review of the Evidence for Policy 
Makers, February 2005; Wim van den Brink, Amsterdam Institute 
for Addiction Research, Academic Medical Center University of 
Amsterdam, “Effectiveness and Cost-Effectiveness of Drug Depen-
dence Treatment“, presentation given at the Donor Conference in 
Support of the UNODC-WHO Joint Program on Drug Dependence 
Treatment and Care, The Hague, 10 February 2010. Results from 
eleven meta studies in the USA suggested that the main economic 
benefits from drug treatment (all drugs; totaling, on average, some 
US$49,500 per patient) were in the form of avoided criminal activity: 
US$42,200 per patient or 85% of total economic benefits. (Kathyrin. 
E. Mc. Collister and Michael T. French, The relative contribution of 
outcome domains in the total economic benefit of addiction interventions: 
a review of first findings, 2003). One previous US study, based on 
more than 500 cocaine dependent patients in the Drug Abuse Treat-
ment Outcome Study suggested that the treatment costs for outpa-
tient cocaine treatment were, on average US$1,422 while the benefits 
from avoided crime among this group amounted to US$1,891 per 
patient, equivalent to a benefit to cost ratio (BCR) of 1.3. The same 
study found that long-term residential cocaine treatment resulted 
in costs of, on average, US$11,016 while average avoided crime 
costs amounted to US$18,461, or a BCR of 1.7. Including other 
economic benefits, the BCR for cocaine was found to amount to 1.6 
and 1.9, respectively, for outpatient and long-term residential cocaine 
treatment, suggesting that for US$1 invested into cocaine treatment 
about US$2 can be expected to be generated in economic benefits. 
(Flynn, P.M., Kristiansen J.V., Porto R.L., “Costs and benefits of 
treatment for cocaine addiction”, Drug and Alcohol Dependence, 57 
(1999), pp. 167-174). A general review of economic benefit to cost 
ratios in drug treatment (all drugs), reported in the literature for 
residential and outpatient drug treatment, found BCRs ranging from 
1.3 to 6.5 (Treatment Research Institute at the University of Pennsyl-
vania, 2005) with an average of 3.4, suggesting that for each dollar 
invested into drug treatment one should expect economic benefits of 
more than US$3 (and thus more than for treating cocaine dependent 
persons). According to a West Coast Cost-Benefit Analysis, every 
dollar invested by the authorities in drug treatment in this region was 
reported to have even saved, on average, US$7 in other costs (health 
care and emergency room visits, criminal justice proceedings, impris-
onment, food stamps, unemployment, workers’ compensation, child 
welfare and other related services; Oregon Research Brief on Addiction 
Treatment Effectiveness, 2003). 
Past month prevalence of cocaine  Fig. 59: 
use among the general population  
versus cocaine use among arrestees  
in England and Wales, 2005/2006
Sources: Home Office, The Arrestee Survey 2003-2006, 2nd 
edition, London, November 2007; Home Office, “Drug Misuse 
Declared: Findings from the 2005/06 British Crime Survey, 
England and Wales,” Home Office Statistical Bulletin, October 
2006
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The concept of shared responsibility has long been 
adopted by UN Member States. They have also recog-
nized the need for a balanced approach between supply 
and demand reduction efforts. Nonetheless, these gen-
eral concepts still need to be better translated into oper-
ational terms. Uncoordinated efforts, leading to isolated 
sectoral and geographical successes, have often only dis-
placed the problem, leaving the global cocaine market 
intact. In the mid-1990s, for example, law enforcement 
efforts put an end to large-scale air trafficking of coca 
paste or cocaine base between Peru and Colombia. Coca 
leaf prices fell in Peru and farmers turned to other crops. 
The problem was, however, not really solved as this 
decline was offset by increases in coca cultivation in 
Colombia. Later, cocaine laboratories emerged in Peru, 
generating new demand for coca and resulting in higher 
coca leaf prices, thus leading to a resurgence of coca 
cultivation in that country in the twenty-first century. 
Similarly, declines in cocaine use in the United States 
prompted drug traffickers to seek alternative markets. 
Thus, reductions in North America were offset by 
increases in the use of cocaine in Europe and South 
America over the last two decades. 
All of this indicates that coordination of national and 
sectoral efforts in the context of an internationally inte-
grated strategy has been missing. Unless a more inte-
grated international strategy is developed, sustainable 
success may remain an elusive goal. Member States rec-
ognized this in their Political Declaration91 of March 
2009, stressing that:
“… the world drug problem remains a common and shared 
responsibility that requires effective and increased interna-
tional cooperation and demands an integrated, multidisci-
plinary, mutually reinforcing and balanced approach to 
supply and demand reduction strategies.”
91 “Political Declaration and Plan of Action on International Coop-
eration towards an Integrated and Balanced Strategy to Counter the 
World Drug Problem”, in United Nations Commission on Narcotic 
Drugs, Report on the fifty-second session (14 March 2008 and 11-20 
March 2009), E/2009/28; E/n.7/2009/12, pp. 37-77. 
1.4 The global ATS market
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What are ATS? 1.4.1 
Amphetamine-type stimulants (ATS) refer to a group of 
synthetic substances comprised of amphetamine-group 
(primarily amphetamine, methamphetamine and meth-
cathinone) and ecstasy-group substances (MDMA and 
its analogues). The amphetamine-group substances were 
originally synthesized in the late nineteenth century and 
marketed as over-the-counter nasal decongestants begin-
ning in 1932. During the Second World War, the vari-
ous amphetamines were used by military personnel and 
stockpiles were released onto the market after the war.1 
The uncontrolled use of the amphetamine-group sub-
stances led to widespread abuse. By the 1970s, the thera-
peutic usefulness of these substances was recognized to 
be limited. National and international control measures 
appeared, as did a decline in licit pharmaceutical manu-
facture. However, demand for these substances did not 
decline at the same rate and clandestine manufacture 
gradually became the primary source of supply for these 
substances. 
The ecstasy-group substances are chemically related to 
the amphetamines. The major compound, MDMA and 
other analogues such as MDA and MDEA were first 
synthesized early in the 1900s. While MDMA found 
limited therapeutic use in the 1970s, its recreational use 
increased dramatically throughout the 1990s and was 
associated with rave culture in the developed world. 
All ATS are available in diverse forms and vary in purity. 
Methamphetamine or amphetamine can be in powder, 
1 UNDCP Technical Series Number 3, Amphetamine-type stimulants: a 
global review, 1996.
tablet, paste or crystalline form while ecstasy is usually 
available in tablet or powder form.
The spreading use of ATS can be attributed to their 
attractiveness to both users and the criminal organiza-
tions who manufacture them alike. They appeal to the 
needs of today’s societies and have become part of what 
is perceived to be a modern lifestyle, both recreationally 
and occupationally. Their use is believed to enhance 
performance including sexual performance and their use 
is often initiated by mouth in ‘convenient’ and discrete 
pill form that avoids the dangers of injection or social 
stigma of smoking. They are affordable, often sold in 
single tablet units, which are often erroneously perceived 
as being less harmful than in other forms.
The popularity of ATS is also a result of a market poten-
tial with continuously high profits and low risks with 
little initial investment. Unlike the cultivation of the 
coca leaf or opium poppy, ATS manufacture is not lim-
ited to certain geographic locations, thus laboratories 
can clandestinely operate anywhere and be relocated as 
risk increases. One unique characteristic is that they can 
be synthesized from a variety of starting materials (pre-
cursor chemicals) using a variety of methods. If a tradi-
tional precursor becomes unavailable, replacements are 
easily found, often facilitated by readily available infor-
mation on the Internet. New synthetic stimulants not 
yet under international controls can also be brought 
quickly to market. Additionally, large profits are not 
only made from the sale of the drug itself, but increas-
ingly from illicit sourcing of the key precursor 
chemicals.

97
1. Transnational drug market analysis Amphetamine-type stimulants market
and – in recent years - also ecstasy), North America 
(methamphetamine and ecstasy in all three countries), 
Europe (mostly amphetamine and ecstasy, with increas-
ing methamphetamine manufacturing), Oceania (meth-
amphetamine and, to a lesser extent, amphetamine and 
ecstasy), and parts of Africa, most notably in the south 
(methamphetamine and methcathinone). 
Since 2000, significant ATS manufacture has been 
reported to UNODC in either number of clandestine 
laboratories or size of operations from Australia, Bel-
gium, Bulgaria, Canada, China,3 the Czech Republic, 
Germany, Indonesia, Malaysia, Mexico, Republic of 
Moldova, Myanmar, the Netherlands, New Zealand, 
Philippines, Poland, the Russian Federation, Slovakia, 
South Africa and the United States of America. The 
overall number of dismantled ATS laboratories rose 
strongly until 2004, but declined thereafter and is now 
back to the level a decade ago. This reflects mainly the 
trends reported from the United States which regularly 
dismantles the majority of all clandestine ATS labs 
worldwide, typically concerning smaller methamphet-
amine incidents. The reported decline after 2004 can be 
linked to improvements in US precursor controls which 
made access to such chemicals in the United States far 
more difficult. The numbers in several regions outside 
the United States, in contrast, increased over the last 
decade, particularly for methamphetamine – though 
some stabilization can be noticed for the period after 
2004.
A shift can be noted in the manufacture of ecstasy-group 
substances, which used to be located predominantly in 
Western Europe, closer to the main consumer market. 
Over the past 10 years, manufacture of ecstasy-group 
3 Includes all provinces and Special Administrative Regions. 
substances has shifted away from Europe to a number of 
consumer markets around the world. Large-scale manu-
facturing operations are more frequently being disman-
tled in East and South-East Asia, the Americas and 
Oceania. In 2008, only four ecstasy laboratories were 
reported to have been seized in West and Central 
Europe.
To supplement quantitative data, UNODC requests 
Member States in the Annual Reports Questionnaire 
(ARQ) to provide insights as to whether experts believe 
the trends in manufacturing are changing over time.
Each year between 2000 and 2008, an average of 23 
countries reported on these trends. Assigning a value to 
Number of reported ATS laboratories (all sizes), by region, 1999-2008Fig. 60: 
Source: UNODC ARQ/DELTA
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the experts’ responses4 and trending them over time 
(indexed using the year 2000 as the baseline of 100) 
suggests that the trend in methamphetamine manufac-
ture is perceived to be on the increase in most reporting 
countries, while until recently amphetamine has 
remained relatively unchanged. Trends in ecstasy manu-
facture, on the other hand, are perceived to have stabi-
lized since 2006. 
The expert perception trends of increased amphetamine 
and methamphetamine manufacture over this period 
are, however, supported by several other data, including 
rising seizures reported throughout this period, a grow-
ing proportion of countries reporting seizures of these 
substances, and both the volume and increasing size of 
dismantled laboratories. 
Over the past decade, the proportion of countries which 
reported seizures of ATS has increased markedly, indi-
cating an increase in the size and spread of the market. 
Whereas in 1999, only 36% of all Member States return-
ing an ARQ reported seizing amphetamine-group sub-
stances (34.4 mt), by 2008 that figure had increased to 
50% (47.4 mt), with ecstasy-group substances following 
a similar pattern. 
Seizures of ATS have also risen significantly. Between 
1999 and 2008, seizures of ATS increased more than 
30% from 39 mt to 51.3 mt. A significant amount of 
this increase was seen in Asia, notably the Near and 
Middle East with unprecedented increases in seizures of 
amphetamine-containing pills sold as Captagon.
Data show that the proportion of seized methampheta-
4 ARQ expert perception data is reported unweighted. The following 
points are allocated if experts perceive: ‘strong increase’ 2; ‘some 
increase’: 1; stable: 0; ‘some decline’ -1; ‘strong decline’ -2. 
mine has declined, from almost 70% of total ATS sei-
zures to 38%. On the other hand, the percentage of 
amphetamine has quintupled. However, the amount of 
ATS diverted from the legitimate market—a significant 
source of illicit use in many regions—is rarely reported. 
The regional breakdown of ecstasy seizures shows a shift 
away from West and Central Europe, the former main 
region of production. 
The trafficking in ATS substances remains to a large 
extent intra-regional, as manufacture can and does occur 
close to the consumer markets. In 2008, significant sei-
zures of methamphetamine occurred in the following 
regions: East and South-East Asia (56%), North Amer-
Expert perceptions (unweighted) on ATS manufacturing trends, 2000-2008Fig. 62: 
Note: Expert perception in manufacturing trends were not weighted by the size of the countries’ ATS manufacture as the latter is difficult to determine. 
Therefore, it cannot be excluded that countries with overall minor ATS manufacture may have a disproportionate influence on the global trend. Figures 
exclude clandestine poly-drug and other synthetic drug manufacture.
Source: UNODC ARQ/DELTA
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Seizure trends of ATS, by type, 1999-2008Fig. 64: 
Source: UNODC ARQ/DELTA
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As prevalence data are simply not available in many 
developing countries, UNODC considers expert per-
ceptions as reported by Member States to help assess 
demand trends. These trend data6 over the 1998 to 
2008 period suggest that there have been continued 
increases in ATS demand for developing countries. 
Beginning around 2000, the rate of increases perceived 
by experts of developed (OECD)7 and developing coun-
tries (non-OECD) diverged, as a number of key indus-
trialized countries showed a stabilization or decline while 
developing countries, particularly those in the Americas 
and parts of Asia reported ongoing increases in ATS use. 
Asia, with between a third and three quarters of esti-
mated ATS users worldwide, has regionally diverse ATS 
user groups. This can be seen, for example, in increased 
treatment demand for problem amphetamine use in the 
Near and Middle East8 and increases in methamphet-
amine use in tablet and high purity crystalline form in 
countries in South-East Asia in 2008.9 
'Ecstasy' use as perceived by experts has steadily increased 
since 1998. Around 2006, developing countries began 
reporting more frequent and more significant increases 
6 If all countries had reported ‘some increase’, the global trend line 
would have increased by one point each year and would have reached 
110 by 2008.
7 OECD Member countries include: Australia, Austria, Belgium, 
Canada, Czech Republic, Denmark, Finland, France, Germany, 
Greece, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Mexico, 
Netherlands, New Zealand, Norway, Poland, Portugal, Republic of 
Korea, Slovakia, Spain, Sweden, Switzerland, Turkey, United King-
dom and United States of America.
8 Abu Madini M. S., Rahima S. I. A., Al-Zahrani M. A. and Al-Johi A. 
O., Two decades of treatment seeking for substance use disorders in Saudi 
Arabia: Trends and patterns in a rehabilitation facility in Dammam, 
Drug and Alcohol Dependence, 97(3), 2008, pp 231-236.
9 UNODC, Patterns and trends of amphetamine-type stimulants and 
other drugs in East and South-East Asia (and neighbouring regions) 
2009, November 2009.
in ecstasy use, with their frequency outpacing that of the 
more mature ecstasy markets in the developed countries, 
which have largely appeared stable since 2004.
The use of 'ecstasy' in developing markets may be 
spreading particularly among youth in Latin America 
and East Europe. For example, between 1995 and 2007, 
increased lifetime prevalence of 'ecstasy' use among stu-
dents aged 15 and 16 from Central and East Europe10 
was reported. The unweighted average for students in 
East European countries in 2007 surpassed that in West 
10 Students of Eastern Europe include: Bulgaria, Croatia, Czech Repub-
lic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Russian 
Federation (Moscow), Slovakia, Slovenia and Ukraine.
ATS use trends (unweighted) by type as perceived by experts of developed (OECD) and  Fig. 69: 
developing (non-OECD) countries: 1998-2008 (baseline: 1998 = 100)
Note: Expert perceptions of ATS use were not weighted by the size of the countries’ population (either total or ATS drug using population), and thus, 
one cannot exclude the possibility that countries with only minor or emerging ATS use may have a disproportionate influence on the global trend.
Sources: UNODC ARQ, UNODC field offices, UNODC’s Drug Use Information Network for Asia and the Pacific (DAINAP) 
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and Central European countries which had remained 
stable since 2003. 
The expert perceptions in the developed countries show 
a stabilization or decline in ‘ecstasy’ use since 2004. This 
is also supported by the results of household surveys in 
these markets. Australia has reported relative stability, 
albeit at comparably high levels, in past year use by the 
general population since 2004 while declines have been 
reported for Spain, the United Kingdom (England and 
Wales) and the United States. 11 
11 Refer to footnote 6
ATS problem drug use represents the only class of drug 
use in the past decade which has increased significantly 
in every region of the world. Although the patterns of 
ATS use with respect to the specific drug type and its 
form vary significantly across regions, unweighted treat-
ment demand increased from between 2 (Africa) and 11 
(North America) percentage points in the past decade. 
While improvements may have been noted in the annual 
prevalence rates among the general population in several 
developed countries, problem drug use as reflected in 
treatment admissions can remain high. For example, 
treatment demand for methamphetamine use in the 
United States declined only slightly in 2007 while annual 
prevalence rates showed a marked decline since 2006. 
Amounts of amphetamine-type  
stimulants available for consumption
Exactly how much ATS is illicitly manufactured is for 
the moment impossible to directly ascertain because 
independent calculations based on remote sensing of 
manufacture cannot be done, as is the case with poppy 
plants and coca bushes.12 Simple counts of clandestine 
laboratories dismantled annually fail to include stand-
ardized measures of manufacture type or capacity inter 
alia the frequency of production cycles, amount of 
output, purity levels, time in operation, thus limiting 
their overall analytical value. Additionally, it is not 
known how many laboratories exist for each laboratory 
discovered. 
Nonetheless, there is value in trying to assess the orders 
12 Previous UNODC models estimated manufacture based on the tri-
angulation of consumption, seized end product, and seized precursor 
chemicals. However, changes in the drug market, particularly related 
to the precursor chemical seizures, and ability to ascertain seizure 
rates made this model less useful.
Trends in annual prevalence of select Fig. 71: 
'ecstasy' markets, 1998-2008 
Sources: Government reports12
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of magnitude of the potential amounts of ATS available 
for consumption at the global level, which can also serve 
as a proxy or tentative result for the calculation of over-
all manufacture levels. Some studies have assessed actual 
consumption of amphetamine, methamphetamine and 
ecstasy, though mostly limited to a few developed coun-
tries.13 Several studies assessed consumption as a prod-
uct of the number of users in a given period, the 
frequency of drug use over that period and the amount 
used per typical episode; others indicated what the total 
consumption of drugs may be in a given year, while 
others calculated what chronic and occasional/recrea-
tional users may consume in a year.
Based on these studies, the orders of magnitude of the 
global amount consumed can be estimated, assuming 
that the values from these studies:
accurately represent the 'typical user', 1. 
can be generalized to other countries, particularly de-2. 
veloping countries, and that 
13 Office of National Drug Control Policy, What America’s Users Spend 
on Illicit Drugs, 1988-2000, Washington, DC., 2001; Bramley-
Harker, E., Sizing the UK Market for Illicit Drugs (RDS Occasional 
Paper. No. 74), London, Home Office, 2001.; Wilkins C., Reilly 
J., Rose E., Roy D., Pledger M. and Lee A., The Socio-Economic 
Impact of Amphetamine Type Stimulants in New Zealand: Final Report, 
Centre for Social and Health Outcomes Research and Evaluation, 
Massey University, Auckland, September 2004; Netherlands Scien-
tific Research and Documentation Centre, Ministry of Justice meet-
ing with UNODC, February 2004; Singleton, N., Murray, R. and 
Tinsley, L. (Eds), Measuring Different Aspects of Problem Drug Use: 
Methodological Developments (Online Report 16/06), London: Home 
Office.; Eisenbach-Stangl, I., Moskalewicz, J., Thom, B. (Eds), Two 
Worlds of Drug Consumption in Late Modern Societies, Farnham (UK), 
Ashgate, 2009. 
the epidemiology of drug patterns from the estimates 3. 
is representative.14
Taking the studies and assumptions mentioned above 
into consideration, the average past year amphetamine-
group substance user (that is, from the casual to problem 
user) may consume an estimated average of 10.9 g of 
pure substance15 per year. The average past year ecstasy 
user may consume an estimated 5.1 g of pure MDMA 
(or analogue) per year, the equivalent of approximately 
two tablets at 50 mg per week. Multiplying these per 
capita use estimates by the range of past year users of 
amphetamine-group substances and ecstasy-group sub-
stances in 2008 provides for an order of magnitude of 
the amounts consumed.
Assuming that drugs seized in 2008 would have been 
consumed in 2008, or assuming that there was no sig-
nificant change in the amounts of ATS stockpiled (if 
any), the amounts consumed plus (purity-adjusted)16 
14 Clearly drug epidemiology is ever changing—some countries have 
newly emerging markets for various ATS with fewer chronic drug 
users while others have more mature markets, where fewer new inci-
dents may be occurring but where a larger number of problem drug 
users may exist. 
15 There were three estimates for methamphetamine users at between 
16.1 and 22.8 pure grams consumed per year (average 19.3), while 
nine estimates for amphetamine (includes one amphetamine and 
methamphetamine combined estimate) had consumer using between 
1.6 and 35.8 grams of amphetamine per year (average 8.1). There 
were 11 estimates for typical ecstasy users. Estimates were for data 
between 1999 and 2008/2009 with the median estimate from users 
in 2005.
16 Adjustment was weighted based on reported purities of both retail 
and wholesale levels for a given country. When a country failed to 
report purities the unweighted regional average for either market 
was substituted. In cases where a country reports both low purity 
methamphetamine (for example tablets) and high purity crystalline 
Amphetamines-group 
(retail purity)
Amphetamines-group (wholesale 
purity)
low estimate high estimate Low Estimate High Estimate
Annual consumers 
(estimated 2008)  13,710,000  52,900,000  13,710,000  52,900,000 
Average consumption 
(pure grams/year) 10.9 10.9 10.9 10.9
Metric tons estimated 
Consumed (pure) 149 577 149 577
Metric tons reported seized 47.4 47.4 47.4 47.4
Metric tons manufactured 
(unadjusted for purity) 197 624 197 624
Purity (weighted) 24% 24% 36% 36%
Metric tons seized 
(adjusted to pure) 11.4 11.4 17.2 17.2
Metric tons manufactured 
(pure) 161 588 167 594
 Estimate of illicit amphetamine-group substances manufactured in 2008 (mt)Table 11: 
Source: UNODC calculation
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seizures provide for a proxy of the total ATS manufac-
tured in 2008.17 
Amphetamine-group substances available for 
consumption in 2008 
The amounts of amphetamine-group substances poten-
tially manufactured (with seizures unadjusted for purity) 
are estimated between 197 and 624 mt, or taking purity-
adjusted seizures into account, between 161 and 594 
mt. The range is larger than was reported in 2007 
because the uncertainty in the annual prevalence 
increased as a number of older estimates (>10 years) 
were no longer considered to be reliable estimates for the 
current ATS use situation. If one assumes that the major-
ity of seizures reported to UNODC best represents retail 
market level seizures at 24% purity,18 the production 
range would decline slightly (161 to 588 mt), due to the 
removal of adulterants and diluents.19 If reported sei-
zures better represented the wholesale market (36% 
purity), the range would amount to between 167 and 
594 mt. A significant amount of the difference between 
bulk and purity adjusted seizures are inter alia the mas-
sive amounts of seized tablets sold as Captagon in the 
Near and Middle East, which recent forensic analyses 
suggested to have an average amphetamine content 
between 1% and 16%.
Given the estimates from above and the amount of 
drugs seized, one can derive estimates of the ampheta-
mine-group substances interdicted in orders of magni-
tude.20 There were 47.4 mt of bulk amphetamine-group 
substances reported seized in 2008, which, adjusted for 
purity at the retail and wholesale levels, is between 11.4 
and 17.2 mt, respectively. Assuming all of the drugs 
seized were interdicted from the retail market, estimates 
would range from 2% (11.4/588) to 7% (11.4/161). If 
the amounts seized were from the wholesale market, the 
estimated range would be between 3% and 10%. Such 
orders of magnitude would be also in line with a few 
other published rates.21 
methamphetamine, the purity was based on a weighted average (from 
seizure data). The reported seizures of 'non-specified amphetamines' 
were assumed to be either amphetamine or methamphetamine, and 
thus were given an average weighted purity of amphetamine and 
methamphetamine, based on total seizures.
17 This does not account for other forms of loss, such as discarding drug 
to avoid capture or spoilage which are assumed to be minimal.
18 Purity data are typically based on seizures which may not be repre-
sentative of all drugs in the market, and given the various methods in 
sampling and forensic reporting (for example, as a drug base versus a 
salt) can impact purity estimates. 
19 Unfortunately only total seizure weight by drug is reported, and not 
the distribution of seizure weights. Therefore, it is not possible to 
assign whether seizures best represented street or wholesale transac-
tion amounts.
20 Annual drug seizures of drugs considerably greatly from year to year 
which impact the rates calculated.
21 Individual interception rates fluctuate considerably over time, place 
In contrast to the apparently low interdiction rates for 
ATS, the calculated interception rates for purity-adjusted 
cocaine have been exceeding 40% in recent years, and 
are around 20% for the opiates.22 There are several rea-
sons which lend support to the findings of far lower 
interception rates for the ATS as compared to cocaine 
and opiates. First, the source of most of the world’s 
cocaine and opiates are restricted to just three specific 
regions: parts of South America (Colombia, Peru and 
the Plurinational States of Bolivia), Afghanistan, and the 
so-called 'Golden Triangle' (mainly Myanmar). Contrast 
that with the number of reported ATS manufacture 
locations which are spreading and shifting throughout 
the world. Second, since manufacture of ATS typically 
occurs close to their consumer markets they cross far 
fewer borders than either cocaine or opiates, and thus 
have significantly less chance of being detected, Next, 
large-scale manufacture locations—such as in East and 
South-East Asia—have porous borders and thousands of 
kilometres of unpatrolled coastline, making transfer of 
products into neighbouring countries a comparatively 
low risk activity. Lastly, ATS awareness remains low as 
governments in many regions continue to remain 
focused on the 'traditional drugs'—namely cocaine and 
heroin.
Ecstasy-group substances available for 
consumption in 2008
Ecstasy-group substances consumed were estimated 
between 53 and 132 mt in 2008. Adding seizures (and 
assuming no significant changes in the stocks) would 
give an estimate of between 57 and 136 mt, or adjusting 
for purity from 55 to 133 mt. The low end estimate is 
somewhat lower than in 2007 because the uncertainty 
in the estimated number of annual users increased. The 
high end estimate of ecstasy-group substances manufac-
tured remained largely unchanged because far less was 
reported seized in 2008 than it 2007.
There were a total of 3.9 mt of ecstasy-group substances 
seized (unadjusted for purity), which, depending on the 
estimates, gives an interdiction rate ranging from 3% to 
7%. 
Adjusting the seizures for purity lowers the calculated 
interdiction rates to between 1% and 3%. Such unusu-
ally low rates—even lower than for the amphetamine-
group substances—seems counter intuitive, as the 
countries known to be significant ecstasy manufactures, 
and drug type. New Zealand (2001) amphetamines-group inter-
ceptions were found to be between 2% and 7% of totals for con-
sumption. Centre for Social and Health Outcomes Research and 
Evaluation, The Socio-Economic Impact of Amphetamine Type Stimu-
lants in New Zealand, Auckland, New Zealand (2004). However, 
those figures changed notably in the following year.
22 World Drug Report 2009 (United Nations publication Sales No. E.09.
XI.12).
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while spreading, remain more limited in number than 
for other ATS. In fact, only 10 countries reported having 
dismantled clandestine MDMA laboratories in 2008. 
Several of these countries have law enforcement person-
nel that are well trained in detecting this type of sub-
stance. Additionally, because of fewer locations, 'ecstasy' 
is likely to be trafficked across more borders when com-
pared to other ATS like methamphetamine. Therefore, 
what could explain such extremely low interception 
rates?
The answer may lie in the fact that ‘ecstasy’ estimates 
assume the consumption of pure MDMA (or its ana-
logues), drugs under international control. However, the 
‘ecstasy’ market is undergoing significant transforma-
tions particularly in Europe. Since about 2007 the 
amount of 'ecstasy' (MDMA) tablets available in Europe 
and the United Kingdom—one of the largest markets—
has been declining while tablets sold as ‘ecstasy’ increas-
ingly contained greater proportions of substitute 
psychoactive substances not under international control, 
such as various piperazines like BZP, mCPP and 
TFMPP.23 For example, in 2006 only 10% of tablets 
sold as ‘ecstasy’ in the EU contained mCPP, but by the 
end of 2008 it was as high as 50% in some large-market 
countries.24 In other words, the model reflects what 
people consider to be ‘ecstasy’, while the actual number 
of MDMA users and the amount of MDMA consumed 
are likely to be lower than the number of ‘ecstasy users’ 
23 1-Benzylpiperazine, 1-(3-chlorophenyl)piperazine, and 1-(3-Trifluor-
omethylphenyl) piperazine.
24 EMCDDA, BZP and other piperazines. (see http://www.emcdda.
europa.eu/publications/drug-profiles/bzp), retrieved 8 April 2010.
or the amounts of ‘ecstasy’ consumed. This leads to—
statistically—very low interdiction estimates which may 
be misleading as they are based on a comparison of 
apples and oranges. Additionally, MDMA purity levels 
(retail or wholesale) typically represent the tablet market 
and not the powder market—which in Europe is roughly 
a third of reported seizures—and which has been associ-
ated with higher purity. Against this background, the 
seizure figures unadjusted for purity, resulting in interdic-
tion rates ranging from 3% to 7%, are probably a far 
better reflection of actual interdiction successes in the 
ecstasy market than the figures based on purity adjusted 
data.
Estimate of illicit ecstasy-group substances manufactured in 2008 (mt)Table 12: 
Source: UNODC calculation
Ecstasy-group (retail purity) Ecstasy-group (wholesale purity)
low estimate high estimate low estimate high estimate
Annual consumers 
(estimated 2008)  10,450,000  25,820,000  10,450,000  25,820,000 
Average consumption (pure 
grams/year) 5.1 5.1 5.1 5.1
Metric tons estimated  
consumed (pure) 53 132 53 132
Metric tons reported seized 3.9 3.9 3.9 3.9
Metric tons manufactured 
(unadjusted for purity) 57 136 57 136
Purity (weighted) 36% 36% 45% 45%
Metric tons seized  
(adjusted to pure) 1.4 1.4 1.7 1.7
Metric tons manufactured 
(pure) 55 133 55 133
Ecstasy (MDMA) tablets reported Fig. 74: 
seized in Europe, 2000-2008
Source: UNODC ARQ
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Unfortunately, despite the efforts of some governments 
to improve the capacity to generate reliable data, the 
quality and timeliness of available data from which these 
estimates are derived are unlikely to improve in the very 
near future. This, coupled with the model’s assump-
tions, suggests that the interdiction rates, derived from 
the tentative manufacture estimates and seizures, are not 
yet robust enough to be an effective indicator of annual 
market change, only its magnitude.
Key ATS issues 1.4.4 
The significant growth seen in the ATS market over the 
past decade has been fueled by increased involvement by 
criminal organizations. Criminal groups have the ability 
to respond to market pressures on a corporate level. 
They are able to quickly retool manufacturing processes, 
develop new products, source new precursor chemicals 
and disguise their intentions by using complex supply 
routes for sourcing the required chemicals. Industrial-
sized operations with production cycles in the hundreds 
and now thousands of kilograms dictate the involve-
ment of organized crime, and have become more com-
monplace among developing countries with examples in 
Fiji, Guinea, Indonesia, Malaysia, Mexico and the Phil-
ippines, among others. Since manufacture often occurs 
in the consumer country or adjacent country, tracing 
trafficking flows of these drugs across regions—given 
the orders of magnitude of interception rates for various 
ATS—are far less meaningful than for either cocaine or 
heroin. Instead the dynamics of the market growth is 
better illustrated by developments in illicit manufacture 
seen by increases in laboratory size, sophistication, yield, 
precursor chemical types and sources, and the shifting 
location of operations into more vulnerable countries.
The importance of precursor control 
Precursor chemicals are to ATS what opium is to heroin. 
These fundamental building blocks are diverted from 
legitimate trade into illicit manufacture. The United 
Nations 1988 Convention against the Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances provides 
for measures to prevent diversion of key precursor chem-
icals for purposes of illicit drug manufacture.25 In their 
bid to obtain these chemicals, criminal organizations 
have become increasingly innovative in circumventing 
these controls, and as such, many countries have also 
enacted progressively stronger domestic controls to stem 
their flow into illicit manufacture. Inter alia as precur-
sors become more difficult and expensive to obtain, 
manufacturing costs to illicit operators increase which 
leads to a variety and combination of events, such as: 
25 As of 31 October 2009, the Convention had been ratified, acceded 
to or approved by 183 UN Member States.
manufacture drops and the price and purity (that is, 1. 
value) of the drug decreases, 
the source(s) and/or supply routes of precursor chemi-2. 
cals change(s), 
the precursor chemical itself (form or type) and/or 3. 
manufacturing process changes,
the location of manufacture shifts to more vulnerable 4. 
lower cost areas, and/or 
substitute psychoactive substances may appear.5. 
The degree to which controls are able to stem the flow 
of the requisite chemicals dictates the degree to which 
these events may occur. How long the effect lasts depends 
on the criminal’s ability to circumvent these controls. 
The impact of regulatory controls on manufacturing 
dynamics is best illustrated with recent events in the 
largest ATS markets of North America, Europe and 
Asia. 
North America: Relocation of methampheta-
mine manufacture to neighboring regions 
Significant methamphetamine manufacture based in the 
United States of America relocated into neighbouring 
Mexico after stricter controls over precursor chemicals 
were enacted in the United States. The United States’ 
methamphetamine market, the largest in North Amer-
ica, is predominantly supplied from Mexican-based 
criminal groups and to a lesser degree from domestic 
manufacture. The implementation in the United States 
over the last 20 years of progressively stricter domestic 
controls over bulk precursor chemicals, primarily pseu-
doephedrine and ephedrine, initially resulted in decreases 
in the purity of the methamphetamine.26 As illicit man-
ufacturers began to identify over-the-counter pharma-
ceutical preparations containing pseudoephedrine (that 
is, cold medicine) as a new unrestricted source of chem-
icals, the number of domestic laboratories, and users, 
increased. In 2005, national controls for pharmaceutical 
preparations were enacted in the United States and 
resulted in a sharp decline in the vast numbers of small 
to medium-size laboratories, although production loss 
was offset by increasing large-scale manufacture in 
neighbouring Mexico. The number, size and sophistica-
tion of laboratories in Mexico increased dramatically 
since then, as did the amount of methamphetamine traf-
ficked back into the US.27 For example, in August 2009, 
Mexico dismantled the largest industrial–scale labora-
tory involving the seizure of a manufacturing complex 
26 Cunningham, J. K., Liu L., and Callaghan, R., “Impact of US and 
Canadian precursor regulation on methamphetamine purity in the 
United States,” Addiction, 104 (4), pp. 441–453, 2009.
27 US Department of Justice, National Drug Threat Assessment 2010, 
National Drug Intelligence Center.
108
World Drug Report 2010 
with more than 31,000 litres of chemicals in the 22 
building complex spread over 240 hectares.28 
Import restrictions on pseudoephedrine and ephedrine 
in Mexico to address the shift in the market dramatically 
cut manufacturing levels in that country in 2007. Mexico 
embarked on a campaign against organized crime groups 
involved in manufacturing of methamphetamine by 
inter alia reducing domestic diversions of precursors 
through the reduction of legitimate imports of ephe-
drine and pseudoephedrine, and ultimately banning the 
28 La Secretaría de la Defensa Nacional informa de la localización de 
un complejo para el procesamiento de drogas sintéticas y mariguana, 
constituido con 22 instalaciones ubicadas en un terreno de 240 hec-
táreas, Secretaría de la Defensa Nacional (SEDENA), 7 August 2009. 
Global SMART Update 2010, vol. 3, March 2010.
import, export of and trade in the substances by mid-
2008. Manufacture dropped and seizures from Mexico 
into the United States subsequently declined nearly 40% 
in 2007/2008 from their peak in 2005/2006. 
The decline in illicit manufacture of methamphetamine, 
first in the United States and then in Mexico, impacted 
the street economics; resulting in an increase in price 
and a decrease in purity. Methamphetamine price and 
purity data from the United States confirm that as 
domestic controls over precursors in the form of phar-
maceutical preparations were strengthened, the price per 
United States seizures of methamphetamine reported near the Mexico border versus sei-Fig. 75: 
zures of large-scale USA-based clandestine methamphetamine laboratories, 2001-2009* 
Source: National Drug Threat Assessment 2010 (and previous years). US Department of Justice, National Drug Intelligence Center
Change in street price and purity of methamphetamine in the United States, 2005-2009 Fig. 76: 
Source: National Drug Threat Assessment 2009 and 2010, US Department of Justice, National Drug Intelligence Center
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pure gram nearly doubled from 2005 to 2006.29 Cuts to 
legitimate imports of precursor chemicals in Mexico had 
a similar effect, again with the price per gram of pure 
methamphetamine nearly doubling in 2007, US$147 in 
the first quarter to US$279 in the final quarter. In both 
cases, the significant effect appeared to have lasted 
between six and nine months before manufacturers were 
able to retool operations and find new sources of chem-
icals to continue production. Since 2008, when manu-
facture in Mexico rebounded (and to a lesser degree the 
United States) the price per pure gram in the United 
States has been on the decline and was US$127 in the 
third quarter of 2009.
As both the United States and Mexico have tightened 
controls over the key precursors for methamphetamine 
both in bulk and in the form of preparations, new 
sources and supply routes of precursor chemicals have 
emerged quickly as organized crime groups exploit Latin 
America to maintain manufacturing operations through-
out Mexico. By 2006/2007 precursor traffickers began 
obtaining and smuggling chemicals increasingly in the 
form of tableted pharmaceutical preparations from West 
29 The United States, with its Drug Enforcement Administration’s 
(DEA) System to Retrieve Information from Drug Evidence (STRIDE), 
is the only country with a detailed administrative data system which 
includes information on drug transactions (undercover purchases, 
sales and seizures) in operation since the early 1980s.
Asia, Africa, and via Europe into Mexico. Many of these 
shipments were identified and subsequently stopped as 
a result of consistent utilization of existing precursor 
control mechanisms (namely online pre-export notifica-
tion systems) and back-tracking investigations of suspi-
cious shipments by law enforcement. However, new 
routes again emerged in 2008/2009 throughout Central 
and South America, and new significant sources of 
diversion were identified, such as Bangladesh.30 Thus, 
criminals increasingly target countries with weak or 
non-existent precursor awareness and/or domestic con-
trol mechanisms and exploit loopholes within the exist-
ing international control mechanisms.
Criminals also continue to circumvent the control 
mechanisms by changing manufacturing processes to 
use chemicals with less strict or no international or 
domestic controls, or they manufacture controlled 
chemicals from non-controlled pre-precursors. During 
2007, manufacturing processes in Mexico began to 
increasingly rely upon alternative manufacturing formu-
las starting from phenylacetic acid (PAA) and its deriva-
tives to manufacture phenyl-2-propanone (P-2-P). In 
2007, only 1% of seized methamphetamine was derived 
from the P-2-P method. However, by the end of 2009, it 
30 INCB, Precursors and chemicals used in the illicit manufacture of nar-
cotic drugs and psychotropic substances, 2009 (United Nations publica-
tion Sales No. E.10.XI.4), and previous years.
Routes from notable ephedrine/pseudoephedrine precursor diversion cases, 2006/2007  Map 10: 
and 2008/2009
Sources: INCB, Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances 
(2009 and previous years), Individual Drug Seizures Database and other government sources
????????????????????????????
????????????????????????????
??????????????????????????????????
Notable ephedrine & pseudoephedrine 
trafficking route cases
??????????????????????????????????????????????????????????????????????? ??????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????? ?????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ????????????????????????????
110
World Drug Report 2010 
had become more prominent with 37% of methamphet-
amine assumed to have been produced using this meth-
od.31 During that same period there was also a decrease 
in the quantities of the more potent d-methamphetamine 
entering the United States as a result of greater reliance 
upon the P-2-P method.32 Since October 2009, Mexico 
has reported seizing nearly 120 mt of phenylacetic acid 
(PAA) derivatives, which are not internationally con-
trolled. These alone could produce up to 30 mt of meth-
amphetamine, which is almost twice the global 
methamphetamine seizures reported in 2008.33 PAA is 
under international control as a Table II substance with 
far fewer controls than other methamphetamine precur-
sors. It was only in March 2010 that the Commission on 
Narcotic Drugs (CND) decided to transfer PAA to the 
same level of control as the other methamphetamine 
precursor chemicals P-2-P, ephedrine and pseudoephed-
rine.34 While PAA derivatives continue to remain outside 
the international control regime, allowing for unfettered 
international trade, the Government of Mexico strength-
ened domestic controls and surveillance over the use and 
import of PAA salts and derivatives in November 2009. 
At the same time there are now indications that signifi-
31 Extraction of Methamphetamine Precursor Material from Medicinal 
Preparations and Methamphetamine Profiling Results, presented by 
the DEA Special Testing and Research Laboratory at the forty-fifth 
regular session of the Inter-American Drug Abuse Control Com-
mission (May 2009); US Department of Justice Drug Enforcement 
Administration, Special Testing and Research Laboratory (Jan 2010)
32 Pseudoephedrine and ephedrine result in the more potent central 
nervous stimulant d-methamphetamine while P-2-P methods result 
in the less potent racemic d,l-methamphetamine, unless separated in 
an additional synthesis step. 
33 Secretaría de Seguridad Pública (SSP) México, Boletín de Prensa/189 
México, D.F., 8 de abril de 2010. Global SMART Update 2010, vol. 
3, March 2010.
34 Member States have now six months to implement the increased 
control measures.
cant manufacture is yet again shifting further south. In 
February 2010, Nicaraguan National Police reported the 
seizure of its first large-scale clandestine methampheta-
mine laboratory which police estimated had a produc-
tion capacity of around 70 kg.35 This is reportedly the 
third laboratory discovered in the country but unprece-
dented size. Manufacture-related activities have also 
been reported from Guatemala and Honduras and sig-
nificant precursor chemical seizures are already being 
reported throughout the region, even though law 
enforcement and regulatory attention there continues to 
focus primarily on the cocaine trade.
There is currently little likelihood of methamphetamine 
substitutes appearing for methamphetamine on the US 
market, as has been observed with other ATS in Europe 
and parts of Asia. Manufacture in the United States 
shows its first signs of rebounding since 2005 with a 
26% increase in laboratory incidents reported in 2009 
over 2008. Greater amounts of high potency domesti-
cally produced methamphetamine will likely comple-
ment the somewhat less potent methamphetamine 
flowing from Mexico. Additionally, there may be 
increased flow of derivatives of PAA trafficked via Cen-
tral American countries for use in retooled production 
operations in Mexico, as manufacturers attempt to cir-
cumvent new restrictions enacted by the Government.
Europe: The changing nature of MDMA 
manufacture
Organized crime groups in Europe, particularly in the 
Netherlands and Belgium, have long been considered a 
major global source of ecstasy (MDMA or its 
analogues).36 Although ecstasy from Europe is still dom-
inant on the global market, fewer countries identify 
Europe as the source for ecstasy seen in their markets. 
While more than 80% of all ARQ reporting countries 
have identified Europe as the source of their seized 
ecstasy in 2002, this share has been declining since 2004 
to 73% in 2009, as a greater proportion of countries 
outside of Europe began reporting that the sources of 
their ecstasy were places other than Europe. This coin-
cided with disruptions to precursor chemical supplies in 
Europe and emergence of MDMA manufacture in other 
locations closer to non-European consumer markets. At 
the same time, European countries continue to report 
that their seized ecstasy is sourced from within Europe. 
There have been no seizures of 3,4-MDP-2-P (PMK), 
the most common MDMA precursor chemical used in 
Europe, since 2007, but there are indications that manu-
facturers are retooling operations to make use of alterna-
35 Policía Nacional de Nicaragua, Policía detecta laboratorio de Anfetami-
nas, 23 February 2010.
36 Europol Organized Crime Threat Assessment, 2009, European Police 
Office, The Hague.
Changes in methamphetamine  Fig. 77: 
manufacturing methods in Mexico,  
2007-2009
Source: US DEA Special Testing Laboratory
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tive chemicals. Europe used to account for the majority 
of reported global 3,4-MDP-2-P seizures. However since 
2004, there has been a decline in the amount of reported 
seizures of 3,4-MDP-2-P with the last reports in Europe 
occurring in 2007.37 The likely reasons for the signifi-
cant shortages may include: an increased demand for 
this precursor chemical in MDMA manufacture in other 
parts of the world, increased law enforcement strategies 
to curtail manufacture, including controlling the avail-
ability of key specialized equipment such as pill presses, 
and significant regulatory efforts to prevent illegitimate 
imports or diversions of precursor chemicals via more 
consistent utilization of pre-export notifications. In 
addition, China, traditionally the source of 3,4-MDP-
2-P, entered into a new agreement with the European 
Union in 2009 to improve precursor controls and coor-
dination. The country also announced tighter controls 
on the manufacture of 3,4-MDP-2-P. Taken together, 
this suggests that the trend towards retooling ecstasy 
manufacture in Europe will continue.38
In fact, criminals are already turning to alternative 
sources to manufacture MDMA to meet the demand in 
Europe. In 2008, 1,900 litres of safrole-rich oils (SRO) 
were reported seized in Europe, the first such seizure of 
any magnitude since 2003. Safrole-rich oils are typically 
sourced from South-East Asia. In 2006, there were an 
estimated 1,360-1,620 mt of SRO produced in East and 
37 The activities of INCB’s Project Prism and the PEN on-line system 
have focused on preventing the smuggling of both 3,4-MDP-2-P 
and P-2-P into the EU for use in the illicit manufacture of MDMA 
and amphetamine respectively. However, seizures have been noted in 
other countries, such as Canada.
38 China also announced tighter controls on the manufacture of ephe-
drine, P-2-P, and hydroxylamine hydrochloride (the precursor of 
ketamine).
South-East Asia, much of it for legitimate industry.39 In 
February 2009, the Government of Cambodia disposed 
of almost 15 mt of safrole-rich oils with an additional 
5.2 mt seized in June 2009, while 45 mt of safrole was 
reported seized by Thailand in 2007. Given the signifi-
cant volume of safrole-rich oils available, there is a high 
likelihood that illicit manufacturers will turn to using 
SRO. It is important to note that SRO-based operations 
are already being reported by countries in Europe and 
around the world.40 
39 UNODC, Essential Oils Rich in Safrole, Survey of Production, Trade, 
and Use in East and South-East Asia, 2006.
40 SYNDEC4, Operation Counter Curse presentation by the DEA, 
November 2009; Two arrested and police uncover first ever clan lab 
used in manufacture of safrole oil precursor for MDMA, New South 
Wales Police Media Release 28 January 2010.
Europe as the source of seized ecstasy-group substances as mentioned by Member States, Fig. 78: 
2002-2008
Source: UNODC ARQ/DELTA.
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The average street price for a tablet sold as ‘ecstasy’ in 
Europe does not appear to have increased, particularly 
in the larger West European markets,46 as the pipera-
zine-containing tablets command a similar street price 
in Europe as MDMA, roughly €4 per tablet. However, 
after controlling for varying purity, the price per pure 
gram of a tablet of MDMA may likely increase in 2009, 
even though the price per tablet may not. 
Illicit manufactures exploit the lack of national and 
international controls over piperazines and other new 
synthetic substances to continue ‘ecstasy’ sales. Pipera-
zines are not under international control,47 and with the 
exception of BZP, most countries have limited or no 
national controls. In addition to piperazines, many new 
synthetic substances are also being sold as or in the 
‘ecstasy’ market.48
One of those, methyl-methcathinone (mephedrone), 
has been related to major headlines in European news, 
because of its association with fatalities. Given their legal 
status, their street sale at a similar price as MDMA 
would command significantly higher profit margins, 
provide little chance of criminal sanctions, and likely 
expand the ‘ecstasy’ user market.49 It is also important 
46 Estimated street price based on Member State responses for ecstasy 
(MDMA) tablets, weighted by population and adjusted for currency 
fluctuation and inflation. In cases where a price range was given, the 
mid-point was substituted. 
47 Note though, that several piperazines have been proposed for critical 
review by WHO, the first step towards international controls.
48 The appearance of synthetic cannabinoid-like substances is not sub-
ject of this report as they are more related to the cannabis market. 
However, the same considerations for legal status, profits and risks to 
users apply.
49 In 2006, legal piperazine party pills in New Zealand emerged as the 
fourth most widely tried drug type with twice as many people (aged 
13-45) having tried legal party pills as the next most commonly 
tried drug, amphetamine. Wilkins C., et al., Trends in drug use in the 
to note that the toxicity in humans of the majority of 
these new substitutes has never been assessed.
Until European demand for MDMA can be met by 
MDMA imported from other manufacturing locations, 
alternative MDMA precursor chemicals such as safrole 
can be adequately sourced, or the traditional MDMA 
precursor (3,4-MDP-2-P) can be obtained from alterna-
tive sources, the trend in end-product substitution can 
be expected to continue into the foreseeable future. 
population in New Zealand: Findings from national household drug sur-
veying in 1998, 2001, 2003 and 2006, Centre for Social and Health 
Outcomes Research and Evaluation, Auckland, 2007. 
The composition of ‘ecstasy’ tablets Fig. 80: 
seized in the United Kingdom,  
2006-2009
Source: United Kingdom Forensic Science Services
Tablets sold as ‘ecstasy’ containing Fig. 81: 
non-controlled psychoactive sub-
stances in the Netherlands, 1999-2008
Source: Vogels N., Brunt T.M., Rigter S., van Dijk P., Vervaeke 
H. and Niesink R.J., “Content of ecstasy in the Netherlands: 
1993-2008,” Addiction 104(12): 2057-66, 2009
Street price of European Fig. 82: 
 ‘ecstasy’ tablets, 2004-2008
*Weighted for population, currency and inflation-adjusted. 
Source: UNODC ARQ
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Asia: Vulnerable to illicit ATS 
manufacture 
To limit the availability of precursor chemicals for illicit 
manufacture of synthetic drugs, there must be an inter-
national regulatory control system for the substance, it 
must be operationally used and enforced, and it should 
be coupled with domestic controls and fit-for-purpose 
cooperation mechanisms with relevant industries. There 
are several examples across Asia where the lack of con-
trols have made countries vulnerable to attempts by 
criminals to obtain precursor chemicals for and/or estab-
lish illicit ATS manufacturing operations. The examples 
below illustrate the continuous flow of methampheta-
mine tablets from areas in Myanmar outside the central 
Government’s control; the dramatically increasing use 
and availability of ketamine in parts of South-East Asia 
linked to the absence of international restrictions on the 
substance; and the unusually high annual legitimate 
requirements of key precursors in the Near and Middle 
East and South-West Asia, which may indicate potential 
for diversion of chemicals for illicit manufacture of 
methamphetamine and amphetamine (specifically in the 
form of Captagon)50. 
Myanmar: continuous flow of methampheta-
mine tablets from areas outside the central 
Government’s control
Myanmar ranks fourth of the countries in East and 
South-East Asia that are most frequently cited as a source 
of methamphetamine (both crystalline methampheta-
50 Captagon was originally the trade name for a pharmaceutical prepara-
tion containing fenetylline, a synthetic stimulant. Today, most tablets 
seized as Captagon essentially contain amphetamine, typically in 
combination with caffeine and sometimes with a few other adulter-
ants.
More methamphetamine in East and South-East Asia
Indicators suggest increased availability and use of methamphetamine throughout East and South-East Asia. All 
countries in East and South-East Asia already report the use of methamphetamine with many reporting it as their 
primary drug of use, either in tablet form (yaba) or high purity crystalline form, with increasing use levels in 2008.1 
Increases in arrests and seizures also point to a significant growth in the availability of methamphetamine tablets on 
the market. Since 2004, methamphetamine arrests in Thailand— one of the largest consumer markets of tableted 
methamphetamine—have increased four-fold to 120,000 arrests in 2008, or 86% of the regional total. The number 
of tablets seized in Thailand also increased, jumping by more than 50% between 2007 and 2008 to 22 million tab-
lets. Preliminary data suggest that further increases in the region are expected again for 2009.2
1 UNODC, Patterns and trends of amphetamine-type stimulants and other drugs in East and South-East Asia (and neighbouring regions) 2009, 
November 2009.
2 Ibid.
Expert perception in the change in use of methamphetamine tablet or  Fig. 83: 
crystalline forms from 2007 to 2008
 Source: UNODC, Patterns and trends of amphetamine-type stimulants and other drugs in East and South-East Asia  
(and neighbouring regions) 2009, November 2009
Methamphetamine pill use trend in East and South-East Asia
Increase
Stable
Decrease
No trend reported 2008/2009
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations.
Crystalline methamphetamine use trend in East and South-East Asia
Increase
Stable
Decrease
No trend reported 2008/2009
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations.
Methamphetamine pill use trend in East and South-East Asia Crystalline methamphetamine use trend in East and South-East Asia
115
1. Transnational drug market analysis Amphetamine-type stimulants market
mine and methamphetamine tablets).51 Of the coun-
tries traditionally associated with illicit methamphetamine 
tablets, Myanmar shares the top rank with Thailand.52 
Forensic data indicate that methamphetamine tablets 
come primarily from Myanmar’s Shan State’s various 
Special Regions near the eastern border with China and 
Thailand, which are under the control of armed ethnic 
groups operating outside the control of the central Gov-
ernment.53 Because laboratories in these areas operate 
without fear of government forces, few significant sei-
zures of precursor chemicals, ATS end-products or clan-
destine laboratories occur. For instance, between 1998 
and 2009, the government reported seizing 39 'tablet-
ing' operations of which only two were reported to be of 
a 'large-scale'.54 There are no reports of laboratories 
manufacturing methamphetamine powder (versus tab-
leting laboratories). Similarly, of the 32 million tablets 
seized in East and South-East Asia in 2008, only about 
3% (or 1.1 million) were reportedly seized in Myanmar. 
However the number of tablets and amount of precursor 
chemicals seized in Myanmar jumped in 2009, when, 
inter alia, the central Government entered by force parts 
of the North and Eastern Shan State not under their 
control.
Increasing amounts of precursors were seized in the form 
of tableted pharmaceutical preparations in 2009 which 
51 Information based on 115 mentions of the source of seized meth-
amphetamine (both crystalline and in tablet form). Mentions of 
Japan as a source country reflects the difficulty in identifying source 
countries and transiting countries. Japan has reported no clandestine 
manufacture to UNODC.
52 Note that Myanmar reports seizures of methamphetamine in the 
form of tablets, powder and in crystalline form.
53 Primarily the north and east Shan State however illicit manufacture 
of methamphetamine is also reported to occur in the Wa and Kokang 
autonomous regions.
54 Myanmar, Central Committee for Drug Abuse Control.
suggests that sourcing bulk precursor chemicals may 
have also become more difficult in Myanmar. Reports in 
2009 identified the trafficking of preparations of ephe-
drine in liquid form with a seizure of 240 litres of ephe-
drine solution contained in more than 120,000 small 
nasal drop bottles, enough for about 5.5 million 30 mg 
methamphetamine tablets. The shift from bulk ephe-
drine to tableted and now liquid forms of pharmaceuti-
cal preparations containing ephedrine may be an 
indicator of a diversification of precursor supplies, a 
scenario which has also been reported in other countries 
with large-scale illicit drug manufacture.55 
Ketamine in South-East Asia
Ketamine, while not under international control, is 
often found along with methamphetamine in tablets 
sold as ‘ecstasy’ and its use is an increasing concern in 
East and South-East Asia. There are also indications that 
it is starting to spread outside South-East Asia, reflected 
in the declining proportion of ketamine seizures in that 
region to 86% of global totals (8.2 mt or more than 
double global 'ecstasy' seizures) in 2008. 
The growing use of ketamine is of particular concern in 
Hong Kong, China, as the demand for high quality 
MDMA ('ecstasy') appears to be decreasing. While the 
number of registered drug users for ecstasy-group sub-
stances has seen a 40% decline since 2004, the number 
of ketamine users has doubled. 
Part of ketamine’s growth in popularity has been its 
55 In June 2009, authorities in Mexico seized 49,630 litres of a pharma-
ceutical solution containing pseudoephedrine. International Narcot-
ics Control Board, Precursors and chemicals frequently used in the illicit 
manufacture of narcotic drugs and psychotropic substances, 2009, New 
York, 2010. 
Sources of seized methamphetamine Fig. 84: 
(both crystalline and in tablet form) 
as mentioned by East and South-East 
Asian countries/territories, 2002-2008
Source: UNODC ARQ
Methamphetamine tablets and precur-Fig. 85: 
sor seizures in Myanmar, 2003-2009
Source: INCB 2003-2009; Central Committee for Drug Abuse 
Control 2009
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continuously low price. For example, between 2007 and 
2009, the average price per pure gram in Hong Kong, 
China was just HK$144, making it a cheap substitute 
for the increasingly expensive 'ecstasy' or methampheta-
mine. 
Diversion from licit trade remains the primary source of 
ketamine with significant seizures being reported in 
various countries over the last couple of years. In Decem-
ber 2009, customs authorities in India seized a record 
440 kg of ketamine en route to Malaysia.56 However, 
industrial-scale illicit ketamine manufacture is also 
emerging. In 2009, China reported seizing two illicit 
laboratories processing hydroxylamine hydrochloride, 
the immediate precursor chemical for ketamine, and 
seizing 8.5 mt of this substance. In 2009, China 
announced tighter controls over the manufacture of 
hydroxylamine hydrochloride and other precursor 
chemicals.
Possible emerging locations for large-scale 
manufacture in parts of Asia
One of the most disturbing new ATS trends is the 
increase of methamphetamine in South-West Asia, a 
region already suffering from large-scale opium produc-
tion and use. This specifically refers to the sudden and 
massive increase of reported seizures of high purity crys-
talline methamphetamine ('Shisheh") from the Islamic 
Republic of Iran which began in 2008. In 2008, the 
country also seized four clandestine methamphetamine 
laboratories—their first reports ever—and has since 
reported quickly decreasing street prices and an increase 
56 DRI Chennai effects single largest ever seizure of 440 kgs. of keta-
mine worth RS. 44 crores at Tuticorin, Government of India, Min-
istry of Finance (Department of Revenue) Directorate of Revenue 
Intelligence, 25 December 2009. 
in methamphetamine use.57 That manufacture outpaces 
domestic consumption is also reflected in the notable 
increase in 2009 in the frequency and extent of reported 
methamphetamine trafficking from Islamic Republic of 
Iran, with much of this destined for lucrative markets in 
East and South-East Asia.58
The starting material used in the illicit manufacture of 
methamphetamine in the Islamic Republic of Iran is 
most likely domestically diverted pseudoephedrine. 
Since 2006, the first year such reporting was required by 
the INCB59, the Islamic Republic of Iran has reported 
notable increases in its annual legitimate requirement of 
the chemical. In just four years, the demand grew to give 
the Islamic Republic of Iran the fourth highest legiti-
mate requirement in the world. Not only does this 
increase the likelihood of domestic diversion, but it also 
makes the country an attractive target for precursor 
diversion by transnational organized crime groups. That 
this may be more than a realistic concern is evidenced by 
recent reports of two stopped shipments of pseudoephe-
drine totaling 11 mt, both destined for Ethiopia.
An example of how rapidly increasing annual legitimate 
57 DCHQ Deputy SG, Prices of the synthetic drugs have dropped to one 
fourth, 6 October 2009, Islamic Republic of Iran National Drug 
Headquarters; UNODC World Drug Report 2009
58 737 kg of various drugs were found in airports this year, Official Islamic 
Republic News Agency; Global SMART Update 2009, vol. 2, October 
2009. 
59 Countries provide INCB with annual estimates of their legitimate 
requirements for various ATS precursor chemicals to prevent their 
diversion into illicit manufacturing. In 2009, 91 countries reported 
their annual legitimate requirements for pseudoephedrine (bulk and 
preparations), 98 for ephedrine (bulk and preparations), and 15 for 
P-2-P. INCB, Annual legitimate requirements reported by Governments 
for ephedrine, pseudoephedrine, 3,4-methylenedioxyphenyl-2-propanone, 
1-phenyl-2-propanone and their preparations, 2 March 2010 and past 
publications. 
Hong Kong, China: ketamine, meth-Fig. 87: 
amphetamine and ecstasy-group drug 
registry cases, 1999-2008
Source: Central Registry of Drug Abuse, Narcotics Division 
(ND), Security Bureau, Hong Kong Special Administrative 
Region, China.
Purity-adjusted quarterly street prices Fig. 88: 
for various drugs sold in the ATS mar-
ket in Hong Kong, China, 2007-2009
Source: Hong Kong Police Narcotic Bureau
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requirements can be an indicator for diversion into illicit 
manufacture can be seen in South-Asia. Since 2006, 
Bangladesh’s annual legitimate requirement for pseu-
doephedrine has tripled, now making it the 6th highest 
in the world. In 2009, Bangladesh was first identified as 
a source country for tableted pharmaceutical prepara-
tions containing pseudoephedrine diverted into illicit 
drug manufacture with multi-million tablet shipments 
being seized in Central America, destined for Mexico. 
Bangladesh may also become a target for diversion of 
pseudoephedrine into neighboring Myanmar’s illicit 
methamphetamine manufacture if pressure upon Myan-
mar’s precursor supply continues. 
A similar situation may also be occurring in the Near 
and Middle East, where the diversion of phenyl-2-pro-
panone (P-2-P) may be fueling the region’s expanding 
Captagon market. Jordan reported its annual legitimate 
requirement of P-2-P at 60,500 kg in 2009, accounting 
for more than half of the global total. The high legiti-
mate need is based on the purported formulation of 
P-2-P into 'cleaning and disinfection' products. How-
ever the volume represents a significant risk of diversion 
into illicit Captagon manufacture, particularly as P-2-P 
is not an essential ingredient in the formulation of clean-
ing and disinfection products and alternative chemicals 
exist.
The most common way of obtaining requisite precursor 
chemicals and some of the common psychoactive sub-
stances substituting for controlled synthetic drugs, such 
as ketamine, is by their diversion from legitimate trade. 
The few examples highlighted herein illustrate that to be 
effective in preventing such diversions, governments 
must not only have functioning regulatory controls in 
place, addressing both international and domestic trade, 
but that they must be vigilantly re-assessed for purpose.
Implications for response1.4.5 
The increasing size and complexity of illicit ATS opera-
tions encountered over the past 10 years point to 
increased involvement of criminal organizations, from 
the sourcing of precursor chemicals to the manufacture 
and trafficking of the ATS end-products. Yet, the intrin-
sic characteristics of ATS manufacture and trafficking, 
namely the independence from geographically defined 
source regions for raw materials and the geographic 
Islamic Republic of Iran annual legiti-Fig. 89: 
mate requirement of pseudoephedrine 
versus crystalline methamphetamine 
seizures, 2005-2009 
Sources: ARQ/DELTA, INCB, Annual legitimate requirements 
reported by Governments for ephedrine, pseudoephedrine, 
3,4-methylenedioxyphenyl-2-propanone, 1-phenyl-2-pro-
panone and their preparations
Bangladesh annual legitimate require-Fig. 90: 
ment of pseudoephedrine, 2006-2009 
Sources: INCB, Annual legitimate requirements reported by 
Governments for ephedrine, pseudoephedrine, 3,4-methylen-
edioxyphenyl-2-propanone, 1-phenyl-2-propanone and their 
preparations
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1. Transnational drug market analysis Amphetamine-type stimulants market
closeness of manufacturing locations and consumer 
markets, limit the range and effectiveness of supply-side 
interventions when compared to heroin and cocaine.
The discussion above indicates that control of ATS pre-
cursors can be successful. In addition, evidence-based 
prevention and treatment have shown some cost-effec-
tive results.60 Both measures work best when imple-
mented in a holistic, comprehensive manner and when 
accompanied by the early identification of emerging 
developments. 
The generation of a timely evidence-base is the only way 
in which to quickly identify the rapidly changing ATS 
market and respond with appropriate policies and pro-
grammes. The expansion of targeted capacity building 
programmes, such as Global SMART, which support 
both forensic and synthetic drug data collection, have 
been shown invaluable in countries and regions with 
significant ATS markets. To avoid shifts from one coun-
try to another, or one region to the next, there is a grow-
ing need for a strategic early warning system to identify 
emerging synthetic drugs, new products and combina-
tions, controlled and non-controlled, substitute precur-
sor chemicals, diversions (including stopped, suspended 
and cancelled shipments), common adulterants and key 
equipment used in their manufacture. This information 
must be shared quickly at national, regional and inter-
national levels so as to allow timely or even preemptive 
responses. 
Given the widespread availability of certain ATS, the 
rapid emergence of new synthetic drugs and non-con-
trolled substitutes, and their use in school, work and 
recreational settings, a holistic approach is required 
which looks beyond internationally controlled ATS into 
the recreational 'pill market' more generally and inte-
grates responses into the wider concept of health promo-
tion. Investments in prevention programmes that 
increase the awareness as to the health risk of these drugs 
appear to have played a role in the decline in use, par-
ticularly among youth in developed countries. This has 
specifically proven successful where prevention and 
treatment services have met the needs of and been 
accepted by ATS users. The expansion of evidence-based 
treatment programmes in developed countries has also 
reduced the likelihood that problem ATS users return to 
patterns of chronic drug use. However, evidence-based 
ATS treatment programmes are often the exception, not 
the rule, especially in countries where emerging problem 
60 Spoth, R. and Guyll, M., Prevention’s Cost Effectiveness Illustrative Eco-
nomic Benefits of General Population Interventions, in United Nations 
Office on Drugs and Crime Technical Seminar on Drug Addiction 
Prevention and Treatment: From Research to Practice, 2008. Iowa 
State University (December 2008); Cost effectiveness and cost ben-
efit analysis of substance abuse treatment: an annotated bibliography, 
National Evaluation Data Services, Center for Substance Abuse Treat-
ment (SAMSHA), US Department of Health and Human Services, 
2002.
ATS use is occurring and health care and treatment 
professionals are simply not trained or do not have the 
resources to identify and respond to the unique charac-
teristics manifested in ATS users.
Precursor control works. It is clear that when existing 
regulatory controls are implemented and all counter-
parts exert the necessary vigilance to identify unusual 
transactions, suspicious legitimate needs and fictitious 
end-uses of precursor chemicals, significant reductions 
in the availability of precursors for illicit purposes can be 
made. Understanding legitimate industrial requirements 
and monitoring the entire chain from precursor manu-
facture, distribution to end-use, both domestically and 
internationally, are the only means to identify unusual 
or suspicious transactions. This also includes scrutiniz-
ing annual assessments of legitimate requirements—
particularly if these increase significantly year-over-year, 
and may initially be considered to reflect a newly devel-
oping legitimate industry. Systematically checking the 
legitimacy of individual precursor chemical shipments 
should become the norm for all countries trading in 
these substances. The tool for this is available in form of 
the INCB Pre-Export Notification (PEN) online system, 
which has already proven successful in international 
precursor operations by stopping suspicious shipments 
before they leave the country. However, currently only 
76 countries (40% of UN Member States) regularly use 
this real-time system.
Regulatory controls must be complemented by law 
enforcement action. Seizures should be the beginning of 
an investigation, not the end. Available specialized inves-
tigative techniques include controlled deliveries and 
back-tracking investigations, which could be utilized 
more systematically for the ATS end-products, their 
precursors, and key manufacturing equipment such as 
new and used pill presses, so as to dismantle the entire 
criminal manufacture chain. This approach will be of 
increasing importance also as an element of precursor 
control strategies, as today diversions often occur at 
national level, followed by smuggling across interna-
tional borders. 
Better and more timely information, combined with 
increased awareness of the peculiarities of ATS and their 
precursors, can be expected to contribute to changing 
the prevailing low attention devoted towards ATS in 
some regions, especially those that have historically been 
associated with the cultivation and/or production of the 
'traditional' drugs opium/heroin and cocaine, thus 
increasing interceptions. Finally, history also shows the 
importance of regionally and internationally coordi-
nated responses to the ever-changing ATS and precursor 
chemical situation both in terms of regional shifts and 
emergence of new precursors, ATS and/or substitutes for 
either. 
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 and nature of drug use
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Globally, UNODC estimates that between 155 and 250 
million people, or 3.5% to 5.7% of the population aged 
15-64, had used illicit substances at least once in the 
previous year. Cannabis users comprise the largest 
number of illicit drug users (129-190 million people). 
Amphetamine-type stimulants are the second most com-
monly used illicit drugs, followed by opiates and cocaine. 
However, in terms of harm associated with use, opiates 
would be ranked at the top. 
A comprehensive understanding of the extent of the 
drug use problem requires a review of several indicators 
– the magnitude of drug use measured by prevalence 
(lifetime, annual, past 30 days) in the general popula-
tion, the potential of problem drug use as measured by 
drug use among young people, and costs and conse-
quences of drug use measured by treatment demand, 
drug-related morbidity and mortality. Additionally, to 
understand the dynamics of drug use in a country or 
region, it is important to look at the overall drug situa-
tion rather than merely the trends for individual drugs. 
This information helps to discern the extent to which 
market dynamics (availability, purity and price) have 
temporarily influenced the use, compared to results of 
long-term efforts such as comprehensive prevention 
programmes and other interventions to address the drug 
use situation. 
To illustrate, long-term trends in use of different drugs 
and overall drug use are presented for the United States 
of America, the United Kingdom, Australia and Spain 
where trend data over a longer period of time is availa-
ble. Although short-term changes and trends might be 
observed in the use of different drugs, long-term trends 
suggest that the magnitude of the core of the problem 
does not change considerably in a few years. Indeed, to 
impact the drug use situation, long-term interventions 
for prevention of drug use and drug dependence treat-
ment and care, along with supply reduction efforts, are 
required.
Number of people who inject drugs
aged 15-64 years : 11-21 million persons
Number of "problem drug users" 
aged 15-64 years : 16-38 million persons
Number of people who have used drugs
at least once in the past year aged 
15-64 years : 155-250 million persons
Total number of people aged 15-64 years
in 2008: 4,396 million persons
Illicit drug use at the global level, 2008Fig. 92: 
Source: UNODC
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United States: Dependence on or Fig. 93: 
abuse of drugs in the past year among 
persons aged 12 or older, 2002-2008*
* The difference between the estimates was only statistically significant 
for opioid painkillers in 2003/2004 and 2008.
Source: Substance Abuse and Mental Health Services Adminis-
tration, Results from the 2000-2008 National Survey on Drug 
Use and Health: National Findings, Office of Applied Studies, 
US Department of Health and Human Services
US: Types of drug use in the past year Fig. 94: 
among persons aged 12 and older, 
2000-2008
Source: Substance Abuse and Mental Health Services Adminis-
tration, Results from the 2000-2008 National Survey on Drug 
Use and Health: National Findings, Office of Applied Studies, 
US Department of Health and Human Services
UK: drug use trends among population Fig. 95: 
aged 16-59, 2000-2008/2009
Source: Hoare J, Home Office Statistical Bulletin, Drug Misuse 
Declared: Findings from the 2008/09 British Crime Survey, 
England and Wales, Home Office, UK July 2009
Australia: drug use trends among  Fig. 96: 
population aged 14 and over, 1991-2007
Source: Australia, National Campaign Against Drug Abuse 
Household Surveys 1991, 1993, National Drug Strategy 
Household Survey 1995, 1996, 2001, 2004 and 2007
+ difference between this  es timate and 2008 estimate is  s tatis tically 
s ignificant at .05 level
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2. Drug statistics and trends Understanding the extent and nature of drug use
Problem drug use
At the core of drug use lie the problem drug users; those 
that might be regular or frequent users of the substances, 
considered dependent or injecting and who would have 
faced social and health consequences as a result of their 
drug use. Information on problem drug users from a 
policy and programme planning perspective is impor-
tant as this drives the need and nature of the services 
required to address the diverse needs for treatment and 
care of drug dependent persons. 
Lack of a global standard definition  
of a problem drug user
One of the main challenges for UNODC remains the 
compilation of data reported by Member States and 
their comparability across countries and regions. The 
Commission on Narcotics Drugs in its forty-third ses-
sion in 2000 endorsed the paper on 'Drug information 
systems: principles, structures and indicators'1 – also 
known as the 'Lisbon Consensus Document'. The docu-
ment outlines the set of core epidemiological indicators 
to monitor the drug abuse situation, against which 
Member States could report their respective situations 
through the Annual Reports Questionnaire (ARQ). One 
of the core indicators in the paper was ‘high-risk drug 
consumption’. The assumption was that some drug-
1 Drug information systems: principles, structures and indicators (E/
CN.7/2000/CRP.3).
taking behaviours were particularly associated with 
severe problems and as such merit the attention of poli-
cymakers. The document further elaborated that high-
risk consumption included information on the number 
of drug injectors, estimates of daily users and those who 
are dependent. One challenge in measuring problem 
drug users or high-risk drug consumption is that most 
of these behaviours are hidden and have low prevalence. 
Therefore, they are poorly covered by general popula-
tion estimates. Specific methods are required to gather 
information on such behaviours.
Out of the 110 Member States who responded to the 
2008 ARQ on the extent and pattern of drug use, only 
24 reported information on problem drug use. The 
definitions and methods of calculation differ from coun-
try to country. One country in Africa defines problem 
drug use as “drug users who constitute social harm and 
insecurity and drug users who relapse after rehabilitation.”2 
In North America, the DSM-IV3 defines the criteria for 
illicit drug dependence or abuse, while one country in 
Asia only considers heroin injectors as problem drug 
users. The European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), in its efforts to compile 
comparable information on problem drug use, defines it 
as “injecting drug use or long duration/regular use of 
2 ARQ: Nigeria 2008.
3 American Psychiatric Association, Diagnostic and Statistical Manual 
on Mental Disorders (see Box in cocaine market chapter).
Spain: drug use trends among  Fig. 97: 
population aged 15-64, 1995-2007/08
Source: UNODC and EMCDDA
Europe: Estimated trends in overall Fig. 98: 
problem drug use in selected  
countries from where data was  
available (2002-2007), rate per 1,000 
population aged 15-64
Source: EMCDDA – Statistical Bulletin 2009
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opioids, cocaine and/or amphetamines.”4 The broad 
scope and differences in defining and understanding 
problem drug use in different regions signifies the need 
for setting common parameters, based on an already 
acceptable definition or criterion, for example, DSM-IV 
or ICD – 10 (WHO International Classification of 
Diseases – Revision 10), for determining, reporting and 
comparing the extent of harmful or high risk drug use 
at global level.
4 EMCDDA Guidelines for Estimating the Incidence of Problem Drug 
Use, February 2008.
The global number of problem drug users is stable
Based on the global estimates of cannabis, opiate, cocaine 
and amphetamine-type stimulant users, and using the 
relative risk coefficient,5 it is estimated that in 2008, 
there were between 16 and 38 million problem drug 
users (between 10%-15% of estimated drug users) in the 
world. The broad range of the estimate reflects the 
uncertainties in the available data globally. 
5 The relative risk coefficient takes opiates as the index drug and cal-
culates the coefficient for treatment, injecting drug use, toxicity and 
deaths.
Drug use – nature and typology
Scientific evidence indicates that the drug use is a result 
of a complex multifactorial interaction between repeated 
exposure to drugs, and biological and environmental fac-
tors. In recent years, the biopsychosocial model has rec-
ognized drug dependence as a multifaceted problem 
requiring the expertise of many disciplines. A health sci-
ences multidisciplinary approach can be applied to 
research, prevention and treatment of drug use.
Recreational 
Some forms of drug use are associated with recreational 
settings or specific sub-populations, for example, ecstasy 
use, which is found more among young people and asso-
ciated with particular lifestyle and events (parties, night-
clubs and dance events) seen in many affluent societies. 
Also among those who use drugs in recreational settings, 
a significant proportion could be induced to substance 
abuse with the purpose of coping with anxiety, poor 
emotional skills, poor capacity to manage stressful stim-
uli and difficult environmental situations, poor engage-
ment in school and lack of vocational skills.
Society, family, life experience
Use of opiates, cocaine, amphetamine and metham-
phetamine, and those injecting, account for a substantial 
proportion of dependent or problem drug users (however 
defined). These drug users also tend to be more chronic 
users, with associated psychiatric and medical co-mor-
bidities, and are either stigmatized or come from margin-
alized segments of society. Many studies have shown a 
strong association between poverty, social exclusion and 
problem drug use. 
Studies also suggest the possibility that childhood experi-
ences of neglect and poor parent-child attachment may 
partially contribute to a complex neurobiological derange-
ment and dopamine system dysfunctions, playing a cru-
cial role in susceptibility to addictive and affective 
disorders.1 
Different kinds of adverse childhood experiences, such as 
self-reported supervision neglect, physical neglect, physi-
cal assault and contact sexual abuse, have been reported 
in association with adolescent cigarette, alcohol, cannabis 
and inhalant use, as well as violent behaviour.2 
Epidemiological data also show a frequent association 
between stress-related disorders such as post traumatic 
stress disorder (PTSD) and substance use disorder. Stud-
ies have examined the association between traumatic 
exposure, PTSD and substance use that have shown early 
onset of marijuana and heroin use, while alcohol depend-
ence and opiate dependence were each associated with 
exposure to a traumatic event.3
Psychiatric disorders
Further studies have shown that individuals with lifetime 
mental disorder were three times more likely than others 
to be dependent on substances. Patients suffering from 
bipolar disorders (manic-depressive disorders) are more 
likely to be using psychoactive substances compared with 
those suffering from unipolar major depression.4 On the 
other hand, use of psycho-stimulants such as ampheta-
mine or cocaine and cannabis can also induce psychotic-
like symptoms in users.
1 Gerra G. et al., “Childhood neglect and parental care perception in 
cocaine addicts: Relation with psychiatric symptoms and biologi-
cal correlates,” Neuroscience and Biobehavioral Reviews, 33 (2009) 
601-610.
2 Hussey J.M., Chang J.J. and Kotch J.B., “Child maltreatment in 
the United States: prevalence, risk factors, and adolescent health 
consequences”, Pediatrics, September 2006, 118(3):933-942.
3 Gerra G., Somaini L., Zaimovic A., Gerra M L., Maremmani I., 
Amore M. and Ciccocioppo R., Developmental Traumatic Experi-
ences, PTSD and Substance Abuse Vulnerability: The Neuroobiologi-
cal Link, Neurobiology of Post Traumatic Stress Disorder, June 
2010 ISBN: 978-1-61668-851-6. 
4 World Health Organization Neuroscience of psychoactive substance 
use and dependence, Geneva 2004.
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In Europe, the prevalence rate of problem drug users 
varies between 2.7 in Greece and 9.0 in UK as rate per 
1,000 population aged 15-64. The United Kingdom, 
Italy and Spain are on the higher end of the range, 
whereas Greece, Germany and Hungary are countries 
with low rates of problem drug use. 
In the United States, 7 million people - or 2.8% of the 
population aged 12 and older - were considered sub-
stance dependent, abusing illicit substances in 2008. 
Cannabis was the illicit substance with the highest rate 
of past year dependence, followed by pain relievers (opi-
oids) and cocaine.6 In Canada, 2.7% of the population 
aged 15 and older were reported to have experienced at 
least one type of harm in the past year due to illicit drug 
use. ‘Harm’ in the Canadian reports is classified as harm 
to physical health, or in the social, employment and 
legal spheres.7
Injecting drug users (IDU)
Among the most problematic drug users are those who 
inject drugs. The last available estimate of the global 
number of IDU remains the one developed by the 
UNODC/UNAIDS reference group in 2008, which 
estimated that there are 15.9 million people who inject 
drugs (between 11 – 21.2 million).8 Of these, 3 million 
may be living with HIV (range 0.5-5.5 million). East 
6 Substance Abuse and Mental Health Services Administration, Results 
from the 2008 National Survey on Drug Use and Health: National 
Findings, US Department of Health and Health Services, Office of 
Applied Studies.
7 Health Canada, Canadian Alcohol and Drug Use Monitoring Survey: 
Summary of Results for 2008.
8 Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., 
Mattick RP., et al. “HIV prevention, treatment and care services fro 
people who inject drugs a systematic review of global, regional and 
national coverage,”The Lancet, 2010; 375(9719:1014-28).
Europe (1.5%) and Australia and New Zealand (1.03%) 
have a high prevalence of injecting drug use. In absolute 
numbers, East Europe has one of the highest numbers of 
injecting drug users. In East Europe most of the injectors 
are using opiates, while in Australia and New Zealand, 
methamphetamine is the main substance being injected. 
Gap in provision of services to problem drug users
The estimate of the global number of problem drug 
users provides the range of the number of people who 
need assistance to address their drug problems, includ-
ing treatment of drug dependence and care. Comparing 
this with the number of people who are in treatment 
provides the magnitude of the unmet need for treatment 
of illicit drug use. Notwithstanding the gap in reporting 
and coverage of services, Member States reported that 
between 42% (in South America) and 5% (in Africa) of 
problem drug users were treated in the previous year. It 
can be estimated that globally, between 12% and 30% 
of problem drug users had received treatment in the past 
year, which means that between 11 million and 33.5 
million problem drug users in the world have an unmet 
need for treatment interventions.
During the High-level Segment of the Commission on 
Narcotic Drugs in 2009, Member States adopted a Polit-
ical Declaration and Plan of Action. The Plan of Action 
called for Member States to ensure that access to drug 
treatment is affordable, culturally appropriate and based 
on scientific evidence, and that drug dependence care 
services are included in the health care systems. It also 
called for the need to develop a comprehensive treat-
ment system offering a wide range of integrated pharma-
cological (such as detoxification and opioid agonist and 
antagonist maintenance) and psychosocial (such as 
counselling, cognitive behavioural therapy and social 
support) interventions based on scientific evidence and 
Europe: Estimates of problem drug use (rate per 1,000 population aged 15-64)*Fig. 99: 
* The methods for estimation of problem drug users differ between countries, but include capture/recapture, treatment multiplier, police multiplier,  
et cetera.
Source: EMCDDA, Statistical bulletin 2009: Problem drug use population, 2009
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focused on the process of rehabilitation, recovery and 
social reintegration.9 
The costs for the delivery of evidence-based treatment is 
seen to be much lower than the indirect costs caused by 
untreated drug dependence (prisons, unemployment, 
law enforcement and health consequences). Research 
indicates that spending on treatment produces savings 
in terms of a reduction in the number of crime victims, 
as well as reduced expenditures for the criminal justice 
system. At a minimum there was a 3:1 savings rate, and 
when a broader calculation of costs associated with 
crime, health and social productivity was taken into 
account, the rate of savings to investment rose to 13:1. 
These savings can improve disadvantaged situations 
where opportunities for education, employment and 
social welfare are undermined, and increase possibilities 
for families to recover battered economies, thus facilitat-
ing social and economic development.10
9 UNODC, Political Declaration and Plan of Action on International 
Cooperation Towards an Integrated and Balanced Strategy to Counter the 
World Drug Problem, High-level segment, Commission on Narcotic 
Drugs, Vienna, 11-12 March 2009
10 UNODC and WHO, Principles of Drug Dependence Treatment: 
Discussion Paper , March 2008, also see Gossop M, Marsden J and 
Stewart D, The National Treatment Outcome Research Study: After 5 
years – Changes in substance use, health and criminal behaviour during 
the five years after intake, National Addiction Centre, London 2001.
Assessment of the services  
provided to injecting drug users  
to respond to HIV
The morbidity and mortality associated with injecting 
drug use (IDU) is a global public health issue. Of par-
ticular significance is the spread of HIV between people 
who inject drugs, through the sharing of injecting equip-
ment, and through sexual transmission to the wider 
population.
Responding to IDU is an essential component of the 
global response to HIV. During the 2009 High-level 
Segment of the Commission on Narcotic Drugs and in 
other forums, countries and UN agencies centrally 
involved in the HIV response for injecting drug users - 
UNODC, WHO and UNAIDS - endorsed a compre-
hensive package of interventions that are necessary to 
prevent and control HIV among IDUs.1 These include: 
needle and syringe programmes (NSP); opioid substitu-
tion therapy (OST) and other drug treatment modali-
ties; HIV testing and counselling; antiretroviral therapy 
for HIV (ART); targeted information and education for 
IDUs; prevention and treatment of viral hepatitis, sexu-
ally transmitted diseases and tuberculosis; and condom 
distribution programmes.
NSPs provide clean injecting equipment to IDUs; a 
crucial way to reduce injecting risk, and a contact point 
for providing health information to IDUs. These exist 
in 82 of the 151 countries where injecting drug use is 
known to occur. Only 7.5% (range 5.4%-11.5%) of 
IDUs worldwide are estimated to have accessed an NSP 
in a 12-month period. Globally, 22 clean syringes are 
estimated to be distributed per IDU in a year, meaning 
most injections worldwide occur with used injecting 
equipment. 
Long acting opioid maintenance therapy, or opioid sub-
stitution programmes (OST) have been introduced in 
71 countries, but remain absent in many where the 
prevalence of opioid injection is high. It is estimated 
that globally there are only 8 (range 6-12) OST recipi-
ents for every 100 IDUs, suggesting coverage of only a 
small proportion of IDUs who might benefit from this 
treatment for drug dependence.
ART is important not only for treating IDUs who have 
contracted HIV, but also in preventing HIV transmis-
sion.2 From the limited data available, it is estimated 
1 WHO/UNODC,UNAIDS, WHO, UNODC, UNAIDS Techni-
cal Guide for countries to set targets for universal access to HIV 
prevention, treatment and care for injecting drug users, Geneva, 
2008.
2 Degenhardt L., Mathers B.M., Vickerman P., Hickman M., 
Rhodes T., Latkin C., “HIV prevention for people who inject 
drugs: Why individual, structural, and combination approaches 
Unmet need for treatment  Fig. 100: 
interventions, 2008
Source: UNODC
Number of people who have used drugs at least once 
in the past year aged 15-64 years: 155-250 million
Number of problem drug users 
aged 15-64: 16-38 million
Number of problem drug users aged 15-64 
who did not receive treatment: 11-33.5 million 
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Trends in the main drugs of concern in problem 
drug users as indicated by treatment demand 
An analysis of the number of treatment services pro-
vided in a country according to the main drug for admis-
sion can provide information on the drugs that are most 
problematic in terms of health and social consequences 
and need for intervention. 
The treatment demand data presented here cover the 
10-year period from the late 1990s to 2008. Data for all 
but 2008 were published in the World Drug Report 2000 
(for 1997/1998, labelled as the late 1990s) and WDR 
2005 through 2009 (for the years 2003 to 2007, or 
latest year available at the time of publication).
The data show that there is generally, in each region, a 
clear, and over the past 10 years consistent, drug type 
that dominates treatment. This suggests marked regional 
differences in the drugs that affect problem drug users. 
Indeed, in the last decade, the primary drug for treat-
ment has remained cannabis in Africa, cocaine in South 
America and opiates in Asia and Europe. The two nota-
ble exceptions are: 1) North America, where a dominant 
drug for treatment demand does not emerge, and rather, 
the percentage breakdown of drugs has become more 
uniform over time, and 2) Oceania, which has experi-
enced over time one of the biggest changes in the pri-
mary treatment drug from opiates to cannabis. 
The changes observed over the last decade in the contri-
bution that each drug has made to treatment admissions 
suggest an ongoing diversification of problem drug users 
in some regions. The contribution of cannabis to treat-
ment demand is increasing in Europe, South America 
and Oceania, while admissions for synthetic opiates in 
North America sharply increased in the last few years, 
compensating for decreased admissions for heroin. In 
Europe, the admissions for stimulants (cocaine and 
amphetamine-type stimulants) and cannabis have also 
increased over time, in parallel with a decline in admis-
sions for opiates. 
Interpreting trends in treatment demand data is chal-
lenging as patterns and trends over time can reflect a 
mixture of factors, such as:
the development and improved coverage of drug   ?
treatment reporting systems;
statistical artefacts, for example, resulting from   ?
diﬀerent countries reporting in a region in diﬀerent 
time periods (notably in Africa);
changing patterns of consumption including   ?
prevalence, frequency of drug use and the typical 
amounts used on each occasion; 
prevention measures and the availability, accessibility  ?
and utilization of treatment services;
response of the criminal justice system to drug   ?
oﬀenders, such as compulsory treatment as an  
alternative to imprisonment.
Opiates main problem drug by far in Europe and 
Asia, but declining in Oceania
Opiates are clearly the main problem drug as indicated 
by treatment demand over the past 10 years in Europe 
(with at least 55% of demand) and Asia (consistently 
more than 60% of demand). 
Opiates have also increased their contribution in Africa 
from 8% (late 1990s) to 20% (2008). While there has 
been an increase in opiate-related treatment in Africa 
over the last decade, the strong increase is, however, to 
some extent, a statistical artefact as previous treatment 
data (dating back more than 10 years) were removed and 
could not be replaced as no new data were forthcoming. 
Therefore, data from smaller island countries - such as 
Mauritius or the Seychelles, where the proportion of 
opiate treatment has historically been very high - con-
tribute more to the treatment demand for opiates in 
Africa.
Opiate-related treatment has recently exhibited a large 
increase in North America, from 10% (2006) to 23% 
(2008), reflecting the rising abuse of synthetic opioids, 
and are possibly starting to emerge in South America. 
Oceania has experienced a striking decline in the contri-
bution of opiates to treatment demand from 66% (late 
1990s) to 26% (2008), in line with the severe heroin 
shortage of 2001 in Australia which convinced many 
heroin addicts to give up their habit.
Effective treatment for heroin  
and crack dependence: UK 
Drug Treatment Monitoring 
System Outcomes Study Group
In the United Kingdom, using data from the national 
Drug Treatment Monitoring System, a prospective 
cohort study looked at treatment outcomes of 14,656 
heroin and crack addicts. The effectiveness of treat-
ment was assessed from changes in the days of heroin 
or crack cocaine use or both in the 28 days before the 
start of treatment and in the 28 days before the study 
review.
The study shows that the first six months of pharma-
cological or psychosocial treatment is associated with 
reduced heroin and crack cocaine use, but the effec-
tiveness of pharmacological treatment is less pro-
nounced for users of both drugs.
Source: Marsden J, Eastwood B, et al, Effectiveness of 
community treatments for heroin and crack cocaine addic-
tion in England: a prospective, in-treatment cohort study
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Regional patterns and trends in main problem drugs as reﬂected in treatment demandFig. 101: 
Sources: UNODC, Annual Reports Questionnaire Data/DELTA and National Government Reports
Notes: Percentages are unweighted means of treatment demand in reporting countries.
 An 'Other drugs' category is not included and so totals may not add up to 100%. Alternatively, polydrug use may increase totals beyond 100%.
 Number of countries reporting treatment demand data: Europe (30 to 45); Africa (15 to 41); North America (3); South America (21 to 26);  
 Asia (27 to 43); Oceania (1 or 2).
 * year specified or latest year available at time of WDR publication.
 # Treatment data dating back more than 10 years were removed from the 2008 estimates and therefore caution should be taken in comparing the  
  data from 2008 with previous years.
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Synthetic opioids are increasingly linked with 
problem drug use in North America
Treatment demand data from the United States of 
America11 and Canada12 both show an increase of prob-
lem drug users linked to the use of synthetic opioids/
prescription medicine and a decline in the heroin-related 
problem users. In the United States, admissions where 
opiates were the primary drug of concern increased by 
34% between 1997 and 2007 (typically representing 
29-32% of demand for treatment, excluding alcohol). 
Heroin is still the major contributor to the treatment 
demand for opioids, but this has become less marked 
with the steady increase in demand for treatment for 
synthetic opioids. The contribution of heroin to opioid 
admissions has continually declined from 94% (1997) 
to 73% (2007), with the number of admissions for 
heroin starting to decline in 2002. In contrast, the 
number of admissions for other opiates/synthetic opio-
ids has increased from 16,274 to 90,516 (more than 
450%) between 1997 and 2007, from contributing just 
6% of opioid admissions in 1997 to 27% in 2007. A 
similar situation is found in Canada. Treatment demand 
for prescription opioids has been greater than for heroin/
opium over the past few years, and it is still increasing. 
Treatment demand data from Ontario show that the 
number of admissions for opioids increased 55% 
between 2004/2005 and 2008/2009, or from 14.7% to 
18.5% of all drug treatment demand (excluding alcohol 
and tobacco). This increase is attributable to the 68% 
rise in admissions for prescription opioids/codeine 
(heroin/opium admissions actually declined 5%). The 
contribution of prescription opioids/codeine to all 
admissions (excluding alcohol and tobacco) has increased 
from 12.1% to 16.5%, while the heroin/opium contri-
bution has declined from 2.6% to 2.0%. 
Cannabis is an increasingly problematic drug 
Although it is the world’s most widely used drug, can-
nabis is often thought to be the least harmful and of 
little interest to public health, in spite of the fact that 
evidence in recent years has shown that the use of can-
nabis can create remarkable levels of harm. Data on 
treatment demand for cannabis and medical research 
have pointed to the potentially severe health conse-
quences of cannabis use.
The most probable adverse effects of cannabis use 
include dependency, increased risk of motor vehicle 
accidents, impaired respiratory function, cardiovascular 
disease and adverse effects of regular use on adolescent 
psychosocial development and mental health.13 The 
11 Office of Applied Studies, Substance Abuse and Mental Health Serv-
ices Administration, Treatment Episode Data Set (TEDS).
12 Substance Abuse Statistical Tables, DATIS Centre for Addiction & 
Mental Health, July 2009.
13 Hall W., and Degenhardt, L., “Adverse health effects of non-medical 
cannabis use,” The Lancet, Volume 374, Issue 9698, Pages 1383 - 1391, 17 October 2009.
Treatment admissions for opiates, Fig. 102: 
1997-2007 (North America)
Note: Percent of admissions excluding alcohol.
Source: Office of Applied Studies, Substance Abuse and 
Mental Health Services Administration, Treatment Episode 
Data Set (TEDS)
Treatment admissions for opiates, Fig. 103: 
2004-2009 (North America)
Note: Percent of admissions excluding alcohol, tobacco and  
not specified.
Source: Substance Abuse Statistical Tables, DATIS, Centre for 
Addiction & Mental Health, July 2009
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rising number of cannabis-related problem drug users is 
often not correlated with a similar rise in the overall 
number of cannabis users, suggesting that the risks asso-
ciated with the use of cannabis have been increasingly 
recognized and diagnosed in recent years. Rising levels 
in cannabis potency in many parts of the world (notably 
in industrialized countries) have also contributed to the 
increased risk of cannabis use.
Cannabis is clearly the dominant drug for treatment in 
Africa with consistently over 60% of demand. Over the 
past 10 years, cannabis has been making an increasing 
contribution to treatment demand in Europe (more than 
doubling from 10% to 22%), South America (more than 
doubling from 15% to 40%) and Oceania (more than 
trebling from 13% to stabilize around 47%). Only North 
America has seen a reduction in the contribution of can-
nabis to treatment demand compared to other drugs.
Harmful levels of cannabis use on the rise  
in Australia
Treatment episodes where cannabis was the primary 
drug of concern increased in Australia by 34%, from 
23,826 to 31,864 between 2002 and 2008 alone,14 
despite a sharp decline in cannabis use among the gen-
eral population. 
Possible explanations for the increasing trend in the 
problematic use of cannabis and cannabis-related harm 
include: increased consumption among older users 
reflecting dependence among those who have had a long 
history of use that was initiated at a relatively young age; 
and the increased availability of cheaper and possibly 
higher potency cannabis. Referrals from the criminal 
justice system do not seem to have had an influence 
on the increase in the numbers entering treatment in 
Australia.15
Contributing factors for increasing treatment 
demand for cannabis in Europe remain uncertain
Cannabis ranks second for treatment demand at the 
European level and its contribution to drug treatment 
demand has been steadily increasing. The EMCDDA 
has been documenting rising levels of demand for treat-
ment from cannabis-related problems since 1996, but 
there are wide discrepancies between countries. In 2006, 
21% of all European clients and 28% of new clients 
entered treatment with cannabis as the primary drug of 
concern. In Denmark, Germany, France, Hungary and 
Turkey the percentage of new clients seeking treatment 
for cannabis as the primary drug was greater than 50%. 
14 Australian Institute of Health and Welfare (AIHW), Alcohol and other 
drug treatment services in Australia 2007–08: report on the national 
minimum data set, Drug treatment series no. 9, cat. no. HSE 73, 
Canberra, 2009.
15 Roxburgh, A., Hall, W.D., Degenhardt, L., McLaren, J., Black, E., 
Copeland, J., and Mattick, R.P. “The epidemiology of cannabis use 
and cannabis-related harm in Australia 1993–2007,” Addiction, 2010 
Mar 12. Pre-publication early view.
However, reasons for the increase in demand have proved 
difficult to identify and EMCDDA recommends further 
research16 to tackle this issue.17 
The effect of poly-drug use in the treatment statistics 
should not be disregarded. While drug treatment seekers 
in the past may have been registered almost automati-
cally for heroin, they may now be more accurately regis-
tered as having cannabis as the primary problem drug 
while consuming other drugs as well. Moreover, the 
increasing complexity of drug use makes it difficult to 
have a simple characterization of problem drug users 
according to a single drug type. In the context of drug 
users combining the use of different drugs to get the 
effect they want to achieve, the use of cannabis becomes 
potentially more harmful because its effect combined 
with other drugs can be very different from when it is 
used alone. 
Cocaine is the main problem drug in the Americas, 
but its contribution is declining in North America
Treatment demand for cocaine is most dominant in the 
Americas, where coca cultivation is concentrated. 
Cocaine is the main problem drug according to treat-
ment demand for South America (with more than 50% 
of demand), and where once it appeared to be on the 
decline, over the last few years, the situation has stabi-
lized. Although cocaine was the main drug for treatment 
in North America in the late 1990s, the cocaine-related 
treatment demand has been declining over the last 
decade, and was responsible for just 31% of total treat-
ment demand in 2008. In Europe, the treatment 
demand, in contrast, increased from 3% to 10% over 
the same period. Cocaine-related treatment demand in 
Africa accounts for less than 10% of the total,18 and in 
Asia and Oceania demand is negligible (<1%).
ATS treatment demand is relatively small but not 
unimportant
Asia has the highest percentage of admissions for 
amphetamine-type stimulants (ATS), where it ranks as 
the second most important drug. In Oceania and North 
America, treatment demand for ATS has increased to 
some 20% since the late 1990s. Otherwise, demand for 
treatment has remained below approximately 10% in 
other regions, with a possible recent emergence in South 
America. It should be noted that treatment for ATS is 
often administered differently than for other drugs, and 
can be easily under-reported. 
16 EMCDDA, A cannabis reader: global issues and local experiences, 
Monograph series 8, Volume 2, Lisbon, 2008.
17 EMCDDA, Annual report on the state of the drugs problem in the 
European Union and Norway. Cannabis problems in context — under-
standing the increase in European treatment demands, Lisbon, 2004.
18 In contrast to the data shown, there are no indications of any decline 
in cocaine-related treatment demand in Africa over the last decade. 
The lower demand shown is a statistical artefact resulting from the 
removal of treatment data dating back more than 10 years.
134
World Drug Report 2010 
Gender and the illicit drug  
markets
The markets for illicit drugs affect more men than 
women worldwide, both in terms of use and trafficking 
of illicit substances. Data that characterize traffickers of 
illicit drugs are scarce. In 2009, the Commission on 
Narcotic Drugs, in its resolution 52/1, stressed the 
importance of collecting and analysing data disaggre-
gated by sex and age, and of conducting research on 
gender issues related to drug trafficking, especially the 
use of women and girls as drug couriers. The Commis-
sion called for improved data collection and recom-
mended the undertaking of a gender analysis based on 
available data. One data source that can be used to gen-
erate a gender analysis of drug traffickers is the Indi-
vidual Drug Seizures Database, where data submitted by 
a limited number of countries (between 30 and 50 from 
all regions) report the characteristics of traffickers associ-
ated with each individual seizure.1 These data show that 
the great majority of drug traffickers are men. They also 
suggest that, irrespective of age, the percentage of female 
traffickers slightly decreased between 2006 and 2009, 
reaching between 15% and 20% of detected traffickers 
in 2009. 
The use of illicit drugs is more balanced between males 
and females, but it still sees a higher number of men 
involved. For all drugs, the gender gap between males 
1 Data on the gender composition of drug-related arrestees could 
also be reported by Member States in the ARQ. However, this 
data can hardly be utilized for a gender analysis because very few 
countries provide the sex-breakdown of the data on arrestees with 
little comparability across countries. 
and females is lower among the young population than 
for the adults. 
Male students outnumber females in the use of cocaine 
and cannabis in all European countries. In contrast, 
female students more frequently report tranquillizer use 
in virtually all countries and ecstasy use in some coun-
tries.2 
A gender gap between the young and older generations 
is also apparent in South America. One comparative 
study shows, for example, that in all six analysed coun-
tries, except Argentina, the gender ratio3 of cannabis use 
is lower for students than the adult population, though 
with large variations across countries. Data from Latin 
America and other parts of the world suggest that the 
more advanced the country, the higher the proportion 
of females among drug users. 
In general, substance dependence and abuse is also 
higher for males than females, although in the United 
States an age-specific analysis reveals that in 2008, the 
rate of substance dependence was higher for females 
(8.2%) than males (7.0%) in the population aged 12 to 
2 EMCDDA, A gender perspective on drug use and responding to drug 
problems, Lisbon 2006. 
3 Ratio of prevalence among males and females. 
Trends in gender distribution of  Fig. 104: 
drug trafﬁckers, 2005-2009
Source: UNODC Individual Drug Seizures Database
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17, while the same rate was almost double for males 
(12.0%) than females (6.3%) in the population 18 
years and older.4 There are few studies that analyse 
gender differences in accessibility of treatment serv-
ices. In 2004 in Europe, there was a ratio of 4:1 
between males and females in treatment. The high 
ratio (higher than the ratio between male and female 
drug users) can be explained by the higher risk of 
becoming problem drug users observed for males. At 
the same time, according to the EMCDDA, there are 
no studies that can provide definitive answers on the 
gender distribution of the unmet treatment needs of 
problem drug users.5 In many countries where gender 
roles are culturally determined and women are not 
empowered, gender differences can be reflected in a 
lack of access to treatment services which could be 
due to: a) higher stigma for women who use drugs 
than for men, and/or b) the fact that services do not 
cater for women (for example, they do not admit 
women or do not cater for the needs of safety and 
childcare). An illustrative example of the lack of 
accessibility can be found in Afghanistan, where in 
2008 there were only three residential drug treat-
ment facilities for women with adjacent child care 
and treatment facilities, despite the high level of 
heroin and opium use among the female popula-
tion.6
 
4 Substance Abuse and Mental Health Services Administration, 
Results from the 2000 - 2008 National Survey on Drug Use 
and Health: National Findings, Office of Applied Studies, US 
Department of Health and Human Services.
5 EMCDDA, A gender perspective on drug use and responding to 
drug problems, Lisbon, 2006.
6 Report to the US Congress, Report on Progress Toward Security 
and Stability in Afghanistan, April 2010. 
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Production2.2.1 
Cultivation
In 2009, the area under opium poppy cultivation 
decreased by 15% from 2008. Similar to the year before, 
this was mainly due to a large decrease in opium poppy 
cultivation in Afghanistan, which was not offset by 
increases in Myanmar and the Lao People’s Democratic 
Republic. In Afghanistan, where in 2009 two thirds 
(66%) of global opium poppy cultivation were concen-
trated, cultivation continued to be concentrated mainly 
in the south and west of the country. Over half of the 
opium poppy area (57%) was located in only one prov-
ince, Hilmand, although most of the decrease in cultiva-
tion from 2008 took place in the same province, in the 
so-called food zone where farmers were supported with 
wheat seeds and fertilizers. Almost the entire Afghan 
opium poppy-cultivating area was located in provinces 
characterized by high levels of insecurity. In 2009, erad-
ication remained at the relatively low level of 2008. A 
preliminary assessment indicated that opium poppy 
cultivation in 2010 may remain at about the 2009 lev-
el.1
In Pakistan, Afghanistan’s neighbour, the 2009 opium 
poppy cultivation remained at about the same level of 
less than 2,000 ha as in previous years. Myanmar, the 
second largest opium poppy cultivating country (17% 
of global cultivation) experienced the third consecutive 
yearly increase in cultivation, although the level remains 
much lower than in the 1990s and early 2000s. Most of 
the cultivation area was concentrated in the eastern part 
1 UNODC/Ministry of Counter Narcotics, Afghanistan Opium Survey 
2010. Winter Rapid Assessment, February 2010. 
of the country (Shan State). Opium poppy cultivation 
in the Lao People’s Democratic Republic remained at a 
low level of about 2,000 ha with no significant changes 
since 2005. Mexico remains the third largest cultivating 
country, showing a large increase in the area under 
opium poppy cultivation between 2007 and 2008. 
Reports on eradication of opium poppy and seizures of 
poppy plant material indicate the existence of illicit 
opium poppy cultivation in many other countries and 
Global opium poppy cultivation (ha), Fig. 106: 
1995-2009
Note: The 2009 estimate for ‘Rest of the world’ is provisional as limited 
information was available for some countries and regions. 
Source: UNODC
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(a) Opium poppy harvestable after eradication.
(b) Afghanistan, sources: before 2003: UNODC; since 2003: National Illicit Crop Monitoring System supported by UNODC. 
(c) Pakistan, sources: ARQ, Government of Pakistan, US Department of State       
(d) Lao PDR, sources: 1995: US Department of State; 1996-1999: UNODC; since 2000: National Illicit Crop Monitoring System supported by UNODC. 
(e) Myanmar, sources: before 2001: US Department of State; since 2001: National Illicit Crop Monitoring System supported by UNODC.
(f ) Due to continuing low cultivation, figures for Viet Nam (as of 2000) and Thailand (as of 2003) were included in the category "Other".
(g) Colombia, sources: before 2000: various sources, since 2000: Government of Colombia. Production: In Colombia, opium is produced as opium latex, which has a higher 
moisture content than opium produced in other regions of the world. The figures presented refer to dry opium. For 2008 and 2009, dry opium production in Colombia 
was calculated based on regional yield figures and conversion ratios from US Department of State/DEA. 
(h)  Figures derived from US Government surveys.The Government of Mexico reported a gross opium poppy cultivation of 19,147 hectares (2006) and estimated gross opium 
production at 211 mt (2006), 122 mt (2007), 144 mt (2008) and 162 mt (2009). These gross figures are not directly comparable to the net figures presented in this table. 
The Government of Mexico is not in a position to confirm the US figures as it does not have information on the methodology used to calculate them. 
(i) Reports from different sources indicate that illicit opium poppy cultivation also exists in other countries and regions, including Algeria, the Baltic countries, Balkan coun-
tries, Egypt, Guatemala, Iraq, Lebanon, Peru, the Russian Federation and other C.I.S. countries, South Asia, Thailand, Ukraine, Venezuela, Viet Nam, as well as in Central 
Asia and the Caucasus region. Starting 2008, a new methodology was introduced to estimate opium poppy cultivation and opium/heroin production in these countries. 
This new series is listed unter "Other countries". The estimates are higher than the previous figures but have a similar order of magnitude. A detailed description of the 
estimation methodology is available in the online version of the World Drug Report 2010.
(j) Potential production refers to the amount of oven-dry opium with unknown morphine content that could be produced if all opium poppy cultivated in an area in one 
year was harvested in the traditional method of lancing the opium capsules and collecting the opium gum or latex. 
(k) In some countries, poppy straw is used to produced acetylated opium rather than opium gum. However, for reasons of comparability, it was assumed that all opium poppy 
cultivation is used for opium gum production.      
(l) This estimate represent the amount of opium, which remains opium and is not processed into morphine or heroin. It refers only to Afghan opium as for other countries, 
the amount of opium which is not processed into morphine or heroin could not be estimated. For years before 2004, no such estimate was available for Afghanistan.
(m) Since 2004: Potential heroin production available outside Afghanistan. Estimates for Afghanistan only include heroin and morphine available for export, i.e. after deducting 
local consumption and seizures, based on the Afghanistan Opium Surveys. The amount of Afghan opium estimated to remain available as opium is not included in this 
figure. For all other countries, it is assumed that all opium gets converted into heroin, disregarding the fact that some opium may be consumed as such or as morphine. 
(n) This series contains all heroin potentially manufactured world-wide, including the heroin and morphine consumed and seized in Afghanistan. The amount of Afghan 
opium estimated to remain available as opium (potential opium, not processed) is not included in this figure.
(o) Potential manufacture refers to the amount of heroin of unknown purity that could be produced if the total potential opium production was converted into heroin, exclud-
ing the opium which is consumed as such and is not processed. Key informant surveys in Afghanistan indicated that 7 kg of air-dry opium are needed to manufacture 1 
kg of brown heroin base of unknow purity. Typical purities found in seized heroin base in Afghanistan range from 50% to 80%. Assuming 10%-15% moisture content 
in air-dry opium, 7 kg of air-dry opium correspond to 6.0 to 6.3 of oven-dry opium. With the indicated typical base purity of 50% to 80%, between 7.4 kg and 12.6 kg 
of oven-dry opium would be needed to produce 1 kg of 100% pure heroin base in Afghanistan. A DEA study on heroin laboratory efficiency in Colombia estimated that 
indeed 8 kg of oven-dry opium were needed to produce 1 kg of 100% pure heroin HCl, corresponding to an overall laboratory efficiency of 67.2% from opium (latex) to 
heroin HCl. This suggests that the currently used ratios for oven-dry opium to heroin 7:1 (Afghanistan), 8:1 (Colombia in recent years) and 10:1 (rest of the world) could 
indeed provide an estimate of pure heroin production. However, the heroin estimates provided are still considered to refer to"heroin of unknown purity" as not enough 
is know about the laboratory efficiency in most producing countries.
Global illicit cultivation of opium poppy and production of opiates, 1995-2009Table 14: 
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
 SOUTH-WEST ASIA
   Afghanistan (b) 53,759 56,824 58,416 63,674 90,583    82,171 7,606 74,100 80,000 131,000 104,000 165,000 193,000 157,000 123,000
   Pakistan (c) 5,091 873 874 950 284 260 213 622 2,500 1,500 2,438 1,545 1,701 1,909 1,779
   Subtotal 58,850 57,697 59,290 64,624 90,867 82,431 7,819 74,722 82,500 132,500 106,438 166,545 194,701 158,909 124,779
 SOUTH-EAST ASIA
   Lao PDR (d) 19,650 21,601 24,082 26,837 22,543 19,052 17,255 14,000 12,000 6,600 1,800 2,500 1,500 1,600 1,900
   Myanmar (e) 154,070 163,000 155,150 130,300 89,500 108,700 105,000 81,400 62,200 44,200 32,800 21,500 27,700 28,500 31,700
   Thailand (f) 168 368 352 716 702 890 820 750
   Viet Nam (f) 1,880 1,743 340 442 442
   Subtotal 175,768 186,712 179,924 158,295 113,187 128,642 123,075 96,150 74,200 50,800 34,600 24,000 29,200 30,100 33,600
 LATIN AMERICA
   Colombia (g) 5,226 4,916 6,584 7,350 6,500 6,500 4,300 4,153 4,026 3,950 1,950 1,023 715 394 356
   Mexico (h) 5,050 5,100 4,000 5,500 3,600 1,900 4,400 2,700 4,800 3,500 3,300 5,000 6,900 15,000 n.a.
   Subtotal 10,276 10,016 10,584 12,850 10,100 8,400 8,700 6,853 8,826 7,450 5,250 6,023 7,615 15,394 15,394
 OTHER (i)
   Combined 5,025 3,190 2,050 2,050 2,050 2,479 2,500 2,500 3,074 5,190 5,212 4,432 4,184
   Other countries 8,600 7,600
 TOTAL 249,919 257,615 251,848 237,819 216,204 221,952 142,094 180,225 168,600 195,940 151,500 201,000 235,700 213,003 181,373
 SOUTH-WEST ASIA
   Afghanistan (b) 2,335     2,248     2,804     2,693     4,565     3,276     185        3,400     3,600     4,200 4,100 6,100 8,200 7,700 6,900
   Pakistan (c) 112        24          24          26          9            8            5            5            52          40 36 39 43 48 44
   Subtotal 2,447 2,272 2,828 2,719 4,574 3,284 190 3,405 3,652 4,240 4,136 6,139 8,243 7,748 6,944
 SOUTH-EAST ASIA
   Lao PDR (d) 128        140        147        124        124        167        134        112        120        43 14 20 9 10 11
   Myanmar (e) 1,664     1,760     1,676     1,303     895        1,087     1,097     828        810        370 312 315 460 410 330
   Thailand (f) 2            5            4            8            8            6            6            9            
   Viet Nam (f) 9            9            2            2            2            
   Subtotal 1,803     1,914     1,829     1,437     1,029     1,260     1,237     949        930 413 326 335 469 420 341
 LATIN AMERICA
   Colombia (g) 71          67          90          100        88          88          80          52          50          49          24 13 14 10 9
   Mexico (h) 53          54          46          60          43          21          91          58          101        73          71 108 149 325 n.a.
   Subtotal 124        121        136        160        131        109        171        110        151 122 95 121 163 335 335
 OTHER (i)
   Combined 78          48          30          30          30          38          32 56 50          75 63 16 15
   Other countries (k) 139 134
 TOTAL 4,452      4,355      4,823      4,346      5,764      4,691      1,630      4,520      4,783      4,850 4,620 6,610 8,890 8,641 7,754
NON-PROCESSED OPIUM (l) 1,382 1,317 2,228 3,698 3,070 2,895
AVAIL. OUTSIDE AFGH. 445         436         482         435         576         469         163         452         478         495 472 606 735 724 634
TOTAL(n) 529 472 629 757 752 657
 POTENTIAL OPIUM PRODUCTION IN METRIC TONS (j) 
POTENTIAL MANUFACTURE OF HEROIN IN METRIC TONS (o)
CULTIVATION(a) IN HECTARES
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regions.2 In countries where information was available 
on eradication and seizures of opium poppy plants but 
not on the area under cultivation between 2003 and 
2009, a methodology was developed to estimate opium 
poppy cultivation. This indirect method does not allow 
for individual country estimates, but can provide an 
estimate of the total level of opium cultivation in this 
residual group of countries which for 2009 amounted to 
7,600 ha, equivalent to 4% of global cultivation. A 
detailed description of the estimation methodology is 
included in the methodology chapter, available on the 
UNODC website at www.unodc.org/wdr. 
Production
In 2009, global potential opium production was esti-
mated at 7,755 mt, a decrease by 10% from 2008. Over 
one third (37%) was estimated to be available on the 
drug market as opium, the remainder being converted 
into morphine and heroin. This would correspond to a 
potential heroin production of 657 mt. This is the 
2 Without detailed information on the circumstances of poppy straw 
seizures, the seizure as such is not proof of illicit opium poppy cultiva-
tion. The material could be diverted from licit cultivation or originate 
from another country. Between 2003 and 2009, on average 18 coun-
tries/territories reported eradication and/or seizures of opium poppy, 
suggesting the existence of opium poppy cultivation, among them: 
Algeria, Argentina, Armenia, Australia, Austria, Bangladesh, Belarus, 
Costa Rica, Ecuador, Egypt, Estonia, Guatemala, India, Japan, Kaza-
khstan, Kyrgyzstan, Latvia, Lebanon, Lithuania, the former Yugoslav 
Republic of Macedonia, the Republic of Moldova, Nepal, Norway, 
Peru, Poland, Romania, the Russian Federation, Tajikistan, Turkmen-
istan, Ukraine, Uzbekistan, the Bolivarian Republic of Venezuela, 
Viet Nam and the Palestinian Territory. Source: UNODC ARQ and 
IDS, US State Department, International Narcotics Control Strategy 
Report (INCSR). 
second consecutive decrease since 2007, when global 
opium production reached a peak of 8,890 mt, with an 
estimated potential heroin production of 757 mt. 
Opium yields in Afghanistan remained very high in 
2009. The potential opium production was estimated at 
6,900 mt. About 56% of the total opium production 
was estimated to be potentially exported as morphine 
and heroin, corresponding to 548 mt in heroin equiva-
Reported opium poppy eradication in selected countries (ha), 1995-2009Table 15: 
* Although eradication took place in 2004, it was not officially reported to UNODC. 
Source: ARQ, Government reports, reports of regional bodies, INCSR
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Afghanistan  400  121 21,430 *  5,103 15,300 19,047  5,480  5,351 
Colombia  3,466  6,885  6,988  2,901  8,249  9,254  2,385  3,577  3,266  3,866  2,121  1,929  375  381  546 
Egypt  15  34  65  45  50  98  121 
Guatemala  489  720  449  536  1,345 
India  29  96  248  153  18  219  494  167  12  247  8,000  624  2,420 
Lao PDR  4,134  3,556  2,575  1,518  779  575  651 
Lebanon  4  67  27  8 
Mexico 15,389 14,671 17,732 17,449 15,461 15,717 15,350 19,157 20,034 15,926 21,609 16,890 11,046 13,095 11,471 
Myanmar  3,310  1,938  3,093  3,172  9,824  1,643  9,317  7,469  638  2,820  3,907  3,970  3,598  4,820  4,087 
Nepal  19  19  1  21  35 
Pakistan  867  654  2,194  1,197  1,704  1,484  4,185  5,200  391  354  614 0 16
Peru  4  18  26  155  14  57  98  92  88  88  23  32 
Thailand  580  886  1,053  716  808  757  832  989  767  122  110  153  220  285  201 
Venezuela 
(Bolivarian 
Rep. of)
 148  51  266  148  137  215  39 0 0  87  154 0 0 0
Viet Nam  477  1,142  340  439  426 125 100  32  38  99 45
Global potential opium production Fig. 107: 
(mt), 1995-2009
Note: The 2009 estimate for ‘Rest of the world’ is provisional as limited 
information was available for some countries and regions.
Source: UNODC
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
95 96 97 98 99 00 01 02 03 04 05 06 07 08 09
M
et
ri
c 
to
n
s
Rest of the World
Lao People's Democratic Republic
Myanmar
Afghanistan
140
World Drug Report 2010 
lent.3 Afghanistan remained by far the largest opium-
producing country, representing 89% of the global illicit 
opium production. Despite the increase in cultivation, 
opium production in Myanmar decreased by 20% to 
only 330 mt, due to lower yields.
Laboratories
Only eight countries reported destruction of clandestine 
opiate-processing laboratories in 2008. In addition to 
countries where opium production takes place, such as 
Afghanistan (69 laboratories), Myanmar (5), Mexico (1) 
and Peru (1), destruction of clandestine opiate process-
ing laboratories were reported from Belarus (1), Greece 
(2), New Zealand (1) and the Russian Federation (1). 
Much higher numbers were reported in 2007 (639). 
However, most of these laboratories were small-scale 
kitchen laboratories reported by the Russian Federation, 
many of which produced acetylated opium from poppy 
straw, which is commonly consumed in this subregion 
only. It can be assumed that most heroin production still 
occurs in countries where opium poppy is cultivated or 
in their close proximity. 
Precursor chemicals
Illicit morphine and heroin production requires large 
quantities of precursor chemicals such as acetic anhy-
dride, a substance which is essential in the refinement of 
morphine to heroin. All acetic anhydride used for heroin 
production in Afghanistan has to be smuggled into the 
country as no known production facilities of the sub-
stance exist in the country nor is there any reported 
legitimate use of this chemical.4 
Large amounts of acetic anhydride seizures were reported 
in 2008, mainly from European and Western Asian 
countries (Afghanistan, Pakistan, the Syrian Arab 
Republic and Turkey), totalling 199,344 litres (57,308 l 
in 2007).5 Large amounts were also seized in East and 
South-East Asia (China, the Republic of Korea and 
Myanmar). In South America, Colombia regularly 
reports seizures of acetic anhydride. Increased interna-
tional control and cooperation helped to prevent the 
diversion of large amounts of precursors. The seizures 
and related information confirmed that large-scale traf-
ficking of morphine and heroin precursors to Afghani-
stan and neighbouring countries occurred but also to 
3 A detailed description of the methodology of the Afghanistan opium 
and heroin estimates can be found in UNODC/Government of 
Afghanistan (Ministry of Counter Narcotics), Afghanistan Opium 
Survey 2009, December 2009. 
4 Information on precursor seizures stems mainly from the Interna-
tional Narcotics Control Board, E/INCB/2009/1. 
5 The total reported seizure amount does not include seizures from 
Afghanistan, which were not officially reported to the INCB. Seizures 
were reported to UNODC by Afghan authorities, at 14,234 l of 
acetic anhydride in 2008.
other opium producing countries. The controls in place 
seem to have led to a high price level of acetic anhydride 
in Afghanistan (US$350/l – US$400/l), which is thought 
to have become a major cost factor in the production of 
heroin.6 
6  UNODC/Ministry of Counter Narcotics, Afghanistan Opium Survey 
2009, December 2009. 
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2.2.2 Seizures
In 2008, seizures of opium continued to increase stead-
ily, together with heroin seizures, which rose for the 
second consecutive year, albeit less sharply. In contrast, 
morphine seizures continued the declining trend which 
started in 2007. Although heroin seizures have followed 
a generally increasing trend since 2002, they have been 
clearly outpaced by growth in global opium seizures. 
This is mainly due to the contribution of the Islamic 
Republic of Iran, which has registered increases in both 
heroin and opium seizures, accounting for an over-
whelming proportion of global opium seizures.
Globally, interdiction of opium is concentrated in the 
area around Afghanistan, while seizures of processed 
heroin are far more geographically dispersed. Not sur-
prisingly, the closer the substance is to the final product 
(heroin), the more ubiquitous it becomes. Moreover, 
opium consumption is to be found mainly in the Near 
and Middle East/South-West Asia.
Total heroin seizures are driven by various factors, 
including law enforcement efforts, as well as the global 
supply of heroin, which in turn depends on the global 
production of heroin and opium. However, global 
heroin seizures tend to respond to changes in produc-
tion levels with a longer time lag than opium as a result 
of the time taken to process the opium into heroin and 
to traffic it. Therefore, the effect of production on sei-
zures is visible later, and may also be less prononced. The 
distinction can be observed, for example, in the sharp 
decline of opium production in 2001, which resulted in 
a sharp drop in opium seizures the same year, and in a 
much less pronounced decline in heroin the following 
year. Over the period 2001-2008, heroin seizure totals 
were more strongly correlated with opium production 
estimates in the previous year, while in the case of opium, 
the best correlation is observed with the average opium 
production in the current and previous years. This sug-
gests that the interception rate for heroin can be best 
assessed if calculated by comparing global seizures with 
the production estimated for the year before. 
The difficulties in calculating the global heroin intercep-
tion rate are further compounded by the necessity to 
adjust for purity in heroin production estimates7 as well 
as heroin seizures – a complication which does not arise 
in the case of opium. 
7 The available heroin production estimates refer to heroin of unknown 
purity. 
Global opiate seizures, 1998-2008Fig. 108: 
Source: UNODC ARQ/DELTA
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Production in same year as seizures
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The interception rate for opium8 rose slightly in 2008, 
from 17% in 2007 to 19%. On the other hand, the ratio 
of the other opiate seizures (heroin and morphine) to 
estimated potential heroin production in the previous 
year dropped from 15% in 2007 to 12% in 2008.9 
Opium
Global opium seizures have risen steadily for six con-
secutive years, from 95.7 mt in 2002 to almost seven 
8 Calculated as the ratio of global opium seizures in a given year to 
the estimated global supply of opium not processed into heroin or 
morphine. The supply is estimated by the average of production in 
the given year and the preceding year.
9 In previous years, UNODC estimated a single interception rate for 
opiates, which expressed total opiate seizures in a given year, con-
verted into heroin equivalents, as a percentage of potential heroin 
production (excluding, since 2004, seizures and consumption in 
Afghanistan) in the same year. 
times more - 646 mt - in 2008, equivalent to consistent 
annual increases of 37%. The growth has mainly been 
driven by the quantities seized in the Islamic Republic 
of Iran, which continues to report by far the largest 
opium seizures worldwide. Most of the remaining sei-
zures happened in Afghanistan and Pakistan. These 
three countries together accounted for more than 97% 
of global seizures in 2007 and 2008.
Every year from 1996 to 2008, the Islamic Republic of 
Iran accounted for more than two thirds of annual 
global opium seizures. For six consecutive years, increas-
ing quantities of opium were seized in this country 
(from 73 mt in 2002 to 561 mt in 2008), setting the 
trend for the global total. According to preliminary data, 
in 2009 seizures stabilized, standing at 579 mt.10
10 Islamic Republic of Iran, Drug Control Headquarters, Drug Control 
Distribution of opiate seizures worldwide (percentage), 2008Fig. 109: 
* The category “Other” refers to a different set of countries according to the drug type.
Source: UNODC ARQ/DELTA
Correlation of global heroin seizures with total opium production, 2001-2008Fig. 110: 
Source: UNODC ARQ/DELTA (seizure data), UNODC (production estimates)
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Opium seizures in Afghanistan fell from 52.5 mt in 
2007 to 42.8 mt11 in 2008. Given the large amounts of 
opium being produced in Afghanistan, these levels imply 
a disproportionately low seizure rate. Based on data 
gathered by UNODC, in 2008, opium seizures mainly 
took place in the provinces of Hilmand (20.8 mt), Nan-
garhar (9.8 mt), Kandahar (4.1 mt) and Hirat (3.4 mt). 
Afghanistan reported seizures of 35.7 mt in 2009. How-
in 2009.
11 UNODC Afghanistan country office.
ever, this may not include seizures made by international 
forces in collaboration with Afghan forces - in the first 
half of 2009 only, military operations seized 50 mt of 
opium.12
In line with the trend in the Islamic Republic of Iran, 
opium seizures in Pakistan rose more than tenfold over 
the period 2004-2008, from 2.5 mt in 2004 to 27.2 mt 
in 2008. Pakistan also reported seizures of 6.9 mt of 
opium poppy straw in 2007, and more than 10 times 
this quantity – 81.7 mt – in 2008. 
Morphine
For the second consecutive year, in 2008, global mor-
phine seizures fell by more than one third, dropping 
from 27.4 mt in 2007 to 17.3 mt. The decline over the 
2006-2008 period was mainly due to a notable down-
ward trend in Pakistan. Seizures of morphine in Pakistan 
fell sharply in 2007, from 32.7 mt in 2006 to 11.0 mt, 
and even further in 2008, to 7.3 mt – the lowest level 
since 2002. The downward trend was in sharp contrast 
with increasing opium seizures in the same country.
In 2008, the largest quantity of morphine was seized by 
the Islamic Republic of Iran, where seizures amounted 
to 9.0 mt,13 essentially stable at the 2007 level (9.7 mt). 
However, according to preliminary data,14 in 2009, 
seizures almost doubled, rising to 16.1 mt.
12 UNODC/Government of Afghanistan (Ministry of Counter Narcot-
ics), Afghanistan Opium Survey 2009, December 2009.
13 Islamic Republic of Iran, Drug Control Headquarters, Drug Control 
in 2009.
14 Ibid.
Comparison of global opiate seizures with global production estimatesFig. 111: 
Source: UNODC ARQ/DELTA (seizure data), UNODC (production estimates)
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Global morphine seizures, 2003-2009Fig. 113: 
* Data for 2009 for the Islamic Republic of Iran are preliminary.
Source: UNODC ARQ/DELTA
Comparison of morphine and opium Fig. 114: 
seizure trends in Pakistan (mt), 2004-
2008
Note: Data are presented for the purposes of a comparison of trends 
over time, not quantities, across different drug types. In no sense 
should 1 ton of opium be considered equivalent to 1 ton of morphine 
(in particular not in terms of potential heroin manufacture).
Source: UNODC ARQ/DELTA
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Heroin
In 2008, global heroin seizures reached a record level of 
73.7 mt, up from 65.5 mt in 2007, registering the 
second consecutive year-on-year increase. Heroin sei-
zures remained much less geographically concentrated 
than seizures of opium and morphine, with large quanti-
ties of heroin being seized in the subregion of the Near 
and Middle East/South-West Asia (39% of the global 
total), South-East Europe (24%), West and Central 
Europe (10%), East and South-East Asia (7.3%), Cen-
tral Asia and Transcaucasian countries (7.3%), East 
Europe (5.4%) and North America (3.1%).
The global increase in heroin seizures over the 2006-
2008 period was driven mainly by continued burgeon-
ing seizures in the Islamic Republic of Iran and Turkey. 
In 2008, these two countries accounted for more than 
half of global heroin seizures, and registered, for the 
third consecutive year, the highest and second highest 
seizures worldwide, respectively. By 2008, heroin sei-
zures in the Islamic Republic of Iran had climbed to 
23.1 mt.15 According to preliminary data, in 2009 
heroin seizures may have stabilized, amounting to 23.4 
mt.16 In Turkey, seizures rose from 13.2 mt in 2007 to 
15.4 mt in 2008.
15 Islamic Republic of Iran, Drug Control Headquarters, Drug Control 
in 2009.
16 Ibid.
Correlation of heroin seizures in Turkey with opium and heroin seizures in the Islamic  Fig. 116: 
Republic of Iran, 2000-2004 and 2004-2008
Sources: UNODC ARQ/DELTA
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Turkey remained a major gateway for heroin destined 
for West and Central Europe. A comparison of heroin 
seizures in Turkey with opiate seizures in the neighbour-
ing Islamic Republic of Iran reveals notable patterns. 
Over the 2000-2004 period, heroin seizures in Turkey 
were more strongly correlated with opium seizures than 
with heroin seizures in the Islamic Republic of Iran, sug-
gesting that the supply of heroin in Turkey was sourced 
to a significant extent from opium transiting the Islamic 
Republic of Iran. In contrast, over the 2004-2008 period, 
the correlation was remarkably strong with both heroin 
and opium seizures in the Islamic Republic of Iran, and 
the discrepancy could no longer be observed, thus 
making it plausible that traffickers in the two countries 
were ultimately drawing from a common supply of 
heroin.
Following a significant decline over the 2004-2007 
period, heroin seizures in China appeared to stabilize in 
2008, amounting to 4.3 mt in 2008, only slightly less 
than the level in 2007 (4.6 mt). China reported that 
West African (especially Nigerian) syndicates were traf-
ficking large quantities of heroin, as well as metham-
phetamine, to China, especially through Guangdong 
province.
Heroin seizures fell both in Afghanistan, from 5.0 mt17 
in 2007 to 2.8 mt15 in 2008, and in Pakistan, from 2.9 
mt in 2007 to 1.9 mt in 2008 – the lowest level in Paki-
stan since 1981. On the other hand, in 2008 seizures 
reached the highest levels on record in Uzbekistan (1.5 
mt) and Kazakhstan (1.6 mt), while remaining essen-
tially stable in Tajikistan (1.6 mt).
17 UNODC Afghanistan country office.
Further indications of changing trafficking patterns in 
Pakistan can be observed from an analysis of significant 
individual heroin seizures reported by this country. 
Among those cases in which a country other than Paki-
stan was identified as the destination, the proportion of 
consignments intended for Malaysia had never exceeded 
1% prior to 2006. In contrast, this proportion rose to 
9% in 2007 and 22% in 2008. Similarly, the proportion 
of consignments intended for China had never exceeded 
1% prior to 2005, but rose to 28% in 2006. However, 
this proportion then declined to 10% in 2007 and 4% 
in 2008.
In West and Central Europe, heroin seizures remained 
stable for the second year in a row, at 7.7 mt in 2008. 
Seizures in the Russian Federation rose in 2007, from 
2.5 mt in 2006 to 2.9 mt, and again in 2008, to 3.4 mt. 
Seizures in the United States fell from 2.4 mt in 2007 to 
2.0 mt in 2008, nevertheless remaining higher than the 
level in 2005 and 2006 (1.7 mt).
Destination of heroin seizure cases reported by Pakistan, 2007 and 2008Fig. 117: 
Source: UNODC Individual Drug Seizures database 
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Prices2.2.3 
Opium farm-gate prices and opium  
production
Both heroin (wholesale) and opium (farm-gate) prices in 
Afghanistan have decreased noticeably over the last 
years, but not at the same speed. A comparison between 
the two price trends reveals that the ratio of heroin to 
opium prices between 2006 and 2009 has indeed 
increased, as opium prices were falling more rapidly than 
heroin prices. Without knowing the composition and 
purity of the heroin sold at the reported prices this trend 
is difficult to interpret. Potentially, a large ratio could 
indicate a larger profit margin for drug traffickers 
involved in heroin production. On the other hand, 
prices for precursors seemed to have reached a very high 
level in 2009, when acetic anhydride, a key element of 
the conversion process, was sold at US$350 to US$400 
per litre. Thus, the high prices for inputs could (partly) 
be compensated by paying less for opium, as the market 
did not allow an increase in heroin prices. Another pos-
sible explanation is that the quality of the opium (mor-
phine content) is lower and more opium is needed to 
produce the same amount of heroin. 
The declining opium prices in Afghanistan are not 
always mirrored by price trends in neighbouring coun-
tries. As one can expect, opium price levels in neigh-
bouring countries are higher than in Afghanistan, as a 
result of transport costs and risk premiums. The opium 
wholesale price in Peshawar, Pakistan, seems to best 
reflect price developments in Afghanistan whereas opium 
price trends in the Islamic Republic of Iran and Tajikistan 
seem to be subject to additional factors. 
Farm-gate prices of opium in Afghanistan have been on 
the decline in recent years, reflecting production increases 
in Afghanistan and a high level of global opium produc-
tion, to which Afghanistan is the main contributor. The 
price decline was steepest in years of large production 
increases in Afghanistan and has ebbed off since 2008, 
despite a decline in production, probably reflecting the 
still very high level of global opium production since 
2006 and the existence of opium stocks. 
Prices in Colombia, where prices refer to opium latex 
which has a higher moisture content than opium gum, 
are not directly comparable to prices in Afghanistan and 
Myanmar, where they refer to air-dried opium gum. 
Converted into air-dried opium equivalents, per kilo 
prices in Colombia would roughly be double to triple 
the price in Myanmar, which is already far higher than 
the price in Afghanistan. Two observations can be made: 
First, farm-gate prices of opium in Myanmar, the second 
largest opium producing country, and in Colombia, 
which has a small but regionally important production, 
showed constant increases over the last five years and do 
not reflect the strong increase in global opium produc-
tion. Second, price levels differ strongly in these three 
regions, with Afghanistan having the lowest prices, 
Myanmar a price level five times higher than Afghani-
stan, and Colombia (in dry opium equivalents about 
US$930/kg) about three times higher than Myanmar or 
15 times higher than Afghanistan. The opium prices in 
Colombia are close to the opium price levels observed in 
Thailand and the Lao People’s Democratic Republic of 
over US$1,000/kg since 2008. 
The disconnect between farm-gate prices and global 
production trends supports the hypothesis of the exist-
ence of separate regional markets, where prices reflect 
the local/regional rather than global opium production 
levels and trends. 
Afghanistan, wholesale opium and Fig. 118: 
heroin price, 2006-2009 
Source: UNODC ARQ
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Heroin wholesale and retail prices
Wholesale prices of heroin (not adjusted for purity) 
follow the well-known trafficking routes from South-
West Asia to Europe, and from South America and 
Mexico to the United States and Canada. In 2008, 
wholesale prices ranged from US$2,400 per kg in 
Afghanistan to US$10,300-US$11,800 per kg in Turkey 
and an average of US$44,300 per kg in West and Cen-
tral Europe. In the Americas, a largely self-sufficient 
market for heroin, prices ranged from US$10,000 per 
kg in Colombia to US$45,000-US$70,000 per kg (for 
heroin of South American origin) in the United States 
and US$119,000 per kg in Canada. The price in Mexico, 
US$35,000 per kilogram, is possibly influenced by two 
contrasting factors – the proximity to the consumer 
market of the United States, which can arguably raise 
the price, and the local production of heroin in Mexico,18 
which would be expected to lower the price. 
Over the 2005-2008 period, heroin retail prices in key 
European markets, when adjusted for purity and infla-
tion, displayed a marked sensitivity to the wholesale 
price in Turkey, confirming the role of this country as a 
18 Mexico is also believed to be a transit point for heroin from South 
America to the United States.
Opium prices in South and Central Asia (US$/kg), 2006-2009Fig. 119: 
Source: National monitoring systems supported by UNODC in Afghanistan, Governments of the Islamic Republic of Iran and Tajikistan
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Opium production and prices in  Fig. 121: 
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Thailand, 2002-2009
Source: National monitoring systems supported by UNODC in 
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major gateway for heroin entering Europe. A notable 
exception was the United Kingdom, where the adjusted 
price remained largely stable. This may reflect the differ-
ent trafficking patterns for heroin reaching the United 
Kingdom, as opposed to continental Europe.19
In the United States, high wholesale purity and low 
prices, as well as other indicators, suggest that heroin 
remains widely available in the country, and that the 
availability is increasing in some areas. Moreover, the 
19 The United Kingdom assessed that, in 2008, 25% of the heroin in its 
market was trafficked from Pakistan, as opposed to the Balkan route. 
Other factors may also distinguish the UK market from continental 
Europe.
results of the Heroin Signature Program (HSP) of the 
US Drug Enforcement Agency point to an increase in 
the availability of heroin from Mexico. The wholesale 
purity of heroin of Mexican origin was at its highest 
(40%) since 2005, while Mexican heroin represented 
39% (by weight) of all heroin analysed through the HSP, 
the highest percentage since 1987.20
20 National Drug Intelligence Center, United States Department of 
Justice, National Drug Threat Assessment 2010, February 2010.
Heroin wholesale prices (not adjusted for purity) in Africa, Asia and Europe, 2008Fig. 122: 
* Average of reported minimum and maximum prices. ** Simple average.
Source: UNODC ARQ
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origin). *** South American origin.
Source: UNODC ARQ
Trends in purity- and inﬂation-adjusted Fig. 124: 
heroin prices in selected European 
countries, 2005-2008 (indexed, base-
line 2005)
* France did not register a variation in purity over the period 2005-
2008. Note: purity-adjusted prices are UNODC estimates based on 
reported prices and purities.
Source: UNODC ARQ, Europol, World Drug Report 2009
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2.2.4 Consumption
In 2008, UNODC estimates that between 12.8 and 
21.9 million people globally used opiates over the past 
12 months, with the prevalence ranging between 0.3% 
and 0.5% of the world’s population aged 15-64. The 
range of the estimated prevalence did not change from 
2007, but the range of the lower bound of the estimated 
number of annual users decreased, reflecting an increased 
uncertainty in South Asia and Africa, but also a possible 
decrease in the total number of users observed, particu-
larly in Europe. More than half of the estimated opiate 
users are in Asia. Despite significant growth in the pro-
duction of opiates in recent years, global consumption 
remains relatively stable, as also perceived by national 
experts.
Opiate consumption in East and South-East Asia is 
stabilizing, but it remains a problematic drug group 
in many parts of the region
While most countries/territories in East and South-East-
Asia have reported some decrease, between 2.8 and 5 
million people aged 15 to 64 are estimated to have used 
opiates in the past year in the subregion. Opiates, and 
especially heroin, is still reported as the most prevalent 
drug in China, Indonesia, Malaysia and Myanmar. The 
highest prevalence of opiate use of 1.3% and 1.2% 
respectively in this subregion are estimated to be found 
in Malaysia (among the population aged 15-64, 2002) 
and Macao, China (among the population aged 15-64, 
2003) respectively. In Malaysia, a similar prevalence of 
injecting drug use among the population aged 15-64 is 
reported with an HIV prevalence of 10.3% among this 
World annual opiates usersFig. 125: 
Source: UNODC ARQ
Global trend in the perception of opiate use: cumulative unweighted average* as reported  Fig. 126: 
by national experts 
* The graph measures the trend from countries reporting an increase or decrease in drug use. It does not measure the trend in terms of number of 
drug users. 
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group.21 Except for Myanmar, there is no new informa-
tion on opiate consumption available for 2008 in the 
subregion. Higher than global average prevalence of 
opiate use is reported in Myanmar, where opium-pro-
ducing villages have a higher consumption rate than 
non-producing villages.22 In Myanmar, heroin use is still 
21 Mathers B., Degenhardt L., Phillips B., Wiessing L., Hickman M., 
Strathdee A., Wodak A., Panda S., Tyndall M., Toufik A.and Mattick 
R., on behalf of the Reference Group to the United Nations on HIV 
and Injecting Drug Use, “Global epidemiology of injecting drug use 
and HIV among people who inject drugs: a systematic review,” The 
Lancet, 2008; 372:1733-1745.
22 UNODC, Opium poppy cultivation in South-East Asia, December 
less widespread than opium use, but data suggest that 
heroin use may have increased in recent years.23 Opium 
use among the population aged 15 and older has 
decreased from 2% among men to 1.4%, and from 
0.2% among women in 2008 to 0.1% in 2009. On the 
other hand, heroin use has increased from 0.1% in 2008 
to 0.3% in 2009.24 
2009.
23 Ibid.
24 UNODC, Opium poppy cultivation in South-East Asia, December 
2008.
Estimated number of people who used opiates at least once in the past year and  Table 16: 
prevalence of opiate use in the population aged 15-64, by region, 2008
Region/Subregion
Estimated  
number of users 
annually (lower)
-
Estimated  
number of users 
annually (upper)
Percent of  
population age 
15-64 (lower)
-
Percent of  
population age 
15-64 (upper)
Africa 680,000 - 2,930,000 0.1 - 0.5
Eastern Africa 150,000 - 1,730,000 0.1 - 1.3
North Africa 130,000 - 540,000 0.1 - 0.4
Southern Africa 240,000 - 320,000 0.2 - 0.3
West and Central Africa 160,000 - 340,000 0.1 - 0.2
Americas 2,290,000 - 2,440,000 0.4 - 0.4
Caribbean 60,000 - 90,000 0.2 - 0.3
Central America 100,000 - 110,000 0.4 - 0.4
North America 1,290,000 - 1,380,000 0.4 - 0.5
South America 840,000 - 870,000 0.3 - 0.3
Asia 6,460,000 - 12,540,000 0.2 - 0.5
Central Asia 340,000 - 340,000 0.7 - 0.7
East/South-East Asia 2,830,000 - 5,060,000 0.2 - 0.3
Near and Middle East 1,890,000 - 3,820,000 0.8 - 1.5
South Asia 1,390,000 - 3,310,000 0.2 - 0.4
Europe 3,290,000 - 3,820,000 0.6 - 0.7
Eastern/South-East Europe 2,210,000 - 2,460,000 0.8 - 0.9
Western/Central Europe 1,090,000 - 1,370,000 0.4 - 0.5
Oceania 120,000 - 150,000 0.5 - 0.6
Global 12,840,000 - 21,880,000 0.3 - 0.5
Range of estimated numbers and annual prevalence of opiate use globally and by regionFig. 127: 
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Opiate use in Central and South-West Asia  
remains the highest 
Most countries in these subregions have opiate use prev-
alence rates that are higher than the world average. New 
information was available for Afghanistan, where a sharp 
increase was observed in opiate use, and in Azerbaijan, 
showing a slight decrease (from a 0.3% annual preva-
lence rate among the population aged 15-64 in 2006 to 
0.2% in 2008). Last year’s drug use survey conducted in 
Afghanistan suggests that the country has one of the 
highest opiate use prevalence rates in the world, ranging 
between 2.3% and 2.9% of the population aged 15-64 
(between 285,000 and 360,000 users). Opium is the 
most commonly used opiate, with estimates ranging 
between 200,000 and 250,000 regular users. The 
number of heroin users in Afghanistan is estimated 
between 100,000 and 135,000. The opiate use preva-
lence in the Islamic Republic of Iran in 1999 was 
reported as 2.8% of the population, and more than 2 
million people were estimated to be regular opiate users. 
However, experts in the Islamic Republic of Iran per-
ceive that there has been a slight decrease in opiate use 
over the last years.25 Both in Afghanistan and the Islamic 
Republic of Iran, opium remains the preferred opiate, 
while heroin remains the main opiate in the rest of the 
subregion. In Pakistan, the opiate use prevalence rate 
was reported as 0.7% or an estimated 630,000 people 
who had used opiates in the past year in 2006.26 
25 Islamic Republic of Iran, Annual Reports Questionnaire: Extent, pat-
terns and trends of drug abuse, 2008.
26 UNODC and the Paris Pact Initiative, Illicit Drug Trends in Pakistan, 
April 2008; UNODC Global Assessment Programme on Drug Use/
Ministry of Narcotics Control of the Government of Pakistan, Anti-
Narcotics Force of the Government of Pakistan, Problem Drug Use 
in Pakistan, Results from the year 2006 National Assessment, Tashkent, 
2007.
In Central Asia, Kazakhstan in particular has a high 
opiate use prevalence rate (1% in 2006), followed by 
Uzbekistan and Kyrgyzstan (0.8% each). Estimates for 
Tajikistan (0.5%) and Turkmenistan (0.3%) are lower.27 
Injecting drug use is reportedly one of the preferred 
methods in Central Asia, with increasing numbers also 
reported in Pakistan and the Islamic Republic of Iran. 
Injecting drug use is fuelling the HIV epidemic among 
injecting drug users in the region. The highest HIV 
prevalence among injecting drug users in the region is 
reported from Uzbekistan, Tajikistan, the Islamic Repub-
lic of Iran and Pakistan.28 
South Asia
No new information was available for South Asia in 
2008, and the lack of accurate, up to date information 
on the prevalence of opiate use among the general popu-
lation in India makes uncertain the estimate of the 
number of users for this subregion. In a national survey 
in 2001, a high prevalence rate was observed among 
Indian males (monthly prevalence rate of 0.7% among 
the male population 12-60 years old), but the lack of 
information on female opiate use prevents the calcula-
tion of a generally accepted, internationally comparable 
prevalence rate.29 In the region, Bangladesh and Bhutan 
have opiate prevalence rates close to the world average 
(around 0.4%). In Bangladesh, India and Nepal, illicit 
use of opioids such as buprenorphine, especially through 
27 UNODC, HIV and AIDS and Injecting Drug Use in Central Asia: 
From Evidence to Action, country reports for Kyrgyzstan, Tajikistan 
and Uzbekistan.
28 Mathers B., Degenhardt L., Phillips B., Wiessing L., Hickman M., 
Strathdee A., Wodak A., Panda S., Tyndall M., Toufik A. and Mattick 
R., on behalf of the Reference Group to the United Nations on HIV 
and Injecting Drug Use, “ Global epidemiology of injecting drug use 
and HIV among people who inject drugs: a systematic review,” The 
Lancet, 2008; 372:1733-1745.
29 Previous UNODC estimates put the rate at around 0.4% for the year 
2001.
Number of injecting drug users and HIV prevalence among those who inject drugsTable 17: 
Source: UNODC and the Paris Pact Initiative, Illicit Drug Trends in Pakistan, April 2008; UNODC Global Assessment Programme on Drug Use; 
Mathers B., et al, on behalf of the Reference Group to the United Nations on HIV and Injecting Drug Use
Estimated number of people who inject 
drugs
Prevalence of HIV among people who inject 
drugs (%)
Low Mid High Low Mid High
Afghanistan 6,870 6,900 6,930 1.7 3.4 5.1
I.R. of Iran - - 180,000 5 15 25
Pakistan 125,000 130,460 150,000 9.6 10.8 13.6
Kazakhstan - - 100,000 8 9.2 10.4
Kyrgyzstan - - 25,000 2.4 8.0 13.6
Tajikistan - - 17,000 11.5 14.7 17.9
Uzbekistan - - 80,000 11.7 15.6 19.5
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injecting, is reportedly common.30 In Sri Lanka, smok-
ing heroin remains the preferred method of use.
Other than Israel, most of the countries in Middle East 
have reportedly negligible opiate use. However, this is 
also due to the fact that there is limited data on drug use 
and treatment demand from the region.
East and South-East Europe as a subregion has the 
second highest number of opiate users, ranging 
between 2.2 and 2.5 million people 
The subregion on the whole seems to have one of the 
highest prevalence rates in the world (0.8% to 0.9% of 
the population aged 15-64), though individual country 
estimates must be treated with caution. The Russian 
30 UNODC, Rapid Situation and Response Assessment of drugs and HIV 
in Bangladesh, India, Nepal and Sri Lanka – a regional report, 2007.
Federation and Ukraine are the two countries in the 
subregion with the highest estimated number of opiate 
users. In the Russian Federation, the number of opiate 
users are estimated between 1.6 and 1.8 million (1.6% 
prevalence) and in Ukraine, between 325,000 and 
425,000 (1.16% prevalence). The only country report-
ing new information in 2008 was the Republic of 
Moldova, showing an increase from a 0.1% annual 
prevalence rate in 2007 to 0.15% in 2008. Both the 
Russian Federation and Ukraine have some of the high-
est HIV prevalence rates among injecting drug users 
(37.2% and 41.8%, respectively).31 The other countries 
in the region have opiate use prevalence rates either 
equivalent to or lower than the world average.
European data suggest that while heroin use is 
decreasing its associated harm is growing
In West and Central Europe, the opiate use prevalence 
is estimated between 0.4% and 0.5% of the general 
population, with the corresponding number of opiate 
users between 1 and 1.4 million. The 2008 range shifted 
slightly down from the one estimated in 2007, when the 
number of opiate users was estimated between 1.2 and 
1.5 million, reflecting a decrease in most of the countries 
which reported new estimates in 2008. Scotland and 
Estonia are the two countries with high prevalence of 
opiate use in West and Central Europe (1.5% among the 
population aged 15-64).
While overall heroin use may be stable or declining in 
West and Central Europe, problems associated with 
heroin abuse seem to increase. Based on a sample of 19 
countries, the overall number of primary heroin users 
entering treatment increased between 2002 and 2007. 
More than half of the reporting countries recorded 
31 Mathers B., Degenhardt L., Phillips B., Wiessing L., Hickman M., 
Strathdee A., Wodak A., Panda S., Tyndall M., Toufik A. and Mattick 
R, on behalf of the Reference Group to the United Nations on HIV 
and Injecting Drug Use, “Global epidemiology of injecting drug use 
and HIV among people who inject drugs: a systematic review,” The 
Lancet, 2008; 372:1733-1745.
Annual opiate users in Asia, 2007-2008Fig. 128: 
Source: UNODC ARQ
Expert perception of the opiates us trend between 2007 and 2008Table 18: 
Source: UNODC ARQ
Region
Member 
States  
providing 
perception 
data
Member 
States  
perception 
response 
rate
Use  
problem 
increased*
Percent 
use  
problem 
increased
Use  
problem 
stable
Percent 
use prob-
lem stable
Use  
problem 
decreased*
Percent 
use  
problem 
decreased
Africa 12 23% 6 50% 2 17% 4 33%
Americas 12 34% 6 50% 5 42% 1 8%
Asia 28 62% 11 39% 11 39% 6 21%
Europe 31 69% 9 29% 19 61% 3 10%
Oceania 1 7% 0 1 0
Global 84 44% 32 38% 38 45% 14 17%
* Identifies increases/ decreases ranging from either some to strong, unweighted by population.
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increasing numbers of drug-induced deaths, mostly asso-
ciated with opioid use, between 2006 and 2007.32 Spain, 
Portugal, Italy and France are the countries with the 
highest prevalence of HIV among injecting drug users 
(39.7%, 15.6%, 12.1% and 12.2% respectively).33
Opiates use remains problematic in  
North America with increasing problems in the 
abuse of prescription opioids
In North America, the highest prevalence of heroin use 
was reported from the United States in 2000 (0.58% of 
the population aged 15-64).34 Household survey data 
suggest that the level of heroin use remained rather 
stable until 2008. Other heroin abuse indicators, includ-
ing heroin treatment admissions and drug overdose 
deaths involving heroin, had, however, increased in 
some parts of the United States in 2008.35 Non-medical 
use of prescription opioids, although stable over the past 
years, remains a major problem across the United States. 
In 2008, 6.2 million people (aged 12 and older) had 
used prescription medication in the month prior to the 
survey.36 Significantly increasing trends in the use of 
prescription and over-the-counter drugs, including oxy-
codone and hydrocodone among teens,37 is reported. 
From 1999 to 2006 the number of fatal poisonings 
32 EMCDDA, Annual Report 2009: the state of the drugs problem in 
Europe, Lisbon 2009.
33 Reference group to United Nations on HIV and Injecting Drug 
Use. 
34 US ONDCP, 2000.
35 NIDA, Epidemiological Trends in Drug Abuse, Proceedings of the 
Community Epidemiology Work Group, Highlights and Executive 
Summary, January 2009.
36 US DHHS, SAMHSA, National Survey on Drug Use and Health 
(NSDUH), 2008 highlights.
37 NIDA, Monitoring the Future Survey, Overview of 2009 Findings.
involving opioid analgesics more than tripled from 
4,000 to 13,800 deaths.38
In Canada, while the overall prevalence of opiate39 use 
is 0.3% of the population, heroin use has also been 
overshadowed by abuse of prescription opioids.40
38 CDC/NCHS, Warner, M., Chen , L-H, et al. Increase in Fatal Poi-
sonings Involving Opioid Analgesics in the United States, 1999 – 2006, 
NCHS Data Brief No. 2, September 2009. 
39 Opiates refer to one of a group of alkaloids derived from the opium 
poppy. The term excludes synthetic opioids (WHO Lexicon of alco-
hol and drug terms). 
40 RCMP, Reports on the Illicit Drug Situation in Canada, 2008.
Trends in prevalence rate of opiate use among the population aged 15-64 in European  Fig. 129: 
countries reporting new or revised data in 2008
Source: UNODC *Estimate for Riga only.
Opioid-related deaths in the USA, Fig. 130: 
1999-2006 
Source: Warner M., Chen L. and Makuc D. M., Increase in 
Fatal Poisonings involving opioid analgesics in the United 
States 1999-2006, National Centre for Health Statistics 
(NCHS) Data Brief Number 22, September 2009, Centers for 
Disease Control and Prevention (USA)
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2. Drug statistics and trends Opium/heroin
In South America, the highest prevalence of opioids41 
use was reported by Brazil and Chile (0.5% of the pop-
ulation between 15 and 64 years, with corresponding 
numbers of 640,000 and 57,000, respectively). In both 
cases, prescription opioids constitute the key problem 
while abuse of heroin is still extremely low. In Chile, the 
2008 estimate (0.5%) represents an increase from the 
0.3% reported in 2006. For the first time, Costa Rica 
reported data on prevalence of opioid users showing that 
in 2006, 2.7% of the population aged 12-70 used opio-
ids at least once during the preceding year. However, this 
estimate needs to be reviewed with caution as it includes 
use of preparations that include all methylphenidate-
type and anorexigenous stimulants prepared with 
codeine.42 Other countries in the region have low opiate 
use prevalence rates ranging from 0.1% in Ecuador to 
0.3% in the Plurinational State of Bolivia. In South 
America, most countries report use of synthetic opioids 
rather than heroin.
Opioid use in Oceania increased
The number of opiate and opioid users in Oceania in 
2008 ranged between 120,000 and 150,000 people, an 
increase from 2007 when 90,000 people were estimated 
41 Opioid is the generic term applied to alkaloids from the opium 
poppy, and their synthetic analogues. The opium alkaloids and 
their semi-synthetic derivatives include morphine, diacetylmorphine, 
codeine and oxycodone as well as fentany, methadone, pethidine, and 
pentazocine, (WHO Lexicon of alcohol and drug terms).
42 Organization of American States, Inter American Drug Abuse Con-
trol Commission (CICAD), Multilateral Evaluation Mechanism 
(MEM) Governmental Expert Group (GEG): Evaluation of Progress in 
Drug Control 2003-2004.
to have used the substances at least once in the previous 
year. The higher estimate reflects a sharp increase 
observed in New Zealand, where the annual prevalence 
among 16-64 year olds reached 1.1% in 2008 from 
0.4% observed in 2006. With the new estimate, New 
Zealand has a much higher prevalence than Australia. In 
New Zealand, street morphine and street methadone are 
the most widely available and used opioids.43 In Aus-
tralia, currently there is no indication of heroin use 
returning to the levels of use seen prior to the 2001 
heroin shortage. Nevertheless, heroin-related overdose 
cases are commonly observed. Non-medical use of opio-
ids including methadone, buprenorphine, morphine 
and oxycodone remain common, however.44 
Opiate use is perceived to be increasing in Africa
There are an estimated 680,000 to 2.9 million opiate 
users in Africa. This wide range reflects missing data and 
information on opiate use from most parts of the conti-
nent. Experts from half of the responding African states 
perceived increasing opiate use, which likely reflected, in 
part, the increasing role of African countries as transit 
areas for heroin from Afghanistan to Europe. Opiates 
are the second most common drug group in terms of 
numbers of individuals seeking treatment.45 Mauritius, 
Kenya and Egypt are the countries in the region with the 
highest prevalence of opiate use (1.9%, 0.7% and 0.4% 
respectively.46) Mauritius also has high prevalence of 
injecting drug use and a concentrated HIV epidemic 
among these users.47 South Africa is the only country 
with a drug use surveillance system based on treatment 
demand (the South African Community Epidemiology 
Network on Drug Use – SACENDU). During the first 
half of 2009, in South Africa, treatment admissions for 
heroin problems have remained stable or declined in 
some parts of the reporting regions; but data also show 
far higher levels than a decade ago.48 
43 Wilkins C., Griffiths R. and Sweetsur P., Recent Trends in illegal drug 
use in New Zealand, 2006 – 2008, Findings from the Illicit drug 
monitoring system (IDMS).
44 Stafford J, Sindiicich N. et al, Australian drug trends 2008. Findings 
from the Illicit drug reporting system (IDRS).
45 World situation with regard to drug abuse – Report of the Secretariat 
(E/CN/2010/2) para. 21.
46 The estimates in Mauritius are derived from a Rapid Assessment 
Study and adjusted for age by UNODC, in Kenya extrapolated from 
the information form the data from Reference group to the UN on 
HIV and Injecting Drug Users, 2009 and in Egypt derived from a 
national household survey.
47 Abdool R., Sulliman R. and Dhannoo M., “The injecting drug use 
and HIV/AIDS nexus in the Republic of Mauritius,” African Journal 
of Drug & Alcohol Studies, 5(2), 2006.
48 Pluddemann A., Parry C., Bhana A., et al, Alcohol and Drug Abuse 
Trends, January – June 2009, Phase 26, South African Community 
Epidemiology Network on Drug Use (SACENDU) 26 November 
2009.
What is known about opiate use 
in the Pacific Islands?
While there is limited information on drug use from 
the smaller Pacific Islands, the United States Centers 
for Disease Control and Prevention has conducted 
surveys among high school students in the Pacific 
Island US territories. Within the territories, the 
results from the Marshall Islands are quite astonish-
ing. The lifetime prevalence of injecting drugs is 
reported as 15.8%, while the lifetime prevalence of 
heroin use is reported as 11.6% among the 9th-12th 
grade students. These are one of the highest rates of 
injecting and heroin use among secondary school 
students in the world and would call for serious pre-
vention and other interventions for the Marshall 
Island students.
Source: Lippe J., Brener N., et al Youth Risk Behaviour 
Surveillance – Pacific Island United States Territories, 
2007 Surveillance Summaries November 21, 2008/55 
(SS212):28-56 (Centers for Disease Control and Preven-
tion, Atlanta, Georgia, USA)
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Production 2.3.1 
Cultivation
The global area under coca cultivation decreased by 5% 
from 167,600 ha in 2008 to 158,800 ha in 2009, mainly 
due to a significant decrease in Colombia, which was 
not offset by increases in Peru and the Plurinational 
State of Bolivia. This is about the same level of cultiva-
tion as during the period 2003 to 2006. Colombia 
remained the country with the largest area under coca 
cultivation but the distance to the second largest, Peru, 
has shrunk due to two consecutive years of decreases in 
Colombia and increases in Peru over the same period. 
In Colombia, the area under coca cultivation decreased 
for a third year to 68,000 ha, a 16% decrease over 2008. 
Most of the reduction took place in the departments of 
Putumayo, Nariño and Antioquía.  
In 2009, coca cultivation in Peru increased by 7% from 
2008 and reached 59,900 ha. Peru remained the second 
largest coca cultivating country, after Colombia. This is 
the country’s third consecutive increase in three years. 
The cultivation level is 55% or 21,200 ha more than in 
1999, when coca cultivation was at its lowest level in the 
last two decades at 38,700 ha. The area under cultiva-
tion in the three main growing regions Alto Huallaga, 
Apurímac-Ene and La Convención-Lares, where large 
parts are already covered with coca plantations, increased 
only slightly. Most of the increase in absolute and per-
centage terms took place in smaller growing regions such 
as Aguaytía, Inambari-Tambopata and Palcazú-Pichis-
Pachitea, which have seen a considerable expansion of 
the area under coca cultivation since 2004. 
Coca cultivation in the Plurinational State of Bolivia in 
2009 remained by and large at the 2008 level with only 
a slight increase of 1% to 30,900 ha. The increase took 
place in both large growing regions, the Yungas of La Paz 
and Chapare. 
Eradication reports from Ecuador indicated the exist-
ence of small-scale coca cultivation. However, surveys 
implemented by UNODC in cooperation with the 
Government of Ecuador in 2006 and 2008 confirmed 
that the level of coca cultivation was insignificant.1 
1 The surveys covered provinces in the north of Ecuador bordering 
Colombia. 
Global coca bush cultivation (ha), Fig. 132: 
1995-2009
Source: see Table ‘Global illicit cultivation of coca bush and 
production of coca leaf and cocaine, 1995-2009’
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Global illicit cultivation of coca bush and production of coca leaf and cocaine, 1995-2009Table 19: 
* Due to the ongoing review of conversion factors, no point estimate of the level of cocaine production could be provided for 2009. Because of the 
uncertainty on the level of total potential cocaine production, the 2009 figure was estimated as a range (842-1,111 mt). For more detailed infor-
mation, see Statistical Annex (4.1.1). It should be noted that the trend estimate of cocaine production between 2008 and 2009 indicate a stable 
situation. 
 a) Potentially harvestable, after eradication.
 (b) Sources: 1995-2002: CICAD and US Department of State, International Narcotics Control Strategy Report. For the region Yungas of La Paz 
since 2002, for all regions since 2003: National Illicit Crop Monitoring System supported by UNODC. Cocaine production: Before 2003, CICAD 
and US Department of State. Since 2003, own calculations based on UNODC (Yungas of La Paz) and DEA (Chapare) coca leaf yield surveys and 
DEA conversion factors from leaf to cocaine HCl (currently under review).
 (c) Sources: 1995-1998: CICAD and US Department of State, International Narcotics Control Strategy Report; since 1999: National Illicit Crop 
Monitoring System supported by UNODC.
 (d) Sources: 1995-1999: CICAD and US Department of State, International Narcotics Control Strategy Report; since 2000: National Illicit Crop 
Monitoring System supported by UNODC.
 (e) Refers to the potential coca leaf production available for cocaine production, i. e. after deducting the amount, which Governments report as being 
used for traditional or other purposes allowed under national law. In the absence of a standard definition of "dry coca leaf" and given considerable 
differences in the processing of the fresh coca leaf harvested, the figures may not always be comparable across countries.   
 (f ) Since 2005, potential sun-dried coca leaf production available for cocaine production, estimated by the National Illicit Crop Monitoring System 
supported by UNODC. This figure does not include the estimated amount of coca leaf produced on 12,000 ha in the Yungas of La Paz where coca 
cultivation is authorized under national law.
 (g) Sources: 1995-2002: CICAD and US Department of State, International Narcotics Control Strategy Report. Since 2003, potential coca leaf 
production available for cocaine production estimated by the National Illicit Crop Monitoring System supported by UNODC. Figures refer to 
oven-dried coca leaf equivalents. 
 (h) Since 2004, fresh coca leaf production figures are available based on coca leaf yield studies done by UNODC and the Government of Colombia. 
Similar to potential cocaine production, fresh coca leaf production in Colombia is calculated based on two-year area averages.  
 (i) Since 2003, potential sun-dried coca leaf production available for cocaine production, estimated by the National Illicit Crop Monitoring System 
supported by UNODC. For the calculation of coca leaf available for cocaine production, 9,000 mt of sun-dried coca leaf were deducted, which, 
according to Government sources, is the amount used for traditional purposes.
 (j) Potential manufacture refers to the amount of 100% pure cocaine that could be produced if all coca leaves harvested from an area under coca 
cultivation in one year were processed into cocaine, based on the information on cocaine alkaloid content of coca leaves and efficiency of clandestine 
laboratories. Estimates for Bolivia and Peru take into account that not all coca leaf production is destined for cocaine production.
 (k) Since 2004, cocaine manufacture is calculated based on the average area under coca cultivation of the reporting year and the previous year. 
This is thought to be closer to the actual amount produced than a figure solely based on the year-end cultivation. Colombian cocaine manufacture 
estimates for 2004 and later are based on new research and cannot be directly compared with previous years. For the calculation of the 2009 cocaine 
manufacture new information on coca leaf yield available for some regions was used. Estimates from 2004 to 2008 were revised in 2010 based on 
more detailed information on the average cocaine base purity (81%) and the cocaine base to HCl conversion ratio (1:1) available from DEA scientific 
studies. 
 (l) Figures from 2003 to 2005 were revised in 2007 based on updated information available on the amount of coca leaf necessary to produce one 
kilogram of cocaine HCl. Estimates based on conversion factors from leaf to cocaine HCl from DEA scientific studies (currently under review). 
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
  Bolivia (b) 48,600 48,100 45,800 38,000 21,800 14,600 19,900 21,600 23,600 27,700 25,400 27,500 28,900
  Colombia (c) 50,900 67,200 79,400 101,800 160,100 163,300 144,800 102,000 86,000 80,000 86,000 78,000 99,000
  Peru (d) 115,300 94,400 68,800 51,000 38,700 43,400 46,200 46,700 44,200 50,300 48,200 51,400 53,700
Total 214,800 209,700 194,000 190,800 220,600 221,300 210,900 170,300 153,800 158,000 159,600 156,900 181,600 167,600 158,800
  Bolivia (f) 85,000 75,100 70,100 52,900 22,800 13,400 20,200 19,800 27,800 38,000 28,200 33,200 36,400
  Colombia (g) 80,900 108,900 129,500 165,900 261,000 266,200 236,000 222,100 186,050 164,280 164,280 154,130 154,000
Colombia (fresh 
coca leaf) (h)
552,800
  Peru (i) 183,600 174,700 130,600 95,600 69,200 46,200 49,300 52,500 72,800 101,000 97,000 105,100 107,800
  Bolivia (b) 240 215 200 150 70 43 60 60 79 98 80 94 104
  Colombia (k) 230 300 350 435 680 695 617 580 550 680 680 660 630 450 410
  Peru (l) 460 435 325 240 175 141 150 160 230 270 260 280 290
Total 930 950 875 825 925 879 827 800 859 1,048 1,020 1,034 1,024 865 *
CULTIVATION OF COCA BUSH IN HECTARES (a)
POTENTIAL PRODUCTION OF DRY COCA LEAF IN METRIC TONS (e)
POTENTIAL MANUFACTURE OF COCAINE IN METRIC TONS (j)
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Production
Due to the ongoing review of conversion factors from 
coca leaves to 100% pure cocaine HCl used to estimate 
the potential cocaine production in the Plurinational 
State of Bolivia and Peru, no point estimate of the level 
of cocaine production could be provided for these coun-
tries in 2009. Because of this uncertainty, global cocaine 
production in 2009 was estimated as a range (842-1,111 
mt).2 The uncertainty concerning conversion factors 
from leaves to cocaine affects the level of cocaine pro-
duction in 2009, but other years prior to 2009 may be 
affected as well. Indeed, production figures provided by 
UNODC between 2005 and 2009 may be revised once 
more precise estimates can be elaborated for the conver-
sion factors, which depend on the alkaloid content of 
the leaves and laboratory efficiency. They do not show 
major changes from one year to another. Thus, in spite 
of the uncertainty around the level of the 2009 estimates 
it can be noted that the total production trend between 
2008 to 2009 remained stable.
Cocaine HCl production estimates for Colombia were 
revised, reflecting the availability of more detailed infor-
mation on specific elements of the conversion process 
from the DEA scientific studies. This led to a slight 
increase in the estimated level of potential cocaine pro-
duction since 2004. However, potential cocaine produc-
tion in Colombia declined by 9% from 450 mt in 2008 
to 410 mt in 2009.3 
In the absence of a point estimate for the level of poten-
tial cocaine production in 2009, estimates of coca leaf 
production can provide additional information on recent 
illicit production trends. To be able to compare coca leaf 
production across countries, fresh coca leaf production 
estimates were used where available (Colombia) or cal-
2 For more detailed information, see Annex ‘The process of estimating 
the production of pure cocaine HCL.’
3 For more details, see Ibid.
culated from sun-dried leaf production (Plurinational 
State of Bolivia and Peru) using a conversion factor.4 
Global potential production of fresh coca leaf was rela-
tively stable between 2004 and 2007 at about 850,000 
mt, but declined significantly between 2007 and 2008 
(by 14%) and again between 2008 and 2009 (by 4%) to 
just over 700,000 mt. Between 2004 and 2009, Colom-
bia always accounted for the largest share of coca leaf 
production. However, while Colombia contributed 
almost two thirds (63%) of total production in 2004, in 
2009, it accounted for less than half (48%). Peru’s share 
grew from 27% in 2004 to 39% in 2009, due to a 
decline in coca leaf production in Colombia in absolute 
terms and an increase in production in Peru over the 
same period. 
4 The average weight loss from fresh to sun-dried leaf measured in 
UNODC’s yield studies ranged from 52% (Bolivia, Yungas of La Paz) 
to 57% (average Peru). Only the amount of coca leaves estimated 
to be available for cocaine production was included in the estimate. 
More details see Table ‘Global illicit cultivation of coca bush and 
production of coca leaf and cocaine, 1995-2009.’
Reported spraying and manual eradication of coca bush (ha), 1995-2009Table 20: 
Note: The Plurinational State of Bolivia: Since 2006, voluntary and forced eradication. Peru: includes voluntary and forced eradication.  
Source: UNODC ARQ, Government reports, US Department of State (INCSR)
Global potential production of fresh Fig. 133: 
coca leaf available for cocaine  
production (mt), 2004-2009
Source: National monitoring systems supported by UNODC. 
For more details see Table ‘Global illicit cultivation of coca 
bush and production of coca leaf and cocaine, 1995-2009’
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Bolivia manual  5,493  7,512  7,000 11,620 15,353  7,653  9,395  11,839  10,089  8,437  6,073  5,070  6,269  5,484  6,341 
Colombia manual  1,487  4,057  2,262  3,126  1,046  3,495  1,745  2,762  4,219  6,234  31,980  43,051  66,805  95,634  60,557 
spraying 23,915 18,519 41,861 66,029 43,112 58,073 94,153 130,364 132,817 136,552 138,775 172,026 153,134 133,496 104,772 
Peru manual  1,259  3,462  7,834 14,733  6,208  6,436  7,134  11,312  10,399  12,237  12,688  12,072  10,143  10,025 
Ecuador manual  4  18  9  12  12  6 
Venezuela manual  181 18 0 0 0 38 47 0 0 118  40  0 0 0
0
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Measuring coca leaf yield
Three elements are needed to estimate cocaine production each year: i) number of hectares under coca leaf cultiva-
tion; ii) annual coca leaf yield (quantity of leaves harvested per hectare in a year); and iii) alkaloid content of the 
leaves and efficiency of clandestine laboratories to extract these alkaloids, which determine the quantity of coca leaves 
needed to produce pure cocaine hydrochloride (HCl). Coca leaf yield is the element that probably shows the high-
est variation since it is affected by unpredictable factors such as weather, plant diseases, as well as eradication activi-
ties. The effect of these factors varies not only from year to year and during the course of a year but also from one 
cultivating region to the other. Thus, the annual coca leaf yield can be estimated with less certainty than the other 
elements. 
Since 2004, UNODC, in cooperation with the respective Governments, undertook coca leaf yield studies in many 
coca growing regions in the Plurinational State of Bolivia, Colombia and Peru. The core element of these studies is 
the controlled harvest of mature coca fields. For this purpose, sample plots are selected randomly among a set of 
fields which are also randomly selected among all fields under coca leaf cultivation. All coca leaves in the sampled 
plots are harvested and weighed on the spot. In the Plurinational State of Bolivia and Peru, where farmers sun-dry 
coca leaves after the harvest, an additional weight measurement is taken after the sun-drying. The weight of the 
harvested coca leaves divided by the area of the sample plots is the yield per hectare of that plot (for one harvest). 
Yield measurements from all plots and fields are used to determine the per hectare yield in the studied area. 
The coca bush allows several harvests per year, with four being a typical number. Depending on seasonal variations, 
such as periods with higher precipitation or variations in farming practices (application of fertilizer and/or irrigation) 
or counter-narcotics activities such as spraying with herbicide, the yield varies from harvest to harvest. These varia-
tions have to be taken into account. Ideally, all harvests in the selected plots should be measured. However, often 
the security situation in coca cultivation regions does not allow for a return to sample fields for further measure-
ments. Then, information from farmers’ interviews can be used to estimate the number and yield of past harvests. 
The annual yield is the sum of all coca leaf yields in the course of one year. 
Due to the different post-harvest processing methods in the Andean countries, coca leaf yield and production figures 
can be expressed in fresh, sun-dry or oven-dry leaf. Fresh coca leaf is typically used in Colombia, where the leaves 
are processed directly after harvesting to extract the alkaloids, often by the farmers themselves. In the Plurinational 
State of Bolivia and Peru, farmers dry the harvested coca leaves in a process referred to as sun- or air-drying before 
the alkaloids are extracted. Sun-drying is also used to produce coca leaves for traditional uses such as tea preparation 
and mastication (chewing). Sun-drying reduces the weight of the fresh leaves by more than 50%. It makes transpor-
tation easier and increases the shelf life of the coca leaves. Oven-dry weight is a standard that allows comparing coca 
leaf yields across countries with different post-harvest processing methods. Coca leaves are dried in an oven to extract 
moisture until their weight is stable. This method requires a scientific laboratory. After oven-drying, coca leaves have 
only about one third of their fresh weight. 
Total cocaine production can be estimated by determining the cocaine alkaloid content of coca leaves and multiply-
ing it with the total coca leaf production estimated from yield and cultivation surveys. As clandestine laboratories 
are not able to extract 100% of the cocaine alkaloids contained in the leaf, a factor representing the efficiency of 
these laboratories is applied. Depending on the extraction method used, clandestine laboratories can extract between 
40% and 80% of the alkaloids present in the coca leaves. 
Sources: United Nations International Drug Control Programme, Guidelines for yield assessment of opium gum and coca leaf 
from brief field visits New York, 2001; US Government, DEA Studies, 1993-2005.
Clandestine laboratories
In 2008, Governments reported the detection of 9,730 
clandestine installations (‘laboratories’) involved in coca 
processing, compared to 7,245 in 2007. As in past years, 
about 4% of the total installations detected were pro-
ducing cocaine HCl. Over 99% of coca processing labo-
ratories were located in the three coca cultivating 
countries, Plurinational State of Bolivia, Colombia and 
Peru. Over the last four years, there was a significant 
increase in coca processing laboratories reported 
destroyed in these countries and also worldwide. 
In 2008, cocaine laboratories were also reported from 
other countries in South America, such as Argentina 
(20), the Bolivarian Republic of Venezuela (10), Chile 
(4) and Ecuador (3). Outside South America, Spain 
(25), the Netherlands (4), the Republic of Moldova (1) 
165
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and Greece (1) reported the detection of cocaine labora-
tories. Preliminary reports from Governments of coun-
tries with coca cultivation indicate that in 2009, the 
number of clandestine coca processing laboratories 
detected was almost as high as in 2008, and significantly 
higher than 2005-2007.
Clandestine coca processing installations, 2005-2008Table 21: 
Note: Previous years’ figures were revised based on updated information received from Governments.  
Source: UNODC ARQ, Government reports
2005 2006 2007 2008
Cocaine paste/base producing installations 5,690 6,849 6,930 9,341
Percentage of coca processing installations 
detected in coca cultivating countries >99% >99% >99% >99%
Cocaine HCl producing laboratories 212 244 315 389
Cocaine HCl labs as % of total installations 4% 3% 4% 4%
Cocaine HCl labs in coca cultivating countries 166 215 308 322
Total coca processing installations detected 5,902 7,093 7,245 9,730
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Seizures2.3.2 
Following a significant increase over the period 2002-
2005, global cocaine seizure totals have followed a stable 
trend, amounting to 712 mt in 2007 and 711 mt in 
2008. Seizures continued to be concentrated in the 
Americas and Europe. However, the transition from 
2007 to 2008 brought about a geographical shift in 
seizures towards the source countries for cocaine. Sei-
zures in South America accounted for 59% of the global 
total for 2008, compared with 45% in 2007. This was 
mainly due to increases in several South American coun-
tries, notably Colombia, and simultaneous decreases in 
North America and Europe. 
More cocaine stopped at the source  
Cocaine seizures in South America reached record levels 
in 2008, amounting to 418 mt (cocaine base and salts) 
– almost one third more than the level in 2007 (322 
mt). In absolute terms, the largest increase from 2007 
was by far the one registered in Colombia (an increase 
of 61.9 mt). In relative terms, significant increases were 
also recorded in Peru (where seizures almost doubled), 
the Plurinational State of Bolivia (where seizures rose by 
62%), Argentina (51%), Brazil (21%) and Ecuador 
(12%). One exception to the generally increasing trend 
prevalent in South America was Chile, which registered 
a decrease of 12%. Seizures in the Bolivarian Republic 
of Venezuela remained essentially stable.
Comparison of cocaine seizures in South America and other regions, 2000-2008Fig. 134: 
Source: UNODC ARQ/DELTA 
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From 2002 onwards, Colombia and the United States 
consistently registered the largest and second largest 
annual cocaine (base and salts) seizures worldwide, 
respectively. Over the 2002-2007 period, cocaine sei-
zures in the United States, the country with the largest 
consumer market for cocaine, were in line with those in 
Colombia, the country with the largest manufacture of 
cocaine, to a remarkable degree (with a correlation coef-
ficient of 0.96). However, the trends in the two coun-
tries diverged in 2008. Seizures in Colombia reached 
record levels, rising from 195 mt in 2007 to 257 mt5 in 
2008, while seizures in the United States fell sharply, 
from 148 mt in 2007 to 98 mt in 2008 (-34%).
5 Observatorio de Drogas de Colombia. Data for Colombia from the 
ARQ (part III) for 2008 were not available.
Mexico continued to be the key transit country for large 
quantities of cocaine trafficked from the Andean region 
to the United States. In line with the trend in the United 
States, cocaine seizures in Mexico fell sharply in 2008, 
amounting to 19.3 mt. Cocaine seizures by authorities 
in the United States along the border with Mexico fol-
lowed a generally decreasing trend between the last 
quarter of 2005 and the second quarter of 2008,6 sug-
gesting that the amount of cocaine reaching the United 
States through the border with Mexico was in decline. 
In fact, between 2006 and 2008, cocaine seizures along 
this border fell by more than 40%. Partial data suggests 
that the decreased level was essentially sustained into 
6 National Drug Intelligence Center, United States Department of 
Justice, National Drug Threat Assessment 2009, December 2008.
Cocaine seizures in Colombia and the United States, 2000-2008Fig. 136: 
Source: UNODC ARQ/DELTA
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ever, seizure data suggest that this pattern may have 
started to subside. Cocaine seizures in West and Central 
Africa increased from 98 kg in 2002 to 4.6 mt in 2007, 
but in 2008 declined to 2.3 mt. 
An analysis of cocaine consignments seized in Europe 
based on the UNODC individual drug seizure database 
confirms this picture. Among those cases in which the 
point of origin was identified, the proportion of cases in 
which African countries (or Africa as a whole) were 
named as the point of origin was negligible until 2002, 
climbed to 34% by 2007 but fell back to 20% in 
2008.
Increased cocaine trafficking in Australia    
Cocaine seizures in Australia rose steadily over the period 
2005-2008, from 87.5 kg in 2005 to 930 kg in 2008. 
With reference to the period 1 July 2007 – 30 June 
2008, Australia8 mentioned the threat arising from traf-
ficking and subsequent trans-shipment of cocaine from 
Canada, as well as the growth in trafficking through 
China (including Hong Kong). China has also reported 
a perceived increase in the use of cocaine in 2008. 
Interception rate
Estimating the global interception rate for cocaine 
depends on a good understanding of  the global supply 
of cocaine as well as the total amount of cocaine seized. 
8 ARQ submitted by Australia for 2008.
Given the time lag incurred between cultivation of coca 
bush, harvesting, processing and trafficking, in a given 
year, supply in a consumer market such as Europe may 
be linked to production occurring in previous years. 
Moreover, the theoretical amount of  pure cocaine seized 
can only be determined by taking into account the 
purity of seizures, which may vary considerably across 
countries and according to various factors, such as the 
size of the transaction (level of sale - retail versus whole-
sale) and the place of seizure (border versus domestic).
Taking into account these considerations, UNODC 
estimates an interception rate range of 37%-50%9 for 
cocaine in 2008.10 This is significantly higher than the 
corresponding rates for opiates, possibly due to the fact 
that a significant proportion of seizures is made in or 
close to the source countries. The range drops to 
27%-33% if seizures in the three producing countries, 
Colombia, the Plurinational State of Bolivia and Peru 
are excluded.
9 This is calculated as the ratio of global seizures to global supply. 
Global seizures are adjusted for purity according to a weighted aver-
age, and include cocaine base, cocaine salts, coca paste and crack 
cocaine (but not coca leaf ). Global supply is estimated by the average 
cocaine production in the preceding two years. The lower end of the 
range is obtained by considering retail purities only, and the upper 
end by considering wholesale purities only.
10 In previous years, UNODC estimated a single interception rate, 
adjusting global seizures for purity using an unweighted average of 
all purity data reported by Member States (retail and wholesale). This 
quantity was then expressed as a percentage of the cocaine production 
in the same year. This method produces an estimate of 42% for the 
year 2008. 
Distribution of number of cocaine  Fig. 139: 
seizure cases in Europe, by transit/ 
origin country,* 2000-2008. 
* This refers to the source of the cocaine as far back as it could be 
traced by the reporting countries.
Source: UNODC Individual Drug Seizures database
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Prices2.3.3 
Cocaine prices in 2008 reflected the well-known traf-
ficking routes from South America  to North America 
and Europe. The lowest wholesale prices were to be 
found in Peru, the Plurinational State of Bolivia and 
Colombia. Prices were, on average, noticeably higher in 
the rest of South America and slightly higher in Central 
America and the Caribbean. There was a clear markup 
in prices outside Latin America and the Caribbean. 
Wholesale prices in West Africa were significantly higher, 
but lower than prices in Europe. The wholesale price in 
Spain was significantly lower than the average in Europe, 
possibly reflecting Spain’s role as a major point of entry 
for cocaine into the European market. Very high whole-
sale prices were registered in Saudi Arabia, Pakistan and 
the Russian Federation. The markup from wholesale to 
retail price can be more clearly observed when typical 
prices are adjusted by typical purities.
A comparison of prices in the producer countries and 
major consumer markets shows a markup of approxi-
mately 30 times between prices of coca derivatives in the 
Plurinational State of Bolivia, Colombia and Peru and 
cocaine wholesale prices in the United States, and 60 
times in the case of Europe.
In the United States, after a sharp increase in 
prices and decrease in purity, 2009 brought 
the first signs of stabilization
In the United States, price and purity data confirmed 
the reduced availability of cocaine. Data from the US 
Drug Enforcement Agency point to a distinct transition 
between the fourth quarter of 2007 and the fourth quar-
ter of 2008, with purity dropping by 27% and the price 
per pure gram of cocaine rising by 72%, suggesting a 
shortage of cocaine in the US market. The increased 
price level was sustained into the third quarter of 2009,11 
when it appeared to stabilize at the higher levels.  
11 US Department of Justice, National Drug Threat Assessment 2010. 
Based on data extracted from System To Retrieve Information on 
Drug Evidence (STRIDE).
Cocaine wholesale prices worldwide, Fig. 141: 
2008
Source: UNODC ARQ
Comparison of coca derivative prices Fig. 142: 
in producing countries and consumer 
markets, 2000-2008 (US dollars)
aWeighted average of 18 countries.
Sources: National monitoring systems in the Plurinational State 
of Bolivia, Colombia and Peru and UNODC ARQ
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Mixed picture in Europe
Prices per pure gram of cocaine for European countries 
were generally not available. On average,12 European 
cocaine prices, expressed in euro and adjusted for infla-
tion (but not for purity), displayed a decreasing trend 
over the period 2006-2008, at both the retail and whole-
sale levels. However, over the same period, prices 
increased when expressed in dollars and adjusted for 
inflation, suggesting that the trend has been more sensi-
tive to the exchange rate between US dollar and euro 
than changes in the market. 
A comparison of purity- and inflation-adjusted prices13 
with cocaine seizures in selected European countries 
suggests a certain sensitivity of prices - notably at the 
retail level - to success in interdiction, as measured by 
seizure totals. In 2006, European seizures peaked, along 
with the purity- and inflation-adjusted retail price in 
France, Germany and the United Kingdom. This was 
due to a change in purity in some cases and a change in 
bulk price in other cases. Since 2006, the purity- and 
inflation-adjusted retail price declined, in line with sei-
zure totals. One possible explanation for the correlation 
between the trends in price and seizures could be related 
to the effect of law enforcement activities: the stronger 
the effect of law enforcement, the higher are the amounts 
seized and the associated risk of trafficking which take 
the price to a higher level.14 
12 Weighted average of 18 European countries, based on ARQ, data 
from Europol and UNODC estimates; see UNODC, World Drug 
Report 2009.
13 UNODC estimates based on reported prices and purities.
14 In contrast, over the period 2000-2006, rising seizures in Europe 
Purity-adjusted and non-adjusted cocaine retail and wholesale prices in US dollars, 2008 Fig. 143: 
(log-log scale)
Note: On a linear scale, the slope of the line of best fit (through the origin) for purity-adjusted prices is 2.94. This means that, overall, there is a markup 
in price of 194% from wholesale to retail level.
Source: UNODC ARQ
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went hand in hand with falling cocaine prices (weighted average 
for 18 European countries, not adjusted for purity), suggesting that 
seizures were reflecting the rising supply of cocaine reaching the 
European market.
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Consumption2.3.4 
UNODC estimates that the prevalence of cocaine use 
worldwide in 2008 ranged from 0.3% to 0.4% of the 
adult population, or between 15 and 19 million people 
who had used cocaine at least once in the previous year. 
Compared to 2007, the range shifted to lower levels, 
suggesting a decrease in the global number of cocaine 
users. This change is due to the decrease in the number 
of cocaine users in North America. In addition, missing 
data and/or absence of recent reliable estimates affect 
many regions, particularly East Africa, Central Asia, the 
Near and Middle East and South Asia. Available qualita-
tive information suggests that the prevalence of cocaine 
use is low in most parts of Asia, although Chinese experts 
reported a recent increase of cocaine use in their country 
(though starting from an almost negligible level)15 and 
other countries have reported increasing trafficking of 
cocaine in Asia. 
15 ARQ submitted by China for 2008.
Estimated number of people who used cocaine at least once in the past year and  Table 22: 
prevalence among the population aged 15-64, by region, 2008
Region/subregion
Estimated  
number of users 
annually (lower)
-
Estimated  
number of users 
annually (upper)
Percent of  
population 
aged 15-64 
(lower)
-
Percent of  
population 
aged 15-64 
(upper)
Africa 1,020,000 - 2,670,000 0.2 - 0.5
Eastern Africa Subregional estimate cannot be calculated
North Africa 30,000 - 50,000 <0.1 - <0.1
Southern Africa 290,000 - 900,000 0.3 - 0.8
West and Central Africa 640,000 - 830,000 0.4 - 0.5
Americas 8,720,000 - 9,080,000 1.4 - 1.5
Caribbean 110,000 - 320,000 0.4 - 1.2
Central America 120,000 - 140,000 0.5 - 0.6
North America 6,170,000 - 6,170,000 2.0 - 2.0
South America 2,330,000 - 2,450,000 0.9 - 1.0
Asia 430,000 - 2,270,000 <0.1 - 0.1
Central Asia Subregional estimate cannot be calculated
East/ South-East Asia 390,000 - 1,070,000 <0.1 - 0.1
Near and Middle East Subregional estimate cannot be calculated
South Asia Subregional estimate cannot be calculated
Europe 4,570,000 - 4,970,000 0.8 - 0.9
Eastern/South-East      
Europe 470,000 - 840,000 0.2 - 0.3
Western/Central Europe 4,110,000 - 4,130,000 1.5 - 1.5
Oceania 330,000 - 390,000 1.4 - 1.7
Global 15,070,000 - 19,380,000 0.3 - 0.4
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Global trend in the perception of cocaine use: unweighted average of trends as reported  Fig. 148: 
by national experts*
* The graph measures the trend of the number of countries reporting an increase or decrease in drug use (not the trend in number of drug users).
Source: UNODC ARQ
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North America, the largest cocaine market,  
is shrinking
The highest prevalence of cocaine use remains in North 
America, at 2% of the adult population aged 15 to 64. 
In the United States, many indicators show a downward 
trend in cocaine use over the past years, which mirrors a 
decreasing trend in cocaine production in Colombia, 
the source country of the cocaine reaching the United 
States, as well as increased difficulties faced by the Mex-
ican drug cartels to have cocaine shipped from Colom-
bia via Mexico into the United States. Data from 2008 
confirm the decreasing trend both in the adult and 
young populations. There has been a significant reduc-
tion in the use of cocaine and crack among the popula-
tion aged 12 and older. The annual prevalence of cocaine 
use declined to 2.1% in 2008 from 2.3% in 2007. The 
perceived easy availability of cocaine among youth aged 
12 to 17 also decreased significantly, from 25% in 2007 
to 22.1% in 2008.16 
16 Substance Abuse and Mental Health Services Administration Results 
from the 2008 National Survey on Drug Use and Health, National 
Findings, Office of Applied Studies (OAS), SAMHSA, US Depart-
ment of Health and Human Services, September 2009.
United States: Annual prevalence of Fig. 149: 
cocaine use among the population 
aged 12 and older
Source: Substance Abuse and Mental Health Services Adminis-
tration, Results from the 2008 National Survey on Drug Use 
and Health, National Findings, Office of Applied Studies 
(OAS), US Department of Health and Human Services
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Similarly, the number of positive tests for recent use of 
cocaine in the general workforce in the United States 
dropped by 29% in 2008 (a decline to 0.41% in 2008 
from 0.58% in 2007 of all urine drug tests). The down-
ward trend in cocaine use also continued in 2009, where 
it was observed in tests for cocaine use among the gen-
eral work force in the first six months of 2009.17 Similar 
downward trends were seen in the annual prevalence of 
cocaine use among high school students. The annual 
prevalence dropped from 2.8% in 2008 to 1.6% in 
2009 among the 8th graders, from 3% to 2.7% among 
10th graders and from 4.4% to 3.4% among the 12th 
grade students.18  
The prevalence of positive test results for cocaine use 
among arrestees appears to be stable or declining across 
many of the US cities where the Arrestees Drug Abuse 
Monitoring Programme (ADAM II) has been imple-
mented. There are statistically significant declines 
between 2003 and 2008 in two of the 10 monitored 
cities: Chicago and Portland. Statistically significant 
declines between 2007 and 2008 were observed in Indi-
anapolis and Washington DC. Nonetheless, cocaine 
remained in 2008 the second most common drug among 
arrestees. The number of problem cocaine users or those 
classified with substance dependence and abuse in the 
household survey declined from 1.5 million in 2002 to 
1.4 million in 2008 among the population aged 12 or 
older, although none of the changes between 2008 and 
previous years is statistically significant. Point estimates 
show a more noticeable decline between 2006 (1.7 mil-
lion) and 2008 (1.4 million).19 
17 Quest Diagnostics, Drug Testing Index, November 2009.
18 National Institute on Drug Abuse, Monitoring the Future, Overview 
of Key Findings in 2009, Bethesda, Maryland, USA, 2010.
19 US Department of Health and Human Services, Substance Abuse 
The 2008 Canadian survey also shows a decrease in the 
annual prevalence of cocaine use, falling from 2.3% of 
the population aged 15-64  in 2004 to 1.9% in 2008.20 
The school survey conducted in Ontario, Canada’s most 
populous province, accounting for close to 40% of Can-
ada’s total population, also indicates a decline in cocaine 
use among school students. The annual prevalence of 
cocaine use, from its peak of 4.8% in 2003 has nearly 
halved to 2.6% in 2009. 44% of the students reported 
greater risk in trying cocaine and nearly half strongly 
disapproved of cocaine use. Cocaine was also reportedly 
less easily available than in 2007 or a decade ago.21 
Cocaine use in Mexico increased over the 2002-2008 
period. The lifetime prevalence of cocaine use among 
the population aged 12 to 65 doubled, from 1.2% in 
2002 to 2.4% in 2008.22 The increase in the annual 
prevalence of cocaine use was, however, less pronounced, 
from 0.35% in 2002 to 0.44% in 2008.  
High prevalence rates continue to be 
reported in West Europe 
In Europe, cocaine remains the second most used illicit 
drug after cannabis. The annual prevalence of cocaine 
use in Europe ranges between 0.8% and 0.9% of the 
population aged 15 – 64, or around 4.5-5 million people 
who had used cocaine in the past year in 2008/2009, a 
slight upward shift from the range reported in 2007 (4.3 
and Mental Health Services Administration, Results from the 2008 
National Survey on Drug Use and Health: National Findings, 2009.
20 Health Canada, Canadian Alcohol and Drug Use Monitoring Survey 
(CADAUMS) 2008.
21 Centre for Addiction and Mental Health, Ontario Student Drug Use 
and Health Survey, Drug use among Ontario students, 1977 – 2009, 
2009.
22 SALUD, Encuesta Nacional de Addicciones 2008, 2009.
Percent testing positive for cocaine  Fig. 152: 
in urine drug tests of the general US 
workforce (percent of all such tests)
Source: Quest Diagnostics, Drug Testing Index 
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- 4.6 million people). An overall increase in cocaine use 
has been observed in Europe in the last decade. In recent 
years, the trend has started to stabilize in some countries, 
while in others it is still increasing.  
Higher cocaine use is reported in West and Central 
Europe (1.5%) than in East and South-East Europe 
(0.3%). Cocaine use appears to be concentrated in a few 
countries in Europe, notably in Spain, the United King-
dom, Italy, Ireland and Denmark, where high cocaine 
use prevalence rates are observed. Use of cocaine is 
reportedly high among young males between 15 – 34 
years old.23 Low prevalence countries in the European 
Union remain Romania, Greece, Hungary, Poland and 
the Czech Republic.
23 EMCDDA, Drug Situation in Europe, Annual Report 2009.
In Spain and Italy, the annual prevalence rates for cocaine 
have stabilized at 3% and 2.2% in 2007 and 2008 
respectively, after reaching high levels in 2005. A stabi-
lization was also reported in 2007 by Germany and 
several other EU countries. The only major European 
market showing an increase is the United Kingdom. In 
England and Wales, cocaine prevalence rates declined in 
2007/2008, but increased to 3% of the population aged 
16-59 in 2008/2009. The highest prevalence of cocaine 
use in Europe is found in Scotland (3.7% of the popula-
tion aged 16-59 in 2008/2009), even though this rate 
has remained stable since 2006. The United Kingdom is 
thus overall Europe’s largest cocaine market in absolute 
numbers with some 1.2 million users in 2009. Increases 
Europe: Increasing trends in annual prevalence of cocaine use among the adult population Fig. 154: 
Source: British Crime Survey, Government reports and UNODC ARQ
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Europe: Stable or declining trends in annual prevalence of cocaine use among the  Fig. 155: 
population aged 15-64
Source: Government reports and UNODC ARQ
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in the annual prevalence rate were also reported in Alba-
nia, the Czech Republic and Denmark over the last 
period. Among the six European countries that reported 
updated information on cocaine use for 2008, only 
Lithuania registered a decrease in the adult prevalence, 
from 0.3% in 2004 to 0.2% in 2008. 
In the United Kingdom, cocaine has been a problem 
drug for some time. Since 2000/2001, there has been a 
large increase in reported episodes of non-fatal hospital 
admissions for cocaine poisoning in England. Since 
2004, there has also been an upward trend of cocaine-
related deaths, which accounted for 14% of all drug-
related deaths in 2008.24
The lifetime prevalence of cocaine use among 15-16 
year old school students in Europe25 was on average 3%. 
Cocaine use, however, remains much lower than can-
nabis use. In half of the 28 reporting countries, in 2007, 
the prevalence rate ranged between 1% and 2%. Most 
of the remaining countries reported prevalence levels 
between 3% and 4%. France, Italy and the United King-
dom reported levels around 5%. Like for most other 
drugs, lifetime prevalence of cocaine use among males is 
higher than among females.26
The number of clients entering drug treatment with 
cocaine as the primary drug has been increasing in 
Europe for several years. Between 2002 and 2007, the 
24 United Kingdom, The Cocaine Trade – Home Affairs Committee, 
Trends in Cocaine Use, March 2010. 
25 European School Survey Project on Alcohol and Other Drugs 
(ESPAD).
26 Hibell, B., Andersson B., et al. ESPAD: The 2007 ESPAD Report: 
Substance use among students in 35 European Countries, The Swed-
ish Council for Information on Alcohol and other Drugs (CAN), 
EMCDDA, Council of Europe, Co-operation Group to Combat 
Drug Abuse and Illicit Trafficking in Drugs (Pompidou Group).
largest proportional increases among new clients were 
reported by Spain, Ireland and Italy. In those countries 
the number of all clients entering treatment citing 
cocaine as their primary drug increased as a proportion 
from 13% to 19%. The proportion of cocaine clients in 
treatment is now also increasing in other countries such 
as Denmark, Ireland, Greece and Portugal.27
Increasing trends of cocaine use in most 
countries in South America
The annual prevalence of cocaine use in South America 
is between 0.9% and 1% of the population aged 15-64, 
thus comparable to cocaine use in Europe, though far 
lower than in North America. The aggregate annual 
prevalence of cocaine use in Central America ranges 
between 0.5% and 0.6%, and in the Caribbean, from 
0.4% to 1.2%. In contrast to North America, national 
experts in South America continue to report an increas-
ing trend in cocaine use.
Increases in cocaine use in recent years were reported by 
the Bolivarian Republic of Venezuela, Ecuador, Brazil, 
Argentina and Uruguay, as well as countries in Central 
America (Guatemala and Honduras) and the Caribbean 
(Jamaica and Haiti). Compared to the previous year, 
new quantitative information for 2008 was available 
only from two countries: Chile, where an increase in the 
annual prevalence among the adult population aged 
15-64 was observed (from 1.7% in 2006 to 2.4% in 
208) and Suriname, where there was a decrease (from 
0.5% in 2002 to 0.3% in 2007). 
The highest prevalence of cocaine use in South America 
27 EMCDDA, Drug Situation in Europe 2009: Problem cocaine use and 
treatment demand, 2009.
United Kingdom: Cocaine-related  Fig. 156: 
poisoning episodes and deaths,  
2000-2008 
Source: United Kingdom, The Cocaine Trade – Home Affairs 
Committee, Trends in Cocaine Use
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was reported from Argentina (2.7%), followed by Chile 
(2.4%) and Uruguay 1.4%). The annual prevalence of 
cocaine use in Argentina and Chile are comparable to 
the prevalence in United States. Brazil and Argentina 
constitute the biggest cocaine markets in South America 
in terms of absolute numbers (more than 900,000 and 
600,000 users, respectively). According to the school 
survey conducted by UNODC and CICAD in the 
South American countries, the highest annual preva-
lence of cocaine use among students was in Chile, fol-
lowed by Uruguay and Argentina.28 The pasta base or 
the cocaine base is also frequently abused in South 
America. However, both for the student and adult pop-
ulations, the use of cocaine HCl is generally higher than 
coca paste. In Chile, the Plurinational State of Bolivia 
and Peru, there were comparable rates of cocaine and 
pasta base use among the students surveyed.
Experts are reporting rising cocaine use  
in Africa  
For most parts of Africa, there are no recent or reliable 
estimates of cocaine use. Nevertheless, the annual preva-
lence of cocaine use in Africa is estimated at between 
0.2% and 0.5% of the population aged 15 to 64. The 
upper bound of the estimate fell compared to last year 
when it was 0.7%. The major reason for this drop is the 
removal of national estimates which were more than 10 
years old. However, experts from Africa report that 
cocaine use has increased in many parts of the continent, 
notably West and Central Africa. In South Africa, one 
of the few countries that have data to substantiate the 
expert perceptions, treatment demand for cocaine-re-
lated problems has shown a strong increase over the past 
28  UNODC and CICAD Informe subregional sobre uso de drogas en 
poblacion escolarizada, 2009/2010.
10 years, where it has increased from 5% of treatment 
demand in 1998 to 8% in the first half of 2009. How-
ever, there has been a declining trend in treatment 
demand for cocaine since 2008.29
For large parts of Asia and the Near and Middle East, 
there are no recent or reliable estimates available on 
cocaine use. In Asia, the annual prevalence of cocaine 
use is estimated at maximum 0.1%, or between 430,000 
and 2.3 million cocaine users. Hong Kong, China is the 
only territory in Asia reporting new information in 
2008, revealing an increase in the estimated annual 
adult prevalence rate from 0.003% in 2003 to 0.3% in 
2008.30 In Hong Kong, China, there are indications of 
increasing availability and decreasing prices of cocaine 
since 2004.31 In the school survey conducted in Hong 
Kong, China in 2008/2009, the lifetime prevalence of 
cocaine and ‘ecstasy’ use among students was 13.8%, 
compared to 11.3% in 2004/2005.32
29 Pluddemann A., Parry C., Bhana A., et al, Alcohol and Drug Abuse 
Trends: January – June 2009 (Phase 26), South African Community 
Epidemiology Network on Drug Use, November 2009.
30 Data extrapolated from the results of a school survey.
31 Narcotics Bureau, Hong Kong Police, Drug Situation Report – Hong 
Kong Special Administrative Region of the People’s Republic of China, 
January 2009.
32 Narcotics Division, Security Bureau, The 2008/2009 Survey of Drug 
Use among Students,  2010.
South America: annual adult (aged  Fig. 158: 
15-64) prevalence of cocaine use in  
selected countries, 2006-2007
Source: UNODC/CICAD, Elementos Orientadores para las 
Politicas Publicas sobre Drogas en la Subregion: Primer Estudio 
Comparativo sobre Consumo de Drogas y Factores Asociados 
en Poblacion de 15 a 64 años, 2008
South Africa: Percent of all treatment Fig. 159: 
admissions for cocaine, 1997-2009
Source: Pluddemann A., Parry C., Bhana A., et al, Alcohol and 
Drug Abuse Trends: January-June 2009 (Phase 26), South Afri-
can Community Epidemiology Network on Drug Use, Novem-
ber 2009
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Production2.4.1 
In the 2009 World Drug Report, UNODC presented an 
inventory of the available data on cannabis production 
and, based on four different methods, estimated that the 
cannabis herb production ranged from 13,300-66,100 
mt and the cannabis resin production from 2,200-9,900 
mt. The resulting total area under cannabis cultivation 
was estimated at 200,000-641,800 ha.1 These estimates 
provided the magnitude of the problem related to the 
illicit cannabis cultivation and production, but they also 
showed a large range, indicating the great uncertainty 
around the estimates.
In this World Drug Report, the above-mentioned esti-
mates were not updated; given the high level of uncer-
tainty and the remaining lack of information in many 
cannabis-cultivating countries, a new round of estima-
tions would have offered an arithmetical exercise rather 
than providing policy-relevant information on the global 
trend of cannabis production and cultivation. The trend 
analysis presented here focuses on some new informa-
tion obtained by UNODC in the last year, with a special 
focus on indoor cannabis cultivation. 
Cannabis cultivation and production  
in Afghanistan
In 2009, the major new piece of information on can-
nabis production relates to an important producer, 
Afghanistan, where the first joint cannabis survey was 
1 The calculation was based on the minimum and maximum levels 
calculated from reported cultivation and production, seizures of can-
nabis and user prevalence rates.
undertaken by UNODC and the Afghan Ministry of 
Counter Narcotics. The results of this survey gave a 
range of cultivated cannabis area from 10,000 to 24,000 
ha, and a resin production range between 1,500 and 
3,500 mt. In terms of production, Afghanistan would be 
the major producer of cannabis resin in the world. This 
is principally due to the high resin yields measured in 
Afghanistan (145 kg/ha), which are four times higher 
than in Morocco (36 kg/ha measured in 2005), where 
cannabis resin is also produced. However, it is not clear 
whether the products are directly comparable.
There is evidence of cannabis production in almost all 
countries in the world. The major source of information 
regarding production continues to be the responses that 
Member States provide to the Annual Reports Ques-
tionnaire (ARQ). Although about 50 countries have 
reported in the last 10 years on the actual extent of can-
nabis cultivation, more countries report seizures of 
plants and eradication of sites, which give another indi-
cation of the presence of cannabis cultivation. Other 
evidence can also be found through seizure statistics, 
where countries provide information on where the 
reported seizure originated. 
Due to the fragmentation and incompleteness of infor-
mation, it is difficult to do a proper analysis over time 
and reveal patterns in cannabis cultivation. However, an 
increase of indoor cultivation has been reported by sev-
eral sources and will be analysed more closely.
Indoor cultivation
Several national studies have indicated an increasing 
trend of indoor cannabis cultivation instead of, or in 
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addition to, outdoor growing.2 Indoor growing has the 
benefit of having lower chances of detection,3 high 
yields with several harvests per year4 with high potency 
cannabis5 and elevated selling prices. The equipment, 
knowledge and seeds for indoor growing have become 
very accessible, for example, from so-called ‘grow shops’ 
2 European Monitoring Centre for Drugs and Drug Addiction, 
Monograph series 8, Volume 1, Lisbon, 2008. 
3 In Canada, a detection rate of 2-3% is estimated. Bouchard, M., 
Journal of Quantitative Criminology 23: (3): 221–241, 2007.
4 The controlled conditions often allow for up to six harvests per 
year.
5 The controlled conditions (often hydroponically grown) normally 
give higher potency of the product, for example, in the production 
of sinsemilla. Sinsemilla are the unfertilised buds of the female plants 
which contain the highest concentration of THC. Controlled condi-
tions include the use of optimal varieties and plants, optimal dosage 
and timing of providing water, nutrients and light.
or from the internet. The costs of building an indoor 
growing site can be quickly recovered, which makes 
indoor cultivation a very lucrative business. 
Based on government reports and scientific literature, 
UNODC could find evidence of indoor cultivation for 
commercial purposes in 29 countries, concentrated in 
the temperate zones of the world: North America, West, 
North and Central Europe and Oceania. There was only 
one report of indoor growing in South America (Argen-
tina) and one in Africa (South Africa). Given the lack of 
a system to monitor indoor cannabis cultivation world-
wide, these 29 countries represent the minimum set of 
indoor cannabis cultivating countries.
With the available data, it is not possible to calculate the 
extent of indoor growing. Often indirect indicators are 
used to estimate the trend, such as the number of seized 
Update of available information on the extent of cannabis cultivation and production in  Table 23: 
major producing countries, 2008*
Country
Cultivated area 
(ha) a)
Eradication
Harvestable 
area (ha)
Production (mt) 
Resin Herb
Afghanistanb) 10,000 – 24,000 (2009) 
10,000 – 24,000 
(2009)
1,500 – 3,500 
(2009)
Boliviac) 1,831
Canadad) 1,399-3,498 (2007)
Colombiae) 5,000 (2006) 4,000 (2006)
Mexico 18,562 hag) 12,000f ) 21,500f )
Moroccog) 64,377 4,377 60,000 877
Netherlandsh) 1,053,368 plants 323-766
Paraguay 6,000i) 1,838 haj) 16,500k)
South Africal) 1,300 1,275 ha 25
United States 
of America
7.6 million out-
door plants / 451 
000 indoor 
plantsm)
3,149-7,349 
* Or other year, if mentioned.
a) In addition, there is some extraction from wild-grown cannabis, for example, areas of 124,000-329,627 ha were estimated in Kazakhstan (1999  
UNDCP, Annual Survey reports Cannabis, Opium Poppy and Ephedra (Vienna, 1998 and 1999). In the Russian Federation, wild cannabis is estimated  
to be cultivated on 1 million ha (US Department of State, International Narcotics Control Strategy Report (INCSR) 2010).
b) UNODC, Afghanistan cannabis survey 2009, Vienna, 2010.
c) Government of the Plurinational State of Bolivia, quoted in INCSR, 2010
d) Governments of the United States of America and Canada, Drug Threat Assessment 2007, March 2008.
e) UNODC, Bulletin on Narcotics, “Review of the world cannabis situation”, Volume LVIII, Vienna, 2006.
f) US Department of State, INCSR, 2010
g) UNODC, ARQ 2008.
h) KLPD-IPOL, Drug seizures and drug prices in the Netherlands, Zoetermeer, The Netherlands, 2008.
i) Secretaria nacional Antidrogas (SENAD), (Asunción, 2008).
j) UNODC ARQ 2008.
k) Secretaria nacional Antidrogas (SENAD), (Asunción, 2008).
l) UNODC, ARQ 2008.
m) DEA, Domestic Cannabis Eradication/Suppression Program (DCE/SP) in National Drug Threat Assessment 2010.
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plants or the number of seizures of plantations. Since the 
way of reporting is not consistent between countries, 
and often not even within one country, it is challenging 
to compare the production levels.6 
For some countries, for example, Australia, New Zea-
land, the United Kingdom and the Netherlands, indoor 
growth is known to be the main method of cannabis 
production. From the Netherlands, indoor cultivation 
has spread to surrounding countries, for example to 
6 Moreover, there is no protocol for the reporting, which makes the 
numbers hard to compare within countries. The number of plants 
often do not differentiate for the type of plant, for example, whether 
the numbers are full grown plants or include seedlings and cuttings. 
Research in the Netherlands indicate that this can give large diver-
gence in the reports (see: Wouters, Korf and Kroeske, Harde aanpak, 
hete zomer, WODC, Amsterdam, 2007).
Belgium, where there is an increase of seized indoor 
plants, to East Europe (the Czech Republic, Poland, 
Hungary and Slovakia) and Austria, and to northern 
Europe (Iceland, Finland, Denmark, Norway, Sweden 
and Latvia). The increases in cultivation are often attrib-
uted to Vietnamese organized crime groups.7 In Canada 
also, Vietnamese/Chinese groups - as well as Hell’s 
Angels - are involved in cannabis cultivation, including 
high-tech indoor cannabis growing. The Canadian pro-
duction is for national consumption, but some is also 
exported to the United States. In the United States, 
indoor growing has become significant, but seizures of 
outdoor-grown plants still exceed the indoor-grown 
plants. 
7 UNODC ARQ 2008; INCSR 2010; Europol, EU Organised crime 
threat assessment, 2009.
Cannabis resin processing in Afghanistan
In 2009, a first cannabis survey was carried out by UNODC and the Afghan Ministry of Counter Narcotics to 
estimate the extent of cannabis cultivation and production in Afghanistan. The survey covered 20 provinces where 
cannabis cultivation had been reported. Information was collected from satellite images and interviews with village 
headmen and farmers in 1,634 villages. 
The complex area of cannabis resin yield was investigated with focus group interviews in more than 45 villages. The 
yield study included observation of the actual production of resin, which is a process of threshing and sieving the 
dried cannabis plants to produce a powdery substance locally called ‘garda’. Garda consists of cannabis resin as well 
as other plant material. Based on the quantity and quality of the resin, garda is categorized as first, second, third 
(and sometimes even fourth) grade. 
At least two farmers are involved in the production of garda. First, they beat the dried cannabis plants on a barrel 
to separate the buds from the main branches. Then, the dried buds, leaves and seeds are separated, after which the 
farmers sift the product through a wooden sieve kept in an inclined position. After sieving, they put the product in 
a bag made of cloth, which is shaken for about five minutes. Most of the dust is filtered out during this process. The 
sieving takes place three times. The remaining powder is split and put into smaller bags. A small quantity of powder 
is put in a cloth pouch and beaten by hand to remove the remaining dust. This product is called first garda. 
Regional differences exist in the processing techniques which give different products and quality levels varying with 
the amount of resin and plant rests. Generally, the north, north-east and west of the country produce higher quality 
garda but in smaller amounts, whereas the south and east have a larger production of the first garda but with lower 
quality. 
Most farmers sell the garda in its powdery form, but it needs another transformation to produce consumable hash-
ish, which is usually done by traders. 
Potential cannabis resin garda production, 2009Table 24: 
1st garda (mt) 2nd garda 
(mt)
3rd garda (mt) 4th garda (mt) Rounded total 
(mt)
Lower limit 693 471 287 19 1,500
Upper limit 1,648 1,120 683 45 3,500
As % of total 
garda 47% 32% 20% 1% 100%
Source: UNODC/Afghan Ministry of Counter Narcotics, Afghanistan cannabis survey 2009
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Seizures2.4.2 
Trafficking of cannabis derivatives continues to affect 
most countries worldwide. Of the 147 countries and 
territories for which UNODC collated records of drug 
seizures in 2008, 137 had seized at least one of the can-
nabis derivatives: 129 had made seizures of cannabis 
herb, 92 of cannabis resin, and 26 of cannabis oil. Based 
on 2003-2008 data, approximately one half of seizure 
cases related to all illicit drugs worldwide involved can-
nabis herb, resin or oil. Cannabis herb was the most 
frequently seized drug8 in Africa, the Americas and Oce-
ania, while cannabis resin was the most frequently seized 
drug in Europe, followed by cannabis herb.
Cannabis herb
Global cannabis herb seizures rose gradually but steadily 
over the period 2005-2008, reaching 6,587 mt in 2008, 
slightly exceeding the peak level attained in 2004 (6,539 
mt). The Americas continued to be the region with the 
highest share of global seizures, followed by Africa. Sig-
nificant increases were registered in South America, 
Africa, Asia and Europe.
8 Frequency measured in terms of number of incidents/seizure cases. 
From 2001 onwards, the largest and second largest 
national annual cannabis herb seizures worldwide were 
reported by Mexico and the United States, respectively. 
In Mexico, following two consecutive year-on-year 
increases, cannabis herb seizures fell by almost one quar-
ter, amounting to 1,658 mt in 2008, the lowest level 
since 2002. In the United States, seizures of cannabis 
herb remained at the high level (1,447 mt) reached in 
2007, at 1,472 mt in 2008. The drop in cannabis herb 
seizures in Mexico was offset by a significant increase in 
South America, mainly owing to the contribution of the 
Plurinational State of Bolivia. Seizures, as reported by 
the Bolivian Government, more than doubled in 2008, 
and increased by a further 74% in 2009, continuing a 
rapidly increasing trend which can be traced back to 
1999. Over the period 2003-2009 in particular, canna-
bis herb seizures in the Plurinational State of Bolivia rose 
steadily, from 8.5 mt in 2003 to 1,937 mt in 2009. This 
represented a 228-fold increase over a period of six years, 
equivalent to six consecutive year-on-year increases of 
147%. The level in 2008 was the third highest reported 
by a single country worldwide, and the level in 2009 was 
0
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Prices2.4.3 
Given the relative ubiquity of cannabis cultivation, local 
demand for cannabis herb tends to be met by produc-
tion occurring in proximity to consumption, resulting 
in trafficking patterns which are generally rather local-
ized. Moreover, cannabis herb undergoes relatively little 
processing before reaching the consumer. Both of these 
factors distinguish cannabis herb from other plant-based 
drugs in terms of the driving forces setting price levels. 
There are a number of factors that may affect prices of 
heroin and cocaine: sharp increases or decreases of its 
cultivation in one or two countries, costs and risks asso-
ciated with processing the drug and its trafficking to the 
destination and the country’s role and position in the 
production and transport chain. All these factors play a 
much lesser role in setting the wholesale and retail price 
of cannabis herb.
Nevertheless, prices of cannabis herb display a noticeable 
variability across different countries and regions, even 
when adjusted for purchasing power parities (interna-
tional dollars). Some regions revealed intra-regional 
consistency, although comparisons across countries 
should be considered with caution since prices may 
relate to different product types. High retail prices were 
reported by Japan, Singapore and two territories in East-
ern Asia (Hong Kong and Macao, China). The high 
price in Japan may be due to the fact that, as reported 
by Japan, in 2007 cannabis herb was mainly imported, 
originating in Canada (74%), South Africa (15%) and 
the Netherlands (11%).9 This is contrary to the preva-
lent pattern in other countries, where most cannabis 
herb is locally sourced. Cannabis herb prices in Europe 
were also relatively high. The lower end of the scale was 
occupied mainly by countries in Africa, South America 
and East, South-East and South Asia.
The analysis of the ratio between wholesale and retail 
prices in selected countries indicates that the markup 
from wholesale to retail varies across countries and 
regions. Although the overall estimate indicates a markup 
9 There are, however, indications of small-scale cultivation of cannabis 
in Japan.
Typical retail and wholesale cannabis herb prices, adjusted for purchasing power parity, Fig. 167: 
2008 (log-log scale)
Note: On a linear scale, the slope of the line of best fit (through the origin) is 2.29. This means that, overall, there is a markup of 
129% in price from wholesale to retail level. ‘International dollars’ are used to express PPP-adjusted values. An international dollar 
represents the purchasing power of one US dollar based on a basket of goods with US prices. 
Source: UNODC ARQ (price data), World Bank (purchasing power parities)
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of 129%, the markup tends to be higher in Africa than 
in Europe. One possible reason for this could be that 
production of cannabis herb occurs on a larger scale in 
Africa, resulting in a more pronounced disparity between 
wholesale and retail prices.
In contrast with cannabis herb, both retail and wholesale 
prices of cannabis resin are more dispersed when 
expressed in purchasing power parities.10 This may sug-
gest that factors other than the purchasing power of 
local consumers and traffickers are more important in 
driving prices. Indeed, cannabis resin is produced in a 
handful of countries and prices are affected by the inter-
regional nature of trafficking routes. 
Very low cannabis resin prices were reported in 2008 by 
10 For this reason, the prices in the figure are expressed in US$.
High cannabis herb prices, adjusted Fig. 168: 
for purchasing power parities, 2008
Source: UNODC (ARQ price data), World Bank (purchasing 
power parities) 
Note: ‘International dollars’ are used to express PPP-adjusted 
values. An international dollar represents the purchasing 
power of one US dollar based on a basket of goods with US 
prices.
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wholesale to retail level.  
Source: UNODC ARQ
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Pakistan and the Islamic Republic of Iran, reflecting 
their proximity to the major producing country Afghan-
istan, as well as Paraguay, another country with signifi-
cant production of cannabis. Countries in West Europe 
also reported relatively low prices, notably Spain, the 
main point of entry for cannabis resin into continental 
Europe from Morocco. High cannabis resin prices were 
reported by the Russian Federation and neighbouring 
Belarus.
 
High cannabis resin prices, 2008Fig. 171: 
Source: UNODC ARQ/DELTA
Low cannabis resin prices, 2008Fig. 172: 
Source: UNODC ARQ/DELTA
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Consumption2.4.4 
Cannabis remains the most widely used illicit substance 
in the world. Globally, the number of people who had 
used cannabis at least once in 2008 is estimated between 
129 and 191 million, or 2.9% to 4.3% of the world 
population aged 15 to 64. Compared to last year, the 
lower bound of the estimate decreased and the range 
widened due to the increased uncertainty of having 
dropped some countries’ estimates which were more 
than ten years old. National experts in many parts of the 
world perceive cannabis use to be either stabilizing or 
increasing, although about 15 countries reported a 
decrease in 2007 and 2008. In Africa, where quantita-
tive information on illicit drugs use is scarce, the major-
ity of national experts perceive an increase in the use of 
cannabis. 
In North America, cannabis use has been 
declining or stabilizing over the past years 
In North America, there are an estimated 29.5 million 
people who had used cannabis at least once in 2008, a 
decrease from the 31.2 million estimated in 2007. This 
decrease reflects the availability of new data for Canada, 
which in 2008 showed a considerably lower number of 
cannabis users compared to their previous 2004 survey 
estimates. Cannabis use in the United States and Canada 
has been declining or stabilizing over the past years, 
although a slight increase was observed in the United 
States in 2008 (from 12.3% of the population aged 
15-64 in 2007 to 12.5% in 2008). In the United States, 
between 2002-2007, there was a significant decrease in 
Estimated number of people who used cannabis at least once in the past year and  Table 25: 
prevalence among population aged 15-64, by region, 2008
Region/subregion
Estimated 
number of users 
annually (lower)
-
Estimated 
number of users 
annually (upper)
Percent of 
population 
aged 15-64 
(lower)
-
Percent of 
population 
aged 15-64 
(upper)
Africa 27,680,000 - 52,790,000 5.0 - 9.6
Eastern Africa 4,500,000 - 9,190,000 3.4 - 7.0
North Africa 4,680,000 - 10,390,000 3.6 - 8.0
Southern Africa 4,450,000 - 11,170,000 4.0 - 10.1
West and Central 
Africa 14,050,000 - 22,040,000 7.8 - 12.3
Americas 38,210,000 - 40,030,000 6.3 - 6.6
Caribbean 430,000 - 1,960,000 1.6 - 7.4
Central America 540,000 - 600,000 2.2 - 2.5
North America 29,950,000 - 29,950,000 9.9 - 9.9
South America 7,300,000 - 7,530,000 2.9 - 3.0
Asia 31,510,000 - 64,580,000 1.2 - 2.4
Central Asia 1,860,000 - 2,140,000 3.7 - 4.3
East/South-East Asia 5,370,000 - 23,940,000 0.4 - 1.6
Near and Middle East 7,790,000 - 10,950,000 3.1 - 4.4
South Asia 16,490,000 - 27,550,000 1.9 - 3.1
Europe 29,370,000 - 29,990,000 5.3 - 5.4
East/South-East Europe 8,520,000 - 9,010,000 3.0 - 3.2
Western/Central 
Europe 20,850,000 - 20,990,000 7.7 - 7.8
Oceania 2,140,000 - 3,410,000 9.3 - 14.8
Global 128,910,000 - 190,750,000 2.9 - 4.3
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the annual prevalence of cannabis use within the popu-
lation aged 12 and older, from 11% to 10.1%. In 2008, 
the annual prevalence of cannabis use increased for the 
first time after 2002, reaching the level observed in 2006 
(10.3% of the population aged 12 and older).11 A simi-
lar trend has been observed among secondary school 
students. 
11 Substance Abuse and Mental Health Services Administration Results 
from the 2008 National Survey on Drug Use and Health, National 
Findings, Office of Applied Studies (OAS), SAMHSA, US Depart-
ment of Health and Human Services, September 2009.
World annual cannabis usersFig. 173: 
Source: UNODC ARQ/DELTA
Cannabis: lower and upper range of Fig. 175: 
numbers and annual prevalence, 
globally and by region
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Despite the large decline from 2002, cannabis remains 
the most commonly used illicit drug among US drug 
users. In 2008, cannabis was used by 75.7% of current 
illicit drug users and was the only drug used by 57.3% 
of them.12 
The annual prevalence among the population aged 15 
and older in Canada has also decreased significantly, 
from 14.1% in 2004 to 11.4% in 2008.13 In 2008, the 
32.7% prevalence of cannabis use among youth aged 15 
to 24 was more than four times higher than the preva-
lence of 7.3% for adults 25 and older. Compared with 
the national average of 11.4%, the prevalence of past-
year use of cannabis was fairly consistent across the 
provinces in Canada.14
In 2008, Mexico conducted a national representative 
household survey for urban and rural populations aged 
12 to 65. Compared with results of the last survey in 
2002, the annual prevalence of cannabis use among the 
general population had increased from 0.6% to 1%.15 
Despite the recent increase, and Mexico’s role as an 
important cannabis supplier to the US market, house-
hold survey results continue to show considerably lower 
prevalence rate for Mexico than for Canada or the 
United States.
12 Ibid.
13 Health Canada, Canadian Centre on Substance Abuse, Canadian 
Alcohol and Drug Use Monitoring Survey, summary of results for 2008.
14 Ibid.
15 Mexico, Secretaria de Salud Mexico, Instituto Nacional de Salud 
Publica, Encuesta Nacional de Adicciones 2008, Cuernavaca, Morelos 
2009.
Increase in cannabis use has been reported in 
South America
In contrast to North America, a perceived increase in 
cannabis use has been reported from almost all national 
experts in South America, although the annual preva-
lence of cannabis use in South America remains consid-
erably lower than in North America. Around 3%, or an 
estimated 7.3 -7.5 million people among the population 
aged 15 to 64, had used cannabis at least once in the past 
year in 2008, which is a decrease from the 8.5 million 
estimated for 2007. This drop does not reflect a real 
change in cannabis use in the region between 2007 and 
2008, but rather a revision of 2005 data reported for the 
Bolivarian Republic of Venezuela, where the prevalence 
estimates were revised from 7.5% to 0.9 %. The highest 
prevalence of cannabis use is found in Argentina (7.2%), 
Chile (6.7%) and Uruguay (6%). However, compared 
to the general population, the highest cannabis use prev-
alence among school students was reported among those 
in Chile (15.6%), Uruguay (14.8%) and Colombia (8.4 
%).16
The comparative study on drug use and associated fac-
tors conducted by CICAD and UNODC in six Latin 
American countries showed that among the recent can-
nabis users (used in the past year) who were interviewed 
in the study, between 20.4% of cannabis users in Argen-
tina to almost half of the recent users in Ecuador were 
diagnosed as dependent users,17 based on the clinical 
criteria of International Classification of Diseases (WHO 
– ICD revision 10).18 
16 UNODC and CICAD, Informe Subregional sobre Uso de Drogas en 
Poblacion Escolarizada, 2009/2010.
17 UNODC and CICAD, First comparative Study on Drug Use and 
Associated Factors in the General Population aged 15-64, April 2008.
18 See: www.who.int/classifications/icd/en.
Annual prevalence of cannabis use Fig. 176: 
among US high school students,  
2000-2009
Source: Data from the Monitoring the Future study, 2009, 
National Institute of Drug Abuse, USA
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Most of the countries in the Caribbean also have higher 
than world average prevalence of cannabis use, with 
rates such as 11.7% in Saint Kitts and Nevis and 10.8% 
in Dominica and Grenada. Haiti (1.4%) and the 
Dominican Republic (0.3%) are the two countries with 
low prevalence of cannabis use. Trends in cannabis use 
in the Caribbean are mixed. An increasing trend in 
prevalence of cannabis use among the general popula-
tion is registered in the Bahamas (from 4.7% in 2003 to 
5.5% in 2008), Grenada (from 6.7% in 2003 to 10.8% 
in 2005), Saint Vincent and the Grenadines (from 6.2% 
in 2002 to 7.1% in 2006), Trinidad and Tobago (from 
3.7% in 2002 to 4.7% in 2006). A decreasing trend, in 
contrast, was observed in the Dominican Republic (from 
Annual prevalence of cannabis use Fig. 178: 
among secondary school students* in 
selected South American countries
Source: UNODC data based on UNODC – CICAD, Informe 
Subregional sobre Uso de Drogas en Pobacion Escolarizada, 
2009/2010 and ARQ 
* The age groups are different for the countries. For Argen-
tina and Uruguay, 13-17; Chile 13-18; Brazil, Colombia and 
Paraguay, 15-16; Peru 11-17 and Ecuador 12-17 year old  
students.
Annual prevalence of cannabis use Fig. 179: 
among the population aged 15-64 in 
selected South American countries
Source: UNODC data based on UNODC estimates for 2007, 
UNODC and CICAD, First comparative Study on Drug Use and 
Associated Factors in the General Population aged 15-64 and 
ARQ
1.9
3.1
4.2
6.3
7.6
8.4
14.8
15.6
0 5 10 15 20
P eru
P araguay
E cuador
Brazil
Argentina
Columbia
Uruguay
Chile
Annual prevalence (%)
Trends in the annual prevalence of cannabis use in the general population in Caribbean Fig. 180: 
countries which reported new data in 2008
Source: UNODC 
0.7
0.7
1.6
2.3
2.6
4.3
6
6.7
7.2
0 2 4 6 8
E cuador
P eru
P araguay
Colombia
Brazil
Bolivia
Uruguay
Chile
Argentina
6.7
10.8
10.7
9.9
6.2
7.1
4.7
5.5
3.7
4.7
1.9
0.3
0 2 4 6 8 10 12
Grenada '03
Grenada '05
Jamaica '01
Jamaica '06
St. Vincent&Grenadines '02
St. Vincent&Grenadines '06
Bahamas '03
Bahamas '08
Trinidad&Tobago '02
Trinidad&Tobago '06
Dominican Republic '00
Dominican Republic '08
Annual Prevalence (%)
Annual prevalence (%)
198
World Drug Report 2010 
1.9% in 2000 to 0.3% in 2008) and in Jamaica (from 
10.7% in 2001 to 9.9% in 2006). The 2005 estimates 
for Haiti were revised from 6.2% to 1.4% based on a 
school survey undertaken by CICAD. 
Africa continues to lack quantitative informa-
tion, but cannabis use is perceived to be 
increasing in most parts of the continent
Except for South Africa, there is no quantitative infor-
mation available for Africa for 2008. The estimates 
provided for the continent are based on older data 
reported by UNODC in previous World Drug Reports. 
Compared to last year, the estimate for Ghana (annual 
prevalence 21.5%) was dropped because it was more 
than ten years old. Based on the available information, 
an estimated 27.7 to 52.8 million people, or 5.0% to 
9.6% of the population aged 15 to 64, used cannabis in 
Africa in 2008. This wide range in the estimated number 
is mainly due to missing information and data from 
most of the African countries. 
In 2008, experts from 73% of the responding states in 
Africa reported increases in cannabis use compared with 
the previous year, with decreases noted only in North 
Africa. Zambia (17.7%) and Nigeria (13.8%) remain 
the countries with high prevalence of cannabis use. The 
only systematic monitoring of drug use in Africa is in 
South Africa where it is based on treatment demand. 
Based on annual data from the different regions in South 
Africa, between 26% and 58% of patients attending 
specialist treatment centres had reported cannabis as 
their primary or secondary drug of abuse.19 
19  Pluddemann A., Parry C., Bhana A., and others, Alcohol and Drug 
Abuse Trends: January – June 2009 (Phase 26), South African Com-
munity Epidemiology Network on Drug Use (SACENDU), Novem-
ber 2009.
In Europe, cannabis use has been stabilizing 
in the past few years, but it is still increasing 
in some countries 
In Europe, an estimated 29.5 million people, or around 
5.4% of the general population aged 15 to 64, used can-
nabis in the previous year. Cannabis use is largely con-
centrated among young people (15 – 34 years old). 
Within Europe, cannabis use differs considerably among 
the general population, with higher prevalence (7.7%) 
reported in West and Central Europe, compared to East 
and South-East Europe (3%). The Czech Republic 
(15.2% - 2008), Italy (14.6% - 2008) and Spain (10.1% 
- 2007) are the three countries with the highest cannabis 
use prevalence rates, accounting for about one third of 
all cannabis users in Europe (5 million only in Italy). 
The use of cannabis in Europe has evolved considerably 
over the last decade. In most countries, cannabis use 
increased during the 1990s and early 2000s, and this 
may now be moving into a new phase in some countries 
where data from the general population and school sur-
veys point to a stabilizing or even decreasing trend. 
Countries that started to indicate a decrease in preva-
lence over the previous years include Spain, France, 
Germany, Austria, Hungary and Sweden. England and 
Wales (the third largest European market of cannabis 
users after Italy and the Russian Federation) had shown 
a strong decline between 2003 and 2008 (from 10.8% 
to 7.4% of the general population), however, in 2009, 
the prevalence increased to 7.9%. New data for Scot-
land, Finland, Romania and Bosnia and Herzegovina 
show a decrease. However, the majority of countries 
with new data in 2008 reported an increase in cannabis 
use from previous estimates. These are Bulgaria, the 
Czech Republic, Denmark, Estonia and Lithuania. 
The last few years have also seen a growing understand-
Annual cannabis users in Africa Fig. 181: 
Source: UNODC ARQ
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ing of the public health implications of long-term, wide-
spread use of cannabis and rising reported levels of 
treatment demand for cannabis-related problems in 
Europe.
Increases in cannabis use among school students occurred 
in a number of European countries between 1995 and 
2003, but in most countries, it stabilized or decreased in 
2007, although different patterns can be found across 
Europe. Seven countries, mainly in northern and south-
ern Europe (Greece, Cyprus, Malta, Romania, Finland, 
Sweden and Norway), have reported overall stable and 
low lifetime prevalence of cannabis use between 2003 
and 2007. Most West European countries, as well as 
Croatia and Slovenia, which had high or strongly increas-
ing lifetime cannabis prevalence until 2003, saw a 
decrease or stabilization in 2007 – most noticeable 
among these countries is Ireland. In most parts of Cen-
tral and East Europe, the increasing trend observed 
between 1995 and 2003 appears to be levelling out.20
20 EMCDDA, Statistical Bulletin 2009 and Hibell, et al, ESPAD Surveys 
1995, 1999, 2003 and 2007.
Europe: Annual prevalence of cannabis use among general population in countries  Fig. 183: 
reporting an increase in 2008
Source: UNODC
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a decrease in 2008
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Cannabis use in Oceania is also declining
In the Oceania region, between 2.1 and 3.4 million 
people are estimated to have used cannabis in the past 
year (9.3% – 14.8% of the general population aged 15 
– 64). Except for Australia, Fiji and New Zealand, there 
are no recent or reliable estimates available of cannabis 
use in the remaining parts of the region. However, infor-
mation from school surveys done in the US Pacific 
Island territories indicate considerable cannabis use 
among the youth where the lifetime prevalence ranges 
from 54.9% in the Commonwealth of Northern Mari-
ana Islands, Guam 45.5%, American Samoa 17.6 and 
the Marshall Islands 13.9%.21
21 Centers for Disease Control and Prevention (CDC), Youth Risk 
Behavior Surveillance – Selected Steps Communities, United States, 
2007.
Varying trends of cannabis use among 15-16 year old students in Europe, 1995-2007 Fig. 185: 
Source: ESPAD
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The 2008 range became larger, due to a higher preva-
lence in New Zealand and new data for some territories 
in the Pacific.
In Australia, the annual prevalence of cannabis use has 
been declining since 1998, with an almost one fifth 
decline between 2004 and 2007. The major decline in 
cannabis use has been observed in the younger popula-
tion (aged 14 to 19) from a prevalence of 34.6% in 1998 
to 12.9% in 2007. In New Zealand, the annual preva-
lence of cannabis use fell from 20.4% in 2003 to 13.3% 
in 2006, to increase again in 2008 to 14.6%. The can-
nabis use prevalence was highest for men in the 18 – 24 
age group and for women in the 16-17 and 18-24 year 
age groups.22
Limited or no recent data on cannabis use 
trends are available from Asia, but experts 
perceive an increase.
In Asia, it is estimated that between 31.5 million and 
64.6 million people had used cannabis in the past year. 
Higher annual prevalence rates of cannabis use is 
reported from Central Asia (3.7% to 4.3% of the gen-
eral population) and the Near and Middle East (3.1% to 
4.3% of the general population). The most populated 
countries in Asia, China and India, do not have esti-
mates of cannabis users among the general population. 
A survey carried out in India in 2001 estimated a 
monthly prevalence rate of cannabis use at 3% of the 
male population aged 12-60. The lack of information 
on cannabis use among the female population prevents 
the development of an accurate estimate of the preva-
lence rate among the Indian population. The national 
drug authorities reporting to UNODC indicate a rise in 
cannabis use in the region over the past year. Since for 
many parts of the region there are no recent or reliable 
estimates available, the perceived trends by experts need 
to be treated with caution. In 2008, experts from 15 
countries in Asia reported an increase in cannabis use 
compared to 13 in 2007 and nine in 2005. Experts from 
seven countries reported a stable trend and eight coun-
tries in Asia reported declines in cannabis use in 2008.
22 Ministry of Health, Drug Use in New Zealand: Key results of the 
2007/08, New Zealand Alcohol and Drug Use Survey, 2010.
 
Australia: annual prevalence of canna-Fig. 186: 
bis use among the population aged 14 
and above, 1998-2007
Source: National Drug Strategy Household Survey, Australia, 
2007
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Manufacture2.5.1 
Synthetic drug manufacture dominated by 
ATS, methamphetamine
The majority (99%) of the detected clandestine syn-
thetic drugs laboratories process amphetamine-type 
stimulants, manufacturing primarily the amphetamine-
group substances methamphetamine, amphetamine, 
methcathinone and ecstasy-group substances. The vari-
ety and easy accessibility of the starting materials needed 
to manufacture synthetic drugs allow production to 
occur virtually anywhere in the world. It is at the 
moment impossible to know precisely how much ATS is 
illicitly manufactured, as independent calculations based 
on remote sensing of manufacture cannot be done, as is 
the case with poppy plants and coca bushes. 
ATS-related manufacture occurs in all parts of the 
world; highest concentrations in East and South-
East Asia, Europe, North America, Oceania and 
Southern Africa 
The number of reported ATS-related clandestine labora-
tories increased by 20% in 2008, and for the first time 
revealed the existence of manufacturing laboratories in 
Argentina, Brazil, Guatemala, the Islamic Republic of 
Iran, Kazakhstan and Sri Lanka. Information on the 
8,408 detected laboratories came from 32 countries, 
with the largest numbers reported from the United 
States of America, the Czech Republic, Australia, China,1 
1 In 2008, China reported 244 unspecified clandestine laboratories. 
However, this figure is also known to included some opium dens and 
was therefore not included in the ATS totals.
Slovakia, New Zealand, the Netherlands, Canada and 
Mexico. However, the number of laboratories is not 
representative of their output, as many countries with 
lower total counts report only laboratories with large-
scale outputs.2
The type and form of ATS manufactured vary across 
regions. For example, in East and South-East Asia, 
manufacture of methamphetamine is primarily in tablet 
form (‘yaba’) and high purity crystalline form (‘ice’), 
although there are increasing incidents of ecstasy 
(MDMA) manufacture. Tablets sold as Captagon in the 
Near and Middle East often contain amphetamine and 
are sourced from South-East Europe and from within 
the region. In Europe, ATS manufacture is mainly 
powder and tableted amphetamine and ecstasy (MDMA), 
with methamphetamine (‘pervitine’) manufactured pri-
marily in the Czech Republic and Slovakia, and other 
east European countries, with evidence that manufac-
ture is further spreading. South Africa-based manufac-
ture is predominately methamphetamine (‘tik’) and 
methcathinone. Methamphetamine and ecstasy are 
manufactured in all countries of North America, and 
there are increasing incidents of methamphetamine-re-
lated manufacture occurring throughout Central and 
South America. Methamphetamine and some ecstasy 
laboratories are commonly encountered in Oceania – 
primarily Australia and New Zealand. 
2 There is no internationally accepted definition of what constitutes a 
clandestine synthetic drug laboratory. Therefore, figures may include 
accounts of ATS precursor extraction, drug synthesis, refinement, 
tableting and packaging, laboratory storage facilities, and chemical 
and equipment dumpsites as broadly defined ‘laboratories.’ 
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Rebound in US methamphetamine laboratory  
incidents drives global increase
Global methamphetamine laboratory counts increased 
29% in 2008 to 8,295, although the numbers are still 
significantly lower than their peak in 2004 (17,853). 
The largest numbers reflected increases reported from 
the United States (7,226), however, along with 3,866 
synthesis laboratories, these figures also include inci-
dents of laboratory storage facilities and chemical/equip-
ment dumpsites. Globally, most of the seized laboratories 
were methamphetamine-related, due to the simplicity of 
its manufacture and availability of inexpensive precursor 
chemicals.
Over the last decade, reports of clandestine laboratory 
incidents have increased in several regions outside of 
North America, with large growth in East and South-
East Asia, Europe and Oceania. Several countries report 
few but mostly industrial-sized operations, particularly 
in East Asia and parts of North America, existing for 
criminal profit. 
Reported amphetamine laboratories in 2008 at the 
lowest level in a decade
In 2008, only 45 amphetamine laboratories were 
reported, the lowest in a decade.3 Most were reported 
throughout Europe, particularly in West and Central 
Europe. The decline in the number of laboratories comes 
at a time when seizures of amphetamine are at record 
highs, particularly throughout the Near and Middle 
East, where not a single laboratory was reported in 
2008. Indeed, part of the decline in numbers is due 
simply to less reporting, such as no reports of ampheta-
3 These represent amphetamine-only laboratories and do not include 
combination ATS laboratories.
mine laboratories being provided from the United States 
in 2008. In general, there are far fewer amphetamine 
and ‘ecstasy’-group laboratories reported because these 
substances require far greater sophistication than meth-
amphetamine manufacture. 
ATS laboratories (all sizes) reported to UNODC, by type, 1999-2008Fig. 187: 
Source: UNODC ARQ
Number of reported methamphe-Fig. 188: 
tamine laboratory incidents (all sizes), 
by notable region, 1999-2008
Source: UNODC ARQ/DELTA
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The number of ecstasy-group laboratories declined 
in 2008, with few reported in Europe
There were 53 ecstasy-group laboratories reported in 
2008, a decline from 2007 (72). Because most MDMA 
operations are medium- to large-scale, the low numbers 
are not necessarily a sign of low production. Ten coun-
tries reported manufacture, with the highest number of 
dismantled laboratories (14) in Canada in 2008. There 
were only four laboratories reported from Europe - in 
Belgium, the Netherlands and Spain - a significant 
decline from past years. The manufacture of ecstasy-
group substances, previously the dominion of West and 
Central Europe, is now reported in other parts of the 
world such as East and South-East Asia, North America, 
Oceania and Latin America. 
Illicit synthetic drug manufacture or processing for sub-
stances other than ATS (such as precursor chemicals 
(ephedrine, pseudoephedrine), fentanyl, gamma-hy-
droxybutyric acid (GHB), ketamine, lysergic acid 
diethylamide (LSD), methaqualone and phencyclidine 
(PCP)) is significantly less common.4 The most com-
monly manufactured substance is GHB, averaging 15 
cases per year. Since 1999, it has been reported in 11 
countries in every region of the world, except for Latin 
America. Illicit manufacture of ketamine has been 
reported in China.5 Methaqualone laboratories are com-
monly seized in South Africa (known locally as ‘man-
drax’), but have also been reported in China, India and 
Kenya.6 Since 1999, the dismantling of illicit PCP labo-
ratories has only been reported in the United States.
4 Neither GHB or ketamine are under international control, although 
they are under control in many countries. As such, their figures may 
be significantly under-reported. 
5 China reported seizing significant ketamine laboratories again in 
2008, however, specific figures were not provided. 
6 Reports of methaqualone manufacture were not provided by South 
Africa in 2008.
Number of reported amphetamine  Fig. 189: 
laboratory incidents (all sizes), by  
notable region, 1999-2008
Source: UNODC ARQ/DELTA
Regional ecstasy-group laboratories Fig. 190: 
reported to UNODC, 1999-2008
 Source: UNODC ARQ/DELTA
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
ATS precursors 0 5 0 0 2 0 0 22 1 3
Fentanyl 0 0 0 0 0 0 0 1 1 1
Gamma-hydroxybutyric acid (GHB) 0 1 0 9 21 17 8 10 8 12
Ketamine 0 0 0 0 0 0 0 0 44 0
Lysergic acid diethylamide (LSD) 1 1 1 0 1 0 1 1 1 0
Methaqualone 0 4 5 6 15 16 5 3 4 1
Phencyclidine (PCP) 1 1 4 6 16 0 11 4 0 16
Total 2 12 10 21 55 33 25 41 59 33
Other synthetic drug manufacture incidents, 1999-2008Table 26: 
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Precursor chemicals for ATS manufacture
Chemical precursors are necessary for the synthesis of amphetamine-type stimulants (ATS), and most of the chemicals 
commonly used fall under international control. Their seizures are typically reported to the International Narcotics 
Control Board (INCB) and can provide some indications about trends in clandestine manufacturing. In 2008, only 
31 mt of ATS-related precursor chemicals under international control were reported seized—the lowest in a decade.
Seizures in 2008 included: 
Amphetamine-group:
Methamphetamine: 12.6 mt of ephedrine and 5.1 mt of pseudoephedrine, suﬃcient to manufacture approxi- ?
mately 11.8 mt of methamphetamine.1
Amphetamine: 5,620 litres of phenyl-2-propoanone (P-2-P), suﬃcient for 2.8 mt of amphetamine or metham- ?
phetamine; 1.5 mt norephedrine, suﬃcient to manufacture 984 kg of amphetamine; and 155 kg of phenylacetic 
acid, suﬃcient for just 39 kg of amphetamine or methamphetamine.
Ecstasy-group: 
2,823 litres of 3,4-MDP-2-P, enough to manufacture 2.3 mt of MDMA;  ?
1,904 l of safrole oil, suﬃcient to manufacture 401 kg of MDMA;  ?
1.4 mt of piperonal which could be converted into 527 kg of MDMA; and  ?
1 l of isosafrole, used in the manufacture of MDMA. ?
The low amounts of precursor chemicals seized are inconsistent with the size of the consuming market, suggesting 
that much of the trafficking of precursors needed for ATS manufacture goes undetected. Some of the decline is due 
in part to shipments being stopped before they depart through notification via INCB’s PEN Online system. There is 
evidence of criminal organizations rapidly adapting their strategies to avoid control and continue illicit manufacture 
by: 1) shifting precursor chemical trafficking routes through new locations, such as Africa; 2) relocating manufactur-
ing operations to new countries, such as moving laboratories from North America to Central America; 3) shifting to 
new physical forms of precursor chemicals, such as pharmaceutical preparations in tablet or liquid forms; and 4) 
utilizing precursor chemicals outside international control, such as derivatives of phenylacetic acid (PAA). In March 
2010, the Commission on Narcotics Drugs at its fifty-third session decided to reschedule PAA to Table I, substantially 
increasing the international control over this precursor chemical.
1 These figures largely represent raw chemical seizures and in some cases pharmaceutical preparations, and thus are not representative of all 
precursors seized.
Reported seizures of ATS precursor chemicals, expressed in mt of ATS equivalents,  Fig. 191: 
1999-2008
Source: UNODC calculations based on INCB data and conversion factors. (INCB, Precursors and chemicals frequently used in the 
illicit manufacture of narcotic drugs and psychotropic substances, 2009, March 2010 and previous years)
19 19
323
0
30
60
90
120
150
180
210
240
270
300
330
360
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
 P
re
cu
rs
o
rs
 in
 m
et
ri
c 
to
n
 A
TS
 e
q
u
iv
al
en
ts
 
Ecstasy precursors (3,4-MDP-2-P,
safrole, isosafrole, piperonal)
Amphetamine precursors (P-2-P,
phenylacetic acid, norephedrine)
Methamphetamine precursors
(pseudoephedrine, ephedrine) 
ATS Trend
2. Drug statistics and trends Amphetamine-type stimulants
207
Seizures2.5.2 
Trafficking of amphetamine-type stimulants (ATS), 
along with their production, has come to affect the 
entire globe. Seizure data, however, point to different 
types of ATS prevailing in different parts of the world, 
and different trends can be observed in global and 
regional seizure totals for the different types of ATS.
Amphetamine-type stimulants are broadly categorized 
into two groups: the amphetamines group, comprised of 
amphetamine, methamphetamine and non-specified 
amphetamines, and the ‘ecstasy’ group. Total seizures in 
the amphetamines group reached 47.4 mt7 in 2008, 
slightly exceeding the level in 2007 (43.8 mt), as well as 
the previous record level registered in 2006 (45.9 mt). 
On the other hand, ‘ecstasy’ seizures fell markedly in 
2008, dropping to 3.86 mt7 – the lowest level since 
1999. Over the period 2000-2008, seizures of ‘ecstasy’ 
fluctuated considerably, while methamphetamine sei-
zures were less erratic; in both cases, seizure totals stayed 
within the same order of magnitude. The most pro-
nounced expansion over this period was observed in 
seizures of amphetamine, which grew almost eight-fold 
over a time span of eight years, mainly due to increases 
in the Near and Middle East. 
While seizures of amphetamine in the Near and Middle 
East/South-West Asia represented almost two thirds of 
the global total in 2008, a majority of methampheta-
mine seizures were attributable to countries in East and 
South-East Asia. North America accounted for most of 
the remaining seizures of methamphetamine, as well as 
– for the first time – more than one half of global ‘ecstasy’ 
seizures. The significant increase in the North American 
share of global ‘ecstasy’ seizures was partly due to an 
increase in ‘ecstasy’ seizures in the United States, but also 
to decreases in other regions, notably West and Central 
Europe. On the other hand, West and Central Europe 
continued to account for approximately one third of 
global seizures of amphetamine. Almost 90% of seizures 
of non-specified amphetamines were recorded in West 
7 Amphetamine-type stimulants are seized in various forms, including 
liquid and tablet form, and may be reported by weight, volume, 
number of tablets or other units. In specific cases, seizure amounts 
may be reproduced as reported by countries, but aggregate quantities 
are expressed by weight. For the purposes of the aggregation, one 
tablet is assumed to contain 30 mg of active ingredient, with the 
exception of ‘ecstasy’ tablets, which are assumed to contain 100 mg 
of active ingredient. Moreover, one litre of liquid is assumed to cor-
respond to one kilogram.
and Central Africa, which remains a priority area in 
terms of responding to the drug problem, starting with 
a better understanding of the nature of drugs in the 
illicit market.
Amphetamine
Global seizures of amphetamine amounted to a record 
24.3 mt in 2008, essentially sustaining the high level of 
2007 (23.7 mt). The Near and Middle East/South-West 
Asia and Europe together accounted for 97% of seizures 
in 2008. Since the year 2000, amphetamine seizures 
have grown considerably in both these regions, but the 
growth rate in the Near and Middle East/South-West 
Asia clearly outpaced that in Europe.
One caveat, however, needs to be made. Most of the 
seizures in the Near and Middle East/South-West Asia 
are in tablet form, and there are indications that – when 
converted into weight terms – the weight of the entire 
tablet is used, and not only the weight of the active 
ingredient (amphetamine). This could inflate the sei-
zures in this part of the world by a factor of ten or 
more.8 It does not seriously impact the growth rates, but 
possibly the absolute levels of seizures reported from the 
countries in the Near and Middle East/South-West 
Asia.
Reports of amphetamine seizures from countries in the 
Middle East continue to refer predominantly to tablets 
bearing the Captagon logo. The nature of the psychoac-
tive ingredients in such tablets is not always clear, but 
reports suggest that amphetamine trafficked from South-
East Europe is the main ingredient in Captagon tablets 
found in the consumer markets of the Middle East 
(notably Saudi Arabia), frequently alongside caffeine. 
Laboratories may also exist in countries along this route, 
possibly carrying out the conversion into tablet form. 
Jordan, Lebanon, Turkey and the Syrian Arab Republic 
serve as important transit points.
8 A recent forensic analysis of some 9,400 Captagon tablets seized 
in Iraq in the border region with Jordan, Saudi Arabia and the 
Syrian Arab Republic in 2009 revealed that the tablets had a weight 
between 163 and 170 mg and contained between 7 and 20 mg of 
amphetamine (in addition to 30-65 mg of caffeine and 8-39 mg of 
theophylline). (UNODC, Global Smart Update, Volume 2, October 
2009, p. 8.) Taking the mid-points, there would be a factor of 12 
between reporting the amphetamine contained in a tablet and the 
whole weight of the tablet. 
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Annual seizures of amphetamine in Saudi Arabia rose 
steadily over the 2000-2007 period, reaching 13.9 mt9 
in 2007.10 Saudi Arabia reported amphetamine seizures 
of 12.8 mt in 2008. The total for the Near and Middle 
East/South-West Asia amounted to 14.8 mt in 2007 and 
9 Data for Saudi Arabia relative to the period 2002-2007 were sourced 
from the World Customs Organization and ICPO/Interpol.
10 These quantities likely represent the bulk weight of seizures, includ-
ing binders and adulterants present in Captagon tablets, and should 
therefore be interpreted with caution. Nevertheless, these remain 
extraordinarily large seizures and denote a clear long-term increasing 
trend.
15.3 mt in 2008. Reports from Lebanon,11 Turkey, the 
United Arab Emirates and Yemen identified Saudi 
Arabia as a major destination for amphetamine (or spe-
cifically Captagon) trafficked on their territory in 2008, 
while Gulf States generally were destinations mentioned 
by the Syrian Arab Republic and Jordan. Large quanti-
ties of tablets believed to contain amphetamine were 
seized by Jordan (14.1 million tablets in 2008, up from 
11 Country report by Lebanon to the forty-third Subcommission on 
Illicit Drug Traffic and Related Matters in the Near and Middle 
East.
Seizures of amphetamine-type stimulants worldwide, 2000-2008Fig. 192: 
Sources: UNODC ARQ/DELTA
Geographic distribution of ATS seizures by type, 2008Fig. 193: 
* The category “Rest of the world” refers to a different set of countries according to the drug type.
Sources: UNODC ARQ/DELTA
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10.6 million in 2007), Yemen (13.4 million in 2008) 
and the Syrian Arab Republic (11.8 million tablets in 
2008 and 12.0 million in 2007).
Amphetamine seizures in Europe amounted to 8.37 mt, 
sustaining the record level of 2007 (8.70 mt). A notable 
increase was registered in United Kingdom: the total for 
England, Wales and Northern Ireland rose by 65%, 
from 1.78 mt in the 2007/2008 financial year to 2.94 
mt12 in 2008/2009. Seizures also rose in Germany, from 
810 kg in 2007 to 1.28 mt in 2008. These increases were 
offset by a decline in seizures in the Netherlands, which 
dropped to 1.16 mt in 2008 (from 2.81 mt in 2007). 
Significant quantities were also seized by Belgium (411 
kg), Sweden (362 kg), Poland (342 kg), Norway (260 
kg), Bulgaria (187 kg) and Turkey (163 kg).
Mexico, which historically has been linked with signifi-
cant manufacture of methamphetamine, reported 251 
kg of amphetamine seizures in 2008 – nine times the 
level in 2007 (27.1 kg). 
Methamphetamine
Global methamphetamine seizures remained stable for 
the fourth year in a row, amounting to 18.2 mt in 2007 
and 19.3 mt in 2008. East and South-East Asia (notably 
China) and North America (notably the United States) 
continued to account for the vast majority of metham-
phetamine seizures.
In 2008, total methamphetamine seizures in East and 
South-East Asia remained stable (10.7 mt). In China, 
seizures amounted to 6.09 mt in 2007 (the largest world-
wide for that year) and 6.15 mt in 2008. According to 
12 The total for the United Kingdom was not available. UNODC esti-
mates total seizures of amphetamine in the UK at 3.55 mt.
Chinese authorities,13 large amounts of amphetamine-
type stimulants entered Yunnan province through the 
border with Myanmar. Seizures of amphetamine-type 
stimulants from Europe and South America also 
increased. China reported 460 arrests of foreign nation-
als for trafficking of amphetamine-type stimulants in 
2007; of these, 397 involved nationals of Myanmar. 
Seizures in Thailand rose to 1.98 mt in 2008, returning 
to a level comparable to that registered in 2004 (2.12 
mt). The World Customs Organization reported14 that, 
in 2008, Thailand was the most frequent destination 
country in the Asia-Pacific region among methampheta-
mine seizure cases recorded in the Customs Enforce-
ment Network database. In particular, 157 seizures were 
made on the route from the Lao People’s Democratic 
Republic to Thailand.
Significant increases in methamphetamine seizures were 
also registered by the Philippines and Malaysia. The 
Philippines also reported 10 clandestine laboratories 
manufacturing methamphetamine in 2008, and a con-
current increase in the price of methamphetamine 
hydrochloride.
North America accounted for total methamphetamine 
seizures of 8.08 mt in 2008. Seizures in the United 
States rose markedly, from 4.89 mt in 2007 to 7.37 mt 
in 2008 (the largest worldwide for that year). The 
increase was offset by the portion of the North American 
total seized by Canada, which reported extraordinarily 
large seizures in 2007 (1.54 mt) but only 360 kg in 
13 China National Narcotics Control Commission. Quoted in country 
presentation by China, Global SMART Programme Meeting for East 
Asia, 29-31 July 2009, Bangkok, Thailand.
14 World Customs Organization Regional Intelligence Liaison Office 
for Asia and the Pacific, Analysis Report 2009.1.
Regional breakdown of global amphetamine seizures, 2000-2008 (ton equivalents) Fig. 194: 
Source: UNODC ARQ/DELTA
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2008. In Mexico, seizures fell from 920 kg in 2007 to 
341 kg in 2008 – the lowest level since 1998. 
According to the United States Department of Justice,15 
available data indicated that methamphetamine availa-
bility in the United States was directly related to meth-
amphetamine manufacture trends in Mexico. Following 
declines in domestic methamphetamine manufacture 
registered after 2004 in the United States — which also 
impacted on the domestic availability of this substance 
— methamphetamine seizures on the south-west border 
of the country rose significantly between 2008 and 
2009. Moreover, price and purity data from the US 
Drug Enforcement Agency indicated an increase in the 
availability of methamphetamine in the United States. 
Between the fourth quarter of 2007 and the third quar-
ter of 2009, the average purity of methamphetamine 
followed a generally increasing trend, rising from 41% 
to 69%, while the price per pure gram followed a gener-
ally decreasing trend, from US$279 to US$127.16 How-
ever, the increased availability of methamphetamine in 
the United States does not appear to have led to increased 
use of this drug.
Although global methamphetamine seizure totals have 
remained stable, seizure data point to illicit trade in 
methamphetamine in countries which have traditionally 
not been linked with this drug. Starting in 2005, the 
Islamic Republic of Iran has seized increasing quantities 
of methamphetamine. The country’s combined seizures 
of amphetamine and methamphetamine amounted to 
1.47 mt in 2008 and 2.43 mt in 2009.17 The results of 
15 US Department of Justice, National Drug Threat Assessment 2010.
16 Ibid. Based on data extracted from System To Retrieve Information on 
Drug Evidence (STRIDE).
17 Islamic Republic of Iran, Drug Control Headquarters, Drug Control 
in 2009.
research undertaken in the Islamic Republic of Iran, as 
reported18 by its Drug Control Headquarters, indicate 
that the use of methamphetamine has increased. In 
Afghanistan, the first confirmed seizure of metham-
phetamine was made in January 2009, in the city of 
Lashkar Gah (Hilmand province), although a survey 
undertaken in 2009 indicates a very low level of ATS 
use. In Europe, while seizures of ATS continue to consist 
predominantly of amphetamine and ‘ecstasy’, seizures of 
methamphetamine have also increased in a number of 
countries, notably the Nordic countries.
'Ecstasy"
Global seizures of ‘ecstasy’ fell from a record level of 7.94 
mt in 2007 to 3.86 mt in 2008, the lowest level since 
1999. The low level was partly due to significantly 
reduced seizures in the Netherlands and Australia. On 
the other hand, seizures increased markedly in the 
United States. North America, Europe and East and 
South-East Asia collectively accounted for 98% of global 
‘ecstasy’ seizures in 2008. 
Over the period 2004-2008, seizures of ‘ecstasy’-type 
substances in the United States followed a generally 
18 Drug control in 2008, Annual Report and Rapid Situation Assessment, 
Drug Control Headquarters, Islamic Republic of Iran.
Methamphetamine seizures worldwide Fig. 195: 
(ton equivalents), 2001-2008
Source: UNODC ARQ/DELTA
Methamphetamine prices and puri-Fig. 196: 
ties in the United States, 2006-2009 
(STRIDE*)
*STRIDE is a database of drug exhibits maintained by the US Drug 
Enforcement Administration. The values reported here represent aver-
ages of all methamphetamine purchases in the database. Although not 
collected as a representative sample of the US market, STRIDE data 
reflect the best information available available on changes in metham-
phetamine price and purity in the US market.
Source: US Department of Justice, National Drug Threat 
Assessment 2010
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increasing trend. This came after declines between 2000 
and 2003 (in line with reports of reduced availability 
and reduced trafficking of ‘ecstasy’ from the Netherlands 
to the United States). In 2008, seizures almost doubled 
to reach a record level, rising from 1 mt in 2007 to 
nearly 2 mt. According to the United States Department 
of Justice,19 the resurgence of MDMA availability in the 
United States was fuelled by manufacture in Canada and 
smuggling into the US across the northern border. 
MDMA seizures at the northern border (measured in 
dosage units) more than doubled between 2008 and 
2009. However, availability appeared to be stabilizing.
In Europe, seizures of ‘ecstasy’ fell sharply, from 3.07 mt 
in 2007 to 1.01 mt in 2008. The drop was mainly due 
to smaller seizures reported by the Netherlands, which 
fell from 2.16 mt to 409 kg. Seizures of ‘ecstasy’ tablets 
in particular by the Netherlands fell from 8.43 million 
tablets in 2007 to 249,000 tablets in 2008. A downward 
trend in ‘ecstasy’ seizures was observed across West and 
Central Europe: of 31 countries and territories for which 
UNODC had collated seizures of ‘ecstasy’ in 2007, 26 
registered a decrease in 2008. There are indications that 
improved precursor controls may have made access to 
the needed chemicals more difficult, thus reducing man-
ufacture and trafficking of MDMA.
Australian ‘ecstasy’ seizures fell drastically, from the 
record level of 2007 (1.97 mt) to 51.4 kg in 2008. The 
figure for 2007 includes a single extraordinarily large 
seizure of approximately 15 million tablets.20 However, 
19 National Drug Intelligence Center, United States Department of 
Justice, National Drug Threat Assessment 2010, February 2010.
20 This was reported by the Australian Crime Commission in Illicit 
Drug Data Report 2006-07, Revised Edition. This seizure, which was 
part of a year-long controlled delivery operation, was also confirmed 
separately to UNODC by the Australian Federal Police. In the reply 
the level in 2008 is low also in comparison with previous 
years. Over the period 2003-2006, ‘ecstasy’ seizures in 
Australia averaged 1.10 mt. Seizures also fell in East and 
South-East Asia, from 740 kg in 2007 to 306 kg in 
2008.
to the annual reports questionnaire for 2007, Australia reported 
seizures amounting to 470 kg.
European methamphetamine seizures Fig. 197: 
2005-2008
Source: UNODC ARQ/DELTA
‘Ecstasy’ seizures worldwide,  Fig. 198: 
2000-2008 (ton equivalents) 
Source: UNODC ARQ/DELTA
Major ‘ecstasy’ seizures in West and Fig. 199: 
Central Europe (excluding the Nether-
lands), 2007-2008
* Figures for the United Kingdom are UNODC estimates based on 
reported totals for England, Wales and Northern Ireland.
Source: UNODC ARQ/DELTA
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Consumption 2.5.3 
Amphetamine-type stimulants (ATS) are various syn-
thetic substances broadly categorized into ampheta-
mines-group substances—primarily amphetamine, 
methamphetamine and methcathinone—and ecstasy-
group substances (MDMA and its analogues). In many 
regions the primary source of amphetamine-group sub-
stances is via illicit manufacture in clandestine laborato-
ries while in other regions they are prescription 
pharmaceutical stimulants obtained via the grey or black 
markets, used non-medically. 
UNODC estimates that between 13.7 and 52.9 million 
people used amphetamine-group substances at least 
once in the preceding year, with a corresponding annual 
prevalence range of 0.3% to 1.2% of the population 
aged 15 to 64. The width of the ranges for ampheta-
mines-group substances - much more than for heroin or 
cocaine - has further widened since last year (15.8 - 50.6 
million). This reflects a higher number of estimated 
users in and new availability of data on ATS in the Car-
ibbean countries, and an increased level of uncertainty 
for the estimates produced for Asia, which is thought to 
be one of the main markets for ATS. The estimates for 
Asia range from 4.4 to 37.9 million users, reflecting the 
uncertainties regarding the use of amphetamine-group 
substances in the region, especially with the lack of 
recent or reliable estimates in countries with large popu-
lations like China and India. 
The number of ‘ecstasy’-group users ranges between 
10.5 and 25.8 million people worldwide, or 0.2% to 
0.6% of the population in the 15-64 age group. This 
range widened from 2007 (11.6-23.5 million). The 
speed with which ATS markets are appearing or expand-
Region/ subregion 
(Amphetamines-group)
Estimated 
number of 
users annually 
(lower)
-
Estimated 
number of 
users annually 
(upper)
Percent of 
population 
aged 15-64 
(lower)
-
Percent of 
population 
aged 15-64 
(upper)
Africa 1,550,000 - 5,200,000 0.3 - 0.9
Eastern Africa Subregional estimate cannot be calculated
North Africa 260,000 - 540,000 0.2 - 0.4
Southern Africa 310,000 - 1,090,000 0.3 - 1.0
West and Central Africa Subregional estimate cannot be calculated
Americas 4,760,000 - 5,890,000 0.8 - 1.0
Caribbean 30,000 - 510,000 0.1 - 1.9
Central America 320,000 - 320,000 1.3 - 1.3
North America 3,090,000 - 3,200,000 1.0 - 1.1
South America 1,320,000 - 1,860,000 0.5 - 0.7
Asia 4,430,000 - 37,990,000 0.2 - 1.4
Central Asia Subregional estimate cannot be calculated
East/ South-East Asia 3,430,000 - 20,680,000 0.2 - 1.4
Near and Middle East Subregional estimate cannot be calculated
South Asia Subregional estimate cannot be calculated
Europe 2,500,000 - 3,190,000 0.5 - 0.6
Eastern/South-East Europe 900,000 - 1,480,000 0.3 - 0.5
Western/Central Europe 1,600,000 - 1,710,000 0.6 - 0.6
Oceania 470,000 - 630,000 2.0 - 2.8
Global 13,710,000 - 52,900,000 0.3 - 1.2
Estimated number of people who used amphetamines-group substances at least once  Table 27: 
in the past year and prevalence among population aged 15-64, by region, 2008
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ing, the general confusion on what constitutes ATS and 
the limited reporting and/or absence of reporting all 
contribute to the limited data availability worldwide. 
The type of amphetamines-group stimulants used in 
different regions varies considerably. Users in East and 
South-East Asia primarily consume methamphetamine, 
while in the Near and Middle East, the use of tablets 
sold as Captagon is more common. In Europe, users 
commonly consume amphetamine, with the exception 
of the Czech Republic and Slovakia, where metham-
phetamine use is predominant. 
In North America, nearly half of the synthetic stimulant 
users consume methamphetamine, while in South 
America and the Caribbean it is mostly pharmaceutical 
stimulants. In West, Central and East Africa and some 
parts of Southern Africa, the amphetamine groups may 
also comprise various pharmaceuticals. In South Africa, 
methamphetamine and methcathinone are the common 
amphetamine-group substances consumed. In Oceania, 
methamphetamine is the common synthetic stimulant 
consumed, though there is also use of amphetamine.
Global trend in the perception of ATS use: cumulative un-weighted average* as reported  Fig. 200: 
by national experts 
* The graph measures the trend from countries reporting an increase or decrease in drug use. It does not measure the trend in terms of number of 
drug users. 
Amphetamine-group substance use: Fig. 201: 
lower and upper ranges of numbers 
and annual prevalence globally and by 
region, 2008
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Out of the 29 Member States in Asia that responded to 
the 2008 ARQ and provided expert perception on ATS 
use, 13 countries reported some increase in ATS use, 
while eight reported a stable trend over the past year. 
Most of the countries that have reported an increase in 
amphetamines-group substance use over the last year are 
from East and South-East Asia, particularly Bangladesh, 
China (including Hong Kong), Indonesia, Japan, Mon-
golia, Myanmar, Thailand and Viet Nam.
Recent data from the Philippines (2.1%, 2008), Thai-
land (1.4%, 2007) and the Lao People’s Democratic 
Republic (1.4%, 200822) place them as the countries 
with the highest annual prevalence of amphetamines-
group substance use in East and South-East Asia.23 
Mixed trends of amphetamines-group substance  
use observed in Europe
In Europe, between 2.5 and 3.2 million people aged 
15-64 had used amphetamines-group substances at least 
once in the past year, and the annual prevalence is esti-
mated at between 0.5% to 0.6% of the population aged 
15-64. The range is higher than the one reported last 
year due to increases observed in countries where new 
data for 2008 were reported (not offset by the decreasing 
trends also observed in some countries). Relatively high 
prevalence rates in the general population were also 
reported for South-East European countries where for 
the first time data on ATS use was made available: Bosnia 
and Herzegovina (1%), Montenegro (0.5%) and Serbia 
(0.2%).24 Bulgaria revised its estimate from 0.5 to 1%. 
The Czech Republic, Denmark, the United Kingdom, 
Norway and Estonia remain countries with higher than 
average annual prevalence of amphetamine-groups sub-
stance use while France, Greece, Romania and Malta 
22 UNODC estimate.
23 Estimates for the Philippines and the Lao People’s Democratic 
Republic are for 2008, while for Thailand, they are for 2007.
24 UNODC estimate extrapolated from school surveys.
remain low prevalence countries. After the general 
increase in the 1990s, in 2007, there were stabilizing or 
even downward trends in amphetamine consumption in 
Europe.25 However, new data for 2008 suggest that the 
trend is increasing again in some countries. 
According to European school survey26 data for 2007, 
the lifetime prevalence of amphetamine use ranged from 
1% to 8% in EU Member States, Norway and Croatia, 
with high levels reported from Bulgaria and Latvia (both 
6%). 
25 EMCDDA, Drug Situation in Europe, 2009.
26  European School Survey Project on Alcohol and Other Drugs 
(ESPAD).
National experts’ perception of trends in ATS use by region, 2008Table 28: 
Source: UNODC ARQ
Trends in annual prevalence of am-Fig. 204: 
phetamine use among the population 
aged 16-59 in England and Wales
Source: Home Office Statistical Bulletin, Drug Misuse Declared: 
Findings from the 2008/09 British Crime Survey, UK Home 
Office, July 2009
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Region
Member 
States 
responding
Use  
problem 
increased*
Percent 
use  
problem 
increased
Use  
problem 
stable
Percent 
use  
problem 
stable
Use  
problem 
decreased*
Percent 
use  
problem 
decreased
Africa 6 2 33% 2 33% 2 33%
Americas 15 4 27% 9 60% 2 13%
Asia 29 13 45% 10 34% 6 21%
Europe 31 8 26% 20 65% 3 10%
Oceania 1 0 0 1
Global 82 27 33% 41 50% 14 17%
* Identifies increases/decreases ranging from either some to strong, unweighted by population.
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While the treatment demand for amphetamine-group 
substances is generally low in Europe, it is particularly 
high (64% of all treatments in 2008) in the Czech 
Republic. This reflects the country’s high prevalence of 
methamphetamine use (1.7% among the general popu-
lation in 2008), the highest in Europe. In Slovakia, the 
percentage of treatment admissions for methampheta-
mine is also high (32%), suggesting that despite the 
relatively low prevalence of methamphetamine use 
reported in 2006 (0.3% of the population aged 15-64), 
problem drug use related to it is sizable. In these two 
countries, injection is the most commonly reported 
route of administration for methamphetamine.27
27 EMCDDA, Drug Situation in Europe, 2009.
In South Africa, amphetamine-group substances use 
is increasing, while there is little information from 
most other parts of the African region
In Africa, between 1.5 and 5.2 million people are esti-
mated to have used amphetamine-group substances in 
the past year, an increase from the 1.4 - 4 million people 
estimated for 2007. The wide range in the estimates is 
due to the lack of recent or reliable estimates in West, 
Central and East Africa. Recent annual prevalence esti-
mates in Africa are available from South Africa (0.7%-
1.4%, 2008), Egypt (0.4%-0.5%, 2006) and Zambia 
(0.1%, 2003). The higher range level in 2008 is mainly 
due to an increase observed in South Africa, where the 
annual prevalence increased from a range of 0.5%-0.8% 
in 2006 to 0.7%-1.4% in 2008. Within South Africa, 
the use of methamphetamine remains particularly high 
in Cape Town, where methamphetamine remained the 
Trends in amphetamines-group substance use among the population aged 15-64  Fig. 205: 
in European countries where new information was reported in 2008 or 2009
Source: UNODC (for Scotland the age group is 16-64)
ESPAD 2007: Lifetime prevalence of amphetamines use among students (aged 15-16) Fig. 206: 
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most common primary drug reported by treatment 
patients in the first half of 2009.28
Decreasing trends in North America
Amphetamine-group substance use remains high in 
North America, though recent survey data suggest a 
decline in the use of amphetamines. The annual preva-
lence of all stimulants use in the United States among 
the population aged 12 years and older was reported as 
1.1% in 2008; a further decline from 1.2% in 2007 and 
1.5% in 2006.29
28 Pluddemann A., Parry C., Bhana A., Dada S., and Fourie D., Alcohol 
and Drug Abuse Trends: January – June 2009, Phase 26 South Afri-
can Community Epidemiology Network on Drug Use (November 
2009).
29 Substance Abuse and Mental Health Services Administration, Results 
from the 2008 National Survey on Drug Use and Health: National 
A decrease in the annual prevalence of methampheta-
mine use was also observed among young adults aged 
18-25, from 0.6% in 2002 to 0.2% in 2008.30 While 
methamphetamine use in the general US workforce also 
dropped from 0.14% in 2007 to 0.11% in 2008, the 
proportion of positive urine test for amphetamine 
increased from 0.40% to 0.45% in the same period.31
Findings,,US Department of Health and Human Services, Office of 
Applied Studies, 2009.
30 Ibid.
31 Quest Diagnostics, Drug Testing Index, May 2009.
Treatment demand for methampheta-Fig. 207: 
mine in the Czech Republic, 2002-2008
Source: Czech National Monitoring Centre for Drugs and Drug 
Addiction, Annual Report: The Czech Republic, 2008 Drug Sit-
uation, September 2009
Annual amphetamine-group users in Fig. 208: 
Africa
Source: UNODC ARQ
United States: Annual prevalence of Fig. 210: 
stimulants and methamphetamine use 
in the population aged 12 and older, 
2002-2008
Source: Substance Abuse and Mental Health Services Adminis-
tration. Results from the 2008 National Survey on Drug Use 
and Health: National Findings
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South Africa: trends in treatment  Fig. 209: 
demand in Cape Town with metham-
phetamine as the primary substance, 
% of all drug treatment, 2001-2009
Source: South Africa Community Epidemiology Network on 
Drug Use (data are reported bi-annually – (a) represents the 
first half and; (b) the second half of the year)
1.4
1.3
1.4
1.3
1.5
1.2
1.1
0.7 0.7
0.8
0.7
0.8
0.5
0.3
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
2002 2003 2004 2005 2006 2007 2008
A
n
n
u
al
 p
re
va
le
n
ce
 (
%
)
Stimulants (all types) Methamphetamine
222
World Drug Report 2010 
In contrast to the United States, Canada registered an 
increase in amphetamine-group substance use between 
2004 and 2008. In Canada, the annual prevalence of 
amphetamines-group stimulants use was reported in 
2008 as 1.5% among the population aged 15-64, com-
pared to 1% in 2004. The current prevalence of amphet-
amine-group substances use is substantially higher than 
that reported for opioid pain relievers. In the Canadian 
Alcohol Drug Use Monitoring Survey, one in four drug 
users reported the use of stimulants to ‘get high’.32 
Experts in Mexico perceive an increase in amphetamine 
use. The annual prevalence of amphetamine use was 
estimated at 0.16% of the population aged 12-65 in 
2008. The annual prevalence of amphetamine and 
methamphetamine use among 12-19 year olds was 
reported as 1% and 0.4%, respectively.
Mixed trends for amphetamines-group substance 
use in South America and Caribbean
Experts in many countries in South America, in particu-
lar Ecuador, El Salvador and Paraguay, report an increase 
in methamphetamine use over the past year. In 2008, 
there were an estimated 1.3 to 1.8 million people (annual 
prevalence 0.5%-0.7%) who had used amphetamine-
group substances in the region. In 2008, new informa-
tion was made available to UNODC from several 
Caribbean countries. The annual prevalence of amphet-
amine-group substance use in this region ranges from 
0.1% to 1.9% of the population aged 15-64 (between 
30,000 and 500,000 people). The wide range is mainly 
due to uncertainties arising from absence of reliable 
estimates in the region and the wide range of estimates 
observed in the countries where data on annual preva-
32 Health Canada, Canadian Alcohol and Drug Use Monitoring Survey: 
Summary of Results for 2008.
lence could be estimated.33 In Central and South Amer-
ica, new information for 2008 show a minor increase in 
Suriname (from 0.6% to 0.7% of the annual prevalence 
of people aged 12-65) and a stabilization in Colombia 
and Chile where the annual prevalence remained at 
0.5% and 0.4%, respectively. Panama revised its esti-
mate for the annual prevalence of ATS use among its 
adult population for 2003 (latest year available) from 
0.6% to 1.2%. 
Problem methamphetamine use high in Oceania, 
though improving 
The prevalence of amphetamines use in New Zealand 
(2.1% among the population aged 16-64) in 2008 and 
Australia (2.7% among the population aged 15-64) in 
2007 remains one of the highest in the world, though 
there are signs of a declining trend in recent years. In 
some of the US territories in the Pacific there are reports 
of high methamphetamine use among young people 
where the lifetime prevalence ranged from 13.1% in 
the Marshall Islands to 5.9% in Guam and 4.9% 
in Commonwealth of the Northern Mariana Islands 
(CNMI).34 
Amphetamine-group substances also remain one of the 
main problem drugs in New Zealand and Australia. In 
the two countries, the Drug Use Monitoring in Australia 
(DUMA) and the New Zealand Arrestee Drug Abuse 
33 A series of school surveys were recently undertaken in selected Car-
ibbean countries. Based on the results of these surveys, the annual 
prevalence among the adult population could be estimated. 
34 Centre for Disease Control and Prevention, Youth Risk Behaviour 
Surveillance – selected steps communities, United States, 2007.
United States: percentage of positive Fig. 211: 
drug tests for amphetamine-group 
substances in the US general work-
force, 2004-2008
Source: Quest Diagnostics, Drug Testing Index
Annual prevalence of amphetamine-Fig. 212: 
group use, 1998-2007
Source: Australian Institute of Health and Welfare, 2007 
National Drug Strategy Household Survey: Drug Statistics, 22, 
Canberra, 2008; Wilkins C. and Sweetsur P., Trends in popula-
tion drug use in New Zealand: Findings from national house-
hold survey of drug use in 1998, 2001, 2003 and 2006, New 
Zealand Medical Journal, 121, 61-71, 2008
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Monitoring (NZ-ADAM) programmes measure drug 
and alcohol use among people who have recently been 
detained by police. In 2008, 21% of detainees across 
Australia had tested positive for methamphetamine – 
although this shows a decline from the previous year 
(27% in 2007) and the lowest positive test rate for 
methamphetamine since 1999.35 Similarly in New Zea-
land, among the police detainees who were tested for 
drugs, methamphetamine and amphetamine were the 
second and third most commonly detected drugs (10% 
and 9%, respectively).36 In Australia, the most com-
monly injected substances were also amphetamines-
group substances, where 67% of the injecting drug users 
interviewed had injected some form of methampheta-
mine in the preceding six months.37
‘Ecstasy’-group consumption 
Globally, between 10.5 and 25.8 million people were 
estimated to have used ‘ecstasy’ group38 substances (pri-
marily MDMA and its analogues) in the previous year. 
This range compares with a range of 11.6 - 23.5 million 
reported for 2007. The highest prevalence of ‘ecstasy’ 
use remains in Oceania (3.6%-4%) while in absolute 
terms, Europe had the highest number of users in 2008, 
35 Gaffney A., Jones W., Sweeney J. and Payne J., Drug use Monitoring 
in Australia: 2008 annual report on drug use among police detainees, 
AIC Monitoring Reports 2009.
36 Hales J. and Manser J., Annual Report 2008, New Zealand Police 
ADAM, Health Outcomes International Pvt. Ltd, October 2008.
37 National Alcohol and Drugs Research Centre, Australian drug trends 
2009: Findings from the Illicit Drug Reporting System (IDRS), Univer-
sity of New South Wales.
38 Reports show that unbeknown to many ‘ecstasy’ users, what is sold to 
them as ‘ecstasy’ (MDMA) is often a combination of many psychoac-
tive substances, such as methamphetamine and ketamine. Ampheta-
mines and Ecstasy: 2008 Global ATS Assessment (United Nations 
publication, Sales No. E.08.XI.12).
with some 3.9 - 4.1 million people aged 15-64 estimated 
to have used ‘ecstasy’ at least once in the previous year. 
For most parts of Asia as well as Africa, information on 
‘ecstasy’ use is missing, which introduces a high level of 
uncertainty in the global estimates. 
Many countries in Asia report an increase in 
‘ecstasy’ use
In 2008, 56 Member States provided information on 
experts’ perception on trends in ‘ecstasy’ use. Experts in 
half of these countries thought that ‘ecstasy’ use had 
been stable in 2008, while one third considered that it 
had increased. Most of the countries/territories report-
ing an increase were in Asia – in particular Bangladesh, 
China including Macao, Indonesia, Mongolia, Pakistan 
and Viet Nam. New estimates provided by Indonesia on 
the annual prevalence of ‘ecstasy’ use among the popula-
tion aged 15-64, however, showed a slight decrease from 
0.3% in 2005 to 0.2% in 2008.
Mixed trends for ‘ecstasy’ use reported in Europe
In Europe the annual prevalence of ‘ecstasy’ use is esti-
mated at 0.7% of the population aged 15-64. A higher 
prevalence rate as well as a higher total number of 
‘ecstasy’ users are reported from West and Central 
Europe as compared to East and South-East Europe. 
The high prevalence countries remain the Czech Repub-
lic, Slovakia, Estonia, the United Kingdom and Latvia, 
while Romania, Greece and Poland have negligible or 
quite low ‘ecstasy’ use. In those countries where data on 
annual prevalence in the adult population was available 
for 2008, the picture is mixed. Some registered an 
increase (the Czech Republic, Denmark, England and 
Wales, the former Yugoslav Republic of Macedonia and 
Slovakia) and others a decrease (Estonia, Lithuania and 
Scotland). 
Australia: percentage of  injecting drug users who reported use of any form of  Fig. 213: 
methamphetamine in the preceding six months, 2003-2009
Source: National Alcohol and Drugs Research Centre, Australian drug trends 2009: Findings from the Illicit Drug Reporting System 
(IDRS) University of New South Wales
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Compared to methamphetamine and amphetamine, use 
of ‘ecstasy’ is much more common among young adults 
aged 15-34 (national estimates ranging between 0.1% 
– 3.1% of past year amphetamine prevalence, compared 
to 0.2% – 7.7% for ‘ecstacy’ use). Most of the countries, 
though, have reported a decreasing or stabilizing trend 
of ‘ecstasy’ use among young adults.39
The school survey conducted under the European 
39 EMCDDA, Annual report 2008: the state of the drug problems in 
Europe, Lisbon 2008.
School Survey Project on Alcohol and Other Drugs 
(ESPAD) and other school surveys conducted in 2007 
suggest, overall, little change in the levels of ‘ecstasy’ use 
among students aged 15 to 16. Compared to 2003, 
overall increases in ‘ecstasy’ use was observed in 12 coun-
tries, with Latvia, Bulgaria, Slovakia, Denmark, Hun-
gary and Malta showing marked increases over this 
period. The Czech Republic, Portugal and Croatia 
reported substantial decreases, while ‘ecstasy’ use 
remained stable in the remaining countries.40
40 Hibel B., Adersson B., Bjarnason T., Ahlstrom S., Balakireva O., 
Estimated number of people who used ‘ecstasy’ at least once in the past year and  Table 29: 
prevalence among the population aged 15-64, by region, 2008
‘Ecstasy’ use: lower and upper ranges of numbers and annual prevalence globally and  Fig. 214: 
by region, 2008
Region/ Subregion  
(Ecstasy-group)
Estimated 
number of 
users annually 
(lower)
-
Estimated 
number of 
users annually 
(upper)
Percent of 
population 
age 15-64 
(lower)
-
Percent of 
population 
age 15-64 
(upper)
Africa 350,000 - 1,930,000 0.1 - 0.4
Eastern Africa Subregional estimate cannot be calculated
North Africa Subregional estimate cannot be calculated
Southern Africa 220,000 - 420,000 0.2 - 0.4
West and Central Africa Subregional estimate cannot be calculated
Americas 3,040,000 - 3,280,000 0.5 - 0.5
Caribbean 10,000 - 240,000 0.1 - 0.9
Central America 20,000 - 30,000 0.1 - 0.1
North America 2,490,000 - 2,490,000 0.8 - 0.8
South America 510,000 - 530,000 0.2 - 0.2
Asia 2,370,000 - 15,620,000 0.1 - 0.6
Central Asia Subregional estimate cannot be calculated
East/ South-East Asia 1,460,000 - 6,850,000 0.1 - 0.5
Near and Middle East Subregional estimate cannot be calculated
South Asia Subregional estimate cannot be calculated
Europe 3,850,000 - 4,080,000 0.7 - 0.7
Eastern/ South-East Europe 1,680,000 - 1,890,000 0.6 - 0.6
Western/ Central Europe 2,180,000 - 2,190,000 0.8 - 0.8
Oceania 840,000 - 910,000 3.6 - 4.0
Global 10,450,000 - 25,820,000 0.2 - 0.6
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‘Ecstasy’ use declined in North America after 2001, 
but there are early signs that it may recover
In the United States, after a decline in the annual preva-
lence of ‘ecstasy’ use from 1.3% in 2002 to 0.9% in 
2003 among the population aged 12 and older, the 
trends have remained stable over the past five years. 
However, there are signs of a possible resurgence. The 
annual prevalence of ‘ecstasy’ use among 10th grade 
students in the United States fell from 6.2% in 2001 to 
2.4% in 2004, and has been increasing since then. The 
annual prevalence among 8th and 12th grade students, 
though, remains stable. It is considered that diminishing 
perceived risks and disapproval among the students in 
US may cause a rebound in ecstasy use.41 In Canada, the 
annual prevalence of ‘ecstasy’ use has increased from 
1.3% in 2004 to 1.7% in 2008.
Kokkevei A. and Morgan M., The ESPAD Report: Alcohol and other 
Drug Use Among Students in 35 European countries, 2003, 2007.
41 National Institute on Drug Abuse Monitoring the Future, Overview of 
Key Findings 2008 (Bethesda, Maryland, USA, 2009).
National experts’ perception of trends in ‘ecstasy’ use by region, 2008Table 30: 
Source: UNODC ARQ
Region
Member 
States  
providing  
perception 
data
Member 
States  
perception 
response 
rate
Use  
problem 
increased*
Percent 
use  
problem 
increased
Use  
problem 
stable
Percent  
use  
problem 
stable
Use  
problem 
decreased*
Percent 
use  
problem 
decreased
Africa 4 8% 1 25% 3 75% 0 0%
Americas 12 34% 1 8% 11 92% 0 0%
Asia 15 33% 8 53% 4 27% 3 20%
Europe 24 53% 7 29% 12 50% 5 21%
Oceania 1 7% 1 0 0
Global 56 29% 18 32% 30 54% 8 14%
* Identifies increases/ decreases ranging from either some to strong, unweighted by population.
Trends in annual prevalence of ‘ecstasy’ use among young adults (aged 15-34)Fig. 215: 
Source: EMCDDA, Annual report 2008: the state of the drug problems in Europe, Lisbon 2008
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Stabilizing trends of ‘ecstasy’ use in South America
Experts from most countries in South America reported 
a stable trend in the use of ‘ecstasy’ in their countries. 
New data from Colombia show an increase in the adult 
prevalence rate of ‘ecstasy’ use (from 0.2% estimated in 
2005 to 0.3% estimated in 2008). Estimates for the 
Bolivarian Republic of Venezuela for 2005 were also 
revised downward (from 0.2% in 2001 to less than 
0.01% in 2005). The annual prevalence in the region 
remains low compared to North America or Europe.
‘Ecstasy’ use still high in Oceania, but the quality of 
‘ecstasy’ may vary
The Oceania region reportedly has one of the highest 
annual prevalence rates of ‘ecstasy’ use, ranging between 
3.6% and 4% of the population aged 15-64. Both Aus-
tralia and New Zealand have reported high levels of 
‘ecstasy’ use, but the annual prevalence remained 
unchanged from the previous years (4.2% and 2.6%, 
respectively). In New Zealand, the extent to which the 
‘ecstasy’ sold in the country contains substances other 
than MDMA, such as benzylpiperazine (BZP) or keta-
mine remains unclear.42
42 Wilkins C., Griffiths R. and Sweetsur P., Recent Trends in Illegal Drug 
Use in New Zealand, 2006 – 2008: Findings from the 2006, 2007 
and 2008 Illicit Drug Monitoring System (IDMS), SHORE, Massey 
University.
European countries with a decrease Fig. 217: 
in ‘ecstasy’ use among students aged 
15-16
Source: ESPAD
United States: Trends in the annual Fig. 218: 
prevalence of ‘ecstasy’ use among  
the population aged 12 and older, 
2002-2008
Source: Substance Abuse and Mental Health Services Adminis-
tration, Results from the 2008 National Survey on Drug Use 
and Health, US Department of Health and Human Services
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3.0 The destabilizing influence of drug trafficking 
on transit countries: The case of cocaine
In the past decade, the United Nations has come to 
recognize the relationship between political instability 
and organized crime, particularly drug trafficking. The 
United Nations Convention against Transnational 
Organized Crime came into effect in late 2003. In 2004, 
the High-level Panel on Threats, Challenges and Change 
argued:
One of the core activities of organized criminal groups 
- drug trafficking – has major security implications… 
In some regions, the huge profits generated through this 
activity even rivals some countries’ GDP, thus threaten-
ing State authority, economic development and the rule 
of law.1
This report was followed by the Secretary-General’s 
report In Larger Freedom, which concludes:
Organized crime contributes to State weakness, impedes 
economic growth, fuels many civil wars, regularly 
undermines United Nations peacebuilding efforts and 
provides financing mechanisms to terrorist groups.2
More recently, in December 2009, the Security Council 
issued a Presidential Statement on Peace and Security in 
Africa, which urged the Secretary-General to consider:
…mainstreaming the issue of drug trafficking as a 
factor in conflict prevention strategies, conflict analysis, 
integrated missions’ assessment and planning and 
peacebuilding support.3 
Taking up this challenge, Secretary-General Ban Ki-
moon, speaking at the African Union summit in January 
2010, concluded, “Drug trafficking is … a rising threat 
to international peace and security in Africa.”4 And in 
February 2010, the Security Council noted with con-
cern “the serious threats posed in some cases by drug 
trafficking and transnational organized crime to interna-
tional security in different regions of the world.”5
1 High-level Panel on Threats, Challenges and Change, A more secure 
world: Our shared responsibility. United Nations, 2004, p.53.
2 Report of the Secretary-General, In larger freedom: towards develop-
ment, security and human rights for all. United Nations General 
Assembly, Fifty-ninth session (A/59/2005), 21 March 2005, p. 27.
3 S/PRST/2009/32.
4 Secretary-General Ban Ki-moon, Remarks to the Summit of the 
African Union – “An Agenda for Prosperity and Peace,” Addis Ababa, 
31 January 2010.
5 S/PRST/2010/4.
Two types of impact
What is behind these assertions? How, exactly, can drug 
trafficking pose a threat to stability? There are at least 
two ways. The first involves countries where insurgents 
and illegal armed groups draw funds from taxing, or 
even managing, drug production and trafficking. The 
second concerns countries that do not do not face such 
a situation, but where the drug traffickers become pow-
erful enough to take on the state through violent con-
frontation, high-level corruption, or (usually) both. 
Not every country is equally vulnerable to this threat. 
Drug trafficking is problematic for any country it touches, 
but it can become particularly destabilizing where there 
are pre-existing governance issues. The small size of the 
local economy relative to the value of the drug flow, as 
the High-level Panel suggested, is also relevant. The two 
are often related: governments in countries with small 
economies may have trouble asserting authority over 
their sovereign territory or developing remote areas of the 
country; prolonged instability can also keep economies 
from growing. This is why the focus has increasingly 
been on Africa, a continent where there are many poor 
and unstable countries, but where, for a variety of rea-
sons, the worst effects of drug trafficking have not yet 
been experienced. When drug routes pass though African 
soil, like the recent flow of cocaine though West Africa, 
the international community is rightly concerned.
Of course, drug trafficking is not unique in this respect. 
The money gained through all forms of organized crime 
can cause trouble, and smuggling of contraband (such as 
cigarettes, diamonds, timber or oil) has been a mainstay 
of rebel financing for decades. But the drug markets are 
simply worth more money than those of other contra-
band goods, and since they are illicit, drugs remain 
unambiguously the domain of organized criminals.
It is also true that certain types of drugs are more rele-
vant than others. Cannabis and synthetic drugs are 
produced almost everywhere, so there is limited need for 
trans-regional trafficking. Cannabis has been suggested 
as a source of funding for rebel movements in regions as 
diverse as Casamance (Senegal), Aceh (Indonesia) and 
southern Nepal. Methamphetamine has been key to 
funding the ethnic militias in Myanmar. But the most 
lucrative drug flows originate in poor and unstable areas 
and end in the richest nations on earth. Cocaine and 
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heroin are strongly associated with specific sources of 
supply in poor areas and specific rich consumer coun-
tries. The value of these flows and the concentration of 
production and trafficking intensifies the destabilizing 
effect. 
Almost all the world’s heroin and the vast bulk of the 
world’s cocaine is produced in countries that have expe-
rienced insurgency problems. While both opium poppy 
and coca bush are optimally productive under particular 
climatic conditions, they could be grown in a much 
wider range of countries than is currently the case (and 
they have been, historically). The production of these 
drugs is reliant on crops that require large cultivation 
areas, however, and the international control system has 
compelled national governments to take strong action 
against any such cultivation that occurs within their 
borders. As a result, wide-scale cocaine or heroin pro-
duction is only possible in countries where there are 
stretches of rural area that the state is struggling to fully 
service and control. These conditions also happen to 
favour the growth of guerrilla armies.
In the absence of the sort of outside funding found 
during the Cold War, insurgents and illegal armed 
groups are often compelled to derive their sustenance 
from the regions they dominate, and these unstable areas 
are often already enmeshed in drug trafficking. The 
money associated with organized crime can be so great 
that militants may forget about their grievances and 
focus on satisfying their greed. Even where this is not 
true, drugs pay for bullets and provide a lifestyle to com-
batants that makes them less likely to come to the nego-
tiating table. It becomes entirely feasible to make a 
career out of militancy, and this prolongs civil conflict.
The best examples of this phenomenon are the primary 
cultivation areas for opium poppy, the crop from which 
heroin is derived: Afghanistan and Myanmar. In both 
countries, rebel armies are at least partly funded by the 
drug trade. Large-scale opium poppy cultivation requires 
large land areas, and is a highly labour-intensive activity. 
To generate the heroin needed to satisfy global demand, 
thousands of hectares and hundreds of thousands of 
workers must be employed without state interference, 
and the best deterrent for state interference with this 
process is a rebel army. Without an active conflict, heroin 
production can be eliminated, as has been done in a 
series of countries where insurgency was either absent or 
had less territorial control, including Turkey, the Islamic 
Republic of Iran, Pakistan, Thailand, the Lao People’s 
Democratic Republic, China and Lebanon. 
Today, heroin production is strongly associated with 
insurgent activity: in 2009, Afghanistan was responsible 
for 90% of global opium production, and 99% of all 
opium produced there came from just seven provinces 
in southern and western Afghanistan, where the rebel 
groups are strongest. But the insurgents do not control 
the trafficking activity. Forces aligned to the Taliban 
garnered at least an estimated US$125 million per year 
through taxation of cultivation, production and traf-
ficking.6 This is about 7% of the value of the trade in 
Afghanistan. While the drug trade provides some funds 
for the conflict, more significant is the cover the conflict 
provides for the drug trade. Those who profit most from 
heroin trafficking are professional criminals and their 
network of corrupt officials.
Conflict zones are not the only places where transna-
tional organized crime can pose a threat to the state, 
however. There are a number of areas around the world 
where criminals have become so powerful that, rather 
than seeking to evade the government, they begin to 
directly confront it (though violence) or usurp it (through 
high-level corruption). The ideal case for traffickers is an 
authoritarian state where the authority is in their pocket. 
Under these circumstances, there is little violence and 
the trafficking may remain completely invisible at the 
national level, only becoming exposed when interna-
tional evidence is brought to bear. Democracies are typ-
ically more challenging, requiring both violence and 
corruption to achieve the traffickers’ objectives.
The violence can assume many forms. Investigators, 
prosecutors and judges who pursue organized criminals 
are threatened and killed. Journalists and activists may 
also be targeted. Portions of the country may effectively 
drift beyond state control, particularly those that were 
under-served by the state in the first place. The effect 
can be very similar to an insurgency, but the two phe-
nomena remain distinct, for reasons discussed below.
Efforts to stop trafficking can temporarily exacerbate this 
violence, particularly where the groups involved have 
begun to command trafficking turf and achieved some 
sort of an institutional identity of their own. Under pres-
sure, groups may inform on one another, using the state 
enforcement apparatus to achieve their commercial objec-
tives and divert attention from themselves. This typically 
results in reprisal attacks. Decapitating trafficking groups 
can trigger succession struggles and the fragmented 
organizations that result can become prey for rivals. 
Organized crime becomes disorganized, releasing vio-
lence as the structures decompose. This violence can fuel 
public demands that enforcement be suspended, but this 
difficult period must be weathered. The smaller groups 
that result will no longer have the same capacity to chal-
lenge the state, and the violence will ultimately decline.
Violence is a visible manifestation of states under stress, 
but even more damaging is the insidious effect of cor-
ruption. Most traffickers seek to pay local officials to 
6 It is estimated that the Taliban pocketed around $350-650 million 
from the opiate trade between 2005 and 2008 through direct taxa-
tion of farmers and traffickers, see Addiction, crime and insurgency: 
the transnational threat of Afghan opium, Vienna: UNODC, 2009, p. 
111.
233
The destabilizing influence of drug trafficking on transit countries: The case of cocaine
look the other way. Destabilization is only really a threat 
when the corruption reaches the top, and those charged 
with stopping the trafficking begin to actively promote 
it. This can cause the entire law enforcement mechanism 
to seize up, as authorities become paralysed by mistrust. 
The effect on public confidence in government can be 
devastating, and democratic governments that seek to 
expose the rot may be penalized at the polls. All the 
incentives are in place for a downward spiral in govern-
ance that can be extremely challenging to reverse.
Organized criminals generally do not seek to topple the 
state. They mostly want to be left alone to pursue their 
illicit profits. But they can provoke a reaction that can 
also threaten long-term prospects for democratic stabil-
ity. A clear sign that crime has become a national security 
threat comes when exceptional legal and security meas-
ures are taken, including calling on the military to help 
re-establish the government’s authority. It is sometimes 
necessary for states to, in effect, reacquire territory lost 
to criminal groups, and, in some countries, the military 
is both more disciplined and less corrupt than the civil-
ian police. In a world where international conflicts are 
becoming less common, using the armed forces to pro-
mote internal stability may be seen as cost effective. 
Such a move may have popular support in countries 
where people fear for their safety and are frustrated with 
the appearance of impunity. This must remain an option 
of last resort, however: the long-term use of regular 
military forces to police civilian populations presents 
risks for the rule of law and civil liberties. Particularly in 
countries where the military has played an important 
role in past authoritarian regimes, putting soldiers on 
the streets can be the first phase in a long-term roll-back 
of democratic values.
Growing popular discontent with the slow pace of civil-
ian enforcement may also trigger a less formal erosion of 
civic values and the rule of law. Military and police offi-
cials may become frustrated with a corrupt or ineffective 
criminal justice system and begin to engage in extrajudi-
cial executions. The public may form civilian “self-pro-
tection” groups as well, and these groups may even 
attract state recognition and support.
Civilian patrols are the normal reaction of citizens who 
feel they cannot rely on the state to protect them, but 
they can become the basis for something more sinister. 
Initially, volunteers may receive ad hoc contributions 
from the people and businesses they protect, but over 
time these fees may become mandatory. In unstable 
areas, a neighbourhood watch can become a protection 
racket, and, once its absolute authority is established, it 
can even become a predatory gang. Over time, these 
paramilitary vigilantes can become as big a security chal-
lenge as the criminals they were formed to combat.
These effects can be seen, to some extent, in many 
countries where cocaine trafficking is an issue. Of the 
countries with the highest murder rates in the world 
today, almost all lie along the key cocaine trafficking 
routes.
In the past, nearly all of the cocaine produced in the 
Andean region was consumed in the United States of 
America, but this has changed. The value of the cocaine 
market has fallen dramatically in the United States in 
the last decade, while it has grown remarkably in Europe 
and the Southern Cone of South America. Today, 
cocaine flows into three main destination markets: the 
United States (responsible for about 40% of the cocaine 
consumed in 2008), Europe (about 25%), and the 
Southern Cone of South America (10%-20%). Of 
course, the trafficking routes are also dynamic. Increas-
ingly, transit countries are used, including the Bolivarian 
Republic of Venezuela and Ecuador. In the 1970s and 
1980s, the Caribbean was the primary conduit for South 
American drugs destined for the United States; today, it 
Global cocaine ﬂows, 1998 and 2008Map 1: 
Source: UNODC Word Drug Report, 2009 and UNODC  
calculations, informed by US ONDCP, Cocaine Consumption 
Estimates Methodology, September 2008 (internal paper)
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is Central America. Transit routes to Europe have also 
shifted, recently including West Africa as a conduit.
Transit countries in South America3.1 
Traditionally, most of the cocaine departing Colombia 
left the country directly, by sea or by air, through the 
Gulf of Mexico or the Pacific. But increased interdic-
tion, combined with changes in market demand, has 
increased the importance of transit countries, particu-
larly the Bolivarian Republic of Venezuela, Ecuador and 
Brazil.
The drug trafficking situation in the Bolivarian Republic 
of Venezuela appears to be deteriorating. In 2008, the 
Bolivarian Republic of Venezuela was fourth in the world 
in annual cocaine seizures (34 mt), ahead of Peru and 
the Plurinational State of Bolivia. According to the new 
Maritime Analysis Operation Centre (MAOC-N), more 
than half of all intercepted shipments in the Atlantic (67 
incidents between 2006 and 2008) started their journey 
in the Bolivarian Republic of Venezuela. Direct ship-
ments from Colombia, in contrast, accounted for just 
5%.7 In addition, many undocumented air flights leave 
the country, and all the clandestine air shipments of 
cocaine detected in West Africa appear to have origi-
nated in the Bolivarian Republic of Venezuela. The 
country also appears to be the source of cocaine flown to 
clandestine airstrips in Honduras, with devastating 
effects there (discussed below).
At the same time, the Bolivarian Republic of Venezuela 
seems to be experiencing a remarkable upturn in crimi-
nal violence. This trend is difficult to track because the 
Venezuelan Government stopped publishing official 
crime statistics after 2003, but some institutions con-
tinue to monitor the issue.8 
The murder rate in the Bolivarian Republic of Venezuela 
has increased markedly since the end of the Cold War, 
but especially since the late 1990s. There may be many 
reasons for this, but it happens to have occurred just as 
Colombian illegal armed groups' involvement in the 
cocaine trade began to pick up. There was a brief drop 
after 2003, when Colombia began to reduce the size of 
the illegal armed groups, followed by a resurgence after-
wards. Today, there are eight times as many murders as 
there were two decades ago, and the murder rate per 
100,000 population appears to be in the low 60s, among 
the highest in the world. Kidnappings also appear to 
have greatly increased, with the areas bordering Colom-
bia being among the worst affected.
 
7 Maritime Analysis Operation Centre (MAOC(N), Statistical Analysis 
Report, Lisbon 2009.
8 Such as the Observatorio Venezolano de Violencia at the Universidad 
Central de Venezuela.
There are other reasons to be concerned about the 
potential impact of cocaine trafficking on Venezuelan 
stability, including parallels to the Colombian situation. 
The Bolivarian Republic of Venezuela has had insurgent 
groups, such as the Bolivarian Liberation Front, which 
are very similar to the FARC. These groups have effec-
tively been co-opted by the Government, but maintain 
armed cells, including some along the borders with 
Colombia, Ecuador and Brazil. The Government has 
also begun arming and supporting civilian militias (the 
'national reserve'). Experience in other countries has 
shown that such a move can fuel organized crime.
Ecuador has long been used by traffickers as a secondary 
corridor for cocaine trafficked through the Pacific, and 
this problem has grown as the importance of the Pacific 
maritime corridor has grown. The role of the FARC in 
Colombian trafficking through Ecuador has also 
increased in importance. The FARC’s forty-eighth front, 
situated along the border with Ecuador, is regarded as 
being central to the illegal armed groups' cocaine traf-
ficking operations. 
Ecuador’s murder rate has been rising for a number of 
years. Ecuador is unusual in that the murder rate in the 
largest city (Quito) is generally less than the national 
average. In 1990, the highest provincial murder rate in 
Ecuador was in Los Rios, a poor province in the centre 
of the country. By 1995, the highest murder rate was 
found in Esmeraldas, a richer coastal province bordering 
Colombia, known for its use by drug traffickers. Esmer-
aldas is the one province of the country where small 
9 Briceño-León, R., “Diez años de Violencia en Venezuela” (and sub-
sequent reports) See: http://www.alertavenezuela.com/documen-
tos/getbindata.php?docid=137&fieldname=documento and http://
informe21.com/actualidad/impunidad-corrupcion-16047-homicidi-
os-nuestro-pais-2009-segun-informe
Departure locations of identiﬁed drug Fig. 1: 
trafﬁcking shipments by sea from 
South America to Europe, 2006-2008
Source: Maritime Analysis Operation Centre
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scale coca cultivation has been detected. By 1999, the 
murder rate in Esmeraldas was more than twice the 
national average, at 34 per 100,000,10 comparable to 
Colombia today.
Transit countries in the Caribbean 3.2 
As a conduit for cocaine imported into the United 
States, the Caribbean has greatly diminished in impor-
tance over the past 15 years. During the early days of the 
trade, traffickers preferred the Caribbean corridor and it 
was used preferentially from the late 1970s.11 In the 
1980s, most of the cocaine entering the United States 
came through the Caribbean into the southern part of 
the state of Florida.12 But interdiction successes, tied to 
the use of radars, caused the traffickers to reassess their 
routes. As a growing share of cocaine transited the south-
west border of the United States, Mexican groups wrested 
control from their Colombian suppliers, further direct-
ing the flow through Central America and Mexico.
Unfortunately, this decline has not necessarily led to 
increased stability or lowered violence in the transit 
countries. On the contrary, it seems that once the drug 
is introduced, instability in the market can drive vio-
lence. Jamaica provides a case in point. Estimates of the 
cocaine flow through Jamaica dropped from 11% of the 
10 Interamerican Development Bank, “Magnitud y Tendencias de la 
Violencia en Ecuador, 1990-1999” in Violencia y seguridad ciuda-
dana. Quito: IADB, 2001.
11 Statement of James Milford, Acting Deputy Administrator, United 
States Drug Enforcement Administration, before the Senate Sub-
committee on National Security, International Affairs, and Criminal 
Justice, 17 July 1997.
12 Statement of Thomas A. Constantine, head of the United States 
Drug Enforcement Administration, before the House of Representa-
tives Judiciary Committee, Subcommittee on Crime, 3 April 1997.
US supply in 200013 to 2% in 2005,14 and 1% in 
2007.15 This is reflected in declining seizures in Jamaica 
and declining arrests and convictions of Jamaican drug 
traffickers in the United States.16 It is also negatively 
reflected in the murder rate, which rose from 34 per 
100,000 in 2000 to 59 per 100,000 in 2008.
13 Statement of the Donnie Marshall, Administrator, US Drug Enforce-
ment Administration before the United States Senate Caucus on 
International Narcotics Control, 15 May 2001. 
14 National Drug Intelligence Centre, National Drug Threat Assessment 
2006. Washington, D.C.: Department of Justice, 2006. National 
Drug Intelligence Centre, National Drug Threat Assessment 2007 
Washington, D.C.: Department of Justice, 2007.
15 National Drug Intelligence Centre, National Drug Threat Assessment 
2009. Washington, D.C.: Department of Justice, 2009.
16 In 2000, the US federal authorities convicted 79 Jamaicans for 
cocaine trafficking. In 2008, they arrested just 35.
Murder count in the Bolivarian  Fig. 2: 
Republic of Venezuela, 1990-2009
Source: Observatorio Venezolano de Violencia24
Murders per 100,000 citizens in  Fig. 3: 
Ecuador, 1990-2008
Source: IADB, UNODC CTS
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There are historical reasons for this paradoxical effect. 
The importance of Jamaica as a transit country in the 
cocaine trade really rose after the violent 1980 elections 
in that country. A large number of important crime fig-
ures (including some so-called 'area dons' and their 
enforcers) left Jamaica for New York, where they became 
key suppliers in the crack cocaine boom. This period of 
growing criminal opportunities represented a time of 
relative calm in Jamaica. When this market died out and 
cocaine flows began to shift westward, these men returned 
to Jamaica to find a much less well organized crime 
scene, where 'neighbourhood dons' had turned to more 
direct means of income generation: violent acquisitive 
crime, including extortion and robbery. The Jamaican 
cocaine trade suffered another blow when cooperative 
efforts between Jamaican law enforcement and the United 
Kingdom sharply reduced the air courier traffic to Europe 
around 2002. Street-level competition for diminishing 
returns has fuelled growing homicide rates; the highest in 
the Caribbean and among the highest in the world.
A similar, but more compressed, effect could also have 
occurred in the Dominican Republic. The share of the 
US cocaine supply that transited Hispaniola dropped 
from 8% in 200017 to 2% in 2004, before rising again 
to 4% in 2005 and 9% in 2007.18 Around this time, the 
murder rate in the Dominican Republic doubled, from 
13 per 100,000 in 2001 to 26 per 100,000 in 2005. It 
has remained at high levels, and the drug trade in the 
Dominican Republic is still volatile. Dominican traf-
17 International Crisis Group, Spoiling security in Haiti, Latin Amer-
ica/Caribbean Report No 13. Brussels: International Crisis Group, 
2005.
18 National Drug Intelligence Centre, National Drug Threat Assessment 
2006. Washington, D.C.: Department of Justice, 2006. National 
Drug Intelligence Centre, National Drug Threat Assessment 2007 
Washington, D.C.: Department of Justice, 2007.
fickers have grown in importance in Europe since about 
2005, and today are second only to the Colombians 
among foreign cocaine traffickers arrested in Spain, the 
primary point of entry.
Another shift that may have affected local stability is the 
reduction in air courier traffic though the Netherlands 
Antilles. In 2000, 4.3 mt of cocaine were seized at 
Schiphol airport in the Netherlands,19 much of it origi-
nating from the Bolivarian Republic of Venezuela, via 
the Netherlands Antilles. A '100% control' strategy was 
introduced at the end of 2003,20 targeting the drugs 
19 INCB, Annual Report of the International Narcotics Control Board, 
Vienna: INCB, 2001.
20 National Ombudsman, 100%-controles op Schiphol: Over bolletjesslik-
kers en onschuldige slikverdachten. The Hague: Office of the National 
Ombudsman, 27 June 2006.
Cocaine seizures and murder rates  Fig. 5: 
in Jamaica, 2000-2008
Source: UNODC
Murder rates in the Dominican  Fig. 6: 
Republic, 1991-2009
Source: UNODC International Homicide Database
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rather than the couriers.21 As a result, this flow was 
almost entirely eliminated by 2006.
These interventions may have displaced some of the 
flow coming from the Bolivarian Republic of Venezuela 
through the Caribbean to Trinidad and Tobago, which 
saw a remarkable surge in seizures from 2000 to 2005. 
At the same time, that country’s murder rate tripled. 
Seizures have declined today, but the murder rate has 
remained high: 40 per 100,000 in 2008.
In addition, a number of other Caribbean countries 
have very high murder rates that are difficult to explain 
except in terms of the drug trade, particularly given 
relatively low rates in neighbouring countries.23
Transit countries in Mesoamerica3.3 
As Mexican traffickers wrested control of the most valu-
able portions of the trafficking chain from the Colom-
bians, Mexico itself has become by far the most important 
conduit for cocaine entering the United States. Today, 
some 200 mt of cocaine transits Central America and 
Mexico annually, bringing some US$6 billion to the 
regional 'cartels'. As a result, those who control the por-
tions of the Mexican border through which the bulk of 
the drug passes have gained wealth and power compara-
ble to that commanded by the Colombian cartels in 
their heyday. These groups command manpower and 
weaponry sufficient to challenge the state when threat-
ened, including access to military arms and explosives. 
21 Europol, European Union Situation Report on Drug Production and 
Drug Trafficking 2003 – 2004, The Hague: Europol, 2005, p. 4.
22 The final quarter (2/2006) is short by two weeks, as current data only 
extends to week 24 of 2006.
23 Due to their small population size, murder rates in the smaller islands 
tend to be highly volatile, so trend data are not presented. Some of 
these rates were higher in the recent past.
They also have the funds to sow widespread and high-
level corruption.
Fortunately, the Mexican Government has several advan-
tages the Colombian Government did not have, includ-
ing much greater resources. Further, the violence, while 
formidable in some areas, comes nowhere close to that 
experienced in Colombia, even when comparing the two 
countries today. It is highly likely that law enforcement 
pressure will have a similar effect in Mexico as in Colom-
bia, and the cartels, however powerful, will be disman-
tled. And, unlike Colombia, there are no comparable 
illegal armed groups around to pick up the pieces after-
wards.
Over 40,000 drug 'cartel' members have been arrested in 
Mexico in recent years, including many of the heads of 
Murders and cocaine seizures in  Fig. 8: 
Trinidad and Tobago, 1992-2005
Source: UNODC International Homicide Database
Caribbean murder rates  Fig. 9: 
(most recent data available)
Source: UNODC International Homicide Database
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these organizations. In 2009, 107 criminals were extra-
dited from Mexico to the United States, including key 
cartel figures, a technique that was pivotal in bringing 
down the big cartels in Colombia. Decapitating the 
Mexican cartels has spurred intra- and inter-cartel vio-
lence, as the survivors jockey for position and try to take 
advantage of rival weaknesses. The murder count has 
shot up, but the rate (about 12 per 100,000 in 2008) 
remains relatively low, and is about the same as in the 
mid-1990s. Most of the victims appear to be cartel mem-
bers, and this violence has further reduced the cocaine 
supply to the United States, creating a downward spiral 
from which the cartels will have difficulty escaping.
In Mexico, the cocaine trade is now dominated by a 
number of these cartels who compete to control border 
crossings and transportation routes. The leadership, turf 
and structure of these groups has shifted over time as 
conflicts both within and between the cartels, as well as 
enforcement efforts, force realignments. As of early 
2010, the dominant cartels were the following:
The Sinaloa Federation ? , led by billionaire, and Mexi-
co’s most wanted man, Joaquin “El Chapo” Guzman;
The Gulf Cartel ? , once the most powerful criminal 
organization in Mexico, now greatly weakened by the 
defection of Los Zetas;
Los Zetas ? , founded when a group of special forces sol-
diers defected to the Gulf Cartel and now operating as 
a traﬃcking organization in its own right;
The Juarez Cartel ? , also know as the Carrillo Fuentes 
Organization, which is struggling to maintain control 
24 Online database of the Mexican National Institute of Statistics 
and Geography (see: http://www.inegi.org.mx/est/contenidos/espa-
nol/proyectos/continuas/vitales/bd/mortalidad/MortalidadGeneral.
asp?s=est&c=11144).
over its plaza (smuggling turf ) in Ciudad Juarez, the 
city most aﬀected by cartel violence;
The Tijuana Cartel ? , also known as the Arellano Felix 
Organization, which is similarly struggling to main-
tain control over the Tijuana plaza;
The Beltran Leyva Organization ? , a breakaway from 
the Sinaloa cartel, now weakened by the recent arrests 
or killings of three of the ﬁve Beltran Leyva brothers; 
and
La Familia Michoacana ? , a Zetas breakaway based in 
Michoacan but expanding, renowned for its penchant 
for beheadings, quasi-religious ideology and domina-
tion of methamphetamine production.
Perhaps due to the recent slump in the cocaine trade, 
these groups are progressively engaging in a number of 
other organized crime activities, including migrant 
smuggling, kidnapping and extortion – all crimes that 
were prevalent in Mexico before cartel involvement. La 
Familia, which espouses a bizarre ideology combining 
aspects of evangelical Christianity with revolutionary 
populism, provides the most extreme example, 'taxing' 
businesses in the areas they control and engaging in very 
public displays of violence to soften resistance.
The most violent city in Mexico has been the plaza of 
Juaréz, where murder rates are among the highest in the 
region. As in Jamaica, murders in Juaréz increased when 
the enhanced security presence stopped the flow of 
cocaine through the city. Street gang members who had 
been stringing for the cartels found themselves without 
an income, and resorted to violent acquisitive crime.
Mexico’s struggle has attracted a lot of attention, with 
much less falling on an area far more threatened: Central 
America. As maritime interdiction has increased and 
Mexico itself has become far more contested, a growing 
Number of homicides in Mexico  Fig. 11: 
(public health data), 1990-2008
Source: Instituto Nacional de Estadística y Geografía40
Comparative regional murder rates  Fig. 12: 
in 2008, selected countries in the 
Americas
Source: UNODC International Homicide Statistics
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share of cocaine headed northward is passing through 
northern Central America, including El Salvador, Hon-
duras, Guatemala and Belize. The murder rates in these 
four countries are three to five times higher than in 
Mexico, and both the economy and the state are far less 
robust and resilient. 
The Northern Triangle of Central America is still reeling 
from the brutal civil wars in Guatemala (1960-1996) and 
El Salvador (1980-1992). The region suffers from having 
one of the most unequal distributions of income in the 
world, comparable only to southern Africa or the Andean 
countries. Small elites working with strong militaries 
have long dominated countries in this region, exporting 
agricultural commodities, as well as engaging in other 
labour-intensive enterprises. The threat of renewed insta-
bility and conflict remains. Guatemala has long had a 
problem with vigilante justice; a response to a lack of 
police presence in much of the country. Honduras expe-
rienced a coup d’état in 2009, when the serving president 
attempted to attain public support for an extended term 
of office.
As a result of this legacy of violence, instability and 
inequality, the Northern Triangle of Central America has 
the highest murder rate of any region in the world, and 
very high rates of other forms of violent crime. It has 
also experienced political violence, and at times the dis-
tinction between criminal and political violence can be 
difficult to discern. The southern countries in Central 
America do not appear to be as affected by drug traffick-
ing as those in the north, and do not have comparable 
murder rates, despite a history of political violence in 
countries like Nicaragua.25
25 There are exceptions in areas highly affected by drug trafficking. 
For example, the murder rate in Panama in 2006 was only 11 per 
100,000, but the rate in Panama City was 30 per 100,000.
Contrary to what would be expected, in none of these 
countries is the highest murder rate found in the largest 
cities. Rather, it is found in provinces that have strategic 
value to rival drug traffickers. For example, Guatemala’s 
Petén province is rural and largely indigenous, two vari-
ables that negatively correlate with violence elsewhere in 
the country. But it is also a major drug trafficking zone, 
where jungle landing strips provide easy access to the 
Mexican border. It may also be a contested area, where 
Los Zetas and the Sinaloa Federation both have an inter-
est. These are likely the reasons it has the highest murder 
rates in the country. 
Other provinces have the misfortune of containing key 
ports for traffickers, such as the provinces of Atlántida 
in Honduras, Sonsonate in El Salvador, Escuintla in 
Guatemala and Michoacán in Mexico. The death count 
has risen over time as a growing share of cocaine traffick-
ing is conducted through this region. It also appears that 
Mexican cartels are settling their differences further up 
the trafficking chain, employing local killers to disrupt 
the operations of their rivals.
Honduras has the unfortunate distinction of having the 
fastest-growing murder rate in the region, which may be 
associated with increased use of the country as a landing 
site for cocaine-laden aircraft from Colombia and the 
Bolivarian Republic of Venezuela. It also hosts the prov-
ince with the highest murder rate in the region: Atlánt-
ida, where one out of every 1,000 people was murdered 
last year. The capital of Atlántida is La Ceiba, a port well 
known for its use by cocaine traffickers, and the site of 
clandestine landing strips.26 In December 2009, Gen-
eral Aristides Gonzalez, director general of the national 
office for combating drug trafficking, was murdered. 
The General had embarked on a campaign against the 
unauthorized airports found across the country, some of 
which are said to be linked to the Sinaloa Federation. 
Just before his murder, he had seized a major strip, and 
threatened to take action against all property owners on 
whose land the strips were found. 
The groups involved in this region are less well-defined 
than in Mexico. For most forms of crime in the region, 
the blame often falls on two street gang confederations 
founded by deportees from the USA: Mara Salvatrucha 
(MS13) and Calle 18 (M18). But there is little evidence 
that these groups, comprised of street youth intensely 
focused on neighbourhood issues, are widely engaged in 
large-scale transnational drug trafficking. Most are based 
in inland cities, far from the maritime routes along 
which most cocaine flows before arriving in Mexico. 
They are certainly culpable in street sales in the areas 
they control, but their capacity to engage in bulk trans-
26 La Ceiba was regarded as a major drug trafficking port by the US 
Drug Enforcement Administration as early as 2001. (See: http://
www.hawaii.edu/hivandaids/Honduras_Country_Brief__Drug_Sit-
uation_Report.pdf ).
Murder rate trends in Mesoamerica Fig. 13: 
(per 100,000 inhabitants), 2003-2008
Source: UNODC International Homicide Statistics
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national smuggling is questionable. Some may be 
recruited as hit men by the Mexican organizations. They 
frequently tattoo their faces as a sign of their commit-
ment to the gang, however, so they are ill-suited for any 
operation involving possible contact with the public or 
the authorities. The maras have engaged in demonstra-
tive violence in the past, including the random killing of 
civilians, but there is little to indicate they have any kind 
of political agenda, aside from avoiding police interfer-
ence with their affairs.
The repeated arrests of high-level officials in the police 
and the military, in contrast, suggest that the main traf-
fickers in Central America are far more sophisticated 
than street gangsters, and are tied to some members of 
the ruling elites, rather than the underclass. There is also 
growing evidence of Mexican cartel penetration into 
Central America, particularly regarding Los Zetas in 
Guatemala and the Sinaloa Federation in Honduras. 
In both Mexico and Central America, trafficking groups 
have gone on the offensive, murdering a number of 
prominent law enforcement officials who dared to 
oppose them. For example, in December 2009, the head 
of the Honduran anti-drug agency was murdered, as was 
Mexico’s federal police chief in 2008. Organized crimi-
nals also target rank-and-file police officers for retalia-
tory killings. In June 2009, 12 federal police agents were 
tortured and killed, and their bodies dumped, when the 
Mexican police arrested a high ranking member of La 
Familia Michoacana. Civilians have also been targeted 
for demonstrative attacks, such as the 2008 Indepen-
dence Day grenade attacks in Morelia.
In all of these countries, cocaine-related corruption at 
the highest levels, on occasion including the national 
heads of police and drug enforcement agencies, has been 
detected. For example, the Guatemalan police have been 
through a long series of purges and reformations. In 
August 2009, President Colom fired the director general 
of the national police, his deputy, his operations head 
and his investigations head after large amounts of cocaine 
and cash went missing. Before this, in 2005, the country 
suffered the indignity of having its top drug officials 
Murder rates in Mesoamerica, 2009Map 2: 
Source: Official sources
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arrested by a foreign government: the head of the drug 
enforcement agency, his deputy and another top drugs 
official were arrested for drug trafficking after being 
lured to the United States on pretence of training. The 
drug enforcement branch they commanded was itself a 
reworking of a previous agency, which had been dis-
banded following arrests of members for similar diver-
sions. The agency was reworked yet again in 2009.
The United Nations Commission against Impunity in 
Guatemala (CICIG) assisted in investigations in which 
the national director of the civilian police, his deputy 
director, the attorney general, the chief prosecutor, the 
head of the public defence institute, and three supreme 
court justices were removed from office. It also assisted 
in the indictment of the former President (Antonio Por-
tillo), the former minister of defence (Eduardo Arévalo 
Lacs), the former finance minister (Manuel Maza Cas-
tellanos), two acting directors of police, the director of 
the Anti-Narcotics Investigation and Analysis Depart-
ment and a major general (Enrique Ríos Sosa, son of the 
former dictator Efraín Ríos Montt). 
Similarly, in August 2008, the Mexican Government 
launched 'Operation Cleanup', aimed at purging the 
top ranks of the police of drug cartel corruption. The 
operation resulted in the jailing of both the interim 
commissioner of the Federal Police and the acting head 
of the counternarcotics division, among others. The 
same month, El Salvador’s chief of police resigned when 
two top aides were accused of drug links. The corrup-
tion extends outside the police, and has implicated other 
criminal justice officials, legislators and members of state 
and local government. 
But this situation is complicated: accusations of drug 
complicity can be used to take out opponents, and some 
of those assassinated by traffickers may have been erst-
while collaborators. The fact that high-level corruption 
continues to be detected and the officials removed shows 
that the struggle is very much alive and that progress is 
being made.
Some have argued that the violence in Mexico is tied to 
the Government’s efforts to stop the drug trade, not the 
drug trade itself. While it is true that enforcement can 
create instability in drug markets that can lead to vio-
lence, enforcement in countries like Guatemala is much 
weaker and the murder rate is at least four times higher. 
In addition, most of the deaths in the 'cartel wars' are of 
cartel members themselves, fighting over trafficking 
routes. These groups have shown their willingness to 
diversify into other areas of crime, and recent losses in 
cocaine revenues seems only to have intensified the vio-
lence. A policy of appeasement is impractical: these 
people, and corrupt officials who support them, cannot 
be allowed to remain in place. The treatment is painful, 
but the alternative is to lose the patient itself.
This may sound like an exaggeration, but many who 
have worked closely with law enforcement in the region 
concur. In December 2008, the head of UN CICIG 
said, “If the Guatemalan authorities are unable to stop 
the infiltration of Mexican drug cartels, in two years 
they could take over Guatemala City.”27 President 
Colom has issued a series of 'state of prevention' orders 
in response to the violence in which constitutional liber-
ties are restricted for a period of time in certain parts of 
the country. Moreover, there have been a series of attacks 
against labour union leaders, environmentalists and 
human rights defenders.28 While Guatemala appears to 
be the most affected, its problems are not unique, and 
the stability of all countries in this region requires that 
transnational organized crime be controlled.
To do this, the countries need support in strengthening 
local law enforcement and governance. But even more 
importantly, they need the assistance of the international 
community in addressing the transnational flows affect-
ing their countries. The drug wars they face are fuelled 
by a cocaine trade that runs the length of the region. 
Mexico’s killers are armed largely by weapons trafficked 
from the north, but potentially also from the south. 
Dealing with these threats requires both national insti-
tution-building and a global strategy to address the rel-
evant trafficking flows.
27 Painter, J., “Guatemala fears Mexico drug spillover”. BBC News, 17 
December 2008: http://news.bbc.co.uk/2/hi/7786392.stm 
28 International Federation for Human Rights, Observatory for the 
Protection of Human Rights Defenders, Annual Report 2009 - Gua-
temala, 18 June 2009, available at: http://www.unhcr.org/refworld/
docid/4a5f301521.html 
Drug trafﬁcking arrests per 100,000 Fig. 14: 
citizens, 2008
Source: UNODC DELTA
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Transit countries in West Africa3.4 
West Africa is one of the poorest and least stable regions 
on earth. All but three of the 16 countries in this region29 
are on the United Nations list of 'least developed coun-
tries', including the five countries with the very lowest 
levels of human development. West Africa has experi-
enced at least 58 coups and attempted coups, including 
some in just the last year. There remain many active 
rebel groups in the region. 
At present, of the 15 nations of the Economic Com-
munity of West African States (ECOWAS), about half 
are experiencing some form of instability. Long-standing 
insurgencies are found in Côte d’Ivoire, Senegal, Mali, 
Niger and, arguably, Nigeria. Both Sierra Leone and 
Liberia are recovering from brutal civil wars. According 
to one recent rating of the 25 countries with the highest 
risks of instability globally, nine were in West Africa: 
Niger, Mali, Sierra Leone, Liberia, Mauritania, Guinea-
Bissau, Côte d’Ivoire and Benin.30
Large-scale cocaine trafficking through West Africa was 
first detected around 2004, symptomatic of a shift in the 
centre of gravity of the global market from the United 
States to Europe. West African traffickers had long been 
active in small-scale import and marketing of cocaine in 
Europe, as they have been in many other parts of the 
world. But around this time, individuals based in West 
Africa began to provide logistic assistance to South 
American traffickers in organizing their maritime ship-
ments to Europe from at least two hubs: one centred on 
Guinea-Bissau and Guinea in the north, and one cen-
tred on the Bight of Benin in the south; both involving 
Nigerian traffickers. 
Mother ships from South America could unload cargoes 
to smaller craft from the coast, and the cocaine could be 
stored, repackaged and redirected to European buyers 
from this vantage. In exchange for their services, it is 
believed that the West Africans were paid in kind: they 
were allowed to retain up to one third of the shipment 
to traffic on their own behalf, which they did mainly via 
commercial air couriers.
By 2008, the situation began to change. Heightened 
international awareness of the threat made trafficking 
via West Africa more difficult. In addition, a series of 
events shifted the political terrain in the northern hub:
In August 2008, the head of the navy of Guinea- ?
Bissau ﬂed the country under allegations that he was 
orchestrating a coup d’état. 
29 For the purposes of this discussion, ECOWAS plus Mauritania, a 
former ECOWAS member.
30 Hewitt, J., J. Wilkenfeld and T. Gurr, Peace and Conflict 2010 . 
Center for International Development and Conflict Management, 
University of Maryland, 2010.
In December 2008, the man who had ruled Guinea  ?
for 24 years died, and a military cabal took control, 
later arresting two of his sons and several prominent 
oﬃcials for their involvement in drug traﬃcking. 
In March 2009, the head of the army of Guinea- ?
Bissau was murdered, and, shortly afterward, in an 
apparent reprisal attack, so was the president. 
Whatever the cause, both maritime seizures and airport 
seizures on flights originating in West Africa virtually 
disappeared at the end of 2008. Some trans-Atlantic 
traffic may have shifted to private aircraft, however. In 
November 2009, a Boeing 727 jet was found alight in 
Central Mali. It is believed that the plane departed from 
the Bolivarian Republic of Venezuela and that it was 
carrying cocaine. Some may be trafficked by means as 
yet undiscovered. The cocaine trade through West Africa 
continues, but apparently at a reduced rate of perhaps 
25 tons per year, with a retail market value of US$6.8 
billion at destination in 2008. However, there is anecdo-
tal information from law enforcement circles that 
cocaine trafficking via West Africa may have started to 
increase again in late 2009.
The greatest danger posed by cocaine is its enormous 
value compared to that of local economies. This allows 
traffickers to penetrate to the very highest levels of gov-
ernment and the military. Law enforcement officials can 
be offered more than they could earn in a lifetime 
simply to look the other way. This extreme leverage has 
allowed traffickers to operate with very little resistance 
from the state, and therefore, there is little need to 
resort to violence. There appears to have been some 
violence in elite circles as rivals compete for access to 
these profits, however.
Guinea-Bissau provides an example. The country was 
one of the first to be affected by the cocaine trade in the 
region, and, due to the small size of its economy (its 
GDP was US$400 million in 2008), one of the worst 
affected. The drug trade seemed to be quickly monopo-
lized by the military, controlled by top-ranking military 
officials. These officials have threatened all who dare to 
discuss their involvement.
From 2007 onwards, high-level officials have accused 
the military of running the drug trade, including the 
Interior Minister and the head of the Judicial Police. 
Drugs have been detected arriving on military air strips, 
military officers have been arrested in possession of hun-
dreds of kilograms of cocaine, and there have been sev-
eral armed stand-offs between police and military forces 
concerning drug shipments. Drugs seized by the police 
have been confiscated by the military and have subse-
quently disappeared. Accused soldiers, as well as foreign 
traffickers, have been simply released from custody. In 
July 2008, both the Attorney General and the Minister 
of Justice said they had received death threats related to 
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investigations into a cocaine seizure.31 Several journal-
ists and activists have had to flee the country or go into 
hiding after they received death threats for reporting on 
military involvement in drug trafficking. Both the (then) 
head of the army (Batista Tagme na Wai) and the head 
of the navy (José Bubo Na Tchuto) appear to have been 
involved in making these threats.32 
Tagme na Wai is now dead, killed in March 2009 by an 
attack that his men blamed on the serving president, João 
Vieira. In retaliation, they attacked the presidential palace 
31 BBC News, Fear after Bissau death threats. 1 August 2008.
32 Vincent, L. Guinea-Bissau: Cocaine and coups haunt gagged nation. 
Paris: Reporters without Borders, November 2007.
and killed the president. Tagme na Wai had accused 
Vieira of involvement in drug trafficking prior to the 
2008 elections, but the attacks appear to be the product 
of a long-standing rivalry between the two men.
Bubo Na Tchuto had to flee the country in August 
2008, after being accused of involvement in a coup to 
overthrow Vieira. He took refuge in the Gambia, where 
he was accused of being involved in illegal activities. 
Upon return to Guinea-Bissau in December 2009, he 
took refuge in the United Nations compound. On 1 
April 2010, soldiers loyal to Bubo Na Tchuto, including 
the deputy head of the military (Antonio Ndjai), took 
the Prime Minister hostage and ousted the head of the 
military, replacing him with Ndjai. This allowed the 
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former navy head to emerge from the UN compound 
and assume the role of Ndjai’s deputy. 
On 8 April 2010, the United States Treasury designated 
Bubo Na Tchuto a drug kingpin, freezing his US-con-
trolled assets and prohibiting any US citizens from 
having any economic transaction with him. The present 
Air Force chief of staff, Ibraima Papa Camara, was simi-
larly designated a drug kingpin. In other words, as of 
April 2010, the armed forces of Guinea-Bissau are con-
trolled by people designated as drug traffickers and their 
associates by the US Government. If these accusations 
are true, it is highly likely that the northern hub of 
cocaine trafficking will be revitalized again.
Guinea-Bissau is not unique in this respect. In Guinea, 
the presidential guard, commanded by one of the presi-
dent’s sons, appears to have been involved in drug traf-
ficking, alongside a number of high-ranking public 
security officials, making use of diplomatic pouches and 
passports to move drugs. Another of his sons has also 
been accused of involvement: both were arrested when 
their father died in late 2009. The leader of the coup, 
Moussa Dadis Camara, was later shot by his aide-de-
camp, Lieutenant Aboubacar (Toumba) Diakete.
After the disruptions in Guinea-Bissau and Guinea, it 
appears this hub relocated to the Gambia, the county 
where Bubo Na Tchuto fled. In the Gambia in March 
2010, the president ordered the arrest of 11 top-level law 
enforcement officials in the country in connection with 
drug trafficking, including the Director of the National 
Drug Enforcement Agency, his deputy and his head of 
operations, the National Police Chief and his deputy, 
the chief of the navy, the deputy chief of the army, and 
the Minster of Fisheries. In Sierra Leone, the Minister of 
Transportation resigned after his brother was implicated 
in the country’s largest cocaine seizure. 
Aside from a few high-level killings, it is difficult to 
measure the impact of the drug trade on local violence 
levels, because reliable current data on homicide in West 
Africa is hard to come by. Given that the drug trade is 
known to have penetrated to the very highest levels of 
government, however, it is unlikely that there is wide-
spread conflict over the cocaine markets, because few 
would dare challenge the reigning authorities. Rather, 
the violence is likely to be episodic, in response to power 
shifts within the structures responsible. There is no need 
for violence when corruption will do.
Similarly, with state authorities dominating the trade in 
some countries, it is perhaps not surprising that there is 
little evidence of insurgents dealing in the drug. There 
have been allegations that rebels in the north of Mali 
and Niger, as well as political militants in Algeria, have 
been involved in trans-Saharan trafficking, but little 
evidence is currently available on this flow. There remains 
a risk that some of the dormant militant groups in West 
Africa will somehow be revivified by the trade, but 
again, there is little evidence of this at present. 
The countries of West Africa need help in strengthening 
their capacity to resist transnational organized crime. 
Recent efforts against the cocaine trade, with the sup-
port of the international community, have shown prom-
ising results. But, rich or poor, there is no region in the 
world that can be entirely shielded against transnational 
organized crime. West Africa remains particularly 
exposed, and the region will continue to face serious 
potential threats to governance and stability as long as 
transnational contraband markets are not addressed.
Share of cocaine couriers detected at selected European airports originating in  Map 4: 
West Africa, by quarters, 2006-2009
Source: IDEAS database
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Conclusion3.5 
This chapter has illustrated the ways that drug traffick-
ing can be both a symptom of, and a factor in, instability 
in transit regions around the world. Both drug traffick-
ing and conflict undermine the rule of law and, in com-
bination, they can have long-term impact on the 
prospects for peace and prosperity. The violence associ-
ated with the cocaine trade can be tantamount to civil 
war in the worst affected areas. Left unaddressed, drug-
derived riches can buy the arms and the influence to 
affect the course of political events, particularly in poorer 
regions. 
The precise effect cocaine trafficking has on an area 
depends on the circumstances of that area, however. In 
Colombia, powerful traffickers posed a direct threat to 
the state, and once defeated, drug-fuelled illegal armed 
groups continued the attack. Dedicated enforcement 
and international cooperation appear to have completely 
turned the tide, but the struggle is far from over. Mexico 
appears to be engaged in an earlier stage of the same 
struggle, but without the illegal armed groups to worry 
about. 
The growth of drug money flows can generate violence, 
as has been the case in Guatemala, but so can their with-
drawal, as appears to have been the case in Jamaica. Any 
sudden change, whether it be in volumes or players, 
seems to have the potential to set off a violent competi-
tion for opportunity. A far more insidious effect is seen 
in West Africa, where the drug trade appears to be con-
trolled by national figures so powerful that little opposi-
tion is possible, but where disputes over markets can 
lead to the toppling of governments.
One area where immediate progress can be made is to 
fully integrate crime prevention into United Nations 
peace operations. A large number of UN peace missions 
are operating in regions affected by drug trafficking, 
including West Africa (UNOCI in Côte d’Ivoire, 
UNMIL in Liberia, UNOGBIS in Guinea-Bissau, UNI-
PSIL in Sierra Leone and UNOWA for West Africa as a 
whole), South-West and Central Asia (UNAMA in 
Afghanistan and UNRCCA in Central Asia) and South-
East Europe (UNMIK in Kosovo). The United Nations 
Police would be in a good position to coordinate the 
international actors engaged in promoting peace to 
ensure that crime prevention measures are built into 
development planning.
Drug money flows can have devastating local effects, but 
their dynamics are almost always international. Target-
ing these international linkages can provide a point of 
insertion for those interested in reducing the potential 
for conflict. Strategies aimed at addressing drug flows, 
executed in areas with stronger governance, could play a 
pivotal role in addressing civil conflict, by removing the 
profit motive that keeps many antagonists armed and in 
the field. Put simply, reducing drug trafficking can help 
foster peace.
The problem is that most efforts against drugs are 
national, or, at best, bilateral, when the scale of the traf-
ficking is global. Without a strategy scaled to fit the size 
of the problem, successful national efforts run the risk of 
simply displacing contraband flows. When opposed, the 
drug markets have consistently adapted, finding new 
cultivation areas, transit zones and consumer markets. In 
many cases, they have settled in the areas of least resist-
ance, which are precisely the areas least equipped to deal 
with the challenge. And it is here that organized crime 
can escalate to the level of being a threat to stability.
The world does have a framework for dealing with these 
drugs internationally, in the form of the Single Conven-
tion on Narcotic Drugs of 1961 (as amended by the 
1972 Protocol); the Convention on Psychotropic Sub-
stances of 1971; the Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988; 
the Convention against Transnational Organized Crime 
of 2000 (and the protocols thereto) and the Convention 
against Corruption. A great deal of successful collabora-
tion has occurred under this aegis, but more could be 
done. Too often, work under the Conventions has been 
limited to law enforcement, while transnational organ-
ized crime cannot be reduced to a criminal justice issue. 
The Conventions provide a bedrock, but they do not 
constitute a global strategy. 
To deal comprehensively with these intractable and 
interlinked issues, there can be no substitute for coordi-
nated international action. The United Nations is well 
suited to provide the coordination needed to address 
these global issues at the level required.

4. STATISTICAL ANNEX

4.1 Production
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Challenges in estimating the  4.1.1 
production of pure cocaine HCl 
For many years, UNODC has estimated the potential 
production of cocaine for each producing country with 
the purpose of providing information on the global 
supply of cocaine. Potential production refers to the 
amount of cocaine that would be produced if all the 
leaves harvested from the area under coca cultivation in 
one year would be converted into 100% pure cocaine 
hydrochloride (HCl).1 The reference to ‘potential’ pro-
duction underscores the fact that the recovery of cocaine 
from the leaves may not be absolute (that is, 100% 
recovery). The term laboratory efficiency is therefore 
employed as a measure of how efficient a particular 
process is. Coca paste and cocaine base (intermediate 
products of the transformation process from leaves to 
cocaine HCl) can also be marketed and consumed. In 
addition, these intermediate products and leaves may be 
seized before they are processed into cocaine. 
Traditionally, the production of cocaine HCl includes 
three steps. The first is the conversion of the coca leaf 
into coca paste; this is almost always done very close to 
the coca fields to cut down on the transport of the coca 
leaves. The second phase is the conversion of coca paste 
into cocaine base. The final stage is conversion of base 
to HCl. In recent years, this process has been cut into 
two stages, where leaves are converted directly to cocaine 
base. 
In order to estimate the total potential production of 
pure cocaine HCl, the following elements need to be 
measured: 
Cultivation ?
Quantity of leaves per ha per year (yield) ?
Quantity of leaves needed to produce 1 kg of 100%  ?
pure cocaine HCl. This includes the following 
elements: 
Alkaloid content of leaves ?
Laboratory eﬃciency  (the percentage of alkaloid  ?
content that can be extracted in the laboratory 
process)
1 In Peru and the Plurinational State of Bolivia, a certain amount of 
coca leaves (leaves harvested from 12,000 ha of coca bush grown 
under law 1008 in Bolivia and 9,000 mt of coca leaves in Peru are 
estimated to be used for traditional purposes) is subtracted from the 
calculation of potential cocaine production.  
Over the years, UNODC has undertaken studies in the 
three producing countries of the Plurinational State of 
Bolivia, Colombia and Peru.2 Of the three components 
needed to estimate the potential production of cocaine 
HCl, UNODC regularly measures cultivation and 
yield,3 but does not undertake any study to measure 
alkaloid content and laboratory efficiency. For this last 
step, it relies on an external source, the US Drug Enforce-
ment Administration (DEA). The DEA is the only 
organization that has undertaken scientific studies to 
measure the alkaloid content of the coca leaves and 
laboratory efficiency in the Andean countries. In Colom-
bia, the estimation process followed by UNODC differs 
from that used in the other two Andean countries. Using 
farmers’ interviews, UNODC can estimate the quantity 
of cocaine base produced from the leaves, although it 
cannot estimate its quality.4 Furthermore, it needs to 
estimate the average purity of the cocaine base produced 
and the conversion factor between cocaine base and 
cocaine HCl. 
There is a certain level of uncertainty in each of the 
three stages necessary to estimate potential cocaine 
production. 
Estimating cultivation 
Since 1999-2002,5 UNODC’s Illicit Crop Monitoring 
Programme (ICMP) has been monitoring coca cultiva-
tion in three Andean countries, the Plurinational State 
of Bolivia, Colombia and Peru. The cultivation esti-
mates provide the situation at the end of each year. All 
coca surveys use remotely sensed images, that is, satellite 
images or aerial photographs,6 which is the best means 
2 In each country, UNODC has project teams to conduct the surveys 
with assistance from a team of experts at UNODC headquarters in 
Vienna. 
3 Yield studies are carried out by UNODC in Colombia (provinces are 
covered every five years on a rotating basis), the Plurinational State 
of Bolivia (Yungas of La Paz, 2005) and Peru (three major growing 
regions in 2003). No yield studies have been so far carried out by 
UNODC in Chapare/Bolivia where DEA yield estimates are used.  
4 Through farmers’ interviews, UNODC can only estimate the quan-
tity of cocaine base produced, not its purity, since farmers are una-
ware of the level of purity of what they produce.  
5 Since 1999 in Colombia, 2000 in Peru and 2002 in the Plurinational 
State of Bolivia. Since 2006, ICMP has been monitoring coca in 
Ecuador as well; however the extent of coca cultivation found there 
is negligible.
6 There are differences between satellite images, for example, in the 
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to undertake a systematic monitoring of the insecure 
and often inaccessible cultivation areas. 
Every year, UNODC purchases satellite images from 
commercial image providers of all the areas where coca 
is grown. It is often a challenge to get images that are 
cloud-free, and therefore, the images are acquired over a 
period of several months, tasking the satellites or search-
ing in recent archives. After acquiring suitable images, a 
team of experts systematically digitizes all the fields with 
coca bushes.7 Identification of the crops can be challeng-
ing. Satellite images are taken at a height of hundreds of 
kilometres above ground and do not give the same 
detailed image as a snapshot taken from the ground. On 
the other hand, satellite images contain more informa-
tion than a normal photo, since the satellites have extra 
sensors to register infrared colours. Precisely these infra-
red colours help to distinguish vegetation types.8  
In the classification process, additional geographical 
information is used to judge whether the fields appear-
ing in the satellite image are really coca fields. For exam-
ple, information on the places that were eradicated or 
sprayed is used as well as information from former sur-
veys or contextual information, such as typical shapes, 
sizes and locations of coca fields. The interpretation of 
this diverse set of criteria is difficult to automate and is 
mostly done by human interpreters. All interpreters have 
extensive experience in working with satellite images 
and they are all familiar with the coca cultivation areas. 
The interpreters follow so-called interpretation keys to 
avoid systematic errors or differences between the inter-
preters.9
Monitoring with satellite images should always be 
accompanied by ground control. Ideally these controls 
are performed by field visits throughout the monitored 
area. Since access to the ground in coca growing regions 
is often dangerous and difficult, UNODC performs 
ground ‘truthing’ by overflights with helicopters or small 
aeroplanes. Moreover, the results of the satellite interpre-
tations are subject to independent quality controls with 
detailed aerial photos. 
detail (‘spatial resolution’ or ‘pixel size’) of the images. The more 
detailed, the more expensive the images. However, the area to be 
monitored in Colombia is about 20 times larger than the areas in 
Peru or the Plurinational State of Bolivia, and therefore, the type of 
images is not the same in the three countries.  
7 The full coverage of all the areas helps the governments to have 
local information on changes and target specific crop reduction pro-
grammes. 
8 Coca is a bush and the leaves can be harvested throughout the year. 
Therefore, the crop stage can vary by field but also within a field. At 
the time a satellite image is taken, a field can contain different crops 
in different growing stages, which gives a different appearance in the 
satellite images. 
9 The keys were developed with the assistance of the University of 
Natural Resources and Applied Life Sciences in Vienna.
Estimating yield 
Coca leaf yield is affected by unpredictable factors such 
as weather and plant diseases, as well as by eradication 
activities. The effect of these factors varies not only from 
year to year and during the course of a year but also from 
one cultivating region to the other. Since 2004, 
UNODC, in cooperation with the respective govern-
ments, has undertaken coca leaf yield studies in many 
coca growing regions in the Plurinational State of 
Bolivia, Colombia and Peru. In the Plurinational State 
of Bolivia, a yield study was carried out in 2005 in the 
Yungas region, where the annual yield was estimated at 
1.3 mt of sun-dried leaves per hectare. In Chapare, the 
other cultivating region, UNODC relies on DEA esti-
mates, which report a yield of 2.7 mt/ha. In Peru, 
UNODC undertook a yield study in 2003, estimating 
the annual average yield to 2.2 mt/ha of sun-dried leaves. 
In Colombia, starting in 2004-2005, UNODC/SIMCI 
fields a yearly yield study which covers one or two 
regions on a rotating basis. The core element of these 
studies is the controlled harvest of mature coca fields. 
The challenges related to the estimation of the annual 
yield relate to the difficulties of measuring the different 
harvests occurring in one year (four on average) and 
capturing the variation that the yield may have from one 
year to another. Ideally, the yield should be measured 
every year, in order to consider the climatic and environ-
mental changes. However, yield studies need substantial 
resources, and not all areas under coca cultivation are 
accessible to field researchers for security reasons. 
Country,  
region
Year of 
study
Yield  
(mt/ha)
Bolivia, Yungas 2005 1.3 mt/ha  sun-dried 
Bolivia, Chapare 2006  (Source: DEA)
2.7 mt/ha  
sun-dried
Peru 2003 2.2 mt/ha  sun-dried
Colombia, Meta-Guaviare 2008 5.1 mt/ha  fresh leaf
Colombia, Sur de Bolívar 2007 5.7 mt/ha  fresh leaf
Colombia,  
Putumayo-Caquetá 2008
4.1 mt/ha  
fresh leaf
Colombia, Orinoco 2005 7.1 mt/ha  fresh leaf
Colombia, Pacífico 2009 3.8 mt/ha  fresh leaf
Colombia, Catatumbo 2007 4.2 mt/ha  fresh leaf
Colombia,  
Sierra Nevada 2007
2.9 mt/ha  
fresh leaf
Latest coca yield estimates
Source: UNODC studies
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Conversion factor from coca leaves to cocaine 
Estimating the conversion factor from coca leaves to 
cocaine requires two steps: i) measuring the alkaloid 
content of the leaves, and ii) calculating the efficiency 
used by traffickers in the laboratory conversion process 
where cocaine base is converted into cocaine HCl. The 
alkaloid content of the leaves can be measured by analys-
ing the chemical composition of a sample of coca leaves 
from the field. Studies have shown that it varies across 
geographical regions, but it does not significantly change 
over time. Alkaloid content is highest in Peru and the 
Plurinational State of Bolivia, where it is about 0.7%, 
and lowest in Colombia, where it is about 0.53%.10 
Laboratory efficiency is more difficult to measure as 
there are different influencing factors: quality of the raw 
material and precursor chemicals used, the technical 
processing method employed, the size and sophistica-
tion of laboratories, and the skill and experience of local 
workers and chemists. Studies to measure the efficiency 
are carried out by trying to simulate the real environ-
ment where traffickers process cocaine in a laboratory. 
According to these studies, there are two main methods 
to produce cocaine: the solvent extraction method and 
the acid extraction method. The solvent method is 
thought to be the most efficient; however, traffickers are 
making the acid extraction method very efficient in 
Peru, where this method is most used.11  
 
10 Although these numbers represent a national average, they can not be 
used to calculate cocaine production at the national level since they 
hide very diversified alkaloid contents measured in different regions 
of the same country.    
11 Taking into consideration the alkaloid content of leaves and the 
laboratory efficiency.
The impact of  conversion factors in the  
production estimates for the three Andean 
countries 
According to the scientific studies conducted by the 
DEA, in the last decade, there has been an increase in 
the efficiency of the clandestine laboratories employed 
in the three Andean countries, which has resulted in 
different conversion factors from leaves to cocaine. These 
changes are mainly due to the higher percentage of traf-
fickers using more efficient methods to extract the 
cocaine.  
Until 2009, UNODC used the conversion factors 
obtained by the DEA in its previous round of studies 
dated 1994 in Peru and 1993 in the Plurinational State 
of Bolivia. In recent years, the DEA obtained new con-
version factors which lead to a higher estimate of cocaine 
production (showing the need for a lower amount of 
leaves to produce pure cocaine).   
In Colombia as well, more recent information obtained 
by UNODC shows that the conversion from cocaine 
base to cocaine HCL requires updated parameters: 
Country Year of DEA study
Conversion factor11 (quantity of leaves needed  
to produce 1 kg of 100% pure cocaine HCL)  
Plurinational State of Bolivia 1993 370 kg sun-dried (Chapare) 315 kg sun-dried  (Yungas)
Plurinational State of Bolivia 2007-2008 256 kg sun-dried (Chapare)244 kg sun-dried  (Yungas)
Peru 1994 400 kg sun-dried
Peru 2005 220 kg sun-dried
Conversion factors from coca leaves to cocaine HCl
Source: DEA scientific studies
Process used by UNODC to estimate 100% pure 
cocaine HCl from cocaine base of unknown purity
Source: DEA scientific studies
Cocaine base to 
cocaine HCl
1:0.9 (1 kg of base needed to 
produce 0.9 kg cocaine HCl)
Cocaine HCl 85% purity 
Revised process to estimate pure cocaine HCl  
from cocaine base of unknown purity
Source: DEA scientific studies
Average purity of 
cocaine base  81%
Cocaine base to 
cocaine HCl
1:1 (1 kg of base needed to  
produce 1 kg cocaine HCL)
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Applying the results of the more recent DEA studies has 
an effect on the level of cocaine production estimated 
for the three Andean countries, as shown in the graph. 
UNODC is currently analysing in more detail these new 
conversion factors. 
Impact of conversion factors on global estimates of potential cocaine HCl production (mt)*
* Assuming that all other parameters remain unchanged.
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1 The information in this section comes from the Afghanistan Opium 
Survey 2009 (UNODC/Ministry of Counter Narcotics) and can also 
be found at http://www.unodc.org/unodc/en/crop-monitoring/index.
html. Source unless otherwise indicated: National Monitoring System 
supported by UNODC.
2 Figures in brackets represent the upper and lower limits of the 90% (for 
2008) and 95% (for 2009) confidence interval.
3 Poppy-free provinces are those which are estimated to have less than 100 
ha of opium cultivation.
4 Garda is the local term used in Afghanistan for the powder obtained 
by threshing and sieving the harvested and dried cannabis plants. This 
process is repeated several times and results in different quality of garda 
(first, second, …). Garda is further processed into hashish, which is the 
traded product.
5 Estimates are based on a population of 25.5 million and an average 
household size of 6.5 persons for 2009 (Afghan year 1387) and a popu-
lation of 24.5 million for 2008 (Afghan year 1386). Source: Gov. of 
Afghanistan, Central Statistical Office. 
6 In 2008, the fresh and dry opium prices at harvest time were based on 
farmers responses collected through the Annual Opium Survey. In 2009, 
prices at harvest time were derived from the opium price monitoring 
system and refer to the month when opium harvest actually took place 
in different regions of the country.
7 Nominal GDP estimates, without the drug economy. For 2008: US$ 
10.2 billion (Afghan fiscal year 2007/08), for 2009: US$ 10.7 billion 
(Afghan fiscal year 2008/2009): Source: Gov. of Afghanistan, Central 
Statistical Office.
Fact sheet – Afghanistan Opium and Cannabis Surveys 20091
2008 Change on 2008 2009
Net opium cultivation (after eradication)2 157,000 ha(130,000-190,000 ha) -22%
123,000 ha
(102,000-137,000 ha)
Cannabis cultivation No data 10,000-24,000 ha
No. of poppy-free provinces3 
No. of provinces affected by opium cultivation
18
16
+2 prov.
-2 prov.
20
14
No. of provinces affected by cannabis cultivation No data 17
Opium poppy eradication 5,480 ha -2% 5,351
Weighted average opium yield 48.8 kg/ha +15% 56.1 kg/ha
Average cannabis resin (garda) yield No data 143 kg/ha
Potential production of opium
 in % of global potential opium production
7,700 mt
89%
-10% 6,900 mt
89%
Potential production of cannabis resin (garda)4  No data 1,500-3,500 mt
No. of household involved in opium cultivation5 
 in % of total population
366,500
9.8%
-33% 245,200
6.4%
No. of households involved in cannabis cultivation No data 40,000  (25,000-60,000)
Average farm-gate price (weighted by production)  
of dry opium at harvest time6 US$95/kg -34% US$64/kg
Average farm-gate price of cannabis resin  
(best quality) at the time of resin processing US$51/kg +14% US$58/kg
Total farm-gate value of opium production
 in % of GDP7
US$730 million
7%
-40% US$438 million
4%
Total farm-gate value of cannabis resin (garda) production No data US$39-94 million
Potential gross export value of opiates
 in % of GDP7
US$3.4 billion
33%
-18% US$2.8 billion
26%
Potential net export value of opiates
 in % of GDP7 n.a.
US$2.3 billion
21%
Average yearly gross income from opium of opium grow-
ing households US$1,997 -10% US$1,786
Average yearly gross income from cannabis of  
cannabis growing households No data US$1,553
Income from opium per ha (gross/net) US$4,700 / 2,585 -23% US$3,600 / 2,005
Income from cannabis per ha (gross/net) No data US$3,900 / 3,341
Income from wheat per ha (gross/net) US$1,600 / 1,280 -25% US$1,200 / 960
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Afghanistan, opium poppy cultivation and eradication (ha), 1995-2009
Note: Although eradication took place in 2004, it was not officially reported to UNODC. 
Source: Cultivation: UNODC (1995-2002), since 2003: National Monitoring System supported by UNODC. Eradication: Government 
of Afghanistan 
Afghanistan, regional distribution of opium poppy cultivation (ha), 2008 – 2009
Region 2008 (ha) 2009 (ha) Change 2008-2009 2009 (ha) as % of total
Southern 132,760 103,014 -22% 84%
Western 22,066 18,800 -15% 15%
Eastern 1,151 593 -48% 0.5%
North-eastern 200 557 179% 0.5%
Central 310 132 -57% 0.1%
Northern 766 Poppy free NA NA
Rounded Total 157,000 123,000 -22% 100%
Estimates are based on a population of 25.5 million and an average household size of 6.5 persons for 2009 (Afghan year 1387) and a population of 24.5 
million for 2008 (Afghan year 1386). Source: Gov. of Afghanistan, Central Statistical Office.
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Afghanistan, potential opium production (mt), 1995-2009
Source: Cultivation: UNODC (1995-2002), since 2003: National Monitoring System supported by UNODC. Eradication: Government 
of Afghanistan 
Afghanistan, monthly farm-gate prices of dry opium (US$/kg), November 2002 to March 2009
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4.1.3 Bolivia (Plurinational State of)
1 The information in this section comes from the report on Coca Cul-
tivation in Bolivia (UNODC/Government of Bolivia, June 2010), 
and can also be found on the internet (http://www.unodc.org/unodc/
en/crop-monitoring/index.html). Source unless otherwise indicated: 
National Monitoring System supported by UNODC.
2 Source: Instituto Nacional de Estadística de Bolivia (INE).
3 Including installations producing cocaine base, HCl or “recycling” 
precursors. Excluding coca leaf maceration pits.
Fact sheet – Bolivia Coca Survey 20091
2008 Change on 2008 2009
Coca cultivation 
 Of which  in the Yungas of La Paz
  in Chapare
  in Apolo
Of which permitted by Bolivian law 1008
30,500 ha
20,700 ha
9,500 ha
300 ha
12,000 ha
+1%
+1%
+2%
0%
30,900 ha
20,900 ha
9,700 ha
300 ha
12,000 ha
Production of sun-dried coca leaf
Potential production of cocaine HCl
54,000 mt
113 mt
+1% 54,800 mt
n.a.**
National weighted average farm-gate price of coca leaf 
(outside state market) US$5.4/kg -9% US$4.9/kg
Total farm-gate value of coca leaf production
GDP2 
 Farm-gate value of coca leaf production in %of GDP
 Farm-gate value of coca leaf production in % of GDP  
 of agricultural sector
US$293 million
US$9.7 billion
3.0%
21%
-10% US$265 million
US$13.0 billion
2%
14%
Reported eradication of coca bush* 5,484 ha +16% 6,341 ha
Reported seizure of sun-dried coca leaves* 2,095 mt -22% 1,624 mt
Reported seizure of cocaine base* 21,641 kg +2% 21,970 kg
Reported seizure of cocaine HCl* 7,246 kg -32% 4,922 kg
Reported destruction of coca laboratories3* 4,999 kg -2% 4,888 kg
Reported seizure of cannabis herb* 1,112,588 kg +74% 1,937,412 kg
* As reported by the Government of the Plurinational State of Bolivia. 
** Conversion rates from coca leaf to cocaine are currently being reviewed. This may lead to a revision of the 2008 figure (and of previous years). An 
estimate of the 2009 potential cocaine production was not available at the time of printing of this report.
260
World Drug Report 2010 
Plurinational State of Bolivia, coca cultivation and reported eradication (ha), 1995-2009
Eradication: Gov. of the Plurinational State of Bolivia. Includes voluntary and forced eradication.
Source: Cultivation: 1995-2002: CICAD and US Department of State. For the region Yungas of La Paz since 2002, for all regions 
since 2003: National Illicit Crop Monitoring System supported by UNODC
Plurinational State of Bolivia, monthly farm-gate prices of sun-dried coca leaf, Chapare region  
(US$/kg), 1990-2009
Source: National Monitoring System supported by UNODC
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4.1.4 Colombia
1 The information in this section comes from the report on Coca 
Cultivation in Colombia (UNODC/Government of Colombia, June 
2010), and can also be found on the internet (http://www.unodc.
org/unodc/en/crop-monitoring/index.html). Source unless otherwise 
indicated: National monitoring system supported by UNODC. 
2 The 2008 estimate of 430 mt  was revised based on  more detailed 
information on the average cocaine base purity (81%) and the 
cocaine base to HCl conversion ratio (1:1) available from the US 
Government/DEA.
3 GDP of the respective year as reported by the Government.
Fact sheet – Colombia Coca Survey 20091
2008
Change on 
2008
2009
Net coca cultivation (rounded total) 
 Of which Pacific region
  Central region
  Putumayo-Caquetá region
  Meta-Guaviare region
  Elsewhere
81,000 ha
29,920 ha
18,730 ha
13,960 ha
12,150 ha
6,200 ha
-16%
-16%
-14%
-35%
+4%
-19%
68,000 ha
25,170 ha
16,130 ha
9,070 ha
12,620 ha
5,010 ha
Potential production of cocaine2 450 mt -9% 410 mt
Average farm-gate price of coca paste
Average wholesale price of cocaine*  
(of unknown purity in major cities)
US$963/kg
COP 1,887,855/kg
US$2,348/kg
COP 4,580,000/kg
-1%
+8%
-9%
0%
US$956/kg
COP 2,047,970/kg
US$2,147/kg
COP 4,587,413/kg
Total farm-gate value of the production of coca leaf and 
its derivatives US$623 million -21% US$494 million
 in per cent of GDP3
 in per cent of agricultural sector
0.3%
3%
0.2%
3%
Reported aerial spraying of coca bush*
Reported manual eradication of coca bush*
Reported seizure of cocaine*
Reported destruction of coca processing laboratories*
 Of which cocaine HCl processing lab.
133,496 ha
95,634 ha
198 mt
3,443
296
-22%
-37%
+3%
-16%
-7%
104,772 ha
60,557 ha
203 mt
2,888
278
Reported opium poppy cultivation* 394 ha -40% 356 ha
Potential opium latex production**
Potential heroin production (rounded) **
31 mt
1.3 mt
-16%
-16%
26 mt
1.1 mt
Average farm-gate price of opium latex* US$318/kg +13% US$358/kg
Average wholesale heroin price* US$9,950/kg +0.4% US$9,993/kg
Reported seizure of heroin* 646 kg +13% 732 kg
* As reported by the Government of Colombia.  
** Own calculations based on regional yield figures and conversion ratios from US Government/DEA.
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Potential manufacture of cocaine in Colombia4
4 In past years, UNODC published a single graph with production 
data up to the latest year available emphasizing the break in series 
between 2003 and 2004. This year three graphs are published empha-
sizing the non-comparability of the data presented for three sets of 
years. 
5 Over the period 1999-2003 UNODC monitored the coca cultiva-
tion in Colombia, but it did not carry out yield studies and therefore 
production figures comparable with the data after 2004 can not be 
calculated. Different figures for the years 1999-2003 can be calcu-
lated using different assumptions on the level of yield during these 
years. Utilizing UNODC cultivation data and a cocaine yield calcu-
lated from US estimates of coca cultivation and cocaine production 
produces the line labelled “Constructed with UNODC cultivation 
and US yield”. The line labelled “US Government estimate” simply 
reports the cocaine production figures published by the United 
States, which are based on their own cultivation and yield estimates 
for Colombia. The line labelled “Constructed with UNODC culti-
vation and UNODC 2005 yield” was calculated utilizing UNODC 
cultivation data and a cocaine yield calculated through a linear 
interpolation of the cocaine yield reported by the Government of 
Colombia for 2000 (5.8 kg/ha) and the cocaine yield estimated by 
UNODC for 2005 (8.2 kg/ha). Although these estimates are not 
comparable with UNODC estimates for 2004 and later, the decrease 
over the period 2001-2003 was additional to the further decrease over 
the period 2004-2009.
Colombia, coca cultivation and reported eradication/spraying (ha), 1995-2009
Sources: Cultivation: 1995-1998: CICAD and US Department of State, International Narcotics Control Strategy Report; since 1999: 
National Illicit Crop Monitoring System supported by UNODC; eradication/spraying: Government of Colombia
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Potential manufacture of cocaine in Colombia 
(mt), 2004-2009
Data estimated on the basis of the cultivation census and the yield 
measurements regularly implemented by UNODC since 2004, as well 
as information on cocaine base purity and cocaine base to HCI conver-
sion ratio from DEA.
Colombia, monthly farm-gate price of coca 
paste, Jan. 2000 to Dec. 2009 (‘000 COP/kg)
Source: National monitoring system supported by UNODC
Colombia, annual average wholesale prices  
for cocaine HCl (US$/kg and ‘000 COP/kg), 
1991-2009
Note: Nominal prices of cocaine of unknown purity in major 
cities of Colombia. 
Source: DIRAN
Colombia, annual farm-gate prices for opium 
latex, 2002-2009
Note: Nominal prices. 
Source: DIRAN
Colombia, annual wholesale price of heroin, 
2002-2009
Note: Nominal prices for heroin of unknown purity. 
Source: DIRAN.
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4.1.5 Lao People’s Democratic Republic
1 The information in this section comes from the report on Opium 
Poppy Cultivation in South-East Asia (UNODC/Governments of 
Lao PDR and Myanmar December 2009), and can also be found 
on the internet (http://www.unodc.org/unodc/en/crop-monitoring/
index.html). Source unless otherwise indicated: National monitoring 
system supported by UNODC. Figures in brackets represent the 
upper and lower limits of the 90% confidence interval. 
2 In the absence of a yield survey in2008 and 2009, the yield per hec-
tare for 2007 was used.
3 Source: LCDC, Provincial authorities survey. Due to the limited 
market for opium, a clear distinction between farm gate, wholesale 
and retail prices could not be established.
4 Source: LCDC. Since 2008, eradication campaigns were conducted 
during and after the survey.
2008 Change on 2008 2009
Opium poppy cultivation 1,600 ha(600-2,700 ha ) +18.8%
1,900 ha
(900-3,000 ha)
Average dry opium yield2 6 kg/ha - 6 kg/ha
Potential production of dry opium 9.6 mt(4.3-16.1 mt) +18.8%
11.4 mt
(5.4-18 mt)
Average retail/wholesale price of opium3 US$1,227/kg +8% US$1,327
Eradication4 575 ha +13% 651 ha
Number of new opium addicts 4,906 - n/a
Average drug prevalence rate  
(based on 7 northern provinces in 2008) 0.19% n/a
Fact sheet – Lao People’s Democratic Republic Opium Survey 20091
Lao People’s Democratic Republic, opium poppy cultivation* and eradication (ha), 2003-2009
* After eradication. Source: Cultivation: National monitoring system supported by UNODC; eradication: Government of Lao PDR
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Lao People’s Democratic Republic, potential opium production (mt), 1995-2009
Source: National monitoring system supported by UNODC
Lao People’s Democratic Republic, annual  
opium prices (US$/kg), 2002-2009
Source: LCDC, Provincial authorities survey
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4.1.6 Myanmar
Fact sheet – Myanmar Opium Survey 20091
1 The information in this section comes from the report on Opium 
Poppy Cultivation in South East Asia (UNODC/Governments of 
Lao PDR and Myanmar, December 2009), and can also be found 
on the internet (http://www.unodc.org/unodc/en/crop-monitoring/
index.html). Figures in bracket refer to the upper and lower limits of 
the 95% confidence interval.
2 Source: CCDAC.
3 For 2008: yearly average price. For 2009: price at harvest time.
4 The farm-gate value should calculated with the price of dry opium. 
However, the price of dry opium is difficult to establish in Myanmar 
because of the selling and storing practices of the farmers. The farm-
gate value here is calculated with the price of fresh opium. This result 
in a lower estimate.
2008 Change on 2008 2009
Opium poppy cultivation in Myanmar 
 Of which in East Shan State
  North Shan State
  South Shan State
  Elsewhere
28,500 ha
(17,900 to 37,000 ha)
9,300 ha
800 ha
15,500 ha
3,200 ha
+11%
+25%
+100%
+10%
-16%
31,700 ha
(24,00 to 42,900 ha)
11,900 ha
1,600 ha
16,500 ha
1,700 ha
Opium poppy cultivation in Shan State 25,300 ha +19% 30,000 ha(24,000 to 40,000)
Average opium yield (weighted by area) 14.4 kg/ha -27.8% 10.4 kg/ha
Potential production of dry opium in Myanmar 
(including the Shan State) 410 mt -19.5%
330 mt
(214 to 447)
Opium poppy eradication in Myanmar2 4,820 ha -15.2% 4,087 ha
Average farm-gate price of opium3 US$301/kg +5% US$317/kg
Total potential farm-gate value of  
opium production4 US$123 million -15%
US$105 million
(68 to 142)
Estimated number of households involved in 
opium poppy cultivation in Myanmar 168,000 +14%
192,000 
(160,000 to 225,000)
Number of persons involved in opium poppy  
cultivation in Myanmar 840,000 +27%
1,066,000 
(890,000 to 1,250,000)
Estimated number of households involved in 
opium poppy cultivation in the Shan State 148,900 19%
176,500 
(141,200 to 235,300)
Average yearly household income in opium  
producing households (Shan State)
 Of which from opium sales
Per capita income in opium producing households 
(Shan State)
US$687
US$253
US$137
+2%
-37%
-9%
US$700
US$160
US$125
Household average yearly income in non-opium 
poppy producing households (Shan State)
Per capita income in non-opium producing  
households (Shan State)
US$721
US$144
+4%
-8%
US$750
US$133
Addiction prevalence rate in Shan State and 
Kachin (population aged 15 and above) 1.1% +36% 1.5%
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Myanmar, opium poppy cultivation (ha),  
1995-2009
Opium poppy eradication reported by the Government of the Union of Myanmar (ha), 2002-2009
Region 2004 2005 2006 2007 2008 2009
East Shan 195 124 32 1,101 1,249 702
North Shan 172 1,211 76 916 932 546
South Shan 2,170 1,203 3,175 1,316 1,748 1,466
Shan State Total 2,537 2,538 3,283 3,333 3,929 2,714
Kachin 126 1,341 678 189 790 1,350
Kayah 83 8 0 12 12 14
Total within the surveyed area 2,746 3,887 3,961 3,534 4,731 4,078
Magwe 0 0 0 45 0 1
Chin 0 3 0 10 86 5
Mandalay 0 0 9 0 3 2
Sagaing 74 17 0 9 0 1
Other States 74 20 9 64 0 0
Total (national) 2,820 3,907 3,970 3,598 4,820 4,087
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4.1.7 Peru
Fact sheet – Peru Coca Survey 20091
 
1 The information in this section comes from the report on Coca 
Cultivation in Peru (UNODC/Government of Peru, June 2010), 
and can also be found on the Internet (http://www.unodc.org/unodc/
en/crop-monitoring/index.html). Source unless otherwise indicated: 
National monitoring system supported by UNODC.
2 Includes all coca leaf potentially produced. For the calculation of coca 
leaf available for cocaine production, 9,000 mt of sun-dried coca leaf 
were deducted from this figure, which, according to Government 
sources, is the amount used for traditional purposes.
3 The weighted average price takes into account that different amounts 
of coca leaf are sold in different regions at different price levels.
4 Takes into account all coca leaf produced, irrespective of its use. For 
the calculation, the weighted average coca leaf price was used.
5 Excluding coca leaf macerations pits.
2008 Change on 2008 2009
Coca cultivation
 Of which in Alto Huallaga
  Apurímac-Ene
  La Convención-Lares
  Elsewhere
56,100 ha
17,800 ha
16,700 ha
13,100 ha
8,500 ha
+7%
-2%
+5%
+1%
+38%
59,900 ha
17,500 ha
17,500 ha
13,200 ha
11,700 ha
Weighted average sun-dried coca leaf yield 2,200 kg/ha -5% 2,100 kg/ha
Potential production of sun-dried coca leaf2
Potential production of sun-dried coca leaf available for 
cocaine production
Potential production of cocaine HCl
122,300 mt
113,300 mt
302 mt
+5%
+5%
128,000 mt
119,000 mt
n.a.**
Average farm-gate price of sun-dried coca leaf
Average farm-gate price of sun-dried coca leaf (weighted)3
Average farm-gate price of coca paste
Average price of cocaine HCl in coca cultivating regions
US$3.4/kg
US$3.1/kg
US$723/kg
US$940/kg
-6%
-3%
+7%
+9%
US$3.2/kg
US$3.0/kg
US$778/kg
US$1,021/kg
Potential farm-gate value of sun-dried coca leaf4 US$379 million +1% US$384 million
Reported eradication of coca cultivation*
Reported seizure of sun-dried coca leaves*
Reported seizure of coca paste*
Reported seizure of cocaine HCl*
Reported destruction of coca laboratories5*
 Of which cocaine HCl processing laboratories
10,143 ha
2,132 mt
11,374 kg
16,203 kg
1,224
19
-1%
-52%
-16%
-34%
+1%
+32%
10,025 ha
1,031 mt
9,914 kg
10,744 kg
1,242
25
Reported seizure of opium latex* 128 kg n.a.
* As reported by the Government of Peru. 
** Conversion rates from coca leaf to cocaine are currently being reviewed. This may lead to a revision of the 2008 figure (and of previous years). An 
estimate of the 2009 potential cocaine production in Peru was not available at the time of printing of this report.
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Peru, coca cultivation (ha), 1995-2009
Source (eradication): CORAH and DEVIDA. Includes forced and voluntary eradication
Peru, monthly farm-gate prices of sun-dried coca leaf and coca paste (US$/kg), 1990-2009
Source: UNODC, National monitoring system supported by UNODC
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
OPIATES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
AFRICA
East Africa
Burundi No recent, reliable estimate located
Comoros No recent, reliable estimate located
Djibouti No recent, reliable estimate located
Eritrea No recent, reliable estimate located
Ethiopia No recent, reliable estimate located
2004 c, i0.16 - 1.30 15 - 64Kenya Reference Group to the UN on HIV I0.73
Madagascar No recent, reliable estimate located
200715 - 54Mauritius ARQ I1.95
200415 - 64Rwanda Cure Research estimate0.14
Seychelles No recent, reliable estimate located
200415 - 64Somalia Cure Research estimate0.16
Tanzania (United Republic of) No recent, reliable estimate located
200415 - 64Uganda Cure Research estimate0.05
North Africa
200415 - 64Algeria UNODC Estimate0.12
2006 a, d0.14 - 0.73 15 - 64Egypt Govt;  Academic Research HHS, SS0.44
200415 - 64Libyan Arab Jamahiriya UNODC Estimate0.14
200315 - 64Morocco ARQ0.02
Sudan No recent, reliable estimate located
200615 - 64Tunisia UNODC Estimate0.09
Southern Africa
200115 - 64Angola UNODC Estimate0.25
Botswana No recent, reliable estimate located
Lesotho No recent, reliable estimate located
Malawi No recent, reliable estimate located
Mozambique No recent, reliable estimate located
Namibia No recent, reliable estimate located
2005 d,e,g,i0.35 - 0.39 15 - 64South Africa ARQ/ Reference Group to the UN on SS, I0.38
200415 - 64Swaziland Cure Research estimate0.17
200315 - 64Zambia UNODC Estimate0.37
200415 - 64Zimbabwe Cure Research estimate0.04
West and Central Africa
Benin No recent, reliable estimate located
Burkina Faso No recent, reliable estimate located
Cameroon No recent, reliable estimate located
200415 - 64Cape Verde UNODC Estimate0.18
200415 - 64Central African Republic Cure Research estimate0.05
200415 - 64Chad Cure Research estimate0.22
200415 - 64Congo Cure Research estimate0.17
200415 - 64Congo (Dem. Rep. of the) Cure Research estimate0.13
Côte d'Ivoire No recent, reliable estimate located
Equatorial Guinea No recent, reliable estimate located
Gabon No recent, reliable estimate located
Gambia No recent, reliable estimate located
200415 - 65Ghana Cure Research estimate0.14
Guinea No recent, reliable estimate located
Guinea-Bissau No recent, reliable estimate located
200415 - 64Liberia Cure Research estimate0.17
Mali No recent, reliable estimate located
Mauritania No recent, reliable estimate located
200415 - 64Niger Reference Group to the UN on HIV I0.20
Nigeria No recent, reliable estimate located
Saint Helena No recent, reliable estimate located
Sao Tome and Principe No recent, reliable estimate located
2006 a, d, e 15 - 64Senegal UNODC Estimate SS0.08
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
Annual prevalence4.2.1 
Opiates4.2.1.1 
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
OPIATES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
200415 - 64Sierra Leone Cure Research estimate0.17
Togo No recent, reliable estimate located
AMERICAS
Caribbean
Anguilla No recent, reliable estimate located
200015 - 64Antigua and Barbuda ARQ0.05
200315 - 64Bahamas UNODC Estimate0.22
200615 - 64Barbados UNODC Estimate0.13
Bermuda No recent, reliable estimate located
British Virgin Islands No recent, reliable estimate located
Cayman Islands No recent, reliable estimate located
Cuba No recent, reliable estimate located
Dominica No recent, reliable estimate located
200115 - 64Dominican Republic UNODC Estimate0.14
Grenada No recent, reliable estimate located
2006 a, d, e0.19 - 0.22 15 - 64Haiti ARQ SS0.20
200115 - 64Jamaica UNODC Estimate0.10
Montserrat No recent, reliable estimate located
Netherlands Antilles No recent, reliable estimate located
200215 - 64Puerto Rico Reference Group to the UN on HIV I1.15
Saint Kitts and Nevis No recent, reliable estimate located
Saint Lucia No recent, reliable estimate located
Saint Vincent and the Grenadines No recent, reliable estimate located
200215 - 64Trinidad and Tobago UNODC Estimate0.09
200215 - 64Turks and Caicos Islands UNODC Estimate0.07
United States Virgin Islands No recent, reliable estimate located
Central America
Belize No recent, reliable estimate located
200612 - 70Costa Rica ARQ HHS2.70
2005 e15 - 64El Salvador UNODC Estimate HHS0.14
200515 - 64Guatemala ARQ0.04
2005 e15 - 64Honduras UNODC Estimate HHS0.15
Nicaragua No recent, reliable estimate located
Panama No recent, reliable estimate located
North America
200815 - 64Canada Govt. source (CADUMS) HHS, x0.50
20080.04 - 0.10 15 - 64Mexico ARQ HHS0.08
Saint Pierre and Miquelon No recent, reliable estimate located
200015 - 64United States of America Govt. source (ONDCP) I0.58
South America
2005 e15 - 64Argentina UNODC Estimate0.16
2007 e12 - 65Bolivia (Plurinational State of) ARQ HHS0.30
2005 e15 - 64Brazil ARQ HHS0.50
200815 - 64Chile HHS HHS0.50
200415 - 64Colombia UNODC Estimate0.10
2005 e15 - 64Ecuador UNODC Estimate0.12
Falkland Islands (Malvinas) No recent, reliable estimate located
200215 - 64Guyana UNODC Estimate0.25
2003 e12 - 65Paraguay ARQ HHS0.03
200512 - 64Peru UNODC Estimate0.18
2002 e15 - 64Suriname UNODC Estimate0.08
2006 e15 - 64Uruguay ARQ HHS0.08
2003 a, d, e0.03 - 0.16 15 - 64Venezuela (Bolivarian Republic of) ARQ SS0.10
ASIA
Central Asia and Transcaucasian countries
200515 - 64Armenia ARQ HHS0.30
2008 i15 - 64Azerbaijan ARQ0.20
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
OPIATES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
200615 - 64Georgia UNODC Estimate0.58
2006 i15 - 64Kazakhstan UNODC (GAP survey)1.00
2006 i15 - 64Kyrgyzstan UNODC (GAP survey)0.80
2006 i15 - 64Tajikistan UNODC (GAP survey)0.54
200715 - 64Turkmenistan ARQ0.32
2006 i15 - 64Uzbekistan UNODC (GAP survey)0.80
East and South-East Asia
Brunei Darussalam No recent, reliable estimate located
20040.01 - 0.09 15 - 64Cambodia INCSR/ Reference Group to the UN I0.03
20050.19 - 0.31 15 - 64China Academic research/ Reference Group I0.25
200615 - 64China, Hong Kong SAR ARQ0.20
200315 - 64China, Macao SAR ARQ1.12
Guam No recent, reliable estimate located
200515 - 64Indonesia ARQ0.16
Japan No recent, reliable estimate located
Korea (Dem. People's Rep.) No recent, reliable estimate located
2004 a,e0.06 - 0.10 15 - 64Korea (Republic of) ARQ HHS0.08
2008 a, c15 - 64Lao People's Democratic Republic UNODC (ICMP) HHS0.37
20021.11 - 1.56 15 - 64Malaysia Reference Group to the UN on HIV I1.33
Mongolia No recent, reliable estimate located
2008 a,c15 - 64Myanmar UNODC (ICMP) HHS0.60
200515 - 64Philippines Reference Group to the UN on HIV 0.05
200615 - 64Singapore ARQ R0.01
200515 - 64Taiwan, Province of China Government source0.20
200715 - 64Thailand ARQ HHS0.20
Timor-Leste No recent, reliable estimate located
20050.25 - 0.28 15 - 64Viet Nam INCSR/ Reference Group to the UN 0.27
Near and Middle East /South-West Asia
20092.34 - 2.96 15 - 64Afghanistan UNODC/ Govt. Source HHS2.65
Bahrain No recent, reliable estimate located
19991.50 - 3.20 15 - 64Iran (Islamic Republic of) UNODC Estimate2.80
Iraq No recent, reliable estimate located
200518 - 40Israel ARQ0.50
200115 - 64Jordan UNODC Estimate0.17
200415 - 64Kuwait UNODC Estimate0.17
200315 - 64Lebanon ARQ0.20
Occupied Palestinian Territory No recent, reliable estimate located
199915 - 64Oman UNODC Estimate0.09
200615 - 64Pakistan UNODC (GAP survey)0.70
Qatar No recent, reliable estimate located
200615 - 64Saudi Arabia UNODC Estimate0.06
200515 - 64Syrian Arab Republic UNODC Estimate0.02
200415 - 64United Arab Emirates UNODC Estimate0.02
Yemen No recent, reliable estimate located
South Asia
2003 a, e15 - 64Bangladesh ARQ HHS0.40
Bhutan No recent, reliable estimate located
India No recent, reliable estimate located
Maldives No recent, reliable estimate located
20060.18 - 0.29 15 - 64Nepal Government source I, b0.24
200615 - 64Sri Lanka ARQ0.11
EUROPE
East Europe
2007 h,g0.08 - 0.74 15 - 64Belarus UNODC Estimate R0.43
2008 e0.12 - 0.17 15 - 64Moldova (Republic of) Government source R, HHS0.15
2007 g15 - 64Russian Federation* ARQ1.64
20061.00 - 1.31 15 - 64Ukraine Reference Group to the UN on HIV I1.16
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
OPIATES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Southeast Europe
2007 h,g15 - 64Albania ARQ R0.45
200515 - 64Bosnia and Herzegovina Reference Group to the UN on HIV I0.30
20070.38 - 0.60 15 - 64Bulgaria ARQ I0.49
200615 - 64Croatia ARQ I0.36
200515 - 64Macedonia (TFYR) ARQ0.50
Montenegro No recent, reliable estimate located
20040.11 - 0.21 15 - 64Romania ARQ I0.16
20080.18 - 0.38 15 - 64Serbia ARQ I0.28
200315 - 64Turkey Government source0.05
West & Central Europe
Andorra No recent, reliable estimate located
200715 - 64Austria ARQ I0.43
Belgium No recent, reliable estimate located
20070.21 - 0.36 15 - 64Cyprus ARQ I0.27
200815 - 64Czech Republic Government source HHS0.40
200515 - 64Denmark ARQ I0.60
20040.89 - 3.79 15 - 64Estonia ARQ I1.52
200515 - 64Finland UNODC Estimate I0.23
20070.42 - 0.51 15 - 64France Government source I0.47
20070.15 - 0.27 15 - 64Germany EMCDDA I0.21
20070.24 - 0.31 15 - 64Greece EMCDDA I0.27
2007 g0.04 - 0.20 18 - 64Hungary Government source HHS0.10
200515 - 64Iceland ARQ0.40
200115 - 64Ireland ARQ I0.50
20080.63 - 0.81 15 - 64Italy ARQ I0.72
20070.70 - 0.80 15 - 64Latvia ARQ HHS0.75
200515 - 64Liechtenstein ARQ SS0.20
200815 - 64Lithuania Government source HHS0.10
200015 - 64Luxembourg EMCDDA I0.93
20070.54 - 0.59 15 - 64Malta ARQ I0.57
Monaco No recent, reliable estimate located
200515 - 64Netherlands ARQ0.31
20080.21 - 0.39 15 - 64Norway Government source I0.30
20050.09 - 0.11 15 - 64Poland ARQ I0.10
20050.43 - 0.50 15 - 64Portugal ARQ I0.46
San Marino No recent, reliable estimate located
20070.18 - 0.49 15 - 64Slovakia EMCDDA I0.25
2004 g0.66 - 0.92 15 - 64Slovenia ARQ I0.74
20070.12 - 0.14 15 - 64Spain Government source I0.13
200415 - 64Sweden ARQ I0.17
20000.51 - 0.78 15 - 64Switzerland Government source I0.61
United Kingdom No recent, reliable estimate located
20070.79 - 0.84 15 - 64United Kingdom (England and Wales) EMCDDA I0.81
200616 - 59United Kingdom (Northern Ireland) Government source0.10
20041.54 - 1.68 15 - 64United Kingdom (Scotland) EMCDDA I1.54
OCEANIA
Oceania
American Samoa No recent, reliable estimate located
2007 a15 - 64Australia ARQ HHS0.40
Christmas Islands No recent, reliable estimate located
Cocos (Keeling) Islands No recent, reliable estimate located
Cook Islands No recent, reliable estimate located
Fiji No recent, reliable estimate located
French Polynesia No recent, reliable estimate located
Kiribati No recent, reliable estimate located
Marshall Islands No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
OPIATES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Micronesia (Federated States of) No recent, reliable estimate located
Nauru No recent, reliable estimate located
New Caledonia No recent, reliable estimate located
200816 - 64New Zealand Government source HHS, x1.10
Norfolk Island No recent, reliable estimate located
Northern Mariana Islands No recent, reliable estimate located
Palau No recent, reliable estimate located
Papua New Guinea No recent, reliable estimate located
Pitcairn No recent, reliable estimate located
Samoa No recent, reliable estimate located
Solomon Islands No recent, reliable estimate located
Tonga No recent, reliable estimate located
Tuvalu No recent, reliable estimate located
Vanuatu No recent, reliable estimate located
Wallis and Futuna Islands No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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World Drug Report 2010 
Cocaine4.2.1.2 
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
COCAINE
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
AFRICA
East Africa
Burundi No recent, reliable estimate located
Comoros No recent, reliable estimate located
Djibouti No recent, reliable estimate located
Eritrea No recent, reliable estimate located
Ethiopia No recent, reliable estimate located
Kenya No recent, reliable estimate located
Madagascar No recent, reliable estimate located
Mauritius No recent, reliable estimate located
Rwanda No recent, reliable estimate located
Seychelles No recent, reliable estimate located
Somalia No recent, reliable estimate located
Tanzania (United Republic of) No recent, reliable estimate located
Uganda No recent, reliable estimate located
North Africa
Algeria No recent, reliable estimate located
2006 a, d15 - 64Egypt Govt;  Academic Research HHS, SS<0.1
Libyan Arab Jamahiriya No recent, reliable estimate located
200415 - 64Morocco ARQ<0.1
Sudan No recent, reliable estimate located
Tunisia No recent, reliable estimate located
Southern Africa
1999 e15 - 64Angola UNODC Estimate0.1
Botswana No recent, reliable estimate located
Lesotho No recent, reliable estimate located
Malawi No recent, reliable estimate located
Mozambique No recent, reliable estimate located
Namibia No recent, reliable estimate located
2008 a, e0.6 - 1.2 15 - 64South Africa ARQ HHS0.8
Swaziland No recent, reliable estimate located
200015 - 64Zambia UNODC Estimate0.2
200015 - 64Zimbabwe UNODC Estimate0.1
West and Central Africa
Benin No recent, reliable estimate located
Burkina Faso No recent, reliable estimate located
Cameroon No recent, reliable estimate located
2004 d, e15 - 64Cape Verde UNODC Estimate0.2
Central African Republic No recent, reliable estimate located
Chad No recent, reliable estimate located
Congo No recent, reliable estimate located
Congo (Dem. Rep. of the) No recent, reliable estimate located
Côte d'Ivoire No recent, reliable estimate located
Equatorial Guinea No recent, reliable estimate located
Gabon No recent, reliable estimate located
Gambia No recent, reliable estimate located
Ghana No recent, reliable estimate located
Guinea No recent, reliable estimate located
Guinea-Bissau No recent, reliable estimate located
Liberia No recent, reliable estimate located
Mali No recent, reliable estimate located
Mauritania No recent, reliable estimate located
Niger No recent, reliable estimate located
199915 - 64Nigeria UNODC Estimate0.5
Saint Helena No recent, reliable estimate located
Sao Tome and Principe No recent, reliable estimate located
Senegal No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
COCAINE
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Sierra Leone No recent, reliable estimate located
Togo No recent, reliable estimate located
AMERICAS
Caribbean
Anguilla No recent, reliable estimate located
2005 d, e0.3 - 1.6 15 - 64Antigua and Barbuda Government source SS0.9
2008 d, e<0.1 - 0.3 15 - 64Bahamas ARQ SS0.2
200615 - 64Barbados CICAD HHS0.4
Bermuda No recent, reliable estimate located
British Virgin Islands No recent, reliable estimate located
200015 - 64Cayman Islands UNODC Estimate0.6
Cuba No recent, reliable estimate located
Dominica No recent, reliable estimate located
2008 d, e0.1 - 0.6 15 - 64Dominican Republic ARQ SS0.3
2005 d, e0.2 - 1.9 15 - 64Grenada CICAD SS0.9
200515 - 64Haiti UNODC Estimate0.9
2006 a, d15 - 64Jamaica UNODC Estimate SS1.1
Montserrat No recent, reliable estimate located
Netherlands Antilles No recent, reliable estimate located
2005 d, e0.3 - 1.4 15 - 64Puerto Rico Government source SS0.8
2006 d, e0.4 - 3.2 15 - 64Saint Kitts and Nevis Government source SS1.7
200215 - 64Saint Lucia UNODC Estimate1.0
200215 - 64Saint Vincent and the Grenadines UNODC Estimate SS0.7
Trinidad and Tobago No recent, reliable estimate located
200215 - 64Turks and Caicos Islands UNODC Estimate0.7
United States Virgin Islands No recent, reliable estimate located
Central America
200512 - 65Belize CICAD HHS0.9
200612 - 70Costa Rica ARQ HHS0.4
20050.2 - 0.5 12 - 65El Salvador CICAD HHS0.4
200515 - 64Guatemala ARQ HHS0.2
200512 - 35Honduras ARQ0.9
20060.5 - 0.9 12 - 65Nicaragua CICAD HHS, c0.7
200312 - 65Panama Government source HHS1.2
North America
200815 - 64Canada ARQ HHS1.9
200812 - 65Mexico Govt. source (ENA) HHS0.4
Saint Pierre and Miquelon No recent, reliable estimate located
200815 - 64United States of America Govt. source (SAMSHA) HHS2.6
South America
200615 - 64Argentina UNODC/ CICAD HHS, a, c2.6
200715 - 64Bolivia (Plurinational State of) UNODC/ CICAD HHS, a, c0.8
200512 - 65Brazil Government source HHS, c0.7
200815 - 64Chile ARQ HHS2.4
20080.7 - 0.9 12 - 65Colombia Government source HHS, c0.8
200715 - 64Ecuador UNODC/ CICAD HHS, a, c0.3
Falkland Islands (Malvinas) No recent, reliable estimate located
Guyana No recent, reliable estimate located
20030.2 - 0.3 12 - 64Paraguay CICAD HHS0.3
20060.3 - 0.6 12 - 64Peru ARQ HHS, c0.5
200712 - 65Suriname Government source HHS0.3
200612 - 65Uruguay UNODC/ CICAD HHS, a, c1.4
200515 - 64Venezuela (Bolivarian Republic of) Government source HHS0.6
ASIA
Central Asia and Transcaucasian countries
200515 - 64Armenia UNODC Estimate HHS0.1
Azerbaijan No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
COCAINE
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Georgia No recent, reliable estimate located
Kazakhstan No recent, reliable estimate located
Kyrgyzstan No recent, reliable estimate located
Tajikistan No recent, reliable estimate located
Turkmenistan No recent, reliable estimate located
Uzbekistan No recent, reliable estimate located
East and South-East Asia
Brunei Darussalam No recent, reliable estimate located
Cambodia No recent, reliable estimate located
China No recent, reliable estimate located
2008 d, e0.2 - 0.3 15 - 64China, Hong Kong SAR Government source SS0.3
China, Macao SAR No recent, reliable estimate located
Guam No recent, reliable estimate located
200815 - 64Indonesia ARQ HHS<0.1
Japan No recent, reliable estimate located
Korea (Dem. People's Rep.) No recent, reliable estimate located
2004 e, f15 - 64Korea (Republic of) ARQ HHS<0.1
Lao People's Democratic Republic No recent, reliable estimate located
Malaysia No recent, reliable estimate located
Mongolia No recent, reliable estimate located
Myanmar No recent, reliable estimate located
200515 - 64Philippines UNODC Estimate HHS<0.1
Singapore No recent, reliable estimate located
200515 - 64Taiwan, Province of China AMCEWG0.1
2007 e15 - 64Thailand ARQ HHS<0.1
Timor-Leste No recent, reliable estimate located
Viet Nam No recent, reliable estimate located
Near and Middle East /South-West Asia
200915 - 64Afghanistan UNODC/ Govt. Source HHS<0.1
Bahrain No recent, reliable estimate located
Iran (Islamic Republic of) No recent, reliable estimate located
Iraq No recent, reliable estimate located
200818 - 40Israel Governmetn source HHS0.6
Jordan No recent, reliable estimate located
2005 g15 - 64Kuwait UNODC Estimate<0.1
2001 d, e15 - 64Lebanon UNODC Estimate0.1
Occupied Palestinian Territory No recent, reliable estimate located
Oman No recent, reliable estimate located
Pakistan No recent, reliable estimate located
Qatar No recent, reliable estimate located
Saudi Arabia No recent, reliable estimate located
2005 g15 - 64Syrian Arab Republic UNODC Estimate<0.1
United Arab Emirates No recent, reliable estimate located
Yemen No recent, reliable estimate located
South Asia
Bangladesh No recent, reliable estimate located
Bhutan No recent, reliable estimate located
India No recent, reliable estimate located
Maldives No recent, reliable estimate located
Nepal No recent, reliable estimate located
Sri Lanka No recent, reliable estimate located
EUROPE
East Europe
2007 d, e<0.1 - 0.1 15 - 64Belarus ESPAD SS<0.1
2008 e<0.1 15 - 64Moldova (Republic of) Government sources HHS<0.1
2007 d, e0.2 - 0.3 15 - 64Russian Federation* ESPAD SS0.2
2007 d, e0.2 - 0.3 15 - 64Ukraine ESPAD SS0.2
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
COCAINE
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Southeast Europe
2006 d, e<0.1 - 1.6 15 - 64Albania ESPAD SS0.8
2008 d, e<0.1 - 1.9 15 - 64Bosnia and Herzegovina ESPAD SS0.6
200715 - 64Bulgaria ARQ HHS0.6
2007 d, e15 - 64Croatia ESPAD SS0.9
200715 - 64Macedonia (TFYR) INCSR<0.1
2008 d, e<0.1 - 1.7 15 - 64Montenegro ESPAD SS0.8
2007 e<0.1 15 - 64Romania ARQ HHS<0.1
2008 a, d, e0.1 - 1.2 15 - 64Serbia Government sources HHS0.5
200315 - 64Turkey UNODC Estimate<0.1
West & Central Europe
Andorra No recent, reliable estimate located
200815 - 64Austria Govt. HHS0.9
2007 c, d, e1.2 - 1.3 15 - 64Belgium ESPAD SS1.2
200615 - 65Cyprus ARQ0.6
200815 - 64Czech Republic Government sources HHS0.7
200816 - 64Denmark ARQ HHS1.4
200815 - 64Estonia Government sources HHS0.6
200615 - 64Finland ARQ0.5
200515 - 64France ARQ0.6
200618 - 64Germany Government source HHS0.7
200415 - 64Greece ARQ0.1
2007<0.1 - 0.4 18 - 64Hungary ARQ HHS0.2
2007 d, e15 - 64Iceland ESPAD SS0.9
200715 - 64Ireland Government source HHS1.7
200815 - 64Italy Government source HHS2.2
200715 - 64Latvia ARQ HHS0.5
200515 - 64Liechtenstein UNODC Estimate0.8
200815 - 64Lithuania ARQ HHS0.2
200315 - 64Luxembourg UNODC Estimate0.9
2007 d, e1.1 - 1.2 18 - 65Malta ESPAD SS1.1
2007 d, e1.7 - 2.0 18 - 66Monaco ESPAD SS1.9
200515 - 64Netherlands ARQ0.6
200415 - 64Norway ARQ0.8
200616 - 64Poland ARQ0.2
200715 - 64Portugal ARQ HHS0.6
San Marino No recent, reliable estimate located
200615 - 64Slovakia ARQ HHS0.6
2007 d, e15 - 64Slovenia ESPAD SS0.9
200715 - 64Spain Government source HHS3.0
2007 d,e0.5 - 0.6 15 - 64Sweden ESPAD SS0.6
2007 d, e15 - 64Switzerland ESPAD SS0.8
United Kingdom No recent, reliable estimate located
200916 - 59United Kingdom (England and Wales) Government source HHS3.0
200715 - 64United Kingdom (Northern Ireland) Government source HHS1.9
20093.7 - 4.0 16 - 59United Kingdom (Scotland) Government source HHS3.9
OCEANIA
Oceania
American Samoa No recent, reliable estimate located
200715 - 64Australia Government Source HHS1.9
Christmas Islands No recent, reliable estimate located
Cocos (Keeling) Islands No recent, reliable estimate located
Cook Islands No recent, reliable estimate located
Fiji No recent, reliable estimate located
French Polynesia No recent, reliable estimate located
Kiribati No recent, reliable estimate located
Marshall Islands No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
COCAINE
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Micronesia (Federated States of) No recent, reliable estimate located
Nauru No recent, reliable estimate located
New Caledonia No recent, reliable estimate located
200816 - 64New Zealand Government source HHS0.6
Norfolk Island No recent, reliable estimate located
Northern Mariana Islands No recent, reliable estimate located
Palau No recent, reliable estimate located
Papua New Guinea No recent, reliable estimate located
Pitcairn No recent, reliable estimate located
Samoa No recent, reliable estimate located
Solomon Islands No recent, reliable estimate located
Tonga No recent, reliable estimate located
Tuvalu No recent, reliable estimate located
Vanuatu No recent, reliable estimate located
Wallis and Futuna Islands No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Cannabis4.2.1.3 
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
CANNABIS
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
AFRICA
East Africa
Burundi No recent, reliable estimate located
200215 - 64Comoros UNODC Estimate2.9
Djibouti No recent, reliable estimate located
Eritrea No recent, reliable estimate located
199915 - 64Ethiopia EADIS2.6
2004 c, d, e, f4.7 - 10.0 15 - 64Kenya ARQ, NGO, Council of Europe SS, A7.1
2004 d, e15 - 64Madagascar ARQ SS, A9.1
200415 - 54Mauritius ARQ3.9
Rwanda No recent, reliable estimate located
Seychelles No recent, reliable estimate located
200215 - 64Somalia UNODC Estimate2.5
Tanzania (United Republic of) No recent, reliable estimate located
Uganda No recent, reliable estimate located
North Africa
2006 d5.2 - 6.4 15 - 64Algeria Council of Europe SS, A5.7
2006 a, d2.9 - 9.6 15 - 64Egypt Govt;  Academic Research HHS, SS6.2
Libyan Arab Jamahiriya No recent, reliable estimate located
200415 - 64Morocco ARQ HHS 4.2
Sudan No recent, reliable estimate located
Tunisia No recent, reliable estimate located
Southern Africa
1999 e15 - 64Angola ARQ2.1
Botswana No recent, reliable estimate located
Lesotho No recent, reliable estimate located
Malawi No recent, reliable estimate located
Mozambique No recent, reliable estimate located
200015 - 64Namibia ARQ3.9
2008 a, e3.5 - 6.2 15 - 64South Africa ARQ HHS4.3
Swaziland No recent, reliable estimate located
200315 - 64Zambia UNODC Estimate17.7
200015 - 64Zimbabwe UNODC Estimate6.9
West and Central Africa
Benin No recent, reliable estimate located
2006 d, e15 - 64Burkina Faso UNODC Estimate2.9
Cameroon No recent, reliable estimate located
2004 d, e15 - 64Cape Verde UNODC Estimate8.1
Central African Republic No recent, reliable estimate located
Chad No recent, reliable estimate located
Congo No recent, reliable estimate located
Congo (Dem. Rep. of the) No recent, reliable estimate located
Côte d'Ivoire No recent, reliable estimate located
Equatorial Guinea No recent, reliable estimate located
Gabon No recent, reliable estimate located
Gambia No recent, reliable estimate located
Ghana No recent, reliable estimate located
Guinea No recent, reliable estimate located
Guinea-Bissau No recent, reliable estimate located
Liberia No recent, reliable estimate located
Mali No recent, reliable estimate located
Mauritania No recent, reliable estimate located
Niger No recent, reliable estimate located
2000 h15 - 64Nigeria ARQ R13.8
Saint Helena No recent, reliable estimate located
Sao Tome and Principe No recent, reliable estimate located
Senegal No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
CANNABIS
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Sierra Leone No recent, reliable estimate located
2006 d, e15 - 64Togo ARQ SS2.7
AMERICAS
Caribbean
Anguilla No recent, reliable estimate located
2005 d, e7.8 - 13.4 15 - 64Antigua and Barbuda Government source SS10.6
2008 d, e3.2 - 7.9 15 - 64Bahamas ARQ SS5.5
200615 - 64Barbados CICAD HHS8.3
Bermuda No recent, reliable estimate located
British Virgin Islands No recent, reliable estimate located
Cayman Islands No recent, reliable estimate located
Cuba No recent, reliable estimate located
2006 d, e6.1 - 15.5 15 - 64Dominica Government source SS10.8
2008 d, e0.3 - 1.4 15 - 64Dominican Republic ARQ SS0.3
2005 d, e7.3 - 14.4 15 - 64Grenada Government source SS10.8
2005 d, e0.4 - 2.2 15 - 64Haiti CICAD SS1.4
2006 d, e7.5 - 12.2 15 - 64Jamaica Government source SS9.9
Montserrat No recent, reliable estimate located
Netherlands Antilles No recent, reliable estimate located
2005 d, e3.1 - 6.7 15 - 64Puerto Rico Government source SS4.9
2006 d, e8.3 - 15.1 15 - 64Saint Kitts and Nevis Government source SS11.7
2006 d, e15 - 64Saint Lucia UNODC Estimate SS9.0
2006 d, e5.1 - 9.1 15 - 64Saint Vincent and the Grenadines Government source SS7.1
2006 d, e2.9 - 6.4 15 - 64Trinidad and Tobago Government source SS4.7
200215 - 64Turks and Caicos Islands UNODC Estimate5.4
United States Virgin Islands No recent, reliable estimate located
Central America
200512 - 65Belize CICAD HHS8.5
200612 - 70Costa Rica ARQ HHS1.0
200512 - 65El Salvador CICAD HHS0.4
2005 c, d15 - 64Guatemala UNODC Estimate HHS, SS4.8
2005 d, e0.4 - 1.6 12 - 35Honduras CICAD SS0.8
200612 - 65Nicaragua CICAD HHS, c1.1
2003 d, e3.4 - 3.7 12 - 65Panama CICAD HHS3.6
North America
200815 - 64Canada ARQ HHS13.6
200812 - 65Mexico Govt. source (ENA) HHS1.0
Saint Pierre and Miquelon No recent, reliable estimate located
200815 - 64United States of America Govt. source (SAMSHA) HHS12.5
South America
200615 - 64Argentina UNODC/ CICAD HHS, a, c7.2
200715 - 64Bolivia (Plurinational State of) UNODC/ CICAD HHS, a, c4.3
200512 - 65Brazil Government source HHS, c2.6
200815 - 64Chile ARQ HHS6.7
200812 - 65Colombia Government source HHS2.3
200715 - 64Ecuador UNODC/ CICAD HHS, a, c0.7
Falkland Islands (Malvinas) No recent, reliable estimate located
200215 - 64Guyana UNODC Estimate2.6
200515 - 64Paraguay UNODC Estimate1.6
200612 - 64Peru ARQ HHS, c0.7
20073.8 - 4.7 12 - 65Suriname Government source HHS4.3
200612 - 65Uruguay UNODC/ CICAD HHS, a, c6.0
2005 a, e0.2 - 1.4 15 - 64Venezuela (Bolivarian Republic of) Government source HHS0.9
ASIA
Central Asia and Transcaucasian countries
200315 - 64Armenia UNODC Estimate3.5
200415 - 64Azerbaijan UNODC Estimate3.5
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
CANNABIS
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
2005 a, d, e0.5 - 1.7 15 - 64Georgia ARQ SS1.1
200315 - 64Kazakhstan INCSR4.2
200115 - 64Kyrgyzstan ARQ6.4
Tajikistan No recent, reliable estimate located
Turkmenistan No recent, reliable estimate located
2003 e15 - 64Uzbekistan UNODC Estimate4.2
East and South-East Asia
Brunei Darussalam No recent, reliable estimate located
200315 - 64Cambodia UNODC Estimate3.5
China No recent, reliable estimate located
2008 d, e0.2 - 2.0 15 - 64China, Hong Kong SAR Government source SS0.4
2003 d, e15 - 64China, Macao SAR UNODC Estimate R0.7
2007 d, e14.7 - 22.0 15 - 64Guam Government source SS18.4
200815 - 64Indonesia ARQ HHS0.4
Japan No recent, reliable estimate located
Korea (Dem. People's Rep.) No recent, reliable estimate located
2004 c, e<0.1 - 0.6 15 - 64Korea (Republic of) ARQ HHS0.3
2008 c, d0.7 - 1.1 15 - 64Lao People's Democratic Republic UNODC report SS0.9
200315 - 64Malaysia UNODC Estimate1.6
Mongolia No recent, reliable estimate located
2005 d, e15 - 64Myanmar UNODC Estimate0.9
2008 c, e0.7 - 0.9 15 - 64Philippines Government source HHS0.8
Singapore No recent, reliable estimate located
200515 - 64Taiwan, Province of China AMCEWG0.3
200715 - 64Thailand ARQ HHS1.2
Timor-Leste No recent, reliable estimate located
200215 - 64Viet Nam UNODC Estimate0.3
Near and Middle East /South-West Asia
20093.4 - 5.2 15 - 64Afghanistan UNODC/ Govt. Source HHS4.3
Bahrain No recent, reliable estimate located
199915 - 64Iran (Islamic Republic of) ARQ4.2
Iraq No recent, reliable estimate located
200818 - 40Israel Government source HHS8.9
2001 a15 - 64Jordan ARQ2.1
200515 - 64Kuwait UNODC Estimate3.1
2001 d15 - 64Lebanon ARQ6.4
Occupied Palestinian Territory No recent, reliable estimate located
199915 - 64Oman 0.1
200015 - 64Pakistan INCSR3.9
Qatar No recent, reliable estimate located
200615 - 64Saudi Arabia Government source/ NGO/Academic R0.3
Syrian Arab Republic No recent, reliable estimate located
200615 - 64United Arab Emirates UNODC Estimate5.4
Yemen No recent, reliable estimate located
South Asia
2004 a, e,f15 - 54Bangladesh Academic research HHS3.3
Bhutan No recent, reliable estimate located
India No recent, reliable estimate located
Maldives No recent, reliable estimate located
Nepal No recent, reliable estimate located
200015 - 64Sri Lanka UNODC Estimate1.5
EUROPE
East Europe
2007 c, d, e0.9 - 1.3 15 - 64Belarus ESPAD SS1.1
200815 - 64Moldova (Republic of) Government source HHS0.9
2007 d, e15 - 64Russian Federation* ESPAD SS3.5
2007 d, e2.4 - 2.6 15 - 64Ukraine ESPAD SS2.5
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
CANNABIS
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Southeast Europe
2006 d, e15 - 64Albania ESPAD SS1.8
2008 c, d, e2.8 - 4.6 15 - 64Bosnia and Herzegovina ESPAD SS2.8
200815 - 64Bulgaria ARQ HHS2.5
2007 d, e5.1 - 5.3 15 - 64Croatia ESPAD SS5.2
2008 d, e0.5 - 2.4 15 - 64Macedonia (TFYR) ESPAD SS0.6
2008 d, e0.2 - 2.0 15 - 64Montenegro ESPAD SS0.2
200715 - 64Romania ARQ HHS0.4
2006 a, d, e2.8 - 5.4 15 - 64Serbia Government source HHS4.1
200315 - 64Turkey UNODC Estimate1.9
West & Central Europe
Andorra No recent, reliable estimate located
2008 a15 - 64Austria Government source HHS3.5
200415 - 64Belgium EMCDDA HHS5.0
200615 - 65Cyprus ARQ2.1
200815 - 64Czech Republic Government source HHS15.2
200816 - 64Denmark ARQ HHS5.5
200815 - 64Estonia Government source HHS6.0
2008 a3.0 - 3.2 15 - 64Finland Government source HHS3.1
200515 - 64France ARQ8.6
200715 - 64Germany Government source HHS4.7
200415 - 64Greece ARQ1.7
20071.7 - 2.9 18 - 64Hungary ARQ HHS2.3
2007 d, e3.2 - 3.5 15 - 64Iceland ESPAD SS3.4
200715 - 64Ireland Government source HHS6.3
200815 - 64Italy Government source HHS14.6
200715 - 64Latvia ARQ4.9
200515 - 64Liechtenstein UNODC Estimate8.6
200815 - 64Lithuania ARQ HHS5.6
200315 - 64Luxembourg UNODC Estimate7.6
2007 d, e4.4 - 4.6 18 - 65Malta ESPAD SS4.5
2007 d, e7.9 - 10.0 18 - 66Monaco ESPAD SS8.9
200515 - 64Netherlands ARQ5.4
200415 - 64Norway ARQ4.6
200616 - 64Poland ARQ2.7
200715 - 64Portugal ARQ HHS3.6
San Marino No recent, reliable estimate located
200615 - 64Slovakia ARQ HHS6.9
2007 d, e15 - 64Slovenia ESPAD SS4.1
200715 - 64Spain Government source HHS10.1
200715 - 64Sweden ARQ HHS2.1
2007 d, e8.5 - 10.9 15 - 64Switzerland ESPAD SS9.7
United Kingdom No recent, reliable estimate located
200916 - 59United Kingdom (England and Wales) Government source HHS7.9
200715 - 64United Kingdom (Northern Ireland) Government source HHS7.2
200916 - 59United Kingdom (Scotland) Government source HHS8.4
OCEANIA
Oceania
2007 d, e4.7 - 9.2 15 - 64American Samoa Government source SS7.0
200715 - 64Australia Government source HHS10.6
Christmas Islands No recent, reliable estimate located
Cocos (Keeling) Islands No recent, reliable estimate located
Cook Islands No recent, reliable estimate located
2004 d, e3.0 - 7.1 15 - 64Fiji Government source SS5.1
French Polynesia No recent, reliable estimate located
Kiribati No recent, reliable estimate located
2007 d, e3.4 - 7.5 15 - 64Marshall Islands Government source SS5.5
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
CANNABIS
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Micronesia (Federated States of) No recent, reliable estimate located
Nauru No recent, reliable estimate located
New Caledonia No recent, reliable estimate located
200816 - 64New Zealand Government source HHS14.6
Norfolk Island No recent, reliable estimate located
2007 d, e18.1 - 26.4 15 - 64Northern Mariana Islands Government source SS22.2
2007 d, e19.8 - 28.6 15 - 64Palau Government source SS24.2
Papua New Guinea No recent, reliable estimate located
Pitcairn No recent, reliable estimate located
Samoa No recent, reliable estimate located
Solomon Islands No recent, reliable estimate located
Tonga No recent, reliable estimate located
Tuvalu No recent, reliable estimate located
Vanuatu No recent, reliable estimate located
Wallis and Futuna Islands No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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Amphetamine-type stimulants4.2.1.4 
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
AMPHETAMINES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
AFRICA
East Africa
Burundi No recent, reliable estimate located
Comoros No recent, reliable estimate located
Djibouti No recent, reliable estimate located
Eritrea No recent, reliable estimate located
Ethiopia No recent, reliable estimate located
Kenya No recent, reliable estimate located
Madagascar No recent, reliable estimate located
Mauritius No recent, reliable estimate located
Rwanda No recent, reliable estimate located
Seychelles No recent, reliable estimate located
Somalia No recent, reliable estimate located
Tanzania (United Republic of) No recent, reliable estimate located
Uganda No recent, reliable estimate located
North Africa
Algeria No recent, reliable estimate located
2006 a, b, d0.4 - 0.5 15 - 64Egypt Govt;  Academic Research HHS, SS0.5
Libyan Arab Jamahiriya No recent, reliable estimate located
199915 - 64Morocco ARQ<0.1
Sudan No recent, reliable estimate located
Tunisia No recent, reliable estimate located
Southern Africa
Angola No recent, reliable estimate located
Botswana No recent, reliable estimate located
Lesotho No recent, reliable estimate located
Malawi No recent, reliable estimate located
Mozambique No recent, reliable estimate located
200015 - 64Namibia ARQ<0.1
2008 a, e0.8 - 1.4 15 - 64South Africa ARQ HHS1.0
Swaziland No recent, reliable estimate located
200315 - 64Zambia UNODC Estimate0.1
200015 - 64Zimbabwe ARQ0.1
West and Central Africa
Benin No recent, reliable estimate located
Burkina Faso No recent, reliable estimate located
Cameroon No recent, reliable estimate located
Cape Verde No recent, reliable estimate located
Central African Republic No recent, reliable estimate located
Chad No recent, reliable estimate located
Congo No recent, reliable estimate located
Congo (Dem. Rep. of the) No recent, reliable estimate located
Côte d'Ivoire No recent, reliable estimate located
Equatorial Guinea No recent, reliable estimate located
Gabon No recent, reliable estimate located
Gambia No recent, reliable estimate located
Ghana No recent, reliable estimate located
Guinea No recent, reliable estimate located
Guinea-Bissau No recent, reliable estimate located
Liberia No recent, reliable estimate located
Mali No recent, reliable estimate located
Mauritania No recent, reliable estimate located
Niger No recent, reliable estimate located
199915 - 64Nigeria UNODC Estimate1.1
Saint Helena No recent, reliable estimate located
Sao Tome and Principe No recent, reliable estimate located
Senegal No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
AMPHETAMINES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Sierra Leone No recent, reliable estimate located
Togo No recent, reliable estimate located
AMERICAS
Caribbean
Anguilla No recent, reliable estimate located
2005 d, e0.2 - 1.2 15 - 64Antigua and Barbuda Government source SS0.6
2008 d, e0.1 - 1.1 15 - 64Bahamas ARQ SS0.4
200612 - 65Barbados CICAD HHS, z0.2
Bermuda No recent, reliable estimate located
British Virgin Islands No recent, reliable estimate located
Cayman Islands No recent, reliable estimate located
Cuba No recent, reliable estimate located
2006 d, e0.3 - 1.6 15 - 64Dominica Government source SS0.9
2008 d, e<0.1 - 2.6 15 - 64Dominican Republic ARQ SS, z1.0
200515 - 64Grenada ARQ0.7
Haiti No recent, reliable estimate located
2006 d, e0.4 - 1.9 15 - 64Jamaica Government source SS1.1
Montserrat No recent, reliable estimate located
Netherlands Antilles No recent, reliable estimate located
2005 d, e0.1 - 1.1 15 - 64Puerto Rico Government source SS0.4
2006 d, e0.1 - 0.6 15 - 64Saint Kitts and Nevis Government source SS, z0.2
2005 d, e0.4 - 1.9 15 - 64Saint Lucia CICAD SS, z1.2
2006 d, e0.2 - 1.3 15 - 64Saint Vincent and the Grenadines CICAD SS, z0.6
2006 d, e0.2 - 1.4 15 - 64Trinidad and Tobago CICAD SS, z0.7
2003 d, e15 - 64Turks and Caicos Islands UNODC Estimate0.3
United States Virgin Islands No recent, reliable estimate located
Central America
200512 - 65Belize CICAD HHS, z1.4
200612 - 70Costa Rica ARQ1.3
200512 - 65El Salvador CICAD HHS, z3.3
2005 d, e15 - 64Guatemala UNODC Estimate0.9
2005 d,e15 - 64Honduras UNODC Estimate0.8
2003 d15 - 64Nicaragua UNODC Estimate0.8
200312 - 65Panama CICAD HHS, z1.2
North America
200815 - 64Canada CADUMS HHS1.5
20080.1 - 0.2 12 - 65Mexico Govt. source (ENA) HHS0.2
Saint Pierre and Miquelon No recent, reliable estimate located
200815 - 64United States of America Govt. source (SAMHSA) HHS1.3
South America
2005 d, e15 - 64Argentina UNODC Estimate SS, z0.6
200712 - 65Bolivia (Plurinational State of) ARQ HHS0.5
200512 - 65Brazil Government source HHS, c0.7
200815 - 64Chile ARQ HHS0.4
2008 a, c, d, e<0.1 - 1.9 12 - 65Colombia Government source HHS, SS0.5
2005 d, e15 - 64Ecuador UNODC Estimate SS, z0.2
Falkland Islands (Malvinas) No recent, reliable estimate located
2002 d, e0.1 - 1.1 15 - 64Guyana CICAD SS, z0.5
2005 d, e15 - 64Paraguay UNODC Estimate SS, z0.5
200612 - 64Peru Govt. HHS0.2
200712 - 65Suriname Government source HHS, z0.7
200612 - 65Uruguay ARQ0.1
2002 d, e15 - 64Venezuela (Bolivarian Republic of) UNODC Estimate0.6
ASIA
Central Asia and Transcaucasian countries
200515 - 64Armenia UNODC Estimate HHS<0.1
Azerbaijan No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
AMPHETAMINES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Georgia No recent, reliable estimate located
Kazakhstan No recent, reliable estimate located
Kyrgyzstan No recent, reliable estimate located
Tajikistan No recent, reliable estimate located
Turkmenistan No recent, reliable estimate located
Uzbekistan No recent, reliable estimate located
East and South-East Asia
2006 g15 - 64Brunei Darussalam UNODC Estimate0.3
2004 d, e15 - 64Cambodia UNODC Estimate0.6
China No recent, reliable estimate located
2008 d, e<0.1 - 1.1 15 - 64China, Hong Kong SAR Government source SS 0.4
China, Macao SAR No recent, reliable estimate located
2007 d, e0.5 - 2.3 15 - 64Guam Government source SS1.4
200815 - 64Indonesia ARQ HHS0.2
Japan No recent, reliable estimate located
Korea (Dem. People's Rep.) No recent, reliable estimate located
2004 b, c, e<0.1 - 0.2 15 - 64Korea (Republic of) ARQ HHS0.1
2008 a, c, d, e1.1 - 1.7 15 - 64Lao People's Democratic Republic Academic research SS1.4
2005 d, g, h15 - 64Malaysia UNODC Estimate0.6
Mongolia No recent, reliable estimate located
2005 d, f15 - 64Myanmar UNODC Estimate0.2
2008 c, e1.9 - 2.4 15 - 64Philippines Government source HHS2.1
Singapore No recent, reliable estimate located
200512 - 64Taiwan, Province of China AMCEWG0.6
200712 - 65Thailand ARQ HHS1.4
Timor-Leste No recent, reliable estimate located
2003 h15 - 64Viet Nam UNODC Estimate0.2
Near and Middle East /South-West Asia
200915 - 64Afghanistan UNODC/ Govt. Source HHS<0.1
Bahrain No recent, reliable estimate located
Iran (Islamic Republic of) No recent, reliable estimate located
Iraq No recent, reliable estimate located
200818 - 40Israel Government source HHS4.5
200115 - 64Jordan UNODC Estimate0.4
2005 g15 - 64Kuwait UNODC Estimate0.3
2001 d, e15 - 64Lebanon UNODC Estimate0.4
Occupied Palestinian Territory No recent, reliable estimate located
Oman No recent, reliable estimate located
Pakistan No recent, reliable estimate located
Qatar No recent, reliable estimate located
2006 g15 - 64Saudi Arabia UNODC Estimate0.4
Syrian Arab Republic No recent, reliable estimate located
United Arab Emirates No recent, reliable estimate located
Yemen No recent, reliable estimate located
South Asia
Bangladesh No recent, reliable estimate located
Bhutan No recent, reliable estimate located
India No recent, reliable estimate located
Maldives No recent, reliable estimate located
Nepal No recent, reliable estimate located
Sri Lanka No recent, reliable estimate located
EUROPE
East Europe
2006 g15 - 64Belarus UNODC Estimate0.4
2008 e15 - 64Moldova (Republic of) Government source HHS<0.1
2007 d, e0.2 - 0.6 15 - 64Russian Federation* ESPAD SS0.4
2007 d, e0.2 - 0.6 15 - 64Ukraine ESPAD SS0.4
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
AMPHETAMINES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Southeast Europe
200415 - 64Albania ARQ<0.1
2008 c, d, e0.4 - 1.7 15 - 64Bosnia and Herzegovina ESPAD SS1.0
200815 - 64Bulgaria ARQ HHS1.0
2007 d, e0.6 - 0.8 15 - 64Croatia ESPAD SS0.7
Macedonia (TFYR) No recent, reliable estimate located
2008 d, e<0.1 - 0.9 15 - 64Montenegro ESPAD SS0.5
2007 e15 - 64Romania Government source HHS<0.1
2006 a, e0.1 - 0.5 15 - 64Serbia Government sources HHS0.2
200315 - 64Turkey UNODC Estimate0.2
West & Central Europe
Andorra No recent, reliable estimate located
2008 a15 - 64Austria Government source HHS0.5
2007 c, d, e0.6 - 1.1 15 - 64Belgium ESPAD SS0.9
200615 - 64Cyprus ARQ0.4
200815 - 64Czech Republic Government source HHS1.7
200816 - 64Denmark ARQ HHS1.2
200815 - 64Estonia Government source HHS1.0
200615 - 64Finland ARQ0.6
200515 - 64France ARQ0.2
200618 - 64Germany Government source HHS0.5
200415 - 64Greece ARQ0.2
20070.2 - 0.8 18 - 64Hungary ARQ HHS0.5
20030.6 - 0.9 15 - 64Iceland ESPAD SS0.7
200715 - 64Ireland Government source HHS0.4
2007 d, e0.6 - 0.7 15 - 64Italy Government source/ ESPAD HHS, SS0.6
200715 - 64Latvia ARQ0.9
2005 d15 - 64Liechtenstein UNODC Estimate0.2
200815 - 64Lithuania ARQ HHS0.7
199915 - 64Luxembourg UNODC Estimate0.4
2007 d, e0.6 - 1.2 15 - 64Malta ESPAD SS0.9
2007 d, e0.5 - 0.6 15 - 64Monaco ESPAD SS0.5
200515 - 64Netherlands ARQ HHS0.3
200415 - 64Norway ARQ HHS1.1
200615 - 64Poland ARQ0.7
200715 - 64Portugal ARQ HHS0.2
San Marino No recent, reliable estimate located
200615 - 64Slovakia EMCDDA HHS0.3
2007 d, e0.5 - 0.6 15 - 64Slovenia ESPAD SS0.5
200715 - 64Spain Government source HHS0.9
2007 d, e0.2 - 0.6 15 - 64Sweden ESPAD SS0.4
2007 d, e0.6 - 0.7 15 - 64Switzerland ESPAD SS0.6
United Kingdom No recent, reliable estimate located
2009 a16 - 64United Kingdom (England and Wales) Government source HHS1.1
200716 - 59United Kingdom (Northern Ireland) Government source HHS1.0
2009 a16 - 64United Kingdom (Scotland) Government source HHS1.4
OCEANIA
Oceania
2007 d, e0.5 - 2.3 15 - 64American Samoa Government source SS1.3
200715 - 64Australia Government source HHS2.7
Christmas Islands No recent, reliable estimate located
Cocos (Keeling) Islands No recent, reliable estimate located
Cook Islands No recent, reliable estimate located
Fiji No recent, reliable estimate located
French Polynesia No recent, reliable estimate located
Kiribati No recent, reliable estimate located
2007 d, e1.4 - 4.0 15 - 64Marshall Islands Government source SS2.7
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
AMPHETAMINES
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Micronesia (Federated States of) No recent, reliable estimate located
Nauru No recent, reliable estimate located
New Caledonia No recent, reliable estimate located
200816 - 64New Zealand Government source HHS2.1
Norfolk Island No recent, reliable estimate located
2007 d, e0.4 - 2.1 15 - 64Northern Mariana Islands Government source SS1.2
2007 d, e0.6 - 2.6 15 - 64Palau Government source SS1.6
Papua New Guinea No recent, reliable estimate located
Pitcairn No recent, reliable estimate located
Samoa No recent, reliable estimate located
Solomon Islands No recent, reliable estimate located
Tonga No recent, reliable estimate located
Tuvalu No recent, reliable estimate located
Vanuatu No recent, reliable estimate located
Wallis and Futuna Islands No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Ecstasy4.2.1.5 
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
ECSTASY
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
AFRICA
East Africa
Burundi No recent, reliable estimate located
Comoros No recent, reliable estimate located
Djibouti No recent, reliable estimate located
Eritrea No recent, reliable estimate located
Ethiopia No recent, reliable estimate located
Kenya No recent, reliable estimate located
Madagascar No recent, reliable estimate located
Mauritius No recent, reliable estimate located
Rwanda No recent, reliable estimate located
Seychelles No recent, reliable estimate located
Somalia No recent, reliable estimate located
Tanzania (United Republic of) No recent, reliable estimate located
Uganda No recent, reliable estimate located
North Africa
Algeria No recent, reliable estimate located
Egypt No recent, reliable estimate located
Libyan Arab Jamahiriya No recent, reliable estimate located
200315 - 64Morocco ARQ<0.1
Sudan No recent, reliable estimate located
Tunisia No recent, reliable estimate located
Southern Africa
Angola No recent, reliable estimate located
Botswana No recent, reliable estimate located
Lesotho No recent, reliable estimate located
Malawi No recent, reliable estimate located
Mozambique No recent, reliable estimate located
200015 - 64Namibia ARQ<0.1
2004 d, e15 - 64South Africa UNODC Estimate0.4
Swaziland No recent, reliable estimate located
2003 e, f15 - 64Zambia UNODC Estimate0.3
Zimbabwe No recent, reliable estimate located
West and Central Africa
Benin No recent, reliable estimate located
Burkina Faso No recent, reliable estimate located
Cameroon No recent, reliable estimate located
2004 d15 - 64Cape Verde UNODC Estimate<0.1
Central African Republic No recent, reliable estimate located
Chad No recent, reliable estimate located
Congo No recent, reliable estimate located
Congo (Dem. Rep. of the) No recent, reliable estimate located
Côte d'Ivoire No recent, reliable estimate located
Equatorial Guinea No recent, reliable estimate located
Gabon No recent, reliable estimate located
Gambia No recent, reliable estimate located
Ghana No recent, reliable estimate located
Guinea No recent, reliable estimate located
Guinea-Bissau No recent, reliable estimate located
Liberia No recent, reliable estimate located
Mali No recent, reliable estimate located
Mauritania No recent, reliable estimate located
Niger No recent, reliable estimate located
Nigeria No recent, reliable estimate located
Saint Helena No recent, reliable estimate located
Sao Tome and Principe No recent, reliable estimate located
Senegal No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
298
World Drug Report 2010 
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
ECSTASY
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Sierra Leone No recent, reliable estimate located
Togo No recent, reliable estimate located
AMERICAS
Caribbean
Anguilla No recent, reliable estimate located
2005 d, e<0.1 - 0.7 15 - 64Antigua and Barbuda Government source SS0.2
2008 d, e<0.1 - 0.6 15 - 64Bahamas Government source SS0.1
200615 - 64Barbados CICAD HHS0.5
Bermuda No recent, reliable estimate located
British Virgin Islands No recent, reliable estimate located
Cayman Islands No recent, reliable estimate located
Cuba No recent, reliable estimate located
2006 d, e<0.1 - 0.5 15 - 64Dominica Government source SS<0.1
2008 d, e<0.1 - 0.5 15 - 64Dominican Republic Government source SS<0.1
2005 d, e<0.1 - 0.7 15 - 64Grenada Government source SS0.2
2005 d, e0.1 - 1.2 15 - 64Haiti CICAD SS0.6
Jamaica No recent, reliable estimate located
Montserrat No recent, reliable estimate located
Netherlands Antilles No recent, reliable estimate located
2005<0.1 - 1.0 15 - 64Puerto Rico Government source SS0.4
2006 d, e<0.1 - 1.0 15 - 64Saint Kitts and Nevis Government source SS0.4
Saint Lucia No recent, reliable estimate located
2006 d, e<0.1 - 0.5 15 - 64Saint Vincent and the Grenadines CICAD SS<0.1
2006 d, e<0.1 - 0.6 15 - 64Trinidad and Tobago CICAD SS0.1
2003 d, e15 - 64Turks and Caicos Islands UNODC Estimate0.7
United States Virgin Islands No recent, reliable estimate located
Central America
200512 - 65Belize Government source HHS0.3
2006 d, e0.1 - 0.4 12 - 70Costa Rica ARQ SS0.2
2005 a, e15 - 64El Salvador CICAD HHS<0.1
200515 - 64Guatemala UNODC Estimate<0.1
2005 d15 - 64Honduras UNODC Estimate<0.1
2006 e12 - 65Nicaragua CICAD HHS, c<0.1
2003 d15 - 64Panama UNODC Estimate0.4
North America
200815 - 64Canada ARQ HHS1.7
200215 - 64Mexico Govt. source (CONADIC)<0.1
Saint Pierre and Miquelon No recent, reliable estimate located
200815 - 64United States of America Govt. source (SAMHSA) HHS1.0
South America
200612 - 65Argentina Government source0.5
200712 - 65Bolivia (Plurinational State of) ARQ HHS, c0.1
200515 - 64Brazil UNODC Estimate0.2
200815 - 64Chile ARQ HHS0.1
200812 - 65Colombia Government source HHS, c0.3
200515 - 64Ecuador UNODC Estimate0.2
Falkland Islands (Malvinas) No recent, reliable estimate located
200215 - 64Guyana UNODC Estimate0.1
200515 - 64Paraguay UNODC Estimate<0.1
200612 - 64Peru ARQ HHS, c<0.1
2007 e<0.1 - 0.2 12 - 65Suriname Government source HHS, c0.1
2006 c, e15 - 64Uruguay Government source HHS, a, c0.2
2005 a, e<0.1 15 - 64Venezuela (Bolivarian Republic of) Government source HHS<0.1
ASIA
Central Asia and Transcaucasian countries
200515 - 64Armenia UNODC Estimate HHS0.1
Azerbaijan No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
ECSTASY
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
2005 d, e0.7 - 2.4 15 - 64Georgia ARQ SS1.7
Kazakhstan No recent, reliable estimate located
Kyrgyzstan No recent, reliable estimate located
Tajikistan No recent, reliable estimate located
Turkmenistan No recent, reliable estimate located
Uzbekistan No recent, reliable estimate located
East and South-East Asia
Brunei Darussalam No recent, reliable estimate located
200315 - 64Cambodia UNODC Estimate0.1
China No recent, reliable estimate located
2008 d, e<0.1 - 0.8 15 - 64China, Hong Kong SAR Government source SS0.2
2002 c, e15 - 64China, Macao SAR UNODC Estimate0.3
Guam No recent, reliable estimate located
200815 - 64Indonesia ARQ HHS0.2
Japan No recent, reliable estimate located
Korea (Dem. People's Rep.) No recent, reliable estimate located
2004 c, e<0.1 15 - 64Korea (Republic of) ARQ HHS<0.1
Lao People's Democratic Republic No recent, reliable estimate located
2003 e, g15 - 64Malaysia UNODC Estimate0.4
Mongolia No recent, reliable estimate located
Myanmar No recent, reliable estimate located
200415 - 64Philippines Government source HHS0.2
Singapore No recent, reliable estimate located
2005 a15 - 64Taiwan, Province of China AMCEWG0.5
200715 - 64Thailand ARQ HHS0.3
Timor-Leste No recent, reliable estimate located
200315 - 64Viet Nam UNODC Estimate0.2
Near and Middle East /South-West Asia
Afghanistan No recent, reliable estimate located
Bahrain No recent, reliable estimate located
Iran (Islamic Republic of) No recent, reliable estimate located
Iraq No recent, reliable estimate located
200818 - 40Israel Government source HHS0.7
Jordan No recent, reliable estimate located
Kuwait No recent, reliable estimate located
2001 d, e15 - 64Lebanon UNODC Estimate0.5
Occupied Palestinian Territory No recent, reliable estimate located
Oman No recent, reliable estimate located
Pakistan No recent, reliable estimate located
Qatar No recent, reliable estimate located
Saudi Arabia No recent, reliable estimate located
Syrian Arab Republic No recent, reliable estimate located
United Arab Emirates No recent, reliable estimate located
Yemen No recent, reliable estimate located
South Asia
Bangladesh No recent, reliable estimate located
Bhutan No recent, reliable estimate located
India No recent, reliable estimate located
Maldives No recent, reliable estimate located
Nepal No recent, reliable estimate located
Sri Lanka No recent, reliable estimate located
EUROPE
East Europe
2007 c, d, e15 - 64Belarus ESPAD SS0.3
200815 - 64Moldova (Republic of) Government sources HHS0.3
2007 d, e15 - 64Russian Federation* ESPAD SS0.7
2007 d, e15 - 64Ukraine ESPAD SS0.7
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
300
World Drug Report 2010 
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
ECSTASY
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Southeast Europe
2006 d, e0.3 - 2.1 15 - 64Albania Government SS1.0
2008 c, d, e0.4 - 2.7 15 - 64Bosnia and Herzegovina ESPAD SS1.4
200815 - 64Bulgaria ARQ HHS0.7
2007 d, e15 - 64Croatia ESPAD SS 0.8
2008 d, e0.2 - 1.8 15 - 64Macedonia (TFYR) ESPAD SS0.8
2008 d, e0.1 - 1.5 15 - 64Montenegro ESPAD SS0.5
200715 - 64Romania ARQ HHS0.1
2008 a, e0.4 - 0.9 15 - 64Serbia Government sources HHS0.6
200315 - 64Turkey UNODC Estimate0.3
West & Central Europe
Andorra No recent, reliable estimate located
2008 a15 - 64Austria Govt. HHS0.5
2007 c, d, e15 - 64Belgium ESPAD SS1.1
200615 - 64Cyprus ARQ1.0
200815 - 64Czech Republic Government HHS3.6
200816 - 64Denmark ARQ HHS0.4
200815 - 64Estonia Government HHS1.2
200415 - 64Finland ARQ0.5
200515 - 64France ARQ0.5
200618 - 64Germany Government source HHS0.4
200415 - 64Greece ARQ0.2
20070.2 - 0.8 18 - 64Hungary ARQ HHS0.5
2007 d, e15 - 64Iceland ESPAD SS0.5
200715 - 64Ireland Government source1.2
200815 - 64Italy ARQ HHS0.7
200715 - 64Latvia ARQ1.5
200515 - 64Liechtenstein UNODC Estimate0.5
200815 - 64Lithuania ARQ HHS1.0
Luxembourg No recent, reliable estimate located
2007 d, e15 - 64Malta ESPAD SS0.9
2007 d, e15 - 65Monaco ESPAD SS0.9
200515 - 64Netherlands ARQ1.2
200415 - 64Norway ARQ0.5
200615 - 64Poland ARQ0.3
200715 - 64Portugal ARQ0.4
San Marino No recent, reliable estimate located
200615 - 64Slovakia EMCDDA HHS1.6
2007 d, e15 - 64Slovenia ESPAD SS0.7
200715 - 64Spain Government source HHS1.1
2007 d, e0.2 - 0.3 15 - 64Sweden ESPAD SS0.3
2007 d, e0.3 - 0.4 15 - 64Switzerland ESPAD SS0.3
United Kingdom No recent, reliable estimate located
200916 - 59United Kingdom (England and Wales) Government source HHS1.8
200715 - 64United Kingdom (Northern Ireland) Government source HHS1.8
200916 - 59United Kingdom (Scotland) Government source HHS2.5
OCEANIA
Oceania
American Samoa No recent, reliable estimate located
200715 - 64Australia Government source/ NGO/Academic HHS4.2
Christmas Islands No recent, reliable estimate located
Cocos (Keeling) Islands No recent, reliable estimate located
Cook Islands No recent, reliable estimate located
Fiji No recent, reliable estimate located
French Polynesia No recent, reliable estimate located
Kiribati No recent, reliable estimate located
Marshall Islands No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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4. Statistical annex Consumption
Annual Prevalence of Use as a percentage of the population aged 15-64 (unless otherwise indicated)
ECSTASY
Country or Territory
Uncertainty  
Range Ages Year Source (original) Method
          
UNODC 
Adjusted
UNODC 
Best 
Estimate
Micronesia (Federated States of) No recent, reliable estimate located
Nauru No recent, reliable estimate located
New Caledonia No recent, reliable estimate located
200816 - 64New Zealand Government source HHS2.6
Norfolk Island No recent, reliable estimate located
Northern Mariana Islands No recent, reliable estimate located
Palau No recent, reliable estimate located
Papua New Guinea No recent, reliable estimate located
Pitcairn No recent, reliable estimate located
Samoa No recent, reliable estimate located
Solomon Islands No recent, reliable estimate located
Tonga No recent, reliable estimate located
Tuvalu No recent, reliable estimate located
Vanuatu No recent, reliable estimate located
Wallis and Futuna Islands No recent, reliable estimate located
Method: HHS=Household survey, SS=School survey, A=Adjusted from other sources, I=Indirect estimates, R=Registry.  * approximate estimates
UNODC Adjustments: a=adjusted for age (15-64), b=population-based/household-type study/survey, c=adjusted from a limited geographic population-based study/survey, d=adjusted from 
school/youth survey, e=adjusted from lifetime/monthly prevalence adjusted to annual prevalence, f=adjusted from specialized population surveys (including Rapid Assessments), g=adjusted from 
treatment data, h=adjusted from drug registries, i=adjusted from HIV, problematic drug users (only for heroin), j=lifetime prevalence reported,
The 'Method' and 'UNODC Adj.' columns have been completed only for more recent data included in previous and present issues of the World Drug Report.
x=figure may include non-medical use of prescription opioids, z=figures may also include other non-ATS stimulants
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In 2009, the UN Member States decided to make 
further and decisive progress, within a decade, in 
controlling illicit drug supply and demand. Many 
illicit drug markets have reached global dimen-
sions and require control strategies on a compa-
rable scale. In that context, there is a need to 
better understand these transnational markets 
and the manner in which they operate. This year’s 
World Drug Report is a contribution towards that 
objective. It opens with an analytical discussion of 
three key transnational drug markets: the markets 
for heroin, cocaine and amphetamine-type stimu-
lants. The market discussion is followed by a pres-
entation of statistical trends for all major drug 
categories. The latest information on drug pro-
duction, seizures and consumption is presented. 
Finally, there is a discussion on the relationship 
between drug trafficking and instability.
